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The kinetics and mechanisms of macromolecular absorption from the airways of the 
rat lung were studied in vivo and in vitro, following identical solute administration 
methods. The isolated perfused rat lung (IPRL) was used as an in vitro model, and the 
disposition of 7.4 and 4.3 kDa fluorophore-labeled polyhydroxyethylaspartamide (F-
PHEA) and other small and macromolecular reference solutes was investigated across 
doses and in the presence of a variety of biochemical inhibitors . 
xxviii 
Absorption profiles of F-PHEA, and the solute's lung distribution at different times 
after administration, were statistically identical in vivo and in vitro, showing that the 
IPRL possessed a viable mucociliary escalator and that macromolecular solute absorption 
rates from the IPRL were predictive of those in vivo. A kinetic model of the IPRL 
incorporating mucociliary clearance alongside active and passive absorption was 
developed and validated. This model was employed successfully to analyze each solute 's  
absorption components from the rat lung following simultaneous, across-dose, nonlinear 
regression analysis of airway-to-perfusate absorption data. 7 .4 and 4.3 kDa F-PHEA 
absorption from the pulmonary lung compartment occurred actively via the 
polyaspartamide transporter with values for Vmax.P and Km.P of 4.37/3 .60 J.1g1min and 
56.6176 .8 J.1g, respectively. In contrast, the magnitude of F-PHEA's passive absorption 
component, ka'p, was inversely related to its molecular weight, consistent with the 
absorption of a small proportion of each solute dose passing by restricted diffusive 
transport through tight junctions in the pulmonary epithelium. 
The active component of 7.4 kDa F-PHEA absorption, which enhanced airway-to­
perfusate transfer at low doses, was significantly inhibited in the IPRL at lowered 
temperature (25 °C; 68.4 %) and in the presence of 1 .0 mM 2,4-dinitrophenol (53 .3  %),  
100 J.1M ouabain (75 .8  %), 30 .0 J.1M monensin (66.0 %) and 30 .0 J.1M nocodazole (68 .4 
%). This suggested that polyaspartamide-transporter was dependent on ATP-derived 
energy, and probably employed an intracellular vesicular transcytotic mechanism. The 
airway-to-perfusate transfer of 376 Da fluorescein and 4.4 kDa fluorophore-labeled 
dextran had no active (dose-dependent) absorption component. However, each of these 
xxix 
solutes showed values for solute's molecular weight-dependent passive absorption and 
solute-independent mucociliary clearance, when compared to those for F-PHEA. 
CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
Innovations in biotechnology have produced a wide variety of new macromolecular 
therapeutics and currently, there are at least 30 compounds approved in the US market 
and over 130 candidates now in human clinical trials (Patton, 1998). Despite this 
tremendous opportunity, the systemic delivery of these macromolecules, mostly proteins 
and peptides is still quite limited due to poor absorption through many of the body's 
epithelia. Oral administration of these large molecules undergoes extensive enzymatic 
and acid digestion in the gastrointestinal (GI) tract, resulting in negligible absorption of 
intact molecules through the GI mucosal membrane. The skin offers an even less 
permeable barrier due to their large molecular size. The nasal route affords only low 
bioavailability for proteins and peptides (e .g . ,  � 3.0 % for insulin) and especially, its high 
variability is believed to be problematic (Patton, 1998). As a result, the major route of 
administration for these compounds has been largely limited to parenteral administration 
via injection. 
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In contrast, it is now becoming clear that inhalation offers promising prospects for 
macromolecular delivery (Patton and Platz, 1 992; Adjei and Gupta, 1 994; Byron and 
Patton, 1 994; Patton, 1 998). The lung is known to have an enormous absorptive surface 
area ( 1 02 m2 in human) covered by an extremely small volume of fluid ( 1 0-20 mL in 
human) and the entire cardiac output rushes through its capillary network which lies:::; 1 
flm beneath the absorptive surface (Patton, 1 996; Patton, 1 998) .  Table I. 1 shows many of 
the proteins and peptides ,  which are currently being developed or studied as inhalation 
drug candidates .  Even following inefficient aerosol administration, the absolute 
bioavailability of leuprolide acetate (MW = 1 .2 kDa) , a nonapeptide with potent 
luteinizing hormone releasing hormone agonist activity, was as high as 1 8  % in healthy 
human volunteers (Adjei and Garren, 1 990) . Insulin (5 1 amino acid, MW = 5 .7  kDa) 
administration via nebulization has been successfully shown to lower blood glucose in 
diabetes patients (Laube et aI. , \993;  Liu et al. , 1 993) .  Table I .2 shows animal studies in 
which macromolecular absorption was studied. Regardless of species, most of the 
proteins and pep tides in Table I.2 were readily absorbed from the lung, demonstrating 
much higher bioavailability, when compared to other routes of administration. 
In order to appreciate the potential for systemic drug delivery of macromolecules 
via the airways, it is necessary to understand and recognize the nature of the pulmonary 
barrier. Typical statistics for average human lung are shown in Table I .3 ,  compared to 
those for Sprague-Dawley rats. Following 17 bifurcations, the surface area of the alveolar 
region has been shown to be enormous,  compared to that of the tracheo-bronchial region 
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Table 1.1. Proteins and peptides that are currently being developed or studied as 
inhalation drug candidates .  
Protein/Peptide MW Indications (Research phase) Reference I 
[kDa] 
Leuprolide acetate 1 .2 Infertility, endometriosis (Ph.I)
2 
Adjei , 1 990 
Cyclosporin 1 .2 Refractory transplant/organ Iacono, 1 996 
rejection, asthma 
Calcitonin 3 .4 Osteoporosis, Pagets disease (Ph . !) Patton, 1 997 
Insulin 5 .7  Type IIII diabetes (Ph. III) Laube, 1 993 
Heparin 1 5-20 Blood clotting Patton, 1 997 
IL-2* I 1 8  Renal cancer Huland, 1 992 
hG-CSF*2 1 8 . 8  Cancer Fuchs, 1 994 
IFN-y *3 1 8-20 Chronic granulomatous diseases Jaffe, 1 99 1  
IFN-�*4 1 9-22 Lung cancer, multiple sclerosis Halme, 1 994 
IFN-a*5 1 9-22 Lung cancer, hepatitis Kinnula, 1 989 
rhDNAse*6 37 Cystic fibrosis (Launched) Gonda, 1 997 
ai-antitrypsin 52 Cystic fibrosis McElvaney, 1 99 1  
ai-antitrypsin deficiency Hubbard, 1 989 
IL-R*7 90 Asthma (Ph.IIII) Patton, 1 997 
I Only first auhors and years of publication; details are described in References. 
2 Ph. = Phase. 
*1 Interleukin-2; *2 human granulocyte colony-stimulating factor; *3 interferon-y ; 
*4 interferon-�; *5 interferon-a; *6 recombinant human deoxyribonuclease and 
*7 interleukin receptor. 
Table 1.2. Bioavailability and T max for proteins and pep tides in experimental 
animals following solution instillation into the lung. 
Protein/Peptide MW Animal Tmax 1 BA%2 Reference3 
[kDa] [hrs] [%] 
RGD peptide' ! 0.7 rat 0.68 22 Adjei, 1 997 
GHR peptide'2 0.9 dog 0. 1 7  43 Adjei, 1 997 
DDAVP'3 1 . 1  rat 1 .3 20-45 Adjei, 1 997 
Cyclosporin 1 .2 dog 1 .0 N/A Adjei , 1 997 
Leuprolide 1 .2 dog 0.37 5-59 Adjei, 1 997 
Detirelex 1 .7 dog 7.6 27 Adj ei , 1 997 
Somatostatin28 3 . 1  rat < 1  N/A Adjei, 1 997 
VIP ' 4  3.3 rat < 1  N/A Adjei , 1 997 
Calcitonim 3 .4 rat 0.25 1 7  Adjei, 1 997 
Glip 3 . 5  rat 0. 1 7  3 . 5  Patton, 1 998 
Glucagon 3 . 5  rat < 1 N/A Adjei, 1 997 
PTH's 4.3 rat 0.25 8 Patton, 1 998 
4 
Insulin 5 . 8  rat 0.33 1 4 Okumura, 1 992 
GM-CSF'6 1 7 .7 rat 0.50 1 6 .9 Patton, 1 998 
G-CSF'7 1 8 .6 rat 2 .5  12  Niven, 1 994 
IFN-a'& 1 9. 0  rat 4 .5 1 9-56  Adjei, 1 997 
hGH '9 22.0 rat 6.0 3-36 Colthorpe, 1 995 
Albumin 68.0 rat 20.0 4 .5 Adjei , 1 997 
IL- I R' ! O  90.0 rat 1 2 .0 1 7 .7 Patton, 1 998 
IgG' ! !  1 50.0 rat 1 6 .0 1 .7 Adj ei ,  1 997 
1 Tmax is used for an indicator of absorption rapidity, though it is a fucntion of both absorption and 
elimination; 2 bioavailability relative to subcutaneous injection and 3 only first authors and years of 
publication; details are described in References. 
' I  Arginine-glycine.aspartic acid peptide; '2 glycine· histidine-arginine peptide; 
'3 1 .deaminocysteine.8-D.arginine vasopressin; '4 vasoactive intestinal peptide; '5 parathyroid hormone; 
'6 granulocyte· macrophage colony-stimulating factor; '7 granulocyte colony-stimulating factor; 
'8 interferon.a; '9 human growth hormone; ' 1 0 interleukin- l receptor and ' I I  immunoglobulin G 
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Table 1.3. Statistics of human lung and its cells, compared to Sprague-Dawley rat. 
Human SD rat 1 Reference 2 
(70 kg) (0.3 kg) 
Airway branching pattern Relatively Strongly Warheit, 1 989 
symmetrical monopoidal 
Number of branches 23-26 1 2-20 Warheit, 1 989 
Surface area [m2] 
Alveoli 1 02 0.4 Stone, 1 992; 
Tracheo-bronchi -2. 5  -0.0 1  Mercer, 1 994 
Cellular thickness [flm] 
Alveoli 0.2 0. 1 Murchie, 1 993 ;  
Tracheo-bronchi 1 0-58 1 3 .2 Patton, 1 996 
Lining fluid volume [mL] 
* 1  Alveoli 7-20 0.08 Anderson, 1 992; 
Tracheo-bronchi 4-9 
Alveoli 
Lining fluid thickness [flm] 0.07 
% surface of type I 92.9 
% surface of type II 7. 1 
Estimated pore diameter [nm] 
*2 Alveoli N/A 
Tracheo-bronchi Nlj(2 
Mucociliary clearance 
Rate [mmlmin] 0.5-2 1 
half-life [min] 0.7, 4.2 
N/A*2 
0.2 
96.4 
3 . 6  
0.4, 50 
1 4- 1 9  
4 .5 
0.6- 1 .3  
Patton, 1 996 
Weibel, 1 963 ;  
Bastacky, 1 995 
Crapo, 1 982; 
Warheit, 1 989 
Chandra, 1 992 
Byron, 1 986 ; 
Taylor, 1 994; 
Adj ei , 1 997 
1 Sprague-Dawley; 2 Only first authors and years of publication; details are described in 
References. 
*1 Calculated from (fluid thickness x surface area); *2 not available. 
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( 1 02 m2 vs. -2.5 m2 ; Stone et ai. , 1 992; Mercer et ai. , 1 994; Patton, 1 996). Furthermore, 
the barrier thickness in the alveolar region is known to be ::; 1 .0 �m (often 0. 1 -0 .2 �m), 
which is much thinner than 2: 1 0  �m of that in the tracheo-bronchial airways (Patton, 
1 996). It is quite reasonable to believe therefore, that the alveolar membranes are 
favorable for large solute absorption, although clearly deep lung delivery via inhalation is 
required (Byron and Patton, 1994; Patton, 1 996). 
Alveolar membranes are composed of alveolar epithelium (adjacent to the airways) ,  
basement membrane and capillary endothelium (adjacent to  the blood vessels ;  Corrin, 
1987). As the barrier becomes thick, alveolar epithelium and capillary endothelium are 
separated by an interstitial space (the origin of the lung lymphatics; Corrin, 1 987) .  On the 
epithelial cell surface, there is a smooth lining fluid layer, topped with a monomolecular 
layer of surfactant. The overall thickness of this barrier ranges from 0. 1 to 1 �m (0.2 �m 
in average; Table I .3) .  Between epithelium and endothelium, it has been shown that small 
solute permeation through capillary endothelium proceeds 10 to 100 times faster than that 
through alveolar epithelium (Barrowcliffe and Jones, 1 987). In mammalian lungs, the 
equivalent pore radii calculated from physiological studies are 0.6- 1 .0 nm for the 
epi thelium and over 4.0-5 .8 nm for the endothelium, showing the latter to be much more 
permeable to solutes and proteins (Taylor et al. , 1 965 ; Taylor and Gaar, 1 970; Gorin and 
Stewart, 1979; Lanken et ai. , 1985 ;  Effros et ai. , 1 986; Barrowcliff and Jones, 1 987) .  The 
interstitial space and the basement membrane is believed to be an insignificant barrier for 
solute and fluid transport, compared to either the epithelial or endothelial membranes 
7 
(Corrin, 1 987). It is likely therefore, that alveolar epithelium is the most formidable 
barrier for solute absorption from this alveolar region. Indeed, a microscopic study 
demonstrated that horseradish peroxidase (MW = 44 kDa) could hardly penetrate to the 
interstitium following airway administration, even though it was abundantly observed in 
the interstitium after intravenous administration (Lee, 1 990; McLaughlin et al. , 1 993) .  
As opposed to the four major cell types found in the tracheo-bronchial airway 
epithelium, the alveolar epithelium is composed of only two principal cells .  These are 
known as type I (squamous or membranous pneumocyte) and type II (granular 
pneumocyte) cells (Corrin, 1 987). Type I cells are observed microscopically as flattened 
cells ,  covering 93-97 % of alveolar surface (Table 1 .3) ,  and are known to have few 
cytoplasmic organelles (Burri, 1 983) .  It appears that these cells are incapable of mitotic 
division (Corrin, 1 987) and their basic physiological function is believed to prevent fluid 
loss into the airways, yet facilitate rapid gas exchange (Burri, 1 983 ;  Corrin, 1 987) .  In 
contrast, type II cells are observed as cuboidal cells, which function to maintain and 
repair the type I cell population by proliferation (Williams, 1 990). These cells are also 
responsible for secreting surfactant and regulating fluid balance and interestingly, have 
much higher metabolic function than type I pneumocytes (Wiliams, 1 990) . Type I cells 
are connected to each other or to type II cells in the epithelial layer by tight junctions ,  
with type I I  cells generally occupying the "corners" of alveoli (Corrin, 1 987; Williams, 
1990) . There is also a small number of alveolar type III cells distinguished by their brush 
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border, occasionally seen in rats, but not in the human (Meyrick and Reid, 1 968 ;  Burri, 
1 983) .  However, their function remains unclear. 
Generally, solutes are believed to be absorbed by diffusion and/or partitioning. 
Typically, in the case of hydrophilic solutes like most proteins and peptides, the tight 
junctions (zonula occludens, ZO; Williams, 1 990) are believed to be the primary 
morphological elements through which solutes can pass by paracellular absorption. 
Because the lipophilic nature of the cellular membranes is  likely to prohibit the passage 
of hydrophilic macromolecular solutes, this would appear to be one possible route of 
transfer for these molecules. The tight junctions are now known to be complex structures 
of multiple proteins, which serve as intricate and dynamic fasteners of cells to each other 
(Schneeberger and Lynch, 1 992). Alveolar epithelial tight junctions have been shown to 
form a network of 3 to 5 interconnected strands that are similar in appearance in both 
alveolar type I and type II cells (Schneeberger and Lynch, 1 99 1 ) .  As an interconnected 
series of strands and grooves, it is believed that these can represent relatively 
impermeable structures in which channel-like discontinuities or "pores" reside. Such 
"pores" may alternate between open and closed configurations like channels in 
biomembranes (Claude, 1 978 ;  Reuss ,  1 99 1 ) , and their tightness may respond to external 
stimuli (Bhat et aI. , 1 993;  Wang et al. , 1 993) .  Thus, it is  possible that increased 
permeability through "opened" tight junctions may be one way in which macromolecules 
could enter the systemic circulation from the airways . These hypothesized aqueous 
"pores " ,  representing various sizes in the pulmonary membrane, were demonstrated in 
early studies by Schanker in the rat (Enna and Schanker, 1 972; Lanman et al. , 1 973 ;  
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Burton and Schanker, 1 974a and 1 974b; Burton et ai. , 1 974; Schanker and Burton,  1 976 ;  
Schanker and Hemberger, 1983 ;  Brown and Schanker, 1 983) ,  although actual "pores"  
have yet to  be confirmed by morphological studies. 
As well as restricted diffusive transepithelial transport via tight junctions 
(paracellular absorption), it is  now known that the alveolar epithelium, especially type I 
cells contain numerous cytoplasmic and cell-membrane-associated clathrin-coated and 
nonclathrin-coated, "caveolae" .  These represent vesicles that actively transport fluid, 
solutes and macromolecules including proteins and pep tides (Patton, 1 996; Campbell et 
ai. , 1 998). These endocytotic and/or transcytotic vesicles have been observed 
microscopically with diameters of 50- 1 00 nm within the cytoplasm of both alveolar type 
I and type II epithelial cells (Williams, 1 990; Williams, 1 992; Campbell et ai. , 1 998) .  
Although the subject of vesicular trafficking is complex (Williams, 1 990; Williams, 
1 992) and vesicles may be trafficked via multiple routes (Patton and Platz, 1 992; Patton, 
1 996), this simple picture is at least capable of explaining some of the results for 
unexpectedly high macromolecular bioavailability shown in Table 1 .2 following solute 
administration into the airways . It is necessary in fact, to explain the rapid and extensive 
pulmonary absorption of insulin (5 .7 kDa) and growth hormone (22 kDa) , compared to 
the much slower absorption for similarly-sized inulin (5 .3  kDa) and dextran (20 kDa) , to 
propose either transcytotic protein absorption via active endocytotic mechanisms or 
spontaneous increases in the size of "pores" in the tight junctions induced by each solute 's 
presence (Enna and Schanker, 1 972; Takada et ai. , 1 978;  Ohtani et ai. , 1 99 1 ;  Colthorpe 
1 0  
e t  al. , 1 992; Folkesson e t  al. , 1 992). I f  vesicular transport i s  the mechanism, which 
currently seems the most feasible, these vesicles must release their contents into the 
interstitium by exocytosis. The solutes could then subsequently traverse the capillary 
endothelial cell either by transcytosis or (more likely) simple diffusion through the more 
"leaky" intercellular endothelial junctions, and enter the systemic circulation (Williams, 
1 990; Williams, 1 992). 
In addition to these absorption processes, solutes deposited in the lung are also 
known to be subject to one or more of its natural defense mechanisms. The most rapid of 
these and thus, the most likely process to affect solute absorption, is that of mucociliary 
clearance (Lansley, 1993 ; Cammer and Mossberg, 1 993;  Kim and Folisbee, 1 997). The 
process is known to occur due to ciliated cells in the conducting airways possessing cilia 
which beat in a coordinated fashion. This occurs within the periciliary t1uid beneath a 
viscoelastic layer lining the respiratory tract (Lansley, 1 993 ;  Cammer and Mossberg, 
1 993 ;  Kim and Folisbee, 1 997) and hence, it is primarily believed to exist in tracheo­
bronchial airways where ciliated cells are found microscopically. Nevertheless, recent 
evidence has also suggested the presence of an alveolo-bronchiolar clearance mechanism, 
in which migrating solutes, lining t1uid and/or macrophages are transporterd from the 
alveoli to mucociliary clearance region, followed by subsequent mucociliary clearance 
(Green, 1 973 ;  Warheit, 1 989). These clearance processes are believed to become slower 
as the respiratory tract is descended (Brain and Blanchard, 1 993 ;  Camner and Mossberg, 
1 993) .  Such clearance kinetics of small particles over 24 hours can be characterized using 
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a bi-exponential kinetic model with half-lives of 0.7 and 4.2 hours in the human. The 
latter half-life probably represents the half-life for alveolo-bronchiolar clearance (Byron, 
1 986). 
Bi-exponential mucociliary clearance kinetics over 24 hours , as seen in the human 
(Byron, 1986), have yet to be demonstrated in small rodents like rats. While highly 
variable, apparent linear rates of mucociliary clearance in the tracheo-bronchial region 
were similar between the human and rat (0.5-2 1 vs. 4.5 mm1min, respectively; Table 1 . 3 ) ;  
other long-term studies (:::0: 24 hours) showed faster mucociliary clearance rates in small 
rodents (rats, guinea pigs and rabbits) than in large mammals such as dogs and humans 
(Snipes et al. , 1983 ;  Warheit, 1989). Despite the uncertainties associated with the 
presence of alveolo-bronchiolar clearance and its interspecies differences, Taylor et aI. , 
( 1 994) recently repOlted a value of 1 . 3 hours for the mucociliary clearance half-life for 
tin colloid in rabbits, following the colloids administration as an aerosol into the deep 
lung. This may represent a mixture between the alveolo-bronchiolar clearance rate and 
tracheo-bronchial rate in small rodents, since the value was larger than that of 0.6 hours 
for tracheo-bronchial mucociliary clearance obtained following intratracheal instillation 
(Taylor et aI. , 1994). Furthermore, recent in vivo studies in rats and guinea pigs have 
shown that mucociliary clearance competes significantly with absorption following deep 
lung administration, especially when absorption is rate-determined (Lansley, 1 993 ; 
Taylor et aI. , 1 994; Sakagami et aI. , 1996; Byron et al. , 2000) . It is likely therefore, that 
mucociliary clearance and alveolo-bronchiolar clearance transport macromolecular 
1 2  
solutes from their primary absorption depot i n  the lower airways quite efficiently, thus 
competing kinetically with absorption processes (Byron et al. , 2000) . 
Solute disposition in the lung following inhalation is a complex function of 
deposition and mucociliary clearance, active and passive absorption, tissue sequestration 
and metabolism (Byron, 1 986;  Byron and Phillips, 1 990). Furthermore, different regions 
of the airways are believed to function differently, at least with respect to absorption and 
mucociliary clearance, as described above. In fact, the absorption could be active and/or 
passive from both alveolar and the tracheo-bronchial regions and region-specific, 
simultaneous mucociliary clearance could function competitively with both of the 
absorption. Unfortunately, the kinetic and mechanistic characterization of these processes 
is quite difficult due to a lack of appropriate experimental systems, and this largely 
remained theoretical (Byron, 1 986; Byron and Phillips, 1 990) . 
Whole rat studies in vivo have been combined with intratracheal instillation and 
used extensively in several laboratories (Enna and Schanker, 1 972; Brain et aI. , 1 976;  
Takada et al. , 1 978; Pritchard et al. , 1985 ;  Folkesson et aI. , 1 996; Leong et ai. , 1 998) .  
These studies have demonstrated some of the solute absorption characteristics from the 
airways, especially as they were related to solute partitioning, diffusion, size and electric 
charge (Enna and Schanker, 1 972; Brown and Schanker, 1 983) .  Some evidence of 
saturable active absorption via carrier proteins (Enna and Schanker et al. , 1 973) has also 
been documented. Unfortunately, these studies require considerable animal sacrifice to 
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avoid the huge inter-rat variations i n  the derived data (Brain e t  aI. , 1 976; Pitchard e t  al. , 
1985 ;  Folkesson et aI. , 1 996; Leong et aI. , 1 998) .  Furthermore, much of the variation 
reported in the literature is associated with non-reproducible airway dosing (CV% > 1 5  
% )  and solute distribution i n  the lung and hence, because o f  the uncertainties related to 
the technique, inter-study comparisons are difficult. On the other hand, recent 
biotechnological advances have allowed scientists to utilize cell culture systems to study 
solute absorption and metabolism (Audus et aI. , 1 990) . Specifically, cultured alveolar 
epithelial cell monolayers have been used increasingly to determine monolayer 
permeability to solutes (Wang et al. , 1 993;  Morimoto et aI. , 1 993;  Kim and Crandall , 
1 996). These in vitro studies provide clear kinetic information specific to each type of 
cell monolayer. They can be manipulated easily by lowering temperatures and the use of 
absorption modulators and/or inhibitors , enabling the identification of possible 
mechanisms and pathways of absorption (Morimoto et aI. , 1 993;  Kim and Crandall , 
1 996). Currently, alveolar type I cell monolayers can be cultured only from alveolar type 
II cells, followed by their differentiation (Cheek et aI. , 1 989;  Kim and Crandall, 1 996). 
However, there are many uncertainties and variables associated with lung cell isolation 
and culture, which remain undescribed in the literature [e .g . ,  enzymes being used, 
contents and concentrations of culture media (Dobbs, 1 990) ] .  Thus, methods rarely 
produce comparable results between laboratories and unfortunately, values for solute 
permeability through such monolayers hardly provide useful predictive information 
relating to solute absorption through the intact lung. 
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The Aerosol Research Group at Virginia Commonwealth University has employed 
the isolated perfused rat lung (IPRL) preparation, combined with the highly reproducible, 
"forced solution instillation" technique for solute administration into the airways for 
some years (Niven and Byron, 1 988 ;  Byron and Niven, 1 990; Sun, 1 995; Visich, 1 996, 
Kovelesky, 1998). The preparation offers the "reality" of a whole lung organ housed in a 
well-controlled environment, without the complications of variability induced by the 
presence of respiration, variable blood flow, solute deposition and the presence of the 
remainder of the body (Levey, 1 966; Mehendale et al. , 1 98 1 ;  Roberts, 1 984; Niven, 
1 988) .  Even though the magnitude of the lung's mucociliary clearance had previously 
been unknown in this preparation, it appeared that some of its effects could be seen over 
the period of an absorption study (Byron et al. , 1 986). Therefore, it was possible that the 
preparation could be used as an in vitro model providing rates and/or rate constants for 
solute absorption from the airways and for mucociliary clearance. Then, these values 
could also be used to interpret an otherwise, exceedingly complex in vivo situation 
following the assembly of data from a series of well-designed in vivo and in vitro studies .  
Because the preparation had been used previously, to  illustrate the presence of a "difficult 
to characterize" polyaspartamide airway-to-pefusate transporter (Sun et al. , 1 999), the 
IPRL was refined in this thesis, and used to investigate and characterize the mechanisms 
of absorption of same well-defined model polypeptides. 
This dissertation targets the knowledge and model deficiency in the area of 
macromolecular pulmonary solute absorption and clearance and aims to enhance our 
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understanding of  solute disposition in the lung following inhalation. By developing and 
validating the IPRL preparation as a model of the in vivo rat lung, it has proven possible 
to describe pulmonary solute disposition in the IPRL, in such a way that the kinetic 
behavior of the polyaspartamide transporter (Sun et ai. , 1 999) in vivo can be predicted. 
Because this transporter operates in the presence of simultaneous mucociliary clearance, 
it was necessary to first characterize the kinetics of that process, as it related to solute 
absorption from the airways .  As a result, this thesis contains a unique kinetic analysis of 
lobar to tracheo-bronchial (mucociliary) solute clearance kinetics in the rat. By studying 
the effects of molecular weight, IPRL perfusion temperature and biochemical process 
inhibitors upon both poyaspartamide (PHEA) transport and the absorption of model 
solutes known to be absorbed passively, the magnitude of the PHEA transporter's 
carrying-power was explored in the rat lung. All of these processes are discussed with 
respect to their importance in the prediction of the biopharmaceutical properties of 
molecules delivered by inhalation. 
CHAPTER II 
HYPOTHESES 
Theoretically, macromolecules and other solutes may be absorbed from the airways 
via vesicular endocytotic or transcytotic transport and/or diffusive transfer through 
intercellular tight junctions (paracellular pathways). However, precise analysis of 
absorption data in the lung is complex and may be confounded by the presence of 
competing mucociliary clearance. In fact, there is a general lack of appropriate models 
for interpreting the pulmonary disposition of solutes in vivo. Thus, the goal of this 
research was to determine and model the kinetics of macromolecular solute absorption 
from the airways of the rat lung in vivo and in vitro. Specifically, the characterization and 
study of the kinetics of the absorption mechanisms and pathways responsible for model 
polypeptidic polymers required the development and study of sophisticated disposition 
models in lung. Then, by studying the pulmonary disposition (in vivo and in vitro) of 4 .3  
and 7 .4 kDa metabolically-stable polyaspartamides (F-PHEA), alongside that of  small 
and large reference solutes, the thesis project was designed to test five major hypotheses. 
These were: 
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(a) That the i n  vitro isolated perfused rat lung (IPRL) possessed a viable mucociliary 
escalator that was kinetically indistinguishable from that in the whole rat. Thus ,  that 
macromolecular mucociliary clearance rates into the tracheo-bronchial regions of the 
lung would occur both in vivo and in vitro, and that absorption rates from the 
pulmonary regions of the IPRL should be predictive of those in vivo. 
(b) That sophisticated kinetic models can be developed which incorporate mucociliary 
clearance and simultaneous active and passive solute absorption from the airways of 
the rat lung. Then, that a study of the pulmonary disposition of actively and passively 
transferred solutes, in a variety of doses, could be used alongside these models to 
correctly characterize the capacity and affinity of the airway-to-blood transporter for 
polyaspartamide (F-PHEA). 
(c) That the IPRL preparation could be manipulated by its maintenance at lowered 
temperature and the presence of metabolic inhibitors. Then, that a similar modeling 
approach could be employed to determine the degree of inhibition of the 
polyaspartamide (F-PHEA) transporter. 
(d) That the magnitude and nature of polyaspartamide transporter inhibition, afforded by 
the presence of metabolic and transcytosis inhibitors , should enable some of the 
transport mechanisms and pathway to be elucidated. 
1 8  
(e) That smaller molecular weight polyasparatamides possess increased passive airway-
to-perfusate transport rates, while their active transport remains comparable to that of 
their large counterparts. 
The work described in Chapters 3, 4 and 5 of this thesis were designed to test each 
of these hypotheses in tum. Chapter 3 is focused on hypothesis (a) and (b), and describes 
the development and in vivo validation of all the kinetic modeling to be employed 
throughout the remainder of the thesis. Chapter 3 i s  limited to work performed at 37 °C or 
the normal rat lung. Chapter 4 describes the effects of reduced temperature and 
biochemical inhibition upon the polyaspartamide transporter. In so doing, it tests 
hypothesis (c) and (d) above. In Chapter 5, the kinetic models are employed to test 
hypothesis (e) and to compare the passive and active components of polyaspartamide 
transport between a 4.3 kDa and a 7.4 kDa F-PHEA. 
CHAPTER III 
MODELING SOLUTE DISPOSITION IN THE RAT LUNG: 
EVALUATING REGIONAL ABSORPTION KINETICS IN VIVO 
AND IN VITRO, IN THE PRESENCE OF CILIARY CLEARANCE 
lILa INTRODUCTION 
Solute disposition in the lung following inhalation is a complex function of 
deposition and mucociliary clearance, active and passive absorption, tissue sequestration 
and metabolism. Because different regions of the airways are believed to function 
differently with respect to the way they handle solutes, complex kinetic models have been 
proposed to describe their disposition following inhalation (Fig. III. l ;  Byron, 1986 ;  
Byron and Phillips, 1990; Byron and Patton, 1 994). Unfortunately however, such models 
are often largely theoretical due to a lack of appropriate experimental systems, which 
enable their study. For example, while conventional "textbook" wisdom states that 
passive absorption of xenobiotics is  more rapid from alveoli than tracheo-bronchial 
airways (Brown and Schanker, 1983 ;  Schanker et at. , 1 986;  Fig. IILl ) ,  proving such an 
assumption is quite difficult, since mucociliary clearance can complicate the analysis of 
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Figure 111. 1 .  A "mechanistic" kinetic model for solutes administered by inhalation. 
Key: D - deposition; A - absorption; Me - mucociliary clearance; TS - tissue 
sequestration; M - metabolism; DI - distribution; E - elimination. The model was 
originally proposed by Byron ( 1 986) and has been modified and redrawn. 
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these absorption data (Colthorpe e t  al . ,  1 992; Byron e t  al. , 2000) . Indeed, the eventual 
proof or disproof of assumptions like this must rely upon either the simultaneous kinetic 
analysis of in vivo data [for blood and several lung compartments in accord with 
model(s) like that shown in Fig. III. I ]  or an assembly of well-designed in vivo and in 
vitro studies ,  in which data and parameters from the in vitro models are well-correlated 
and can be incorporated in the analysis of the in vivo situation. Thus, such in vitro models 
are required for providing transport rates and/or rate constants, which can be used to 
interpret an otherwise, exceedingly complex in vivo situation. The isolated perfused rat 
lung (IPRL), as used in this thesis will be shown to be ideal for this purpose. The 
preparation offers the "reality" of a whole lung organ housed in a well-controlled 
environment, without the complications of variability induced by the presence of 
respiration, variable blood flow, solute deposition and other biological variations due to 
the presence of the remainder of the body (Levey, 1 966; Mehendale et al., 1 98 1 ;  Roberts, 
1 984; Niven, 1 988) . 
In this chapter, the IPRL will be shown to possess a viable, reproducible, solute­
independent mucociliary clearance that is kinetically indistinguishable, statistically, from 
that in the whole rat . By careful selection of non-sequestered and non-metabolized 
solutes [TS = M = 0 ;  Fig.  III. I ; Appendix V] and their airway administration in vivo and 
in vitro (IPRL), solute absorption rates from the IPRL will be shown to be predictive of 
those from the pulmonary lung compartment in vivo. Using improved kinetic analyses 
based on the model shown in Fig. 111. 1 ,  the capacity and affinity of a previously reported, 
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active transport process for macromolecular absorption (Niven et al. , 1 990; Byron et ai . ,  
1 99 1 ,  Byron et ai . ,  1 994; Sun, 1 995 ; Sun et ai. , 1 999) will be evaluated and shown to be 
a property of only the pulmonary region of the rat lung preparation (that region which is 
perfused by the pulmonary circulation). For these purposes, solute disposition kinetics  of 
model small and macromolecules [376 Da sodium fluorescein (F-Na), 4.4 kDa FITC­
labeled dextran 40 (FD-4) and 7.4 kDa fluorophore-labeled polyhydroxy­
ethylaspartamide (F-PHEA») following identical initial regional distribution in the lung 
were followed with time in the IPRL and compared to those seen in vivo. 
IIl.b MATERIALS AND METHODS 
III.b . I MODEL SOLUTES : F-Na, FDA AND F-PHEA 
Sodium fluorescein (F-Na; 376 Da) and the macromolecular polysaccharide, FITC­
labeled dextran (FDA; weight- (Mw) and number- (Mn) averaged molecular weights = 
4.4 and 3 .4 kDa; polydispersity, Pd (Mw/Mn) = 1 .3 )  were purchased from Sigma 
Chemical Company (St. Louis, MO). These model solutes were used as indicators for 
passive absorption in the IPRL and/or in vivo (Byron et al. , 1 986; Matsukawa et al . ,  
1 997). Weight-averaged 7.4 kDa fluorophore-Iabeled poly-a,�- [N(2-hydroxyethyl)-D,L­
aspartamide) (F-PHEA) was synthesized, purified and characterized by Dr. Frantisek 
Rypacek at the Institute of Macromolecular Chemistry, Czech Academy of Sciences, 
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Prague, Czech Republic (Niven et ai. , 1 990 and Appendix III) . This was used as a non-
metabolized model macromolecule with a peptidic backbone in the IPRL, which was 
known to be absorbed by a combination of active and passive mechanisms into perfusate 
(Niven et ai., 1 990; Byron et ai. , 1 99 1 ,  Byron et ai. ,  1 994; Sun, 1 995; Sun et ai . ,  1 999). 
All these molecules are shown in Fig. 111 .2 .  Briefly, F-PHEA was synthesized as follows :  
polysuccinimide (PSI), prepared by polymerization of D,L-aspartic acid, was reacted 
with small amounts of 2-aminoethyl-carbonyl-6-aminofluorescein (to give F-PSI with 0 .3 
mole% of fluorophore with respect to monomer subunits) .  F-PSI was reacted with excess 
ethanolamine to give the completely ring-opened product, F-PHEA. Following 
purification and lyophilization, the polymer was characterized in terms of its molecular 
weight distribution (MWD) by high performance gel permeation chromatography 
(HPGPC) or calibrated columns (Appendix III) . The single batch of F-PHEA (FR7 l 50) 
used throughout these experiments had a weight- (Mw) and number- (Mn) averaged 
molecular weights of 7420 and 6620 Da, respectively, and a polydispersity (Pd=Mw/Mn) 
of 1 . 1 2 (Appendix III) . Its fluorophore content was 0.3 mole% with respect to the 
monomer (Appendix III) . 
III .b .2 ANIMALS 
The research adhered to the NIH Principles of Laboratory Care and was approved by 
the Institutional Animal Care and Use Committee (IACUC; Project 97 1 0-2468) at 
(a ) 
(b )  
o 
NaO 
o 0 
.......-�2 
OH H o 0 
H2 OH o 
0"""'- 2 0 h H2 0 
HO 
OH 0 0 
09 OH 0 OH 0 
NH OH 
o n 
Figure 111.2. Chemical structures of model solutes used in the IPRL and the in 
vivo studies: (a) sodium fluorescein (F-Na); (b) FITC-labeled dextran 4000 (FD-
4). Weight- (Mw) and number- (Mn) averaged molecular weights ofFD-4 (Lot 
1 06Hl 1 80) were 4400 and 3385 ,  respectively, with a polydispersity (Mw/Mn) = 
l .3 .  FITC-substitution sites are randomly associated with any free hydroxyl group 
(De Belder and Gratath, 1 973). In the above diagram, the fluorophore is shown 
attached at the 4-hydroxyl for illustrative purposes only. The degree of 
fluorophore substitution was 0.5 mole% fluorophore per glucose unit. 
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Figure 111.2. Chemical structure of model solutes used in the IPRL and the in 
vivo studies: (c) fluorophore-labeled poly-a,�- [N(2-hydroxyethyl)-D,L­
aspartamide] (F-PHEA) . Weight- (Mw) and number- (Mn) averaged molecular 
weights ofF-PHEA were 7420 and 6620, respectively, with a polydispersity 
(MwlMn) = 1 . 1 2 .  The polymer was labeled randomly with 0.3 mole% of 
fluorophore with respect to monomer subunits; the remaining R-groups were 
hydroxyethyl. The ratio ofx:y is believed to be approximately 50 % (Niven and 
Byron, 1 988 ; Sun, 1 995, Sun et al., 1 999). 
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Virginia Commonwealth University. Specific pathogen free (C.V.F.-certified virus free) ,  
male Sprague-Dawley rats weighing 3 1 0-390 g were purchased from Hilltop Lab 
Animals Inc. (Scottsdale, PAl. Prior to experimentation, the animals had free access to 
water and food and were housed in rooms controlled between 1 8-26 °C and 40-70 % 
relative humidity. Dark-light cycling occurred every 1 2  hours and animals were 
acclimated for � 7 days prior to use. 
III .b. 3 IN VIVO LUNG ABSORPTION FOLLOWING "FORCED 
SOLUTION INSTILLATION" 
A series of in vivo whole animal studies were performed using methods modified 
from those developed by Enna and Schanker ( 1 972), but employing the reproducible 
"forced solution instillation" technique for solute administration into the airways 
described by Byron and Niven ( 1 988) .  Rats were anesthetized by intraperitoneal injection 
of pentobarbital (50 mg/kg; Abbott Laboratories, North Chicago, IL) . Each rat was 
placed in the supine position and the trachea cannulated with a stainless cannula (od = 2 .2 
mm, id = 1 .9 mm, length = 32 mm) at  i t s  4'h cartilaginous ring and tied in place; 22 mm 
of the cannula was inserted into the trachea from the 5'h tracheal cartilaginous ring.  
Immediately following natural expiration, a metal dosing cartridge (od = 1 .2 mm, id = 1 .0 
mm, length = 1 3 8  mm) containing nominal doses of F-Na (0.02 mg) or F-PHEA (0.2 and 
1 .0 mg) in 0. 1 mL aqueous solution was inserted through the tracheal cannula until its tip 
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was projected 0.5 mm beyond the cannula terminus, into the trachea. The dosing solution 
was administered as a coarse spray into the airways by a single actuation of a propellant­
only metered dose inhaler (25 ilL; Byron and Niven, 1 988 ;  Sun, 1 995 ;  Sun et al., 1 999); 
this inflated the lung with about 5 .5 mL of propellant vapor and simultaneously, 
accomplished "forced solution instillation" (Byron and Niven, 1988 ;  Sun, 1 995 ;  Sun et 
al. ,  1 999) . The dosing cartridge was removed within 1 -2 seconds of actuation allowing 
the recommencement of normal respiration. Body temperatures and anesthesia were 
maintained using a heat lamp and repeat pentobarbital injection (25 mg/kg every 60 
minutes). The tracheal cannula was left in place throughout each experiment, irrespective 
of the time allowed for absorption to preclude solute absorption from swallowed 
materials .  At the end of each experiment, the cannula was washed and solute remaining 
in the cannula was determined by the validated analytical methods described in Section 
m.b.5 and Appendix IV. At different time intervals following administration (sacrifice 
times of 0, 5 ,  10, 20, 30, 60, and 1 20 minutes for F-Na and 0, 5, 10, 20, 30, 45, 60, 1 20 
and 1 80 minutes for F-PHEA following administration), solute remaining in each lung 
region was determined as follows: the thorax was opened and the ribs flapped backward 
to expose the lungs . The tracheal cannula was attached to a positive pressure ventilator 
(tidal volume = 4.5 mL and respiration rate = 1 6 /min; Model 802, New England Medical 
Instruments Inc . ,  Medway, MA) . The pulmonary artery was cannulated through the upper 
right ventricle and the bottom of the left auricle and both sides of each ventricle were 
promptly amputated and the blood flushed from the lung by continuous free perfusion of 
oxygenated Krebs-Henseleit buffer solution containing 4 % (w/v) bovine serum albumin 
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(pH 7 .4) at a flow rate of 1 5  mUmin for 1 -2 minutes (Byron and Niven, 1988 ;  Sun, 1 995 ;  
Appendix II) . The lungs were then removed from the body exactly as  if an IPRL 
preparation was to be performed (Byron and Niven, 1988 ;  Sun, 1 995 ; Appendices I and 
II) except that the removal was immediately followed by a visual inspection for any signs 
of pulmonary edema (glossy appearance on lung lobes; Roberts, 1 984, Sun, 1995; Sun et 
al. , 1999); lung preparations showing edema were discarded. The complete procedure 
from the first incision to tissue isolation was accomplished in � 5 minutes .  Viable lungs 
were dissected into tracheo-bronchi and the five lung lobe regions (left lung (L), right 
postcaval or median lobe (PC), right superior or apical lobe (RS) ,  right middle lobe (RM) 
and right inferior or diaphragmatic lobe (RI» . At each sacrifice time, four rats with fully 
viable lungs were studied for each dosing solution. Each lung region was weighed and 
homogenized ( 1 0,000 rpm for 2 minutes; Biohomogenizer, Fisher Scientific, Springfield, 
NJ) in phosphate buffered saline (PBS ;  pH 7.4, 0.05 M phosphate in 0. 1 5  M NaCI 
solution) . Homogenates were centrifuged (Fisher Scientific, Springfield, NJ) at 1 ,500 g 
for 1 5  minutes, the supernatants filtered (0.45 11m nylon, 4 mm, Alltech Associates, 
Deerfield, IL) and the solute remaining uncleared determined by the validated analytical 
methods described in Section m.b.5 and Appendix IV. The absorption results were 
expressed as mean % of administered dose remaining to be absorbed in the lung ± sample 
standard deviation V.I'. time. The individual results from each rat are reported in detail in 
Appendix VII. 
m.b.4 PULMONARY ABSORPTION IN THE IPRL FOLLOWING 
"FORCED SOLUTION INSTILLATION" 
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The IPRL preparation and the dosing method ( "forced solution instillation") are 
carefully controlled in these laboratories and have been described in detail previously 
(Byron and Niven, 1988 and Appendix I). They were used unchanged in this thesis . 
Briefly, a rat lung was surgically removed and housed in an artificial glass thorax (AGT) 
maintained at 37 °C. Krebs-Henseleit solution with 4 % (w/v) bovine serum albumin was 
used as perfusate (200 mL) and recirculated through the pulmonary circulation via the 
pulmonary artery at a constant flow rate of 15 mUmin. A metal dosing cartridge 
containing nominal doses of F-Na (0.0 1 ,  0.02 and 0.04 mg) , FD-4 (0. 1 and 0.2 mg) or F­
PHEA (0. 1 ,  0.2, 0.5 ,  1 .0 and 5.0 mg) in 0. 1 mL aqueous solution was inserted into the 
trachea via a tracheal cannula; the tip of the cartridge was allowed to project 0 .5 mm 
beyond the cannula 's  terminus into the trachea. A metered dose inhaler (containing 
propellants only) was connected to the dosing cartridge and cannula and actuated once 
(Byron and Niven, 1988 ;  Sun, 1 995 ;  Sun et al. ,  1999). The dosing solution was propelled 
into the lung as a coarse spray and the lung was inflated simultaneously with 5.5 mL of 
propellant vapor ("forced solution instillation") .  The dosing cartridge was removed and 
the lung allowed to deflate to a residual volume dictated by the maintenance of 2-5 cm 
H20 negative pressure in the artificial glass thorax (AGT; Fig. ALl  in Appendix J) . At 37 
°c, the IPRL viability was maintained for 1 80 minutes as evidenced by the absences of 
any sign of edema and/or a discontinuous increase in the amount of solute absorbed into 
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the perfusate (Roberts, 1 984; Sun et al. ,  1 999; Appendix I) . The perfusate samples were 
taken from a well-mixed reservoir at different time intervals following administration. 
Solute concentrations in the perfusate were determined by using validated analytical 
methods described in Section III.b .S and Appendix IV. Four fully viable preparations 
were studied for each dosing solution and the results expressed as mean % of 
administered dose transferred to perfusate ± sample standard deviation vs. time. 
Individual results from each IPRL are reported in Appendix VII. 
In some experiments, the initial and the final regional solute distributions in the 
IPRL were studied in groups of four IPRL preparations. In these experiments, IPRL 
perfusion was halted either immediately after administration (for initial distribution) or at 
the end of the experiment ( 1 20 and 1 80 minutes following administration for F-Na and F­
PHEA, respectively). Subsequently, the lung was removed from the artificial glass thorax 
(AGT) and dissected into tracheo-bronchi and five lung lobe regions, as described above. 
Following homogenization and clean up, remaining solutes were determined by using 
validated analytical methods described in Section III .b.S and Appendix IV. The 
absorption results from each group (n=4) were expressed as mean % of administered dose 
± sample standard deviation. The individual results from each IPRL are reported in 
Appendix VII. 
III .b .S  QUANTITATIVE DETEMINATION OF MODEL SOLUTES IN 
AQUEOUS, PERFUSATE AND LUNG HOMOGENATE SAMPLES 
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Highly sensitive and quantitative determination methods for F-Na, FD-4 and F­
PHEA in aqueous, perfusate and lung homogenate samples were developed and 
validated, as described in Appendix IV. Fortunately, there was no evidence of lung tissue 
binding seen with any of these solutes; homogenate supernatants contained � 98 % of the 
expected concentrations of fluorophore in all cases (Appendix IV) . Solutes in aqueous 
and perfusate samples were analyzed directly or following appropriate dilution by the 
methods described below for F-Na, FD-4 and F-PHEA. Those in lung were determined 
by either fluorimetry or HPGPC after filtration of supernatant samples (0.45 !lm nylon, 4 
mm, Alltech Associates, Deerfield, IL) , derived from centrifugation (Marathon 22K; 
1 ,500 g for 15 minutes; Fisher Scientific, Springfield, NJ) following lung homogenization 
in 10 mL phosphate buffered saline (PBS;  pH 7 .4, 0.05 M phosphate in 0. 1 5  M NaCI 
solution) at room temperature using a Biohomogenizer ( 10,000 rpm for 2 minutes; Fisher 
Scientific, Springfield, NJ). 
(1 ) F-Na 
F-Na was analyzed by fluorimetry using a luminescence spectrometer (Model LS 
50; Perkin Elmer Ltd. ,  Norwalk, CT; Aex = 490 nm and Aem = 520 nm) with 3 mL ( l cm) 
quartz cells (Fisher Scientific, Pittsburgh, PA) following appropriate (� I O-fold) sample 
dilution with 0. 1 M NaOH. At these wavelengths ,  it was found that substantial 
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fluorescence intensity could originate both from the perfusate and the filtered, centrifuged 
supernatants of lung homogenate. However, this background fluorescence was :s; 10 % of 
fluorescence due to F-Na in all cases, and could be successfully minimized by sample 
dilution. The LOD for F-Na in the worst case scenario (perfusate samples following 1 1 -
fold dilution) was 0.55 ng/mL. The calibration curves for fluorescent intensity due to F­
Na concentration were found to be linear within a range of 2-50 ng/mL with precision 
and accuracy, indicated by RSD (relative standard deviation; n = 6) :s; 3.0 % and %error 
(DFN; % difference from nominal ; n = 6) :s; 9. 1 % in all cases. 
(2) FD-4 and F-PHEA 
Irrespective of the analytical matrix, FD-4 and F-PHEA were analyzed by high 
performance gel permeation chromatography (HPGPC) coupled with fluorescence 
detection (Model RF-535 ;  Shimadzu Corporation, Kyoto, Japan; Aex = 486 nm and Aem = 
5 1 6  nm) . The HPGPC column was a Separon™ HEMA-Bio 40 column (8 x 250 mm, 1 0  
11m particle size ; Tessek Ltd . ,  Prague, Czech Republic) with a guard column, HEMA-Bio 
40 (4.6 x 1 0  m m ,  10 11m particle size; Tessek Ltd . ,  Prague, Czech Republic) and mobile 
phase of phosphate buffered saline solution (PBS ;  pH 7.4, 0.05 M phosphate in 0. 1 5  M 
NaCl solution) supplied at 1 .0 mUmin. The protein content of the perfusate and/or the 
filtered supernatants of lung homogenates contained a fluorescent component interfering 
with the early peak portion of FDA and F-PHEA chromatograms following their direct 
injection into the HPGPC system. Thus, a rigorous curve stripping procedure was 
employed for the area under the curve (AVC) determination of the chromatograms, as 
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described previously (Byron et al. , 1 990; Sun, 1 995 ;  Appendix IV) .  Briefly, this involved 
subtracting blank, matrix-only, chromatograms from each test chromatogram. Corrected 
values for area under the curve (AUC) for each solute were linearly related to solute 
concentration over the ranges of 0.08- l .8 J.lg/mL (FD-4) and 0.3-2 .5 J.lg/mL (F-PHEA). 
Subsequently, the calibration curves for each solute were found to be insignificantly 
different across matrixes (ANOV A), indicating the absence of quenching of solute 
fluorescence due to matrix or tissue binding effects in lung, for both of these solutes 
(Appendix IV) .  Sensitivity, precision and accuracy were determined in all cases and 
indicated for FD-4 and F-PHEA, respectively, by LOD � 0.03 and � 0. 1 1  J.lg/mL, RSD � 
1 0.7 and � 9 .3 % and %error � 8 .8 and 8 .2 % (n = 6). 
III .b .6 A KINETIC MODEL FOR SOLUTE DISPOSITION IN THE 
AIRW A YS OF THE IPRL AND IN VIVO 
A single kinetic model was proposed to describe the disposition of these solutes 
following their administration into the airways of the intact rat (in vivo) or the IPRL. This 
model is shown in Fig. IIL3 .  The model assumed two lung regional components, 
separated based on their perfusion; the pulmonary (lobar) and tracheo-bronchial regions, 
which are perfused, respectively, by the pulmonary and the bronchial circulations. 
Tracheal cannulation throughout all of these experiments precluded absorption from the 
gastrointestinal (GI) tract. Our choice of solutes also precluded interference from 
(I-F) Dose 
- _ _ 9 0/0 - - -
F 
91 0/0 I 
t 
Pu lmonary 
[M]p 
Passive 
absorption 
ka P  , 
- - - - - � 
Mucociliary .-r 
clearance, . . . · · . . . . . ' 
kE,PT 
Active 
absorption 
Vmax,p 
Km,p 
Passive * 
absorption 
ka,TB 
Perfusate [P] or b lood [8] 
Figure 111.3. A new kinetic model for solutes administered into the airways of the 
rat ilmg. 
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* Passive absorption from the tracheo-bronchial region is not present in the IPRL due 
to the severance of the bronchial circulation during surgery (ka,TB = 0 in the IPRL) . 
Key: F - initial average penetration fraction following administration (0.9 1 ) ;  v,lIax.P 
and Kill P - the maximum rate and "affinity" of Michaelis-Men ten-type active 
absorption, respectively; ka P and ka TB - first-order rate constants for passive absorption 
from the pulmonary and th� trache�-bronchial regions, respectively; kE.P1' - first-order 
rate constant for mucociliary clearance. 
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metabolism and/or tissue sequestration (Niven, et al. ,  1 990; Byron et al. ,  1 99 1 ;  Sun, 
1 995;  Appendix V). In the IPRL, unlike the in vivo situation, the tracheo-bronchial 
perfusion is severed and hence, only pulmonary lobar absorption is possible (ka•TB = 0 in 
Fig. III. 3 ;  Mehendale et al. , 1 98 1 ) ;  absorption from both regions is possible in the intact 
rat. Initially (immediately following administration), solutes were distributed between the 
two lung regions in a known and reproducible fashion. In practice, this resulted in an 
initial average penetration fraction, F = 0.9 1 of each administered dose, reaching the 
pulmonary region independent of either dose or solute (Section III.b.7) . The absorption 
processes were assumed to be active (Michaelis-Menten-type) and/or passive (first-order 
kinetics) from the pulmonary region in the IPRL, while absorption from the tracheo­
bronchial region in vivo was assumed to be first-order only (ka.TB) .  Mucociliary clearance 
was assumed to be a viable, equivalent first-order process (kE,PT) in both preparations 
(Byron, 1 986) .  
Thus, in the case of the IPRL, it follows that the rate of change for the amount of 
solute in perfusate, d[Pj/dt due to active, passive or simultaneous active and passive 
absorption, from the pulmonary region can be described, respectively as : 
(d[Pj/dt)Active, IPRL = Vmax,p · [Mjp/(Km,p +  [Mjp) (Eqn. III. I ) 
(d [P]/dt)Passive,IPRL = ka,P' [M]p (Eqn. III .2) 
(d [Pj/dt)Activc+Passive, IPRL = Vmax,p· [Mjp/(Km,p + [Mjp) + ka,p · [Mjp (Eqn. UI.3) 
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Similarly, the rates of change for the amounts of solute in the pulmonary, tracheo-
bronchial and total (pulmonary + tracheo-bronchial) lung compartments are described, 
respectively as : 
(d[M]p/dt),pRL = - (d[P]/dt) - kE,pr [M]p (Eqn. III.4) 
(d[MhB/dt)IPRL = kE,pr[M]p (Eqn. III .5 )  
(d[M]p+TB/dt)wRL = - (d[P]/dt) (Eqn. III .6) 
where [P] is the cumulative solute amount absorbed from the pulmonary region into the 
recirculating perfusate of the IPRL, [M]p, [MhB, [M]P+TB are the solute amounts 
remaining to be absorbed from the pulmonary, tracheo-bronchial and total lung airway 
regions, respectively; Vmax,P is the maximum rate of active absorption, Km,p is the 
"affinity" or dose at which the active absorption rate = 0.5 · V max.P, ka.P is the first-order 
passive absorption rate constant from the pulmonary region and kE,PT is the first-order 
mucociliary clearance rate constant from the pulmonary to the tracheo-bronchial region. 
It should be noted that the rates of change for solute amount in the perfusate of the IPRL, 
d[P]/dt, is a function of the solute amount remaining to be absorbed from the pulmonary 
region, [M]p (Eqns. III. 1 -3) and thus, a function of the mucociliary clearance rate 
constant, kE.PT. 
In vivo, when absorption into blood can also occur via the bronchial circulation, an 
additional passive absorption rate from the tracheo-bronchial region (ka,TB · [MhB) is 
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reguired in the model, even though mucociliary clearance and absorption from the 
pulmonary region were assumed eguivalent to those in the IPRL. As a result, the rates of 
change for solute amounts in the blood, d[B]/dt, and the pulmonary, d[M]p/dt, tracheo­
bronchial, d[MhB/dt, and total (pulmonary + tracheo-bronchial ;  d[M]p+TB/dt) lung 
compartments are described, respectively as : 
(d[B]/dt)in vivo = (d[P]/dt) + ka,TB · [MhB (Egn. III .7) 
(d[M]p/dt)in vivo = (d[M]p/dt)JPRL = - (d[P]/dt) - kE.pdM]p (Egn. III .8 )  
(d [MhB/dt)in vivo = - (d[Mhs/dt)JPRL - ka,TS · [Mhs (Egn. lII .9) 
(d[M]p+TB/dt)in v ivo = - (d[P]/dt) - ka.TW [MhB (Egn. III. I 0) 
where [B] is the cumulative amount of solute absorbed into the blood in vivo, ka.TB is the 
first-order passive absorption rate constant from the tracheo-bronchial region and d [P]/dt 
is the rates of change for solute amount in the perfusate of the IPRL due to active, passive 
or simultaneous active and passive absorption from the pulmonary region, as described in 
Egns. III. I -3 .  Therefore, the rates of change for cumulative solute amount in the blood 
circulation in vivo, d[B]/dt, remains a function of the mucociliary clearance rate constant, 
IILb.7 SIMULTANEOUS CURVE FITTING AND PARAMETER 
ESTIMATION 
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For each solute, curve fitting and parameter estimation to the model shown in Fig. 
III .3 was performed by un weighted, nonlinear least-mean-square regression analysis 
(Scientist™, MicroMath Scientific Software, Salt Lake City, UT) of all data, across doses 
following its collection from either the IPRL or the in vivo experiments. 
(1 ) Curve fitting in the IPRL 
In the IPRL, the unweighted data for mean % of administered dose transferred to 
perfusate vs. time was fitted across doses (e.g. ,  all data points in Fig. III. lO) ,  in order to 
determine the best estimates of the solute-specific rate constants for each process .  The 
fraction of the administered dose delivered to the pulmonary region, F, was fixed 
throughout this process at its experimentally-determined average value, 0 .9 1 
(0. 9 10±0.003 ; mean±SD; n= 1 2), so that the initial conditions were: 
[M]p. ,=o / [administered dose] = 0 .91  
[Mhs. ,=o / [administered dose] = 0.09 
[P],=o / [administered dose] = 0.00 
<F-Na and FD-4> 
Absorption of F-Na and FD-4 in the IPRL was assumed to be passive and apparent 
first-order from the pulmonary compartment only. Accordingly, average data for % of 
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administered dose transferred to perfusate was fitted across doses to the following 
equations : 
(d[Pj/dt)Passive, IPRL = ka,P, [Mjp (Eqn, III .2) 
(d [Mjp/dt) IPRL = - (d[Pj/dt) - kE,PT' [Mjp (Eqn, IlIA) 
(d[MhB/dt)IPRL = kE,PT' [Mjp (Eqn, III .S) 
with the initial conditions described above, 
<F-PHEA> 
Absorption of F-PHEA in the IPRL was assumed to be due to the sum of active 
(dose-dependent) and passive (first-order) processes from the pulmonary compartment 
Accordingly, average data for % of administered dose transferred to perfusate was fitted 
across doses to the following equations: 
(d [P]/dt)Active+Passive, IPRL = Vrnax,dMjp/(Km,P + [Mjp) + ka,P, [Mjp (Eqn, III. 3 )  
(d[M]p/dt)lpRL = - (d[P]/dt) - kE,prfM]p (Eqn, IlIA) 
(d [MhB/dt)IPRL = kE,pr [Mjp (Eqn, III .S) 
with identical initial conditions to those described above, 
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(2) Curve fitting in the intact rat 
Absorption of F-Na in the intact rat was assumed to be due to the sum of its passive 
(first-order) absorption from both the pulmonary and the tracheo-bronchial 
compartments. Accordingly, average data for % of administered dose remaining to be 
absorbed was fitted to the following equations : 
(d [B]/dt)in vivo = (d[P]/dt) + ka.TB · [MhB 
(d[M]p/dt)in vivo = (d[M]p/dtJIPRL = - (d[P]/dt) - kE,Pr [M]p 
(d[MhB/dt)in vivo = - (d [MhB/dt)IPRL - ka.TB , [MhB 
(d[P]/dt)Passive.lPRL = ka.p· [M]p 
with identical initial conditions to those described above. 
(Eqn, III. 7) 
(Eqn. III .8)  
(Eqn, III .9) 
(Eqn. III .2) 
The model fits were assessed using "goodness-of-fit" parameters, such as the 
program's  calculated Model Selection Criterion (MSC), R-squared (R2), a review of 
standard deviation of final parameter estimates and visual inspection of all residuals .  
Initial estimate assignment for each solute to initiate the fitting and additional 
methodological details are described in Appendix VI. 
III.c 
IILc . l 
4 1  
RESULTS 
INITIAL REGIONAL DISTRIBUTION OF SOLUTES IN LUNG: IN 
VIVO VS. THE IPRL 
Because the regional deposition of solutes in the lung is believed to be a 
determinant of subsequent absorption and mucociliary clearance kinetics (B yron, 1 986 ;  
Byron and Phillips, 1 990; Colthorpe et ai. , 1 992; Byron and Patton, 1 994; Hill et ai. , 
1 996), it was necessary to ensure that "forced solution instillation" ,  as used in this thesis, 
provided identical initial solute distribution both in vivo and in vitro. The percentages 
propelled from the identical dosing cartridges for F-Na (nominal dose = 0.02 mg) and F­
PHEA (nominal dose = 1 .0 mg) , in vivo and in vitro are shown in Table III. I alongside 
their coefficients of variation. Mean percentages propelled from the cartridge differed 
insignificantly across solutes and studies (ANOV A) and thus, dosing was highly 
reproducible (CV% ::; 5.6 %) and solute/dose-independent. Figures III.4 and IlL5 show 
initial regional distributions for F-Na and F-PHEA, respectively between the in vivo and 
in vitro studies. Despite preferential solute distributions in the left (L) lung and the right 
inferior (RI) lobe, it was found that overall regional lobar distribution of solutes was not 
effectively different across both solutes and studies .  These results demonstrated that the 
"forced solution instillation" technique successfully provided identical initial regional 
distribution of solutes in the rat lung between in vivo and in vitro . 
Table 111.1. Percentages propelled from the dosing cartridge and their 
coefficients of variation (CV%) for F-Na and F-PHEA following "forced solution 
instillation" in vivo and in vitro (IPRL). 
In vivo IPRL 
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% propelled CV%b % propelled CV%b from the cartridgea from the cartridgea 
F-NaC 92.28±5 . 1 8  5 .6 94.73±1 .70 1 . 8 
F-PHEAc 97.25± 1 .92 1 . 8 93 .35±3 .78 4 . 1 
Data: mean ± standard deviation (n=4) 
% propelled from the dosing cartridge were not significantly different across solutes 
and studies (Two-way ANOV A). 
% propelled from the cartridge 
(Loading dose) - (dose remaining in the cartridge) 
(Loading dose) 
(Standard deviation) 
CV% = --------
(Mean) 
x 1 00 (n = 4) 
Nominal doses : F-Na = 0.02 mg; F-PHEA = 1 .0 mg 
x 1 00 
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Figure 111.4. Initial regional F-Na distribution in the lung following "forced solution 
instillation" in vivo and in vitro at a nominal dose of 0.02 mg. Error bars are sample 
standard deviations with n=4. 
Overall regional distribution between the in vivo and the IPRL studies was found to 
be insignificantly different (Two-way ANOY A with an interaction). Keys : TB -
trachea and major bronchi; L through RI = lobes e .g . , L - left lung; PC - right 
postcaval; RS - right superior; RC - right center; RI - right inferior (Byron and Niven, 
1 988) .  
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Figure 111.5. Initial regional F-PHEA distribution in the lung following "forced 
solution instillation" in vivo and in vitro at a nominal dose of 1 .0 mg. Error bars are 
sample standard deviations with n=4. 
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Regional distribution between the in vivo and the IPRL studies was found to be 
insignificantly different except right center (RC) distribution (Two-way ANOV A with 
an interaction). * indicates significant difference (p<0.05) . Keys : TB - trachea and 
major bronchi; L through R1 = lobes e.g. , L - left lung; PC - right postcaval; RS - right 
superior; RC - right center; R1 - right inferior. 
III .c .2  ABSORPTION OF SODIUM FLUORESCEIN (F-Na) AND FITC­
LABELED DEXTRAN (FDA) 
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Average percent remaining (±SD) of the administered dose is shown in Fig. 1II .6 for 
F-Na in vivo and in vitro and FDA in the IPRL alone. Each data point of the in vivo 
profiles shows the mean of four separate rat experiments, while each IPRL curve is the 
mean of several doses (individual doses were repeated four times). Doses are defined in 
the figure legend. The IPRL profiles were calculated from Eqn. lIL l i ,  assuming mass­
balance and an absence of tissue sequestration or metabolism (Appendix V) : 
(% of dose remaining in the lung) 
= 100 % - (% of dose transferred to perfusate) (Eqn. III. 1 1 ) 
The solid curves drawn through the IPRL data in Fig. TIT .6 are the results of simultaneous 
curve fitting across doses to the model shown in Fig. 111 .3 ,  assuming that solute transport 
occurred by passive absorption from the pulmonary region and simultaneous mucociliary 
clearance. Curves were generated from Eqns. 111 .2, I1I.4 and II1 .S using "Scientist" along 
with the best estimates for the model ' s  rate constants shown in Table 111.2 for each solute . 
The solid curve drawn through the in vivo data for F-Na shows the result of linear 
regression of the log % remaining vs. time data. This showed first-order absorption from 
the lung with an "apparent" rate constant for absorption = 0.043 min- ' (half-life = 1 6 . 1  
minutes) . This value represents the rate constant for absorption, as it i s  determined using 
the empirical approach of Brown and Schanker ( 1 983) and Schanker et al. ( 1 986). 
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Figure 111.6. Mean percentage of administered dose remaining to be absorbed 
from the rat lung vs. time from in vivo and IPRL studies. Error bars are sample 
standard deviations with n=4. 
The IPRL curves are the results of simultaneous across-dose data fitting and the 
best estimates for each process are shown in Table III .2 ; the in vivo straight line is 
a regression of the profiles. All doses (IPRL) : F-Na - 0.0 1 ,  0.02 and 0.04 mg; FD-
4 - 0. 1 and 0.2 mg 
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Notably, while absorption in the intact rat was complete, in the IPRL, only 6 1 .6±6.7 % 
was absorbed at all sample times 2': 60 minutes across three doses of F-Na (n=4) .  This 
indicated the presence of a substantial unabsorbed portion of the dose (38.4 %; including 
9.0 % of the initial tracheo-bronchial deposition) residing in the unperfused (tracheo­
bronchial) lung regions at the effective completion of the IPRL absorption process .  
Absorption of macromolecular FD-4 was found to be slower than F-Na in the IPRL, 
leaving an unabsorbed residual of about 68.6 %. Thus, for FD-4, 3 1 .4±9.3 % (mean±SD; 
n=32;  at  times 2': 60 minutes) of the administered dose was absorbed, similarly reaching 
an asymptote at times 2': 60 minutes following administration. 
These asymptotic values for % remaining to be absorbed from the airways of the 
IPRL were consistent with the presence of a viable mucociliary clearance operating 
throughout the lifetime of the preparation. Dissection and assay for the % of solute 
remaining in the tracheo-bronchial and pulmonary lobar regions at fixed times following 
solute administration are shown for F-Na in Fig. III.7 resulting from both in vivo and in 
vitro experiments. While F-Na was absorbed from both regions of the lung in vivo (Fig. 
I1L7 (a» , a substantial amount (> 30 %) of F-Na was found in the tracheo-bronchial 
region of the IPRL following its accumulation there by the mucociliary clearance. 
Notably, at the time of administration (t = 0), only 9 % of the dose was delivered to the 
tracheo-bronchial regions (Section III .b.7) . 
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Figure 111.7. Mean percentage (±SD; n=4) of administered dose ofF-Na remaining 
to be absorbed from the tracheo-bronchial and the pulmonary lobar regions (a) in vivo 
and (b) in vitro at 5 and 60 or 1 20 minutes following administration. 
III .c .3  ABSORPTION OF FLUOROPHORE-LABELED 
POL YHYDROXYETHYLASPART AMIDE (F-PHEA) 
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Figure III .8 shows the percent of each administered dose of 7.4 kDa F-PHEA 
remaining to be absorbed vs. time following airway administration in vivo and in vitro at 
two nominal doses (0.2 and 1 .0 mg). IPRL profiles were calculated from Eqn. III. 1 1 by 
assuming mass-balance. Both pairs of profiles were statistically superimposable at each 
dose (ANOY A). Furthermore, the profiles were clearly dose-dependent and thus, 
absorption was non-first-order. At the lower 0.2 mg dose, only 60 % of the administered 
dose was absorbed, reaching an asymptote at times ;::: 60 minutes, similar to that seen in 
the case of F-Na in the IPRL (Fig. 1lI.6). 
The remaining mean % of administered dose of F-PHEA at 5 and 1 80 minutes 
following administration in vivo and in vitro are shown in Fig. 111 .9 .  Similar to the 
behaviors of F-Na in the IPRL, substantial amounts of F-PHEA were transported from 
the pulmonary into the tracheo-bronchial regions. There was no difference in these 
effects of the mucociliary clearance in vivo (Fig. 111.9 (a» or in vitro (Fig. III .9 (b) ; 
IPRL) at 1 80 minutes following administration. However, it appeared that a portion of 
the dose residing anatomically in the pulmonary region of the lung remained unabsorbed 
in the case of F-PHEA, while none of the dose which was deposited in, or transported to, 
the tracheo-bronchial region was absorbed in vivo and in vitro. 
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Figure 111.8. Mean percentage of administered dose of 7.4 kDa F-PHEA remaining 
in the lung vs. time in vivo and in vitro. Error bars are sample standard deviations with 
n=4. The curves are the results of linear interpolation. There was no significant 
difference between in vivo and in vitro data at either of the dose levels tested 
(ANOYA). 
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KINETIC MODELING OF PULMONARY SOLUTE ABSORPTION 
IN THE IPRL 
Data for % transfer to perfusate vs. time from IPRL experiments in which F-Na or 
FD-4 was administered to the airways could be fitted to the model shown in Fig. IlI .3  
with ka.TB , Ymax.P and Km.P held at  zero (= 0). In these cases, % transfer was dose­
independent and the across-dose data fits to Eqns. III .2, III.4 and III .5 yielded values for 
ka,p and kE,PT as shown in Table IIT .2. However, despite numerous attempts using mean % 
transfer to perfusate vs. time data from individual doses of F-PHEA, it was not possible 
to obtain unambiguous parameter estimates for Yrnax,P, Km•p, ka•p and kE,PT unless 
simultaneous curve fitting was employed across doses. The best estimates for the kinetic 
parameters describing F-Na, FD-4 and F-PHEA disposition in the IPRL are shown in 
Table ITI .2 with curve fits displayed as solid lines in Figs. III.6 and IlUO; the latter 
shows the results of simultaneous across-dose curve fitting of the IPRL data at a series of 
different nominal doses of F-PHEA (0. 1 ,  0 .2 , 0 .5 , 1 .0 and 5 .0 mg) using Eqns. III. 3 .  IlI.4 
and IlLS .  The "goodness-of-fit" parameters as provided by "Scientist"-calculated Model 
Selection Criterion (MSC) were consistently :2: 2.83 with R-squared, R2 :2: 0.986. 
Individual values for MSC, R2 and the standard deviations of each kinetic parameter in 
Fig. IlL3 are also shown in Table IlL2 following these unweighted nonlinear least-me an­
square regression analyses. 
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Table 111.2. Disposition parameters for active and passive absorption and 
mucociliary clearance for 7.4 kDa F-PHEA, FD-4 and F-Na following their 
administration into the airways of the isolated perfused rat lung (lPRL) at 37 DC. 
Active Passive Mucociliary 
absorption absorption clearance Solutes MSC ;  R2 
(Mw) kE,PT Vrnax,P Krn,P V max,p/Km,P ka,p 
[/lg/min] [/lg] [min- I ]  [min- I ]  [min-I ]  
F-PHEA 4.37  5 6 . 6  0 .077 0 .00 1 0 .023 3 . 1 2 ; 0.986 
(7.4 kDa) (0 .57) ( 1 4 .7) (0.00 1 )  (0.00 1 )  
FD-4 N/A N/A N/A 0.0 1 6  0 .029 2.83 ; 0 .990 
(4 .4 kDa) (0.00 1 ) (0.003) 
F-Na N/A N/A N/A 0.048 0. 022 3 .37 ;  0.992 
(376 Da) (0.003) (0.002) 
Values are the best estimates (SD) following analysis of across-dose data from: 
F-PHEA - nominal doses : 0. 1 ,  0.2, 0 .5 , 1 .0 and 5 .0 mg; FD-4 - nominal doses : 0 . 1 and 
0.2 mg; F-Na - nominal doses : 0.0 1 , 0 .02 and 0.04 mg. 
MSC (Model Selection Criterion) and R2 (R-squared) were as calculated by "Scientist" 
(Appendix VI) . 
NI A indicates "not applicable" (no dose-dependency was observed) . 
The rate constants for mucociliary clearance, kE•PT were not significantly different across 
solutes, based on overlapped 95% confidence intervals. 
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Figure 111.10. Mean percentage (±SD; n=4) of administered dose of 7.4 kDa F-PHEA 
absorbed from the airways of the IPRL into the perfusate vs. time at 37°C. The solid 
curves are the results of simultaneous across-dose curve fitting of all profiles. These 
were generated using best estimates for each parameter in Fig. IlL3 ,  as described in 
Table m.2.  
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The rate constants for mucociliary clearance, kE,PT were found to be 0,022±0,002, 
0.029±0.003 and 0.023±0.00 1 min" for F-Na, FD-4 and F-PHEA, respectively (Table 
II1 .2) .  These were not significantly different across solutes, based on the overlapped 95% 
confidence intervals (95%CI). Thus, a solute-independent mucociliary clearance with a 
half-life of 24-32 minutes was shown to exist in the IPRL. The "true" rate constants for 
passive absorption, ka.p (Fig. III .3)  were found to be inversely related to the molecular 
weights of each of the model solutes, demonstrating the existence of a size-dependent 
passive absorption mechanism which was probably by simple restricted diffusion 
(smaller solutes diffuse faster; Martin, 1 993;  Byron and Patton, 1 994) . More importantly, 
even in the case of a small solute, F-Na, the absorption rate constant (ka,p = 0.048±0.003 
min" ) was found to be only 2-fold greater than the mucociliary clearance rate constant 
(kE,PT = 0.022±O.002 min" ) .  Quite clearly therefore, mucociliary clearance competed 
with the passive absorption process for most of these solutes after their administration 
into the airways. Best estimates of V max,P and Km,p enabled calculation of their ratio ,  
V max.p/Km,P = 0.077 min" as  an " intrinsic " rate constant for the active absorption of F­
PHEA with comparable units to the first-order constants, ka,p and kE,PT. When the value 
for the ratio, V max,p/Km.P was compared to the rate constant for passive absorption of F­
PHEA, ka,P = 0.00 1  min" , it was clear that the absorption was dominated by the active 
process at the lower doses, thus enhancing polymer's absorption rates dramatically. 
Indeed, the absorption rate seen at nominal 0.2 mg dose of 7 .4 kDa F-PHEA was 
comparable to that for F-Na (376 Da) despite the more than 20-fold difference in the 
molecular weight. 
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III.d DISCUSSION 
All model solutes used in this thesis were selected so that no degradation, 
metabolism or significant tissue sequestration (uptake from pulmonary circulation into 
the lung; Appendix V) was seen. Data in Appendix V shows quite clearly that reverse 
transfer from perfusate into the lung was negligible for all of these solutes. Thus, 
absorptive transfer which is shown as a unidirectional process in Fig. III. l was 
uncomplicated in these cases by the absence of significant reversible kinetics. 
Furthermore, tracheal cannulation was maintained during in vivo and in vitro 
experiments, precluding clearance into extra-lung regions like the gastrointestinal (GI) 
tract. Both F-Na and FD-4 are known to be absorbed passively from the lung in vivo and 
in vitro, in the IPRL as well as through in vitro alveolar monolayers (Clark and Byron, 
1985 ;  Byron et ai. , 1 986; Matsukawa et ai. , 1 997). Consequently, absorption of these 
solutes could be studied across doses and expected to show % transfer vs. time profiles 
(Fig. III.6), which were dose-independent. In contrast, it was shown in a series of our 
previous IPRL studies that F-PHEA absorption was size-selective (:0; 8 kDa) and dose­
dependent, but molecular charge-independent (Niven et ai. , 1 990; Byron et ai., 1 99 1 ;  
Byron et ai. , 1994; Sun, 1995;  Sun et ai . ,  1 999). Specifically, 7.4 kDa F-PHEA was 
believed to be absorbed by both active and passive mechanisms (Sun et ai. , 1 999), 
although quantifying these processes has pro\(ed extremely difficult prior to this 
investigation (Byron et ai. ,  1 994) 
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The validation of the "forced solution instillation" technique in vivo and in vitro 
(CV% ::; 5 .6  %) and the proof of its provision of statistically identical initial regional 
solute distribution in the rat lung (Table III. 1 ; Figs . III .4 and IlI.5) was crucial in the 
investigation of the mucociliary clearance and the correction of the kinetic analysis for 
the effects of this clearance in vivo and in vitro . This highly reproducible dosing 
technique compares favorably to others in the literature which typically have CV% � 1 5  
% following intratracheal instillation and/or aerosol administration (Brain e l  al. , 1 976 ; 
Pritchard el al. , 1985 ;  Ruzinski el al. , 1995 ; Leong el al. ,  1998) . Preferential solute 
distribution into the left lung (L) and the right inferior (RI) lobe was similarly observed 
following intratracheal instillation and aerosol administration in vivo (Brain el ai, 1976; 
Pritchard el al. , 1985; Ruzinski et al. , 1995; Leong et aI. , 1998) as well as in our previous 
studies (Byron and Niven, 1988) . This seemed inevitable, based on the rat lung ' s  
anatomical characteristics, especially when the technique was used during i n  vivo 
respiration (Byron and Niven, 1988 ;  Leong et al., 1998) . 
The IPRL preparation differs from the in vivo rat lung primarily due to its lack of 
solute absorption from the upper tracheo-bronchial airways; this is due to the severance 
of the bronchial circulation during surgery (Mehendale et al. , 198 1 ) .  In contrast, 
mucociliary clearance was shown to be viable in the IPRL for the duration of these 
experiments and identical to that seen in vivo. As a result, both F-Na (Fig. III.7  (b)) and 
F-PHEA (Fig. 111 .9 (b)) were transported into the upper airways quite rapidly and found 
to accumulate there at 120 and 1 80 minutes, respectively following administration 
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predominantly into the alveolar regions of the lung. Interestingly, although the tracheo-
bronchial circulation in vivo remained intact and hence, perfused by the bronchial 
circulation, F-PHEA accumulation in the upper airways was also observed in vivo (Fig.  
III .9 (a)) and appeared to be consistent with that seen in the IPRL. This showed that F­
PHEA absorption from the upper airways was negligible, due probably to the formidable 
tight junction for passive diffusion and the absence of active transporters for F-PHEA in 
this region. In contrast, :e: 99.4 % of administered dose of a small solute, F-Na was 
absorbed in vivo in an "apparent "  first-order fashion over the 1 20 minutes following 
solute administration (Fig. III .6) .  This demonstrated the presence of significant passive 
absorption from the tracheo-bronchial region for this smaller solute. 
The kinetic model shown in Fig. III .3 along with a high precision, cross-dose, cross­
solute data set was used successfully to characterize "region-specific" disposition of these 
model solutes. Mucociliary clearance kinetics were found to be solute-independent and 
relatively rapid (kE•PT = 0.022-0.029 min'\ such that mucociliary clearance offered 
significant competition to absorption of most solutes, especially in the IPRL. Clearly, it 
was necessary to fit the complete kinetic model shown in Fig. III .3 to % solute transfer 
data, in order to correctly ascribe values to the individual rate processes. The resultant 
passive absorption rate constants (ka.p) were inversely related to solute molecular weight, 
reasonably demonstrating that this was due to diffusive transport through the pulmonary 
membranes .  Modeling also facilitated the characterization of complex,  simultaneous, 
active and passive absorption of 7.4 kDa F-PHEA alongside its mucociliary clearance 
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into the tracheo-bronchial airways . As a result, the transporter for 7 .4 kDa F-PHEA from 
the pulmonary airways to blood (Fig. IlL8) ,  shown to be present in vivo and in vitro was 
successfully characterized in the IPRL. A Michaelis-Menten-type active mechanism with 
maximum rate, Vmax,p = 4,37±0,57 �g/min and "affinity" ,  Km,p = 56,6± 14 ,7 �g was 
deduced after taking mucociliary clearance and passive absorption into account (Table 
IIJ ,2) .  Thus, the IPRL and model shown in Fig, III ,3  can best be thought of as a means of 
analyzing the "region-specific" disposition of solutes in the rat lung, 
An attempt to describe such kinetics has been made previously (Byron et ai" 1 994) , 
In that case, V max,P and KIll,p were reported as 3 ,0±0,3 �g/min and 33 1±  1 63 �g for 8 .4  
kDa F-PHEA, respectively. They were estimated from curve fitting of single data points 
for the individual amounts of F-PHEA absorbed after 30 minutes vs. administered dose 
(Byron et ai" 1 994), Unfortunately, the transfer data used for that curve fitting showed 
large variance and the kinetic model assumed negligible passive absorption of F-PHEA, 
irrespective of dose, More importantly, the curve fitting procedure assumed that the 
absorption rate was unchanged throughout the first 30 minutes , As a result, the value for 
Km,p was found to be larger and less precise, compared to that estimated in this thesis 
(Km,p = 56,6± 14.7 �g) , In contrast, the kinetic model in this thesis and subsequent curve 
fitting to this model assumed simultaneous active and passive absorption and it employed 
the transfer data across time and dose. This included doses well below the value for Km,p 
(Table III .2) ,  Furthermore, the model (Fig. III .3) enabled the absorption rate to change as 
a function of time throughout each experiment. Consequently, the values reported for 
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V max,P = 4,37±O.57 Jlg/min and Km,p = 56.6± 14.7 Jlg in this thesis are believed to be much 
more reliable than those described previously (Byron et at. , 1 994). 
Figure III. 1 1 shows the results of IPRL experiments performed with F-Na and FD-4 
presented in the form of log-linear (first-order) plots. Mean data from all doses were 
employed for this purpose. The mean percentage of each administered dose absorbed as 
time -+ 00 was first determined by averaging all IPRL data in Fig IIL6 at time � 60 
minutes for both solutes. Percentage values for "transferable dose remaining to be 
absorbed" were then determined from: 
(% of transferable dose remaining to be absorbed) 
(% absorbed) 1;",,= - (% absorbed) l;m'=1 
(% absorbed) I;m,= 
x 100 (Eqn. III. 1 2) 
and plotted on Fig. III. I I .  These log-linear (first-order) plots and their negative slopes 
provide values for the apparent absorption rate constants, ka,app, for each solute. These 
were values which would be obtained if the effects of mucociliary clearance was ignored 
and the data treated in a conventional fashion (Enna and Schanker, 1972; Lanman et ai . ,  
1 973 ;  Burton and Schanker, 1974a and 1 974b; Burton et ai. , 1 974; Schanker and Burton, 
1 976; Schanker and Hemberger, 1 983 ;  Brown and Schanker, 1 983) .  Because of the 
absence of a bronchial circulation in the IPRL, the absorption kinetics illustrated in Fig. 
IlL 1 1  would be attributed to absorption from the deep lung into the pulmonary circulation 
(Mehendale et ai., 1 98 1 ;  Roberts, 1984). Unfortunately, the negative log-linear slopes, 
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Figure 111. 1 1 .  Mean percentage (±SD) of the transferable dose ofF-Na and FD-4 
remaining unabsorbed in the airways of the IPRL vs. time. Data shown are means 
from all doses ofF-Na (0 . 0 1 ,  0.02 and 0.04 mg; n=1 2) and FD-4 (0. 1 and 0 .2 mg; 
n=8) .  Solid lines are the results of log-linear regression of each data set. The 
negative, natural logarithmic slopes provided values for commonly-called, 
"apparent rate constants for absorption", ka,app = 0.072 and 0.039 min·1 for F-Na 
and FD-4, respectively. 
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shown in Fig. 111 1 1  grossly overestimate the true values of ka.P for each of these solutes ;  
this because mucociliary clearance was ignored when attributing the figure's slopes 
entirely to absorption. Table III .3 shows a comparative summary of the rate constants for 
absorption for F-Na and FD-4. Comparing the values for ka.app with others in Table III .3  
shows that the value for the mucociliary clearance constant, kE.PT, is a significant 
component of each apparent rate constant. In practice, ka•app is equaled to the sum of all 
clearance rate constants existing in the lung (Notari, 1 987) and the true values for the 
fractions of each solute's disappearance which are due to absorption, must take other 
clearance mechanisms into account. While this point has been noted previously for both 
in vivo and in vitro studies (Byron, 1 986), the magnitude of mucociliary clearance's 
influence has never been included correctly in a kinetic analysis of solute absorption from 
the IPRL. 
While attempts have been made to correct the values for absorption rate constants 
obtained in vivo for the effects of mucociliary clearance (Colthorpe et al. , 1 992; Taylor et 
al., 1994), these efforts suffer from uncertainties attached to assigning true values for 
mucociliary clearance rate constants to these phenomena. In practice, the variance of 
mucociliary clearance kinetics which is known to be associated with different regions of 
the lung (Byron et al. ,  2000) mandates the correct assignment of clearance kinetics to 
each of the organ's absorptive regions. Byron et al. (2000), when analyzing in vivo data 
for beclomethasoone absorption in humans, showed its clear dependence upon regional 
deposition. Mucociliary clearance, which was known to become faster as the respiratory 
tract is ascended (Byron, 1 986; Brain and Blanchard, 1993 ; Camner and Mossberg, 
Table 111.3. Summary of mean rate constants obtained from different 
kinetic treatments ofF-Na and FD-4 IPRL data at 37 °C. 
Rate F-Na FD-4 
constant (Mw) (376 Da) (4.4 kDa) 
ka,pa (min- I )  0.048 0 .0 1 6  
[ka,p + kE,PTl b (min-I )  0.070 0 .045 
ka,appc (min- I )  0.072 0.039 
ka,TB d (min-I )  0.042 N/A 
a Following kinetic analysis in accord with Section III .c .4 (Table 111 .2) .  
b The sum of ka.p and kE,PT following analysis in accord with Section 
III.c.4 (Table III .2) . 
C The negative log-linear slope of the linear regression curves shown in 
Fig. III. l l .  
d Following kinetic analysis using Eqns III. 7- 1 0 (and the model in Fig. 
111 .3), fixing ka,p = 0.048 min- I and kE•PT = 0.022 min- I ,  obtained from the IPRL. 
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1 993), was shown to have increasing effects upon that drug's apparent absorption rate 
constant from lung, as its aerosol deposition became more central (Byron et ai . ,  2000) . 
Thus, from an in vivo perspective, solutes which are known to be absorbed both from the 
pulmonary and tracheo-bronchial regions ,  should be analyzed carefully for the effects of 
region-dependent absorption kinetics and corresponding mucociliary clearance changes 
between these regions. In this thesis, only F-Na was studied in vivo and in vitro, as a 
solute whose absorption was significant from both the upper and lower airways. In the in 
vivo studies, solute clearance to (and absorption from) the gastrointestinal (GI) tract was 
precluded by continuous intratracheal intubation. 
Based on this rationale, Eqns. III.7-III. lO  (and the model in Fig. III. 3) were used to 
fit the in vivo absorption profiles for F-Na (Fig. III. 6) . By fixing ka.p = 0.048 min- ! and 
kEYT = 0.022 min- ! , their best estimates from the IPRL (Table 1lI.2), it was possible to 
determine a value for fluorescein's first-order absorption rate constant from the tracheo­
bronchial region, ka.TB . The in vivo profiles shown in Fig. 111 .6 were successfully fitted 
using this approach (MSC = 4.70 and R2 = 0.997). The best estimate for ka•TB was 
0.042±O.0 1 1 min- ! (half-life = 1 6.5±5 .9 minutes), a value which was insignificantly 
different from that for pulmonary absorption (ka•p = 0.048±0.003 min- ! ; based on their 
overlapped 95 %CI) . Thus, fluorescein's passive absorption kinetics appeared to be 
independent of regional deposition. This observation may or may not be true for other 
solutes in the lung. However, the result for fluorescein was consistent with those from 
previous in vivo studies in dogs, where similar F-Na absorption was observed following 
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the dye's different initial regional lung distribution (Clark and Byron, 1 985) ,  although 
those studies, like the classical absorption works of Schanker's group (Enna and 
Schanker, 1972; Lanman et al. ,  1 973 ;  Burton and Schanker, 1 974a and 1 974b; Burton et 
al. , 1974; Schanker and Burton, 1 976; Schanker and Hemberger, 1983 ;  Brown and 
Schanker, 1983), failed to account correctly for the presence of competing mucociliary 
clearance from different lung regions .  
The multiple absorption profiles for F-PHEA in the IPRL enabled a unique, across­
dose data fit to determine values which describe this solute's dose-dependent active 
absorption kinetics (V max.P and Km.P), in the presence of passive absorption and 
competing mucociliary clearance from the pulmonary lung compartment (Fig. III. 3 ) .  The 
" intrinsic rate constant" ,  V max,p/Km,p for macromolecule's active absorption was 0.077 
min' l . This value represents a first-order rate constant for F-PHEA absorption which 
would be observed as dose --7 0 and demonstrates the importance of F-PHEA-specific 
carriers/transporters which enhance the absorption of this 7.4 kDa macromolecule 
("intrinsic absorption half-life" = 9.0 minutes). Even at doses as high as I mg, apparent F­
PHEA absorption half-lives (30 minutes) were observed which exceeded all expectations 
for a molecule of this size. Furthermore, there was no statistical difference between in 
vivo and in vitro results for this macromolecule (Fig. III. 8) .  This rapid F-PHEA active 
transport was pulmonary-region-specific and there was no evidence of significant F-
PHEA tracheo-bronchial absorption. Thus, F-PHEA absorption characteristics obtained 
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from the IPRL studies were predictive of the solute's absorption from the "whole-lung" ,  
in vivo. 
III.e SUMMARY AND CONCLUSION 
A comparison of solute disposition profiles following identical initial regional lung 
distribution by "forced solution instillation" in vivo and in vitro has shown the presence 
of a reproducible and viable mucociliary clearance process in the IPRL which is 
predictive of that seen in vivo. Similarly, macromolecular F-PHEA absorption in the 
IPRL was predictive of that seen in vivo (ANOY A) because transport kinetics and 
mucociliary clearance of this macromolecule were comparable in the two models. On the 
other hand, tracheo-bronchial absorption for small solutes like F-Na was significant and 
hence, F-Na absorption in the IPRL underestimated in vivo absorption. In spite of this 
fact, simultaneous determinations of small solute (F-Na) absorption in vitro and in vivo, 
enabled correct kinetic model ing and estimation of the solute's regional ahsorpti on mte 
constants, k,.p and ka,TS ' 
A new "pulmonary-region-specific" kinetic model was developed to characterize 
solute absorption in the presence of competing mucociliary lung clearance in vitro, in the 
IPRL, and in vivo, The model successfully determined pulmonary-region-specific 
descriptors for active (F-PHEA) and passive (F-Na, FD-4 and F-PHEA) absorption. 
Mucociliary clearance was found to be relatively rapid (half-life values between 24 and 
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32 minutes), competing with absorption for many solutes administered into the airways . 
Pulmonary-region-specific rate constants for passive absorption (ka•p) were inversely 
related to molecular weights of solutes, probably corresponding to the restricted diffusive 
transport theory through pulmonary membranes which is predominant in the literature. 
The pulmonary-passive absorption rate constant for F-Na (0.048±0.003 min' l ) was 
insignificantly different to its tracheo-bronchial counterpart (0.042±0.0 1 1  min' l ) obtained 
in vivo, suggesting deposition-independent absorption for this small solute . 
Characterization of F-PHEA's active absorption, alongside simultaneous passive 
absorption and competing mucociliary clearance, revealed its carrieritransporter kinetics 
from the whole lung organ (V max.P = 4.37±0.57 Ilg/min and Km.P = 56.6±14.7 Ilg) . The 
value of F-PHEA's Vmax.p/Km.p ratio (0.077 min' l ) demonstrated that, at lower doses (::; 
nominal 0.2 mg dose), this macromolecular model polypeptide was capable of achieving 
greater or similar absorption rapidity from the lung than 376 Da fluoresein. 
CHAPTER IV 
PULMONARY ABSORPTION KINETICS OF F -PHEA : 
EFFECTS OF LOw TEMPERATURES AND METABOLIC 
INHIBITORS 
IV.a INTRODUCTION 
A series of our isolated perfused rat lung (lPRL) studies have confirmed the 
existence of dose-dependent absorption kinetics for a range of co-polymers based on 
differently substituted polyaspartamides (Niven et aI. , 1 990; Byron et al. , 1 99 1 ;  Byron et 
aI. , 1 994; Sun, 1 995;  Sun et aI. , 1 999). The tendency of these pulmonary absorption 
enhancement mechanisms to follow Michaelis-Menten kinetics has suggested the 
presence of unique airway-to-blood active transporters or carriers for fluorophore-Iabeled 
poly-a,P-[N(2-hydroxyethyl)-D,L-aspartamide] (F-PHEA) in the lung's pulmonary 
airways. These transporters were capable of dramatically enhancing systemic absorption 
of F-PHEA and its co-polymers following administration into the airways (Niven et aI. , 
1 990; Byron et aI. , 1 99 1 ;  Byron et aI. , 1 994; Sun, 1 995 ;  Sun et aI. , 1 999).  The absorption 
was size-selective and dose-dependent (Niven et aI. , 1 990; Sun, 1 995 ; Sun et aI. , 1 999) 
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as well as being subject to competition from similar-sized, fluorophore-free PHEA 
(Byron et aI. , 1 994) . Specifically, the 7.4 kDa F-PHEA used in this thesis demonstrated 
simultaneous active and passive absorption and the rate and extent of its airway-to­
perfusate transfer appeared to be independent of molecular electronic charge (Sun, 1 995 ; 
Sun et aI. , 1 999). 
The presence of airway-to-blood active transporters/carriers has been documented 
previously in lung (Gardiner and Schanker, 1 970; Enna and Schanker, 1 973 ;  Meredith 
and Boyd, 1 995 ; Hastings et ai. , 1 995; Kim and Crandall ,  1 996; Folkesson et ai. , 1 996; 
Shen el aI. , 1 999) . Airway-to-blood carriers for fluid, electrolytes, hexoses and amino 
acids are believed to be important and tightly regulated in order to maintain homeostasis 
physiologically (Wangen steen and Bartlett, 1 984; Kim and Crandall , 1 988 ;  Basset et ai. , 
1 994; Effros, 1 994; Kim and Crandall ,  1 994; ,  Matthay et ai. , 1 994) . Relatively specific 
carrier transporters for small anions (Gardiner and Schanker, 1 970; Enna and Schanker, 
1 974; Kim and Crandall , 1 994) , organic cations (Foth, 1 995 ; Shen et ai. , 1 999) and di­
and tri-peptides (Helliwell et ai. , 1 994; Morimoto et ai. , 1 994; Meredith and Boyd, 1 995 ; 
Yamashita et ai. , 1 997 and 1 998) are also present in alveolar and tracheal epithelium. 
These are known to enhance the active absorption of substrates and enable more rapid 
passi ve absorption through tight junctions. Furthermore, it has been shown that extremely 
large plasma proteins, albumin (68 kDa) and IgG ( 1 50 kDa) were actively transcytosed 
across alveolar epithelium via specific receptors (Albondin and FcRn receptors, 
respectively; Hasting et ai. , 1 994; Kim et aI. , 1 995 ; Folkesson et ai. , 1 996). Non-specific 
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fluid-phase transcytosis has also been shown for horseradish peroxidase (HRP; 44 kDa) , 
but the process was relatively slow (Schneeberger and Karnovsky, 1968 ; Matsukawa et 
aI. , 1 996) . It seems quite possible therefore, that specific or non-specific airway-to-blood 
transporters/carriers exist in deep lung, which rapidly transcytose certain 
macromolecules. Clearly, F-PHEA may be a candidate for such a carrier, while FD-4 was 
not (Chapter 3). However, whether F-PHEA's dose-dependent absorption is truly due to 
the presence of an active (energy-dependent) transporter, remains to be substantiated. 
Active absorption processes via transporters or carriers are generally believed to 
rely on the reversible interaction of the substrate with a membrane protein which acts as a 
carrier (Alberts et aI. , 1983 ;  Macheras et aI. , 1995) . Following the formation of the 
substrate-carrier complex, the complex may be internalized into endosomes where 
cytoplasmic clathrin-coated or nonclathrin-coated vesicles are formed. The vesicles are 
then believed to be trafficked along micro tubules and transcytosed (or absorbed; 
transporter/receptor-mediated transcytosis). Otherwise, the complex is subjected to 
changes in conformation in order to discharge the substrate into the cytosol without 
translocation or transcytosis (carrier-mediated endocytosis). These processes must be 
directly or indirectly coupled to a source of cellular metabolic energy and most often, this 
is believed to involve ATP hydrolysis (ATP --+ ADP + Pi + �Go') .  Hydrolysis and energy 
liberation may be effected directly by the transporting carrier proteins or be brought 
about by the co-transport of Na+ or H+ down their electrochemical gradient (Alberts et 
aI. , 1983 ;  Andreoli et al. , 1986). Several biochemical approaches are now known to be 
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capable o f  manipulating these processes and thus, shedding light o n  the mechanisms and 
pathways involved with transport. Lowering temperatures in the experimental systems 
used to study each transporter are believed to non-specifically inhibit ATP hydrolysis 
rates and thus, decrease utilization of cellular energy required for active absorption 
(Wangensteen, 1990; Rutschman et al. , 1 993 ;  Serikov et al. , 1 993) . Several metabolic 
inhibitors are also useful for specific or non-specific identification of the cellular 
mechanisms used in transcytosis. 
In Chapter 3 ,  the absorption kinetics for 7 .4 kDa F-PHEA from the pulmonary 
airways of the IPRL were precisely characterized at 37 °C using kinetic modeling. The 
approach used in that chapter allowed for the presence of competing mucociliary 
clearance, as shown in Fig. IV. I .  In this chapter, airway-to-perfusate transport of 7 .4 kDa 
F-PHEA in the IPRL will be described following its manipulation by several different 
biochemical approaches. Each of these approaches will be shown to inhibit different 
aspects of F-PHEA's active absorption, thus enabling us to kinetically analyze the solute's 
pathways of pulmonary absorption. For these purposes, 7.4 kDa F-PHEA absorption in 
the IPRL was studied at 25, 30 and 37 °C, and in the presence and absence of several 
metabolic inhibitors : 2,4-dinitrophenol (DNP), ouabain (OUA), monensin (MON) and 
nocodazole (NOC) . DNP and �UA purported to specify the importance of ATP-driven 
intracellular energy (Goodman et aI. , 1983 ;  Steen et aI. , 1 993 ; Alberts et ai. , 1 994) for F­
PHEA's active absorption, whereas MON and NOC were used as biochemical tools to 
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Figure IV.I .  Kinetic model and its rate constants for 7.4 kDa F-PHEA disposition in 
the airways of the isolated perfused rat lung (IPRL) at 37 °C, as described in Chapter 3 
Key: F - initial average penetration fraction following administration (0 .9 1 ) ;  Vmax,P 
and K P - the maximum rate and "affinity" of Michaelis-Menten-type active 
abso��ion, respectively; ka,p - first-order rate constant for passive absorption from the 
pulmonary region; kE,PT - first-order rate constant for mucociliary clearance. 
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disrupt endosome and microtubule formation, respectively, during vesicular transcytosis 
(Mollenhauler et al. , 1 990; Hastings et al. , 1 994; Wangensteen et aI. , 1 996). 
IV.b MATERIALS AND METHODS 
IV.b . 1 MODEL SOLUTES : 7 . 4  kDa F-PHEA AND REFERENCE SOLUTES 
Synthesis and preparation of 7 .4 kDa fluorophore-labe1ed poly-a,�- [N(2-
hydroxyethyl)-D,L-aspartamidel (F-PHEA; FR7 150) has been described in detail 
previously (Chapter 3 and Appendix III) . Its weight- (Mw) and number- (Mn) averaged 
molecular weights were 7420 and 6620 Da, respectively, with a polydispersity, Pd 
(Mw/Mn) = 1 . 1 2 (Sun, 1 995;  Appendix III) . Its 0 .3 mole% fluorophore content (Niven et 
ai. , 1 990; Appendix III) enabled a high sensitivity assay (Appendix IV) .  The polymer has 
shown no degradation, metabolism or lung tissue sequestration in rat lung (Sun, 1 995 ;  
Appendix V). 
Sodium fluorescein (F-Na; Mw =376 Da) and FITC-Iabeled dextran (FD-4; Mw = 
4.4 kDa) were purchased from Sigma Chemical Company (St. Louis ,  MO). These solutes 
were used as reference solutes for passive absorption when validating airway-to-perfusate 
transfer and mucociliary clearance kinetics at 25 °C and/or in the presence of metabolic 
inhibitors. 
IV .b . 2 METABOLIC INHIDITORS : 2 ,4-DINITROPHENOL, OUABAIN, 
MONENSIN AND NOCODAZOLE 
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All metabolic inhibitors, 2,4-dinitrophenol (DNP; lot: 49H5077), ouabain ·8H20 
(OUA; lot: 27H092 1 ) ,  monensin (MON; sodium salt; lot: 28H50 l2) and nocodazole 
(NOC; lot: l OK40 1 3) were purchased from Sigma Chemical Company (St. Louis, MO) 
as the purest grades commercially available. These chemical structures are shown in Fig. 
IV.2 .  Ethyl alcohol USP (EtOH; AAPER Alcohol and Chemical Company, Shelbyville, 
KY) and dimethyl sulfoxide (DMSO; HPLC grade � 99.96 % pure; EM Science, 
Gibbstown, NJ) were used in the vehicles for MON and NOC studies, respectively. 
IV.b. 3 PULMONARY ABSORPTION IN THE IPRL: EFFECTS OF Low 
TEMPERATURES AND METABOLIC INHIDITORS 
The IPRL preparation and the dosing method used to deliver solutes into the 
airways ( "forced solution instillation") have been described in detail previously (Byron 
and Niven, 1988; Chapter 3 and Appendix I) . These were used unchanged with the 
exception of the experimental perturbations described below. The general experimental 
format which was used for experiments performed in this chapter is shown in Table IV . ! .  
For each experimental condition and/or solution, four fully viable preparations were 
studied. The absorption results from each group (n=4) were expressed as mean % of 
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Figure IV.2. Chemical structures of metabolic inhibitors used in the IPRL: 
(a) 2,4-dinitrophenol (DNP); (b) ouabain (OUA); (c) monensin (MON); (d) 
nocodazole (NOC). 
Table IV.I .  Summary o f  experimental conditions used i n  this Chapter. 
Dosing 
Solute 
Temp.! 
[0C] 
Nominal dose Vehicle Metabolic inhibitor 
[mg] 
Name Conc.2 Inhibitor added 
<Effect of temperature> 
F-PHEA 37  0 . 1 ,  0.2, 0 . 5 ,  Water None 
1 .0, 5 .0 
30 0 . 2  Water None 
25 0 .2 , 0 .5 ,  1 .0 Water None 
5 .0  
None 1 5 , 1 0, 4 N/A3 N/N None 
FD-4 37 , 25 0 . 1 , 0.2 Water None 
F-Na 37 , 25 0 .0 1 , 0.02, Water None 
0.04 
<Effect of inhibitor> 
F-PHEA 37  0 .2 
{ 
Water DNP4 0 .05 , 0 . 1 ,  0 .2 } To perfusate 
F-Na 37  0.02 0 .5 , 1 .0 mM 1 5  min. prior 
to dosing 
Water OUA5 5, 1 0, 1 00 /lM 
F-PHEA 37 0.2 
{ 
1 . 5 % EtOH MON6 5 , 1 0, 30, 
} 
To airways 
F-Na 37  0 .02 1 00 /lM with solute 
1 . 5  % DMSO NOC7 0 .5 ,  1, 1 0, 
3 0, I OO /lM 
1 Temperature; 2 concentration; 3 not applicable; 4 2,4-dinitrophenol ; 5 ouabain; 6 monensin and 7 nocodazole. 
Study 
period 
1 80 min. 
1 80 min. 
1 80 min. 
:<:; 30 min. 
1 5 0  min. 
120 min. 
60 min. 
60 min. 
1 20 min. 
120 min. 
-J ry, 
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administered dose i sample standard deviation. The individual results from each IPRL 
are reported in Appendix VII. 
For lower temperature studies, perfusate temperatures were adjusted and maintained 
either at 4, 10, 1 5 ,  25 or 30 (iO.5) DC by modifying the setting of a thermostatically­
controlled water circulator (Model 9505, Fisher Scientific, Pittsburgh, PAl used to supply 
water to the jacketed equipment showing in Fig. AI. l (B) (Appendix I). Briefly, a rat lung 
was removed from the body and housed in the jacketed artificial glass thorax (AGT), 
maintained at those lower temperatures .  Its pulmonary circulation was perfused with 
circulating perfusate solution (Krebs-Heinseleit solution with 4 % bovine serum albumin) 
from a reservoir whose temperature was similarly controlled by the circulator. Following 
equilibration for :::: 5 minutes, F-PHEA (nominal doses of 0.2, 0.5, 1 .0 and 5.0 mg) or 
reference solute (FDA: 0. 1 and 0.2 mg, F-Na: 0.0 1 , 0.02 and 0.04 mg) was administered 
into the airways as a coarse spray by "forced solution instillation" (Table IV. I ) .  
Absorption was followed as a function o f  time b y  sampling and analyzing the perfusate, 
as described in Chapter 3 and Appendix I. Attempts to reduce temperatures below 25 °C 
were found to induce rapid edema formation at time :::; 30 minutes preparation. Thus, the 
low temperature studies described in this thesis with solutes, only employed perfusate 
temperatures of 25 and 30 °C. At these temperatures ,  IPRL viability for :::: 1 80 minutes 
was attained, as evidenced by the absence of edema and a lack of sharp discontinuities in 
solute absorption profiles (Figs. IV.6 and IV.7;  Appendix I) 
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The experimental protocols for studying effects of metabolic inhibitors on F-PHEA 
and F-Na absorption were optimized and/or selected based on the results of preliminary 
studies and literature information (Basset and Fisher, 1 976; Goodman et ai. , 1 983 ;  Basset 
et ai. , 1 987; Effros et aI. , 1988 ;  Hastings et aI. , 1 994; Wangen steen et aI. , 1 996) . Briefly, 
all these experiments were performed at 37 DC. After the cannulated IPRL was placed in 
the artificial glass thorax (AGT) and perfusate recirculation commenced (Appendix I) , 50 
mL of the perfusate was removed from the 1 00 mL reservoir and replaced by 50 mL of 
fresh perfusate containing various concentrations of DNP or OUA; the inhibitors were 
directly dissolved in this 50 mL of fresh perfusate. The amounts of each were calculated 
to result in final concentrations in the circulating perfusate of 0.05, 0 . 1 ,  0 .2 , 0.5 and 1 .0 
mM for DNP and 5, 50 and 1 00 11M for OUA following the replacement. At 1 5  minutes 
following perfusion with each of these inhibitors, F-PHEA (nominal dose = 0.2 mg) or F­
Na (nominal dose = 0.02 mg) was administered into the airways by "forced solution 
instillation" and its absorption followed with time, as described in Chapter 3 and 
Appendix 1. "Control" absorption profiles, determined in the absence of the inhibitors, 
were obtained according to an identical protocol (F-PHEA was administered at 1 5  
minutes following perfusion in the absence of inhibitors) .  IPRL viability was reduced in 
the presence of DNP and/or OUA to times ::; 60 minutes. For this reason, absorption 
profiles were discontinued at times > 60 minutes, when edema onset began. The 
inhibitors , monensin (MON) and nocodazole (NOC) were co-administered independently 
with F-PHEA or F-Na. Fluorophore absorption was then followed with time, as described 
in Chapter 3 and Appendix 1. MON and NOC were prepared as stock solutions of 1 0.2 M 
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in EtOH and DMSO, respectively, and stored at ::; - 20 °C. Prior to experimentation in the 
IPRL, dosing solutions (0. 1 mL) were prepared from aqueous F-PHEA or F-Na solutions 
(so that nominal 0.2 and 0.02 mg doses, respectively, were present following admixture 
with each inhibitor) . Various concentrations of MON in EtOH or NOC in DMSO were 
employed although the final concentrations of these non-aqueous solvents in each dosing 
vehicle (EtOH and DMSO) were held ::; 1 .5 % (v/v) throughout. The final concentrations 
of inhibitors in each dosing solution were adjusted to achieve 5 ,  10, 30 and 100 J.l.M for 
MON and 0.5 ,  I ,  10, 30 and 100 J.l.M for NOC (Table IV. I ) .  "Control " absorption profiles 
for F-PHEA were determined in the absence of inhibitors following solute administration 
in vehicles containing 1 .5 % (v/v) EtOH or DMSO. IPRL viability, evidenced by the 
absence of pulmonary edema was maintained for 2: 120 minutes in the presence of MON 
and NOC. Thus, absorption profiles in the presence of these inhibitors were terminated 
120 minutes after solute administration. 
IV.bA KlNETIC MODELING, FITTING AND PARAMETER ESTIMATION 
The kinetic model for F-PHEA absorption in the IPRL is summarized in Fig. IV. I 
along with the solute's disposition rate constants at 37 °C, as described in Chapter 3 .  This 
model and the method used for data analysis in Chapter 3 was also employed for 
analyzing absorption at lower temperatures (Sections III .b.6 and III.b.7 in Chapter 3) .  
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Thus, average data for % of administered dose transferred to perfusate (Fig. IV.6) was 
fitted across doses to the following equations (Eqns .  111 .3-5 from Chapter 3 ) :  
(d [P)/dt)Aclive+Passive. IPRL = V max.p· [M)p/(Km.P + [M)p) + ka'p" [M)p (Eqn. UI.3)  
(d[M)p/dt)IPRL = - (d[P)/dt) - kEydM)p (Eqn. IlI.4) 
(d[Mhs/dt)IPRL = kE.pr [M)p (Eqn. III .5 )  
where [P) is the cumulative solute amount absorbed from the pulmonary region into the 
recirculating perfusate of the IPRL, [M) p and [Mhs are the solute amounts remaining to 
be absorbed from the pulmonary and the tracheo-bronchial regions, respectively; V max.P is 
the maximum rate of active absorption, Km.p is the "affinity" or dose at which the active 
absorption rate = O.S ·Vmax.P , ka.p is the first-order passive absorption rate constant from 
the pulmonary region and kE.PT is the first-order mucociliary clearance rate constant from 
the pulmonary to the tracheo-bronchial region. The curve fitting and parameter estimation 
was performed by unweighted, nonlinear least-mean-square regression analysis 
(Scientist™, MicroMath Scientific Software, Salt Lake City, UT) . The fraction of the 
administered dose delivered to the pulmonary region, F, was fixed throughout fitting at 
its experimentally-determined average value at 25 °C, 0.9 1 (0.9 l 2±0.0 1 3 ;  mean±SD; 
n=4), so that initial conditions were : 
[M)p. 1=0 I [administered dose) = 0.9 1 
[Mhs . 1=0 I [administered dose) = 0.09 
[P) t=o I [administered dose) = 0.00 
8 1  
The model fits were validated using "goodness-of-fit" parameters such as the 
program's  calculated Model Selection Criterion (MSC), R-squared (R\ a review of 
standard deviation of final parameter estimates and visual inspection of the residuals .  
Additional methodological details are described in Appendix VI. 
IV.b .S DATA ANALYSIS FOR ACTIVE ABSORPTION INHIBITION IN 
THE PRESENCE OF METABOLIC INHIBITORS 
The rate constants for active and passive absorption of F-PHEA at 37 °C, 
determined in Chapter 3 (Fig. IV. I ) ,  enabled estimation of the contribution of each of 
these (in the first 30 minutes following administration) to the total absorption rates for 
this polymer, as a function of administered dose. These are shown in Fig. IV.3 as 
theoretical curves and actual data points; absorption rates determined between time = 0 
and time = 30 minutes. Despite the saturation seen at :::: 1 .0 mg doses, the theoretical 
active absorption was found to contribute > 50 % of the total process up to and including 
nominal 5.0 mg dose. At the lower 0.2 mg dose, 97.7 % of this theoretical total 
absorption rate resulted from active absorption, whereas only 2.3 % was derived from the 
passive absorption component. The percentage reduction of F-PHEA's active transport 
seen with inhibitors at 37 °C, was determined (over the first 30 minutes of its absorption) 
by (a) ensuring that neither kE.PT values (mucociliary clearance) nor ka.P values (passive 
absorption) for the (passively-absorbed) solute, F-Na, were significantly affected by a 
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Figure IV.3. F-PHEA amount transferred to perfusate in the first 30 minutes after 
administration vs. initial F-PHEA dose in the airways, at 37 °C. The solid curve was 
generated using the best estimates for each process in Fig. IV. I ,  based on Eqn. III . 3  in 
Chapter 3. The dashed and dotted curves, respectively were the model-simulated 
results for active and passive absorption, based on the rate constants in Fig. IV. l .  
Data points were the results of each IPRL experiment. 
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particular inhibitor and (b) comparing the experimental value for absorption of F-PHEA 
in the presence of the inhibitors, to that obtained in its absence. In each case, a solute­
dose-dependent theoretical correction was applied to remove the contribution of passive 
absorption from these considerations [even though this contribution accounted for only 
2.3 % of total absorption rates at a nominal 0.2 mg dose of 7.4 kDa F-PHEA] . Thus, the 
% of each F-PHEA administered dose transferred after 30 minutes by active mechanisms 
in the presence of inhibitors, [% Tlactive.inh , was calculated by: 
[%T]active. inh = [%T]obs.inh - [%T]pas.<ive (Eqn. IV. I )  
where [%T]obs.inh was the experimentally-observed result for % of administered dose 
transferred to perfusate in 30 minutes in the presence of inhibitor and [%T]pasJive was 
determined from the dotted curve in Fig. IV.3 .  As a result, the percent of control by each 
of the inhibitors was calculated from: 
[% Tlactive.inh 
(% of control) = x 100 (Eqn. IV.2) 
[0/0 T]active,control 
where [%T]actice.control was the % of administered dose transferred to perfusate in 30 
minutes in the absence of inhibitors . Concentrations, at which SO % of active absorption 
inhibition was obtained, or apparent IC50 values for inhibition, were estimated, when 
possible, by extrapolation of data for inhibition (based on Eqn. IV.2) vs. logarithmic 
inhibitor concentrations. 
IV.c 
IV .c . l 
RESULTS 
PULMONARY ABSORPTION IN THE IPRL AT Low 
TEMPERATURE 
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At temperatures < 25 °C. rapid edema formation was seen as a glossy sheen on the 
pulmonary lobes beginning within 30 minutes (Appendix I) . In contrast, at 25 and 30 DC, 
edema was absent and the preparation successfully maintained viability for 1 80 minutes, 
as evidenced by the lack of sharp discontinuities in solute absorption profiles (Figs. IV.6 
and IV.7; Sun, 1995; Appendix I). 
Figure IV. 4 shows the percent of each administered dose of 7 .4 kDa F-PHEA 
(nominal 0.2 mg dose) transferred to perfusate in the IPRL vs. time at 37, 30 and 25 °C. 
The rate and extent of absorption were dramatically reduced with lowering perfusion 
temperatures .  This absorption suppression due to reduced temperature was moderated 
with increasing doses of F-PHEA and .  at a nominal 5.0 mg dose, the profiles at 25 °C 
were insignificantly different from those at 37 °c (Fig. IV .5 ;  ANOVA). This indicated 
that lowering temperature preferentially suppressed F-PHEA's active absorption 
component, which was predominant at the lower doses ; the passive absorption 
component was largely unaffected by this maneuver (Table IV.2). Despite this absorption 
suppression, the absorption profiles at 25 °C were still slightly dose-dependent, as shown 
in Fig. IV .6. The solid curves through the data in Fig. IV.6 are the results of simultaneous 
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Figure IV.4. Mean percentage of administered dose of 7.4 kDa F-PHEA (nominal 
dose = 0.2 mg) absorbed from the airways of the IPRL into the perfusate vs. time at 
37 , 30 and 25 cC. Error bars are sample standard deviations with n=4. The solid curves 
are the results of linear interpolation. 
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Figure IV.S. Mean percentage of administered dose of 7.4 kDa F-PHEA (nominal 
dose = 5 .0  mg) absorbed from the airways of the IPRL into the perfusate vs. time at 3 7  
and 25 °C. Error bars are sample standard deviations with n=4. The solid curves are 
the results of linear interpolation. 
87 
Table IV.2. Disposition parameters for active and passive absorption and 
mucociliary clearance for 7.4 kDa F-PHEA following its administration into the 
airways of the isolated perfused rat lung (IPRL) at 37 and 25 DC. 
Active Passive Mucociliary 
absorption absorption clearance Temp. MSC; R2 kE,PT Vmax,P Km,P V max,P/Km,P ka,p 
[Jlglmin] [Jlg] [min-I ]  [min- I ]  [min- I ]  
* * *  37 °C 4 .37  56 .6  0.077 0.00 1 0. 023 3 . 1 2 ; 0 .986 
(0.57) ( 14.7) (0.00 1 )  (0.00 1 )  
* * *  25 °C 0.67 30 .3  0 .022 0 .002 0 .0 1 6  3 . 74; 0 .991 
(0. 1 0) ( 1 6.4) (0.00 1 )  (0.00 1 )  
Values are the best estimates (SD) following analysis of across-dose data for F-PHEA. 
Nominal doses : 0. 1 ,  0.2, 0 .5 , 1 .0 and 5.0 mg at 37 DC; 0.2, 0 .5 ,  1 .0 and 5.0 mg at 25 DC. 
MSC (Model Selection Criterion) and R2 (R-squared) were as calculated by "Scientist" 
(Appendix VI) . 
* and ** indicate significant difference (p<0.05) between values ofVrnax.!' and kE•PT' 
respectively, based on overlapped 95% confidence intervals. 
The values for K",.? and ka,p were insignificantly diHerent between 37 and 25 "C, based on 
the same approach. 
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Figure IV.6. Mean percentage (±SD; n=4) of administered dose of 7.4 kDa F-PHEA 
absorbed from the airways of the IPRL into the perfusate vs. time at 25 °C. The solid 
curves are the results of simultaneous across-dose curve fitting of all profiles. These 
were generated using the best estimates determined for each parameter at 25 DC, as 
described in Table IV.2 (V max,P' K"" p, ka,p and kE,PT = 0.67 [flg/min] , 30 .3 [ flg] , 0 .002 
[min- I ]  and 0.0 1 6  [min- I ] ,  respectively). 
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curve fitting across doses of the 25 °C data (nominal doses of 0 .2 , 0 .5 ,  1 .0 and 5 .0  mg) to 
the model shown in Fig . IV. l .  The best parameter estimates from which these curves 
were generated are shown in Table IV.2 along with those at 37 °C (Chapter 3 ) .  The 
"goodness-of-fit" parameters provided by "Scientist"-calculated Model Selection 
Criterion (MSC) and R-squared (R2) were 3 .74 and 0.99 1 ,  respectively, for the 25 °C 
data, and the parameters were successfully estimated with relatively small standard 
deviations (Table IV.2) .  An "intrinsic rate constant" for active absorption, calculated by 
Vmax'p/Km.P was found to be much smaller (0.022 min· l )  than that determined at 37 °C 
(0.077 min, I ) .  This active absorption suppression was apparently dominated by the 
significant decrease in the value of V max.P (maximum rate ; 4.37±0.57 � 0.67±0. 1 O  
Jlg/min ; p < 0.05, based o n  non-overlapped 9 5 %  confidence intervals (95%CI» . The 
"affinity" of the transporter, Km•p, remained effectively constant (56.6± 14.7 VS. 30.3± 1 6 .4 
Jlg, based on overlapped 95%CI). It appeared therefore, that the lower 25 °C perfusion 
temperature slowed the active absorption process for F-PHEA without modifying the 
value of dose, at which 50 % saturation was achieved. Nevertheless, the contribution of 
active absorption to F-PHEA's airway-to-perfusate transfer was still significant at 25 °C 
(Fig. IV .6) .  
Average percent transfer (±SD) of administered dose vs. time for F-Na and FDA at 
25 °C is shown in Fig. IV.7 .  As seen at 37 DC (Fig. III .6 in Chapter 3) ,  these profiles were 
found to be dose-independent. Data could be fitted to the model shown in Fig. IV . l  in 
which only passive absorption from the pulmonary region, ka.p, and simultaneous 
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Figure IV.7. Mean percentage of administered dose of F -N a and FD-4 absorbed 
from the airways of the IPRL into the perfusate vs. time at 25 °C. Error bars are 
sample standard deviations with n=4. 
The solid curves are the results of simultaneous across-dose curve fitting and the best 
estimates for each process are shown in Table IV.2 .  All doses : F-Na - 0.0 1 ,  0 . 02 and 
0 .04 mg; FD-4 - 0. 1 and 0.2 mg. 
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mucociliary clearance, kE,PT, occurred (V  max,P and Km,p = 0) . The across-dose 25 °C data 
fits to Eqns . III .2, IlI.4 and IlLS (Chapter 3)  successfully yielded values for ka.p and kE.PT' 
as shown in Table IV.3 along with the values for F-PHEA. The rate constants for passive 
absorption, ka,p, at 25 °C were found to be smaller, compared to those at 37 °c (Table 
II1 .2 in Chapter 3), due probably to the solute's lower diffusivity and/or partitioning to the 
membrane at lower temperatures (Notari , 1 987;  Martin, 1 993) .  Thus, while it should be 
noted that there was no significant difference between the values for ka.P for F-PHEA at 
37 and 25 °C (0.00 1±0.00 1 vs. 0.002±0.00 1 min- I , respectively; based on overlapped 
95%CI), these values were less precisely estimated than those for F-Na and FD-4. This 
was due to the difficulty involved in multiple parameter estimation for solutes like F­
PHEA which also possess a much longer passive absorption half-life (0.693/ka.P ; � 6 
hours) ;  one, in fact, which is far larger than the 1 80 minute IPRL viability during which 
absorption data could be obtained. For similar reasons, the rate constants for mucociliary 
clearance, kE,PT, were found to be solute-independent, but also smaller at 25 °C, compared 
to those at 37 DC. This decrease of mucociliary clearance rates with lowering temperature 
has been consistently observed in other studies (Mercke et al. , 1 974; Sanderson and 
Dirksen, 1 985) and is most likely to be related to cAMP- and ATP- dependent regulation 
mechanisms for this process (Lansley, 1 993 ;  Camner and Mossberg, 1 993) .  
Table IV.3. Disposition parameters for active and passive absorption 311d 
mucociliary clearance for 7.4 kDa F-PHEA, FD-4 and F-Na following their 
administration into the airways of the isolated perfused rat lung (IPRL) at 25 °C. 
Active Passive Mucociliary 
absorption absorption clearance 
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Solutes 
(Mw) kE,PT MSC; R2 Vrnax,P Krn,P 
(Jlglmin] [Ilg] 
F-PHEA 0.67 30.3 
(7 .4 kDa) (0. 1 0) ( 1 6.4) 
FD-4 N/A N/A 
(4.4 kDa) 
F-Na N/A N/A 
(376 Da) 
V rnax,p/Krn,P ka,p 
[min' ! ]  [min' ! ]  
0 .022 0 . 002* 
(0.00 1 ) 
N/A 0.008* 
(0.00 1 )  
N/A 0 .023 * 
(0.00 1 )  
[min' ! ]  
0 .0 1 6  
(0.00 1 )  
0 .0 1 2  
(0.002) 
0 .0 1 0  
(0.002) 
3 . 74; 0 .99 1 
2 .87 ;  0 .985 
3 . 1 2 ;  0 .987 
Values are the best estimates (SD) following analysis of across-dose data from: 
F-PHEA - nominal doses 0.2, 0.5, 1 .0 and 5.0 mg; FD-4 - nominal doses 0. 1 and 0.2 mg; 
F-Na - nominal doses 0 .0 1 ,  0 .02 and 0.04 mg. 
MSC (Model Selection Criterion) and R2 (R-squared) were as calculated by "Scientist" 
(Appendix VI). 
N/A indicates "not applicable". 
* indicates significant difference (p<0.05) between values ofka.p, based on overlapped 
95% confidence intervals. 
The values for kE•PT were insignificantly different across solutes, based on the same 
approach. 
Values ofka.p and kE,PT for FD-4 and F-Na at 37 °C were as follows (Table III .2 , 
Chapter 3) : 
FD-4 - ka,p = 0.0 1 6  (0.00 1 )  min'! and kE,PT = 0.029 (0.003) min'l ; 
F-Na - ka,p = 0.048 (0.003) min'l and kE,PT = 0.022 (0.002) min' l . 
IV.c .2  PULMONARY ABSORPTION AT 37 DC IN THE PRESENCE 
OF METABOLIC INHIBITORS 
93 
IPRL viability could be maintained for only 60 minutes in the presence of the 
highest concentrations of DNP and OUA in perfusate and for 1 20 minutes in the presence 
of the highest concentrations of MON and NOC in the airways . The lungs displayed 
edema formation as the appearance of a glossy sheen on the pulmonary lobes thereafter. 
No data is included in this thesis from such edematous preparations. 
(1 ) Passive absorption and mucociliary clearance kinetics in the presence of inhibitors 
The average percent transfer (±SD) of a passively-absorbed small solute, F-Na 
(nominal dose = 0.02 mg), from airway-to-perfusate is shown in Fig. IV.S  in the absence 
and the presence of various metabolic inhibitors. The highest concentrations of the 
metabolic inhibitors used in this thesis ( 1  mM DNP or 100 11M OUA in perfusate or 1 00 
11M MON or NOC in the airways) showed no significant changes in F-Na absorption 
profiles throughout the available, viable lifetime of the preparation, when compared to 
those in the absence of inhibitors (ANOVA). Because F-Na's transfer kinetics were 
shown previously (Chapter 3) to be passive, and clearly dependent upon mucociliary 
clearance, this demonstrated that passive absorption and mucociliary clearance kinetics 
were unaffected by the presence of these inhibitors at the concentrations employed in this 
thesis. 
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Figure IV.S. Mean percentage (±SD; n=4) of administered dose ofF-Na (nominal 
dose = 0.02 mg) absorbed from the airways of the IPRL into the perfusate vs. time. 
Data shown is in the absence (control) and the presence of (a) 1 mM 2,4-dinitrophenol 
(DNP) and 1 00 IlM ouabain (OUA) and (b) 1 00 IlM monensin (MON) and 1 00 I-lM 
nocodazole (NOC) at 37 °C. The solid curves are the results of linear interpolation. 
DNP and OUA were placed in the perfusate at 15 minutes prior to F-PHEA 
administration and MON and NOC were co-administered into the airways with F­
PHEA. Profiles in the presence of the metabolic inhibitors were insignificantly 
different from the controls (ANOV A). 
(2) Pulmonary absorption of 7.4 kDa F-PHEA in the presence of2,4-dinitrophenol 
(DNP) 
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2,4-Dinitrophenol (DNP) was used to inhibit intracellular mitochondrial A TP 
synthesis (Goodman et ai. , 1 983 ;  Steen et al. , 1 993 ;  Muranushi, et ai. , 1 994; Alberts et 
aI. , 1 994) which was presumed to be necessary to provide energy for F-PHEA's active 
absorption from the airways. The experimental protocol was optimized based on 
preliminary studies in which different DNP perfusion periods were employed prior to F­
PHEA administration into the airways . When l .0 mM DNP was recirculated for either 5, 
15 or 30 minutes prior to F-PHEA administration, the mean values for % of each 
administered dose of F-PHEA (nominal dose = 0.2 mg) transferred to perfusate in 30 
minutes were found to be 24.5±2.4, 1 6.2±5 .3 and 1 3 .4±2.5 % (mean±SD;  n=4), 
respectively. Because the latter two were insignificantly different (t-test), a 15 minute 
pre-perfusion time period was employed in the protocol to maximize the inhibition of F­
PHEA absorption without unnecessarily shortening the viable lifetime of the WRL. 
Figure IV.9 shows the percent transfer of F-PHEA (nominal dose = 0.2 mg) from 
airways to perfusate vs. time in the absence (control) and the presence of 0.05 , 0. 1 ,  0 .2 ,  
0.5 and 1 .0 mM DNP in perfusate. Clearly, F-PHEA absorption was suppressed by DNP 
in a concentration-dependent fashion, demonstrating the likelihood that ATP-driven 
intracellular energy was necessary for this F-PHEA active absorption from the airways to 
occur. Based on the assumption that the first 30 minute's data was most reliable, DNP­
concentration-dependent inhibition of F-PHEA's active absorption was calculated using 
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Figure IV.9. Mean percentage of administered dose of 7.4 kDa F-PHEA (nominal 
dose = 0.2 mg) absorbed from the airways of the IPRL into the perfusate vs. time in 
the presence of various concentrations of 2,4-dinitrophenol (DNP) at 37 °C. DNP was 
placed into the perfusate at 15 minutes prior to F-PHEA administration. Error bars are 
sample standard deviations with n=4. The solid curves are the results of linear 
interpolation. 
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Eqns. IV. I -2 .  This is shown in Fig. IV. 10 .  Despite its evident concentration-dependence, 
the maximum extent of F-PHEA's active absorption inhibition by DNP was found to be 
only 53 .3±7 .9 % (mean±SE; n=4) and thus, DNP's ICso value was estimated to be 
between 0.5 and 1 .0 rnM in perfusate. 
(3) Pulmonary absorption 0/ 7.4 kDa F-PHEA in the presence olouabain (OUA) 
Ouabain (OUA) is a well-known Na+IK+-ATPase inhibitor (Basset et al. , 1 987 ;  
Saumon and Martet, 1 993 ;  Alberts et  al. , 1 994; Rose and Valdes 1 994; Michaut et ai. , 
1 996). In this thesis, it was used to relate its inhibition effects of indirect intracellular 
ATP hydrolysis with F-PHEA's active absorption, since active transport must consume 
ATP-derived hydrolysis energy either directly or indirectly (Rose and Valdes 1 994; 
Michaut et ai. , 1 996) . S imilar to the studies using DNP, the experimental protocol was 
optimized based on preliminary studies in which OUA perfusion periods prior to F­
PHEA administration were varied. In the presence of 1 00 11M OUA circulating for 1 ,  1 5  
or 3 0  minutes prior to F-PHEA administration, the % transfer of F-PHEA (nominal dose 
= 0.2 mg) into perfusate over a 30 minute period was found to be 26.0±2.9 ,  8 . 8±3.4 or 
1 1 .4±3 .7 % (mean±SD; n=3-4) , respectively. Because the latter two values differed 
insignificantly (Hest), a 1 5  minute pre-perfusion time period was again employed to 
maximize transport inhibition without unnecessarily shortening the IPRL's viable 
lifetime. 
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Figure IV.IO. Mean percentage o f  control value for F-PHEA active transfer in the 
first 30 minutes following administration at 37 DC. The effect of the presence of 
various concentrations of 2,4-dinitrophenol (DNP) in the perfusate is illustrated 
(control = 0 mM DNP). Error bars are sample standard errors (SE) with n = 4. DNP 
was placed in the perfusate at 1 5  minutes prior to F-PHEA administration. 
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* indicates significant difference, compared to the control (Dunnett method following 
multiple ANOV A; p<0.05) . 
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The average percent transfer (±SD; n=4) of F-PHEA at a nominal 0.2 mg dose is 
shown vs. time in the absence (control) and the presence of 5 ,  50 and 1 00 J..lM OUA in 
Fig. IV . I I . F-PHEA absorption was inhibited by OUA in a concentration-dependent 
fashion, suggesting the likelihood that F-PHEA's active absorption required OUA­
inhibitable ATP hydrolysis energy in the cells .  Figure IV. 1 2  shows the effects of OUA on 
F-PHEA active absorption over the first 30 minutes, calculated using Eqns .  IV. I -2 .  The 
maximum absorption inhibition due to OUA was found to be 75 .9±5 . 1  % (mean±SE; 
n=4) with an apparent its ICso value of 30-50 J..lM in perfusate. 
(4) Pulmonary absorption of 7.4 kDa F-PHEA in the presence ofmonensin (MON) and 
nocodazole (NOC) 
Monensin (MON) is a Na+/H+ ionophore used to prevent acidification of 
intracellular endosomal vesicles (Mollenhauer el al. , 1 990; Dinter and Berger, 1 998) ,  
while nocodazole (NOC) is known to depolymerize microtubules in an energy-dependent 
process (Turner and Tartakoff, 1 989; Dinter and Berger, 1 998) .  Both inhibitors were used 
to inhibit endocytotic (transcytotic) transport processes (Mollenhauer et aI. , 1 990; Dinter 
and Berger, 1 998; Hastings et aI. , 1 994 ; Deffebach et al. , 1 996; Wangen steen et aI. , 
1 996; Dinter and Berger, 1 998) and their inhibition evidence suggested an involvement 
of intracellular vesicular transport for F-PHEA between the airways and the perfusate. 
The experimental protocols for these inhibitors were selected from literature in which co-
administration of both MON (30-35 J..lM) and NOC (30-35 J..lM) had been used to inhibit 
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Figure IV. 1 t .  Mean percentage of administered dose of 7.4 kDa F-PHEA (nominal 
dose = 0.2 mg) absorbed from the airways of the IPRL into the perfusate vs. time in 
the presence of various concentrations of ouabain (OUA) at 37 °C. OUA was placed 
into the perfusate 15 minutes prior to F-PHEA administration into the airways. Error 
bars are sample standard deviations with n=4. The solid curves are the results of linear 
interpolation. 
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Figure IV.12. Mean percentage of control value for F-PHEA active transport in  the 
first 30 minutes following administration. The effect of the presence of various 
concentrations of ouabain (OUA) in the perfusate is illustrated (control = 0 flM OUA). 
Error bars are sample standard errors (SE) with n = 4. OUA was placed in the 
perfusate at I S  minutes prior to F-PHEA administration. 
* indicates significant difference, compared to the control (Dunnett method following 
multiple ANOV A; p<0.05) . 
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receptor-mediated transcytotic absorption of albumin and its riboflavin-conjugates from 
the airways of the IPRL (Hastings et al. , 1 994; Wangensteen et aI. , 1 996). 
The average percent (±SD; n=4) transfer to perfusate of F-PHEA at nominal 0 .2 mg 
doses is shown vs. time in the absence (control) and the presence of MON (5, 1 0, 30 and 
1 00 11M) and NOC (0.5 , 1 ,  1 0, 30 and 1 00 11M) in Figs. IV. 1 3  and IV. 14, respectively. F-
PHEA active absorption was inhibited in a concentration-dependent fashion by both 
inhibitors, as shown in Fig. IV. 1 5 .  Apparent ICso values = 1 0-30 11M for MON and 1 -5 
11M for NOC were calculated. Based on these results, it appeared that F-PHEA absorption 
may involve endosomal and microtubular vesicular transport during active transcytosis . 
IV.d DISCUSSION 
While biochemical approaches like lowered temperature studies and the use of 
metabolic inhibitors are generally used, these require a thorough validation in each 
experimental system to ensure that all possible effects of experimental perturbation are 
considered. To characterize the mechanisms responsible for active absorption of 7 .4  kDa 
F-PHEA from the airways of the IPRL, the viability (absence of pulmonary edema) under 
all conditions and/or a lack of changes in other kinetic components (e .g . ,  passive 
absorption and mucociliary clearance) were demonstrated for all metabolic inhibitor 
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Figure IV.13. Mean percentage of administered dose of 7.4 kDa F-PHEA (nominal 
dose = 0.2 mg) absorbed from the airways of the IPRL into the perfusate vs. time in 
the presence of various concentrations ofmonensin (MON) at 37 ac.  MON was co­
administered into the airways with F-PHEA. Error bars are sample standard deviations 
with n=4. The solid curves are the results of linear interpolation. 
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Figure IV.14. Mean percentage of administered dose of 7.4 kDa F-PHEA (nominal 
dose = 0.2 mg) absorbed from the airways of the IPRL into the perfusate vs. time in 
the presence of various concentrations ofnocodazole (NOC) at 37 °C. NOC was co­
administered into the airways with F-PHEA. Error bars are sample standard deviations 
with 11=4. The solid curves are the results of linear interpolation. 
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Figure IV.IS. Mean percentage of control value for F-PHEA active transport in the 
first 30 minutes following administration. The effect of the presence of various 
concentrations of monensin (MON) and nocodazole (NOC) in the airways is 
illustrated (controls involved sham experiments performed in the absence of 
inhibitors). Error bars are sample standard errors (SE) with n = 4. MON and NOC 
were co-administered into the airways with F-PHEA. 
* indicates significant difference, compared to each control (Dunnett method 
following multiple ANOV A; p<0.05). 
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studies. Effects of altered vehicle composition and pre-incubation periods were also 
studied in control experiments . 
In early studies, we found that a lower 4 DC perfusion induced pulmonary edema 
formation quite rapidly (:<=; 12 minutes; Sun, 1 995) and this was also found to be true at 
intermediate temperatures which were significantly < 25 DC (Section IV.c. I ) .  In fact, not 
only edema, but also discontinuities in the absorption profiles for F-PHEA were observed 
at 15 DC, as shown in Fig. AI.7 (b) (Appendix I) . These effects precluded the use of such 
low temperature conditions in this thesis. Table IV.4 is a summary of the isolated 
perfused lung (IPL) studies in the literature, in which low temperature perfusion has been 
used. Most IPL study periods have been limited to :<=; 30 minutes at 4- 10  DC and thus,  it is 
likely that pulmonary edema occurred rapidly in all rat studies. The use of autologous 
blood or plasma as the perfusate in larger animal studies may well reduce this problem 
(Table TV.4). In contrast, in this thesis, extremely low temperatures were found to be 
unacceptable, while 25 DC perfusion was tolerable and successful in maintaining IPRL 
viability for 2': 1 80 minutes; this ,  with no display of pulmonary edema and no 
discontinuities in absorption profiles (Figs. IV.6 and IV.7). Because all metabolic 
inhibitors used in this thesis (2 ,4-dinitrophenol (DNP), ouabain (OUA), monensin 
(MON) and nocodazole (NOC)) also induced edema formation concentration­
dependently (those with highest concentrations being the greatest offenders) ,  IPRL 
studies were limited to only 60 minutes in the presence of DNP and �UA and 1 20 
minutes for MON and NOC at their highest concentrations. It is likely that the occurrence 
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Table IV.4. Summary of the isolated perfused lung (IPL) studies performed 
at lower temperatures (from the literature) . 
IPL Temp. Perfusate Study Substrate Reference! 
period 
<Studies for pulmonary disposition> 
Rat 4 °C Buffer 30 min Imipramine Junod, 1 972 
Buffer < 1 0  min Propranolol Dollery, 1 976 
Buffer 30 min Choline Johnson, 1 979 
Buffer 30 min Phenylamine Ben-Harari, 1 980 
Buffer 7 min Albumin-gold Villaschi, 1 986 
Buffer < 1 5  min Propanediamine Slosman, 1 987 
Buffer < 1 5  min Guanidine Slosman, 1 988  
8 °C Buffer 1 min Antipyrine Cua, 1 990 
Guinea pig 5 °C Buffer 30 min PGE2 ' \  Pitt, 1 985 
Rabbit 5 °C Buffer 1 min Antipyrine Effros, 1 985 
10  °C Buffer < 20 min BPAAP'2 Ashton, 1 985 
Rabbit 1 2 °C Blood 4.5 hr BSA'3 Hostetler, 1 9 8 1  
Dog 1 5 °C Plasma < 1 min 3H2O Chinard, 1 986 
Goat 7, 1 8 , 30 °C Blood 4 hr Albumin Serikov, 1 993 
<Studies for pulmonary edema> 
Rabbit 28 °C Buffer < 2  hr Nicolaysen, 1 97 1  
Plasma < 6 hr 
Dog 25 °C Blood 2 hr Veith, 1 97 1  
\ Only flIst authors and years o f  publication; details are described in References. 
'\ Prostagrandin E2, '2 benzoyl-phenylalanyl-alanyl-proline and '3 bovine serum albumin 
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of pulmonary edema was related to the inhibition of Na+-dependent active fluid 
resorption from the airways at reduced temperatures and/or the presence of metabolic 
inhibitors (Hostetter et al. , 1 98 1 ;  Serikov et aI. , 1 993 ;  Basset et aI. , 1 994; Cott, 1 994; 
Effros ,  1 994; Hastings et al. , 1 994; Wangensteen et aI. , 1 996) . Rates of fluid resorption 
have been studied in several IPL preparations and found to be 27-34 pUcm2/s at 37 °C 
(Basset et aI. , 1 987a and b; Effros et aI. , 1 989;  Berg et aI. , 1 989), which can account for 
0.5-0.6 mUhr from the rat lung (assuming its alveolar surface area = 0.5 m2; Weibel , 
1 985) .  This rapid fluid absorption capability is tightly regulated by apical Na+ channel 
(ENaC) and basolateral Na+/K+-ATPase on alveolar type II epithelial cell membranes and 
hence, both processes are Na+-dependent and energy consuming (Basset et aI. , 1 994; 
Cott, 1 994; Effros, 1 994) . Unfortunately, these active transport processes are also subject 
to inhibition or modulation by lowered temperature and the same metabolic inhibitors 
used in this thesis, due to their function-specific inhibition mechanisms. In fact, alveolar 
fluid absorption was slowed (but not abolished) at 4 °c and also by the presence of I mM 
DNP in rat alveolar type II epithelial cell systems (Goodman et al. , 1 983) and 1 00-500 
11M ouabain in the IPRL (Basset et aI. , 1 987;  Saumon and Martet, 1 993 ;  Saldias et aI. , 
1 998a and b). 
Passive absorption and mucociliary clearance kinetics for the small model solute, F­
Na were unaffected by the presence of the metabolic inhibitors (DNP: I mM; �UA: 1 00 
11M; MON: 100 11M; NOC: 1 00 11M) used in this thesis, as shown in Fig. IV.8 .  Similarly, 
it was demonstrated in other IPRL studies ,  that the absorption of small hydrophilic 
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solutes, mannitol ( 1 82 Da) and sucrose (342 Da) were unaffected by the presence of 
�UA in perfusate (200-500 11M; Sauman and Martet, 1 993 ;  Salidias et aI. , 1 998a and b) 
and MON and NOC administration to the airways (35 11M; Wangensteen et aI. , 1 996), 
respectively. These results were used to argue that passive absorption and mucociliary 
clearance kinetics for macromolecular F-PHEA should also be unchanged in their 
presence, thus enabling a kinetic analysis of F-PHEA's active absorption inhibition due to 
manipulation of the readily available cellular energy supplies . 
In order to maximize the inhibitory effects of metabolic inhibitors on F-PHEA 
absorption, it was found that 15 minute pre-perfusion in the presence of the inhibitor, 
prior to solute administration, was required in the case of DNP and �UA. Similarly, and 
for dissolution purposes, 1 .5 % (v/v) EtOH and DMSO solutions were used as 
administration vehicles for MON and NOC, respectively. Even though these 
perturbations produced modest changes in the percent of F-PHEA transfer over 30 
minutes at a nominal 0.2 mg dose, the overall % transfer in each control group differed 
insignificantly from the values obtained following aqueous F-PHEA solution 
administration immediately after perfusion was commenced (0 minute interval ; Dunnett 
method following multiple ANOYA; p > 0.05) . This is illustrated in Fig. IV. 1 6 .  In the 
perfusate-recirculated IPRL, ATP levels and cellular energy charge are maintained for :e: 
100 minutes at 37 °C according to the literature (Basset et aI. , 1 987;  Baker et aI. , 1 999). 
Furthermore, 1 .5 % (v/v) of EtOH and DMSO used as airway administration vehicles 
were shown to have no effects on protein absorption from the airways (Hastings et al. , 
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Figure IV.16. Effect of perfusion intervals (prior to administration) and composition 
of administration vehicles on the mean percentage of the administered dose of 7.4 kDa 
F-PHEA (nominal dose = 0.2 mg) absorbed from the airways over a 30 minute time 
period at 37 °C. Each experimental condition was employed as a control group for 
studying F-PHEA absorption in the presence of metabolic inhibitors. Error bars are 
sample standard errors (SE) with n = 4. No significant differences were observed in 
the amounts transferred between control groups, when compared to aqueous F-PHEA 
administration immediately after perfusion commenced (Dunnett method following 
mUltiple ANOV A). 
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1 994; Wangen steen et al. , 1 996). It is likely therefore, that the active absorption kinetics 
reported for F-PHEA in Chapter 3 in this thesis were unaffected by the presence of either 
15 minute pre-perfusion prior to dosing or the use of EtOH and DMSO in the dosing 
vehicle. Consequently, inhibitory effects on F-PHEA active absorption should be 
comparable across inhibitors and be primarily due to the action(s) of the inhibitors 
themselves .  
PULMONARY ABSORPTION KINETICS FOR 7 .4 kDa F-PHEA AT Low 
TEMPERATURE 
Active absorption is generally known to be temperature-sensitive in mammalian 
cells (Willingham and Pastan, 1 985) .  Its activity is maximal at physiological 
temperatures (37 °C) , decreased between 1 5  and 30 °C and abolished at 4 °C (Williams et 
al. , 1 979; Wangensteen, 1 990; Rutschman et aI. , 1 993) .  These effects are mostly caused 
by non-specific reduction of ATP utilization and oxidative phosphorylation in combined 
cell systems at lower temperatures (Williams et aI. , 1 979; Goodman et aI. , 1 983) .  Thus, 
reduced temperature, especially the extreme of 4 °C,  has been extensively used to inhibit 
active absorption processes in solute disposition studies (Borchardt et aI. , 1 996). 
Unfortunately, in the IPRL preparation used in this thesis, the minimum temperature was 
limited to 25 °C due to the rapid induction of pulmonary edema at lower temperatures .  As 
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a result, F-PHEA absorption at 25 DC was suppressed, but still evidently dose-dependent 
(Fig. IV.6). 
Generally, inhibition kinetics and mechanisms are best examined graphically using 
the double reciprocal plot established by Lineweaver and Burk (Sperelakis ,  1 995) .  Such 
an approach can be criticized because of the need for data transformation prior to curve 
fitting. Moreover, the approach was not applicable here due to the additional presence of 
simultaneous passive absorption and competing mucociliary clearance. Thus ,  the best 
estimates for each process at 25 DC were obtained by simultaneous across-dose curve 
fitting (MSC =3.74; R2 = 0.99 1 )  to the kinetic model shown in Fig. IV. I ,  by nonlinear 
least-mean-square regression analysis .  The results are shown in Tables IV.2 and IV. 3 .  
The active absorption component for F-PHEA a t  25 DC  was dramatically suppressed with 
respect to its maximal rate, Vmax.P, while the affinity term, Km,p, remained largely 
unaffected. Although similar effects were observed at 15 DC for the saturable uptake of 
propranolol in isolated and minced rat lung tissues (Iwamoto et aI. , 1 989), this type of 
inhibition mechanism has been rarely shown at lowered temperatures. The result was 
consistent with the inhibition of oxidative phosphorylation, similarly to that induced by 
DNP, but through a different mechanism (Goodman et aI. , 1 983) ,  DNP has often been 
reported to induce a type of active transport systems (Slater, 1 963 ; Rounds and 
McMurtry, 198 1 )  where the maximal rate was reduced but "affinity (Km)" remained 
unchanged. It may be therefore, that F-PHEA's active absorption was similarly, yet "non-
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competitively" inhibited at 25 °C,  due simply to the depletion of available energy for its 
transporter. 
The rate constants for passive absorption of F-Na and FD-4, ka,p were found to be 
about 50 % lower at 25 °c than those at 37 °c (Table IV,3) ,  Based upon passive diffusion 
theory via partitioning through pulmonary cell membranes (Byron and Patton, 1 994), the 
rate constant, ka,p is described as: 
(Eqn, IV.3 )  
The parameters DM,  AM,  Ko,  h and V are, respectively, the solute's diffusion coefficient 
through the pulmonary membranes, the total membrane surface area available for 
absorption, the solute's membrane/donor solution phase partition coefficient, the 
thickness of the membranes and the effective fluid volume in the airways (in which the 
solute is dissolved) , Provided that AM, h and V remain unchanged between 37 and 25 °c, 
the ratio of the rate constants, R(250C/37oC) should be described by: 
ka,p (25oC) DM (250C) , KD (25oC) 
R(250C/37oC) (Eqn, IVA) 
ka,p (37oC) DM (37oC) , Ko (37oC) 
If the diffusion coefficient, DM is assumed to be proportional to the absolute temperature, 
T, based on either Stokes-Einstein (Eqn, IV,S) or Wilke-Chang correlation (Eqn, IV,6) 
equations: 
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(Egn. IV.5) 
(Egn . IV.6) 
where R is the gas-law constant, T is the absolute temperature, llB is the viscosity of the 
medium in which diffusion occurs, No is Avogadro's number, rA is the effective radius of 
the solute molecule, <l>s is the solvent's association factor, MB is the solvent molecular 
weight and V'A is the solute's molar volume at its normal boiling temperature, the rate 
constant ratio, R(250C/37oC) (Egn. IVA) can be rewritten as : 
kay (25oC) KD (25oC) 
R(250C/37oC) ____ = 0.96 · ___ _ (Egn . IV.7) 
ka,p (37oC) KD (37oC) 
On such assumption, the value, 0.96 is obtained from the absolute temperature ratio of 25 
and 37 °C. 
The partition coefficients, KD for F-Na at 37 and 25 °C between octanol and 
phosphate buffered saline (PBS ;  pH 7 04) were found to be 0.79±O.05 and 0.35±0.05 
(mean±SD; n = 3 ;  Sakagami et aI. , 1 997), enabling a calculation of R(250C/37oC) = 0043 
using Egn. IV.7 .  This value was surprisingly consistent with R = 0048,  the 
experimentally-determined ratio of ka,p at 25 and 37 °C (0.023 and 0.048 
. - I min , 
respectively) obtained from across-dose curve fitting. The experimental value of R for 
FD-4, hydrophilic macromolecule absorbed solely by passive mechanisms was 0.5 (0.008 
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and 0.0 1 6  min- I at 25 and 37 °C, respectively) . The value was again, surprisingly 
consistent with theory outlined above, although FD-4 was predominantly absorbed 
through tight junctions between epithelial cells and it was likely that its absorption was 
diffusion-determined. This remains to be substantiated in future studies .  
Mucociliary clearance rate constants, kE•PT were found to be solute-independent, but 
significantly slowed at 25 °C, compared to those at 37 °c (Table IV.3) .  While clearance 
has been shown to be a complex function of ciliary beat frequency and mucus and 
periciliary fluid secretions, the rate of mucociliary clearance is known to be regulated by 
several intracellular ciliomodulators, such as ATP, Ca2+, cAMP, cGMP and protein 
kinase C (Wanner, 1 99 1 ;  Camner and Mossberg, 1 993) .  Moreover, the process is known 
to be cellular energy-dependent and recent evidence has suggested that the process could 
be largely activated by cAMP- and/or ATP- dependent phosphorylation (Lansley, 1 993 ;  
Camner and Mossberg, 1 993) .  Therefore, i t  was quite reasonable that a t  25 °C, the 
process was slowed due to an inhibition of cellular energy utilization . 
PULMONARY ABSORPTION OF 7 .4 kDa F-PHEA IN THE PRESENCE OF 
MET ABOLIC INHIBITORS 
Active absorption by transporters or carriers must be directly or indirectly coupled 
to a source of cellular metabolic energy. In most cases , the energy is generated by ATP 
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hydrolysis (Alberts et al. , 1983 ;  Andreoli et aI. , 1 986). A substrate, ATP is primarily 
synthesized by oxidative phosphorylation catalyzed by ATP synthase in mitochondria, as 
well as by glycolysis in the cytosol; the former is known to be a predominant mechanism 
for producing intracellular ATP (Liberman and Sleight, 1 995). Subsequent ATP 
hydrolysis (to ADP, inorganic phosphate and ilGo') is catalyzed by several types of 
ATPase, such as phosphoenzyme ATPase and mitochondrial ATPase. Among them, 
Na+/K+-ATPase, one of phosphoenzyme ATPase, is known to be responsible for the 
catalytic hydrolysis of ATP, while simultaneously driving active transport of Na+ and K+ 
ions against their electrochemical gradient across cell membranes (Alberts et al. , 1 994; 
Sperelakis, 1995). 
2A-Dinitrophenol (DNP; Fig. IV.2 (a)) is a lipid-soluble weak acid (pKa = 4. 1 ) , 
pharmacologically a proton ionophore. In mammalian cells, the compound removes the 
proton gradient across mitochondrial membrane without changing electron transport or 
proton pumping in the organelle. This is known as an uncoupling effect (Alberts et aI. , 
1994) and provides an additional pathway to the use of ATP synthase to enable inward­
flow of protons across the mitochondrial membrane ( "short-circuiting" ;  Rognstad and 
Katz, 1 974; Hanstein, 1 976; Alberts et aI. , 1983) .  Thus, DNP dissipates the proton­
motive force in mitochondria and abolishes the organelle's ATP synthesis by oxidative 
phosphorylation. Because of this action, the compound has been extensively used in 
several in vitro and in vivo systems, as summarized in Table IV.5 ,  as an ATP-depleting 
agent and/or ATP-synthesis inhibitor, to study the requirement for cellular energy in 
Table IV.5. Summary of absorption inhibition studies using 2,4-dinitrophenol (DNP; from the literature). 
Cells/Organs Substrate Application Concentration % Inhibition Reference! 
Rat lung: Slice DSCG03 Co-incubation l O mM 14 . 1 % Gardiner, 1 976 
Minced Propranolol 1 5min pre-incubation 0.05 mM 50 .5 % Iwamoto, 1 989 
Type II Na+ Co-incubation I mM 75 .4 % Goodman, 1 983 
Pneumocytes Paraquat Co-incubation I mM 63 .0 % Saito, 1 986 
Bullfrog lung H2O Co-incubation I mM 67.0 % Schaeffer, 1 984 
Rabbit alveolar Mfl Propranolol Co-incubation 0 .5 - 1  mM 52.3 % Vestal, 1 980 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Caco-2 Ceftibuten 3hr pre-incubation 0 .5 mM 93.4 % Muranushi, 1 994 
AT 2-antagonist*4 2hr pre-incubation I mM 79.3 % Soldner, 2000 
Hamster intestinal Linolenic acid 1 0min pre-incubation 0.25 mM 79.4 % Gore, 1 993 
cell culture 
Rat hepatocyte Cholic acid Co-incubation I mM 30.0 % Ohkuma, 1 983 
Vecronium Co-incubation I mM 5 1 .5 % Mol, 1 988  
Pravastatin Co-incubation I mM 30. 1 % Komai, 1 992 
TBuMA05 3min pre-incubation 0 .01 mM 50.0 % Steen, 1 993 
IPRK02 Digoxin Pre-incubation I mM 37 .5 % Hori, 1 993 
1 Only first authors and years of publication; details are described in References. 
° 1 Macrophage; °2 isolated perfused rat kidney; °3 disodium cromoglycate; °4 angiotensin II antagonist (tosartan) and 
°5 n-butylmethylammonium :::; 
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active transport processes (Table IV.5 ) .  It should also be noted that, unlike other 
"uncouplers " (deoxycholate, oligomycin and unsaturated fatty acids) ,  DNP inhibits 
mitochondrial ATP synthesis without disrupting the mitochondrial structures at relatively 
low concentrations (0.5-2.0 mM; Slater, 1 963). Furthermore, it has been shown that the 
compound inhibits all possible pathways of oxidative ATP production in the respiratory 
chain, whereas other chemical inhibitors, such as rotenone, antimysin A, cyanide and 
sodium azide, inhibit only parts of the process as well as acting as cell toxins due to their 
inhibitory effects on oxygen uptake (Sharon and McMurtry, 198 1 ) .  
A concentration-dependent inhibition of  F-PHEA's active absorption was observed 
in the presence of DNP (Fig.IV. lO) ,  demonstrating the necessity of intracellular ATP­
derived energy in the active absorption process. However, in the IPRL, it has been shown 
that depletion of mitochondrial ATP synthesis by DNP (0.8 mM) can be quite readily 
compensated by the use of glycolytic pathway driven by enhanced glucose uptake 
(Bassett and Fisher, 1976), causing cellular ATP levels to decrease only by about 63 % 
following 60 minutes perfusion in the IPRL (Bassett et ai. , 1989). Consistent with this 
observation, the maximum magnitude of inhibition for F-PHEA absorption was found to 
be only 53 .3±7 .9 % (mean±SE; n=4) at 1 .0 mM DNP in perfusate (Fig. IV. 10) .  This was 
quite different from in vitro cell culture systems like alveolar type II cells or hepatocytes 
which showed ;::: 75 % inhibition of active processes as a result of ;::: 80 % decrease in 
cellular ATP in the presence of DNP (Goodman et ai. , 1 983 ;  Muranushi et aI. , 1 994; 
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Soldner et aI. , 2000). Nevertheless, comparable concentrations of DNP produced 
inhibition of the F-PHEA transporter in our preparation (Ieso = 0.5- 1 .0 mM).  
Ouabain (OUA; strophantin G; Fig. IV.2 (b»  is a plant-derived cardiotonic steroid 
or cardiac glycoside and chemically, water-soluble ( 1 . 1  mg/mL) and extremely 
hydrophilic (KD = 0.01 between octanol and PBS (pH 7 .4» . In contrast to DNP's 
synthetic inhibition of cellular ATP, OUA is known to specifically inhibit a 
phosphoenzyme, Na+/K+-ATPase (Mercer, 1 993;  Alberts et aI. , 1 994). As a result, the 
compound inhibits both Na+ (outward) and K+ (inward) transport across cell membranes 
and their concomitant ATP hydrolysis that may generate metabolic energy for active 
transport either directly (ATP-driven or primary active mechanism) or indirectly (ion­
driven or secondary active mechanism; Alberts et aI. , 1994; Rose and Valdes, 1 994). 
Unfortunately, the inhibition mechanisms for direct, ATP-driven active transport by this 
Na+/K+-ATPase are not fully understood, while it is speculated that such active transport 
somehow utilizes ATP hydrolysis energy directly generated from Na+/K+-ATPase 
(Miller, 1973; Byrne et aI. , 199 1 ) .  Meanwhile, it can be also speculated that inhibition of 
Na+ and K+ transport by OUA may alter the membrane potentials across the cells and 
thus ,  active transport may be inhibited (Alberts et at. , 1 994). In contrast, the inhibition of 
indirect, ion-driven active transport is more likely to be associated with intracellular Na+ 
regulated by Na+/K+-ATPase (Byrne et aI. , 199 1 ) . Such Na+-dependent carriers are co- or 
counter- transport systems, coupled with downhill movement of Na+ into the cells. OUA 
inhibits Na+/K+-ATPase, causing an increase of intracellular Na+ concentration. As a 
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result, co- or counter- transport systems are no longer driven forward due to the OUA-
induced lack of a downhill Na+ gradient across the membranes. Finally, as a secondary 
response of an increase of intracellular Na+ concentrations through Na+IK+-ATPase 
inhibition, OUA must increase intracellular Ca2+ concentrations, driving Na+ICa2+-
counter-transport systems (Alberts et aI. , 1994). 
The Na+IK+-ATPase is predominantly located on the basolateral (blood/perfusate) 
side of the pulmonary membranes and OUA binds to the outer site of this transmembrane 
protein, competing with K+ (Alberts et al. , 1 994) . Inhibition of this Na+IK+-ATPase is 
reportedly obtained when 10-500 11M ouabain is applied to the basolateral side (rather 
than the apical side) in most experimental systems (Alberts et aI. , 1994; Cott, 1 994). 
Table IV.6 summarizes such organ or cell studies in which OUA has been used. In most 
cases, OUA has been used to elucidate Na+-dependent, indirect (ion-driven) active 
transport mechanisms. 
F-PHEA active absorption was found to be significantly inhibited by 62.3 and 75 .9  
%,  respectively, at 50 and 100 11M OUA in perfusate (Dunnet method following multiple 
ANOV A; P < 0.05 ; Fig. IV . 1 2) .  This proposed the involvement of OUA-inhibitable ATP 
hydrolysis, specific membrane potentials or Na+ and/or Ca2+ downhill movement into the 
cells being associated with the active absorption process for F-PHEA. However, it has 
been shown previously that F-PHEA absorption from the airways was not affected in the 
presence of Na + following iso-osmotic NaCI solution administration (to the apical side of 
the pulmonary epithelium; Sun, 1 995). This suggested therefore, that Na+ ion-driven 
Table IV.6. Summary of absorption inhibition studies using ouabain (OUA; from the literature). 
Cells/Organs Substrate Application Concentration % Inhibition 
IPRL'I Na+ 20 min pre-perfusion 0 .025-0.05 mM 1 9 .2 % 
Na+ 1 0  min pre-perfusion O. l mM 58 .4 % 
Na+ 1 0  min pre-perfusion 0.2 mM 34.3 % 
Na+ 1 0  min pre-perfusion 0 .5 mM 6 1 .3 % 
Na+ o min pre-prefusion 0 .5 mM 50.0 % 
Rat Type II Na+ Ihr co-incubation 0. 1 mM 43 .0 % 
Rat hepatocyte Cholic acid Co-incubation I mM 39 .0 % 
Vecronium Co-incubation I mM 56 .3 % 
Rabbit alveolar Mf2 Propranolol Co-incubation 0.5- 1 mM 1 8 . 3  % 
Bovine BCEC*3 �-alanine Co-incubation 0 . 5 mM 56 .7 % 
1 Only first authors and years of publication; details are described in References . 
' I Isolated perfused rat lung; '2 macrophage and '3 bovine brain capillary endothelial cells . 
Referencel 
Goodman, 1 987 
Basset, 1 987 
Sauman, 1 993 
Barnard, 1 997 
Saldias, 1 998 
Filippatos, 1 997 
Ohkuma, 1 983 
Mol, 1 988 
Vestal, 1 980 
Komura, 1 996 
N 
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secondary active transport mechanisms were less likely. This required additional firmer 
evidences for conclusions and detailed mechanisms of the inhibition remained to be 
substantiated in the future. 
PULMONARY ABSORPTION OF 7 .4 kDa F-PHEA IN THE PRESENCE OF 
INHIBITORS OF VESICULAR TRAFFICKING 
As opposed to carrier-mediated endocytotic absorption, active absorption by 
transporters (transcytosis) undergoes intracellular trafficking and vesicular sorting 
(Alberts et aI. , 1994). Generally, endosomal pathways in which cytoplasmic clathrin­
coated and/or nonclathrin-coated (caveolae) vesicles are formed, are followed by vesicle 
travel along microtubules to the other side of the membranes (partially by lysosomal 
degradation; Alberts et aI. , 1 994). Endogenously in the lung, extremely large plasma 
proteins, albumin (68 kDa) and IgG ( 1 50 kDa) have been shown to be transcytosed quite 
rapidly by specific transporter-mediated mechanisms across extremely thin (:::; I ]..lm) 
alveolar membranes (Hastings et al. , 1994; Kim et aI. , 1 995 ;  Folkesson et al. , 1 996). 
These processes differ with respect to their endosomal and macrotubular cytoplasmic 
pathways from the relatively slow adsorptive fluid-phase transcytosis seen with 
horseradish peroxidase (HRP; 44 kDa) and ferritin (500 kDa; Patton, 1 996). 
Monensin (MON; Fig. IV.2 (c» is a carboxylic and/or Na+ ionophore which exerts 
stochiometric Na+/H+ exchange following its relatively rapid incorporation into biological 
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membranes (due to its hydrophobicity; Dinter and Berger, 1998). Chemically, its open 
chain structure is capable of ion complexation through a cyclic form stabilized by 
hydrogen bonding between carboxyl and hydroxyl groups and a metal ion, especially 
Na+, can be incorporated to form an ionophore-ion complex through MON's ligand site 
(Mollenhauer et aI. , 1990). This complex can traverse biological membranes quite readily 
and exchange H+ and Na+ across those membranes by reversible association. As a result, 
the compound is known as a classical secretion or exocytosis inhibitor whose action leads 
to the formation of swollen vesicles near Golgi region at a minimum concentration of 1 0'7 
M in mammalian cells (Tartakoff and Vasalli, 1 977; Mollenhauer et aI. , 1 990) . However, 
its precise mode of action is unclear; it appears likely that MON somehow affects 
cytoplasmic acidification mechanisms ("Golgi-perturbing agent" ;  Dinter and Berger, 
1 998). The induction of swollen vesicles caused by inhibition of acidification in 
intracellular organelles, especially in endosomal contents , and their subsequent delivery 
to lysosomes, has initiated extensive research to study intracellular trafficking during 
endocytosis and transcytosis, as summarized in Table IV.7. MON has been used as an 
"endosomotropic agent" providing evidence for intracellular endosomal vesicular 
transport during transporter/receptor-mediated and fluid-phase endocytosis of several 
small and macromolecules (Potau et aI. , 1984; Whittaker et aI. , 1 986; Wilcox et aI. , 
1 989; Stenseth et al. , 1989; Hastings el al. , 1 994; Wangensteen el aI. , 1 996). 
F-PHEA's active absorption was inhibited by 57.9 and 66. 1 %,  respectively, when 
30 and 100 !lM MON were employed in co-administration experiments (Dunnet methods 
Table IV.7. Summary oftrancytosis and endocytosis studies using monensin (MON; from the literature) . 
Cells/Organs 
<Transcytosis> 
Rat Type II 
Rabbit in vivo 
IPRL*I 
GP*2 trachea 
primary culture 
<Endocytosis> 
Rat embryo 
fibroblast 
hepatocyte 
M<I>*3 
Mouse M<I>*3 
Hamster kidney 
BHK-2 1  
Substrate 
FITC-Alb*4 
HSA*5 
Riboflavin-BSA*6 
BSA 
TR-BSA 
OA*7 
HRP*S 
Asialo-gP*9 
Mannose-gp*9 
IgG-coated 
particles 
Ferritin 
HRP*s 
SF-virus* lo 
Application Concentration 
Ihr pre-incubation 30 f.lM 
Co-administration 30 f.lM 
Co-administration 3 5  f.lM 
Co-administration 35 f.lM 
Co-incubation 1 - 1 0  f.lM 
Co-incubation I f.lM 
Co-incubation 1 f.lM 
(IC50�O.3 11M) 
Co-incubation 25 f.lM 
Co-incubation 1 0  f.lM 
Co-incubation 1 0  f.lM 
Co-incubation 3 f.lM 
Co-incubation 1 - 1 0  f.lM 
Co-incubation 1 0  f.lM 
1 Only first authors and years of publication; details are described in References . 
% Inhibition Reference! 
52 .0 % Hastings, 1 994 
No uptake 
64.3 % Wangensteen, 1 996 
24.0 % 
95 .0 % Deffebach, 1 996 
94.6 % 
75 .0 % Wilcox, 1 982 
75 .0 % Berg, 1 983 
74.5 % Wileman, 1 984 
97 . 1 % Hedin, 1 985 
1 7 . 5  % Stenseth, 1 989 
70.0 % 
97.0 % Marsh, 1 982 
*1 Isolated perfused rat lung; *2 guinea pig; *3 macrophage; *4 albumin; *5 human serum albumin; *6 bovine serum albumin; 
*7 ovalbumin; *8 horseradish peroxidase; *9 glycoprotein and * \ 0  Semliki Forest virus. 
N .. 
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following multiple ANOVA; p < 0.05 ; Fig. IV. I S) .  This suggested that F-PHEA's active 
absorption involved endosomal vesicular transport. In the IPRL, Wangensteen et  at. 
( 1 996) found similar effects and values for % inhibition of receptor-mediated transcytosis 
of riboflavin-albumin conjugate from airways following 35 11M MOC co-administration 
(Table IV.7) .  Furthermore, effective inhibitory concentrations seen in other endocytosis 
and transcytosis studies (Table IV.7) were almost consistent with the ICso values obtained 
from Fig. IV. I S  ( 1 0-30 11M). Thus, it appeared that F-PHEA's active absorption was via 
specific transporter-mediated transcytosis which involved endosomal vesicular transport. 
Nocodazole (NOC) has been proven to depolymerize microtubules in energy­
dependent processes (Turner and Tartakoff, 1 989), thus leading to a breakdown in Golgi 
apparatus structure. The compound has been extensively used for studying Golgi function 
as a "Golgi-perturbing agent" (Eiler et al. , 1 989; Alberts et at. , 1 994; Dinter and Berger, 
1998) as well as interupter of microtubule-mediated transport in the cell's endosomal 
network (e .g . ,  early endosomes through late endosomes), which sorts endosomes and 
defines their disposition (Alberts et at. , 1994; Hastings et al. , 1994; Deffebach et at. , 
1 996). Overall, and in this thesis, NOC has been used as a "microtubule-disrupting agent" 
to elucidate several transporter-mediated transcytotic processes, as shown in Table IV.8 .  
NOC inhibited F-PHEA's active absorption by  75 % following � 10  11M NON co-
administration into the airways (Fig. IV. lS) .  Its ICso value ( 1 -5 11M) was reasonably 
consistent with other studies in Table IV.8 and therefore, it is suggested that F-PHEA's 
Table IV.S. Summary of trancytosis studies using nocodazole (NOC; from the literature). 
Cells/Organs 
Rat Type II 
Rabbit in vivo 
IPRL" 1 
GP"2 trachea 
primary culture 
Caco-2 
MDCK"3 
Substrate 
FITC-Alb "4 
HSA*5 
Riboflavin-BSA *6 
TR-BSA 
OA"7 
Aminopeptidase N 
Botulinum 
neurotoxin 
IgG-pIgGR*8 
85 kDa gp*9 
Application Concentration 
1 hr pre-incubation 30 �M 
Co-administration 30 �M 
Co-administration 3 5  �M 
Co-incubation 1 0-75 �M 
Co-incubation 50 �M 
3hr pre-incubation 30 �M 
30 �M 
Co-incubation 1 0  �M 
2hr pre-incubation 33 �M 
Co-incubation 33 �M 
1 Only first authors and years of publication; details are described in References. 
% Inhibition Reference! 
20.0 % Hastings, 1 994 
No uptake 
62.3 % Wangensteen, 1 996 
73 .8  % Deffebach, 1 996 
5 1 . 1  % 
24. 1 % Eilers, 1 989 
50.0 % Matter, 1 990 
42 .0 % Maksymowych, 1 998 
60.8 % Breitfeld, 1 990 
19 .6  % Brandli, 1 990 
*1 Isolated perfused rat lung; *2 guinea pig; *3 Madin-Darby canine kidney cells; *4 albumin; *5 human serum albumin; 
*6 bovine serum albumin; *7 ovalbumin; "8 immunoglobulin G-poly IgG receptor complex and "9 glycoprotein. 
N 0-
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active absorption involved microtubule-mediated transport during the polymer's 
endosomal vesicular transcytosis. 
As summarized in Fig. IV. 1 7  , F-PHEA's active transport from airways to perfusate 
in the IPRL was signiticantly inhibited at low temperature (25 DC) and by the presence of 
several metabolic inhibitors at quite reasonable effective concentrations, when compared 
to the literature. The inhibition evidence at 25 DC and 1 .0 mM DNP indicated the 
requirement for ATP-driven intracellular energy, while MON (30 �M) and NOC (30 �M) 
inhibition suggested that endosomal formation and microtubular transcytosis were 
required for F-PHEA's active absorption from the airways . Indirect ion (Na+- and/or 
Ca2+_ driven secondary active mechanism remained a possible explanation of the 
inhibition seen in the presence of OUA ( 1 00 �), although it was unlikely with respect 
to Na+, based upon the appearance that process was Na+-independent, when the apical 
side of the membrane was exposed to NaCI in the dosing vehicle (Sun, 1 995). However, 
this mechanism was not truly elucidated and required additional substantiation in the 
future. Thus, a possible mechanistic scheme for F-PHEA's active absorption, which was 
consistent with the absorption inhibition evidence shown in Fig. TV. 17 ,  is described in 
Fig. IV. 1 8 . 
In summary, F-PHEA was actively absorbed from the airways of the rat lung by an 
ATP-driven energy-dependent, intracellular vesicular transcytotic mechanism, probably 
via a specific transporter process .  While the presence of such transporters on alveolar 
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Figure IV.17. Mean percentage of actively-absorbed F-PHEA transferred to perfusate 
over the 30 minute period following solute administration. Graph shows the absence 
(control) and the presence of various metabolic inhibitors. Error bars are sample 
standard errors (SE) with n = 4. 
Key: DNP - 2,4-dinitrophenol; OUA - ouabain; MON - monensin; NOC - nocodazole. 
* indicates significant difference, compared to the control (Hest; p<O.05). 
Apical 
airway side 
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mitochondria  
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Figure IV.IS. Proposed mechanisms for active and passive absorption ofF-PHEA 
and their sites of inhibition from the airways of the IPRL. 
Key: DNP - 2,4-dinitrophenol; OUA - ouabain; MON - monensin; NOC - nocodazole. 
OUA inhibited F-PHEA's active absorption, but without a direct link to its Na+/K+­
ATPase inhibitory effects, which required further substantiation. 
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membranes has yet to be identified and intracellular trafficking through alveolar 
epithelial transcytosis is controversial (transcytotic vesicles are often larger than the 
thickness of alveolar epithelial cells ;  Patton, 1 996), the fact that lysosomes are absent 
from much of the cytoplasm and abundant vesicles (caveolae) are found in alveolar 
epithelial cell membranes (Patton, 1 996; Campbell et aI. , 1 998) implies that significant 
transcytotic activity is possible in the pulmonary regions of the lung. It is probable that 
these mechanisms are involved with the rapid transcytosis of F-PHEA from the airways 
and that other macromolecular transporters remain to be elucidated in the future. 
CHAPTER V 
PULMONARY ABSORPTION KINETICS OF F -PHEA: 
EFFECTS OF MOLECULAR SIZE 
V.3 INTRODUCTION 
In previous chapters, the kinetics and mechanisms describing 7.4 kDa F-PHEA 
disposition in the airways of the IPRL were characterized precisely, in the presence of 
competing mucociliary clearance. As a result, simultaneous active and passive absorption 
kinetics were differentiated and analyzed independently by across-dose curve fitting at 37 
and 25 °C .  In this chapter, similar kinetic analysis was extended to describe the 
disposition of a differently-sized, 4.3 kDa F-PHEA in the IPRL. By comparing the rates 
of active and passive absorption between the two polymers (7.4 VS. 4.3 kDa), the 
molecular size-selectivity of each process could be studied. For these purposes, 4.3 kDa 
F-PHEA absorption was studied in the IPRL at 37 and 25 °C and its absorption kinetics 
from the pulmonary airways compared to those of its larger counterpart, 7.4 kDa F­
PHEA. 
1 3 1  
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V.b MATERIALS AND METHODS 
V.b. I 7.4 kDa AND 4 . 3  kDa F-PHEA 
Two, differently-sized, fluorophore-Iabeled poly-a,p- [N(2-hydroxyethyl)-D,L­
aspartamides] (FR7 150 and FR7002-5 ;  F-PHEA) were used as model macromolecules .  
Synthesis and preparation of these polymers has been described in detail previously 
(Chapter 3 and Appendix III) . Their normalized weight-based molecular weight 
distributions (MWD) were determined by Dr. Rypacek in Prague from their elution 
profiles following high performance gel permeation chromatography (HPGPC) on 
calibrated columns. Detection employed UV absorbance at 220 nm (Appendix III) . 
Weight- (Mw) and number- (Mn) averaged molecular weights of each polymer were 
calculated, based on these profiles. These are shown in Table V. l along with the 
polydispersity values (Pd =MwlMn; Appendix III) and their complete MWD (Fig. V. l ) .  
The polymers were defined a s  7 . 4  and 4 . 3  kDa F-PHEA i n  this chapter, based upon their 
weight-averaged molecular weights (Mw), even though there was a degree of overlap in 
each case (Fig. V. l ) .  Similar to 7.4 kDa F-PHEA, 4.3 kDa F-PHEA was found to carry 
0.3 mol% fluorophore with respect to monomer, enabling a similar high sensitivity assay 
by HPGPC (HEMA-Bio 40 column) to be employed with fluorescence detection (Aex = 
486 nm and Aem = 5 1 6  nm; Appendix N). Once again, a rigorous curve stripping 
procedure was employed to determine the area under the curve of F-PHEA's 
Table V.l .  Fluorophore content and molecular weight distributions of 7.4 and 
4.3 kDa F-PHEA polymers. 
Ra [mol%] M e M e w n F-PHEA 
Fb HEb [Da] [Da] 
FR7150 0.3  99 .7  7420 6620 
FR7002-5 0.3  99.7 4308 2245 
a A substituent group, R in F-PHEA structure shown below. 
b F and HE are fluorophore and hydroxyethyl substituents, respectively. 
p d  
d 
1 . 1 2 
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C Mw and Mn are HPGPC-determined weight- and nurnber- averaged molecular 
weights, respectively. 
d Pd = Mw / � ; polydispersity. 
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Figure V.l .  Nonnalized weight-based molecular weight distributions of two, 
differently-sized F-PHEAs, FR7 1 50 and FR7002-5 . The chromatograms were 
monitored by UV absorbance at 220 nm. The column was calibrated with 
PHEA standards, polyethyleneoxide (PEO), hydroxyethyl glutamine (REG) 
and water. Weight- (Mw) and number- (�) averaged molecular weights were 
calculated to be 7420 and 6620 Da for FR7 1 50 and 4308 and 2245 Da for 
FR7002-5, respectively. Data was supplied by Dr. Rypacek. 
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chromatograms in both perfusate and filtered supernatant of lung homogenate (Appendix 
IV; Sun, 1 995) .  
V.b.2 PULMONARY ABSORPTION IN THE IPRL 
The IPRL preparation and the dosing method used to deliver F-PHEA into the 
airways have been described in detail previously (Byron and Niven, 1988 ;  Chapters 3 and 
4; Appendix I). These were used unchanged and F-PHEA absorption was studied at both 
37 and 25 Dc. Briefly, a rat lung was removed from the body and housed in the jacketed 
artificial glass thorax (AGT), maintained at either 37 or 25 DC by water supplied from a 
thermostatically-controlled water circulator (Model 9505, Fisher Scientific, Pittsburgh, 
PA) . Its pulmonary circulation was perfused with circulating perfusate solution (Krebs­
Heinseleit solution with 4 % bovine serum albumin) from a reservoir whose temperature 
was also controlled by the circulator. 4 .3 kDa F-PHEA (nominal doses of 0. 1 , 0 .2 and 1 .0 
mg) was administered into the airways as a coarse spray by "forced solution instillation" 
and its absorption was followed as a function of time by sampling and analyzing the 
perfusate, as described in Chapters 3 and 4 (37 and 25 DC) .  Four fully viable preparations 
were studied for each dosing solution and temperature partnership. The absorption results 
were expressed as mean % of administered dose transferred to perfusate ± sample 
standard deviation vs. time. The individual results from each IPRL preparation are 
reported in Appendix VII. 
V.b .3  
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KINETIC MODELING, FITTING AND PARAMETER ESTIMATION 
The kinetic model shown in Fig. IV. l (Chapter 4) and the method used for 
analyzing F-PHEA absorption data at both 37 and 25 °C have been described in detail 
previously and were used unchanged (Chapters 3 and 4). Briefly, average data for % of 
administered dose transferred to perfusate (Figs. V.2 and V.3)  was fitted across doses to 
Eqns. III .3-5 (from Chapter 3)  and the model shown as Fig. IV. 1 .  These equations are 
restated below: 
(d[Pj/dt)Activc+Passive. lPRL = V max.P · [Mjp/(Km.P + [Mjp) + ka.p· [Mjp 
(d[Mjp/dt)lPRL = - (d[Pj/dt) - kE.p"dMjp 
(d [MhB/dt)IPRL = kE.p"dMjp 
(Eqn. III .3 )  
(Eqn. IlI.4) 
(Eqn. III .5 )  
where [Pj is the cumulative solute amount absorbed from the pulmonary region into the 
recirculating perfusate of the IPRL, [Mjp and [MhB are the solute amounts remaining to 
be absorbed from the pulmonary and the tracheo-bronchial regions, respectively; V max.P is 
the maximum rate of active absorption, Km.P is the "affinity" or dose at which the active 
absorption rate = O.5 ·V max.P, ka.P is the first-order passive absorption rate constant from 
the pulmonary region and kE.IT is the first-order mucociliary clearance rate constant from 
the pulmonary to the tracheo-bronchial region. Unweighted, nonlinear least-mean-square 
regression analysis was employed for curve fitting and subsequent rate constant 
determination using Scientist™ (MicroMath Scientific Software, Salt Lake City, UT) 
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where Vmax,P, Km,p, ka,p and kE,PT were allowed to float. The fraction of the administered 
dose delivered to the pulmonary region, F, was fixed throughout at its experimentally­
determined average value, 0.9 1 (0,9 1 3±0.037 ;  mean±SD; n=4), so that initial conditions 
were : 
[M]p, ,=0 I [administered dose] = 0 .91  
[Mhs, ,=0 I [administered dose] = 0.09 
[P] ,=o I [administered dose] = 0.00 
The model fits were assessed using "goodness-of-fit" parameters (Model Selection 
Criterion (MSC), R-squared (R2) ,  a review of the standard deviations of final parameter 
estimates and visual inspection of the residuals), as described in Chapter 3. Additional 
methodological details are described in Appendix VI. 
V.c RESULTS AND DISCUSSION 
The analytical sensitivity, precision and accuracy of determination for 4.3 kDa F-
PHEA in all matrixes were characterized by an LOD :0; 0.02 Ilg/mL, RSD :0; 8 .5  % and 
%error :O; 6.2 % (n=6) over the concentration ranges of 0.06- 1 .0 IlglmL (Appendix IV). 
Similar to 7.4 kDa F-PHEA, there was no evidence of degradation, metabolism or lung 
tissue sequestration in rat lung observed with 4.3 kDa F-PHEA (Appendix V), although 
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the HPGPC technique employed for quantification and MWD assessment o f  the 
polyaspartamide was unable to accurately assess changes in the MWD of the smaller (4. 3  
kDa) polymer used in  this thesis. 
Average percent transfer (±SD) of 4 .3 kDa F-PHEA VS.  time at 37 and 25 °C are 
shown in Figs. V.2 and V.3 across doses . The solid curves drawn through the data points 
are the results of simultaneous curve fitting across doses to the model shown in Fig. IV. I 
(Chapter 4). Curves were generated by "Scientist" using the program's best estimates for 
the model's rate constants as reported in Table V.2.  The rate constants for each process 
were successfully estimated at both temperatures .  Model Selection Criteria (MSC) values 
;:0: 3.7 and R-squared, R2 ;:0: 0.996 were achieved, although parameter estimates were 
somewhat less precise when compared to those for 7.4 kDa F-PHEA. Unfortunately, 
several attempts to decrease the variance of 4.3 kDa F-PHEA's parameter estimates by 
fixing kE,PT, the first-order rate constant for mucociliary clearance, at "across-solute 
weighted mean values" specific to 37 or 25 DC (while allowing other kinetic parameters 
in the model to float) were unsuccessful. 
The absorption profiles of 4.3 kDa F-PHEA at 37 DC were found to be dose­
dependent (Fig. V.2) and the magnitude of this dependence was suppressed dramatically 
at 25 DC (Fig. V.3) .  This indicated the presence of a saturable active absorption 
mechanism which contributed significantly to enhance the polymer' s  absorption from the 
airways, as seen in the case of 7.4 kDa F-PHEA (Fig. IV,3 ,  Chapter 4). The absorption 
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Figure V.2.  Mean percentage (±SD; n=4) of administered dose of 4.3 kDa F-PHEA 
absorbed from the airways of the IPRL into the perfusate vs. time at 37 °C. The solid 
curves are the results of simultaneous across-dose curve fitting of all profiles. These 
were generated using the best estimates determined for each parameter at 37 °C, as 
described in Table V.2 (V max p, K", p, ka P and kE PT = 3.60 [f!g!min] , 76.8 [f!g] , 0.0 1 4  
[min- I ]  and 0.0 16  [min- I ] ,  re�pecti�ely): 
' 
� 60 o Q) "'O +-' 
"'0 ro 50 
Q) CJ) I.... :::J 
2 � 40 CJ) 
Q. C 0 E +-' 30 
"'0 "'0 
� � 20 o �  
'(f:. � 1 0  
c ro 
m .b  0 
� o 
Nominal  doses 
• 0 . 1  mg 
6 0.2 mg 
• 1 .0 mg 
20 40 60 
1 40 
80 1 00 1 20 1 40 1 60 1 80 
Time [m i nutes] 
Figure V.3.  Mean percentage (±SD; n=4) of administered dose of 4.3 kDa F-PHEA 
absorbed from the airways of the IPRL into the perfusate vs. time at 25 °C. The solid 
curves are the results of simultaneous across-dose curve fitting of all profiles. These 
were generated using the best estimates determined for each parameter at 25 °C, as 
described in Table V.2 (V max,P' K"" p, ka,p and kE,PT = 0.92 [flglmin] , 84.7 [flg] , 0.005 
[min" ] and 0.0 1 2  [min" ] ,  respectively). 
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Table V.2. Disposition parameters for 4.3 kDa F-PHEA following its administration 
into the airways of the isolated perfused rat lung (IPRL) at 37 and 25 °C. 
Active Passive Mucociliary 
Temp. absorption absorption clearance MSC ;  R2 
Vmax,P Km,P V max,p/Km,P ka,p kE,PT 
[�g/min] [�g] [min-I ] [min-I ] [min-I ] 
* * *  * * *  37 °C 3 . 60 76_8  0 _047 0 .0 1 4  0 .0 1 6  3 . 70; 0.996 
( 1 .53) (46.4) (0.003) (0.00 1 )  
* * *  * * *  25 °C 0 .92 84.7 0. 0 1 1 0 .005 0 _0 1 2  4.68; 0.998 
(0. 3 1  ) (39.3) (0.001 ) (0.001 )  
Values are the best estimates (SD) following analysis of across-dose data for 4 .3 kDa 
F-PHEA. Nominal doses: 0. 1 ,  0.2 and 1 .0 mg at 37 and 25 °C. 
MSC (Model Selection Criterion) and R2 (R-squared) were as calculated by 
"Scientist" (Appendix VI) . 
*, ** and * * *  indicate significant difference (p<0.05) between values of V max,P' ka,p 
and kE,PT at 37 and 25 °C, respectively, based on non-overlapped 95% confidence 
intervals. 
The values for �,p were insignificantly different between the 37 and 25 °C 
conditions, based on the same approach. 
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profiles are compared between 4.3 and 704 kDa F-PHEA at a nominal 0. 1 mg dose in Fig .  
VA, alongside that of the model polysaccharide, FD-4 (weight-averaged molecular 
weight (Mw) = 404 kDa) in the same dose. Clearly, because of the contribution of the 
active transport at this small dose, 4.3 kDa F-PHEA showed much faster absorption than 
FD-4 despite the similarity in their molecular sizes. Interestingly, at a nominal 0. 1 mg 
dose, where active absorption is presumably dominant, the absorption of the 4.3 kDa F-
PHEA was found to be no different, statistically, to that of 7 04 kDa F-PHEA (ANOVA); 
both showed 10- 1 5  minute apparent absorption half-lives. In contrast, at a higher nominal 
dose of 1 .0 mg, the smaller 4.3 kDa F-PHEA showed significantly faster absorption than 
its larger counterpart, as shown in Fig. V.5 (ANOVA; p < 0.05) .  These results suggested 
the likelihood that passive absorption contributed significantly to the airway-to-perfusate 
transfer of 4.3 kDa F-PHEA, whereas the active absorption of the polymer was 
effectively unchanged for this altered molecular weight distribution (MWD). 
The best parameter estimates for each disposition constant in the kinetic model 
(Fig. IV. l ;  Chapter 4) are shown in Table V.2 for 4.3 kDa F-PHEA. At 37 °C, an 
"intrinsic rate constant" for active absorption, calculated by V max,p/Km,p was found to be 
0.047 min· t , whereas a rate constant for passive absorption, ka,p was 0.0 1 4  min· t , again 
demonstrating a significant contribution due to active absorption at low doses of this 
small-sized F-PHEA. This component was dramatically suppressed at 25 °C (V max,p/Km,p 
= 0.01 1 min· t ) in a parallel fashion to the solute's passive absorption. The suppression of 
the transporter was apparently dominated by a significant decrease in the values for 
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Figure V.4. Mean percentage (±SD; n=4) of administered dose of 4.3 and 7.4 kDa F­
PHEA and FD-4 absorbed from the airways of the IPRL at 37 DC (nominal dose = 0. 1 
mg). The solid curves were generated using best estimates of parameters for each solute 
at 37 °C according to the model shown in Fig. IV. l  and as described in Tables III .2 
(Chapter 3) and V.2 (Chapter 5) . Thus, values for V max P' � P' ka P and kE PT were 3 .60 
[flglmin], 76.8 [flg] , 0.014 [min·l ]  and 0.0 1 6  [min-I ]  an"d 4.3"7 [fl8;min] , 56 .6 [ flg] , 
0.001 [min· l ]  and 0.023 [min- I ] ,  respectively (4.3 and 7.4 kDa F-PHEA), while those 
for ka•p and kE•PT were 0.0 16  [min- I ] and 0.029 [min-I ]  
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Figure V.S. Mean percentage (±SD; n=4) of administered dose of 4.3 and 7.4 kDa F­
PHEA absorbed from the airways of the IPRL at 37 DC (nominal dose = 1 .0 mg) . The 
solid curves are the results of the simultaneous across-dose curve fitting for each 
MWD. These were generated using best estimates determined for each polymer at 3 7  
DC, a s  described in Tables III.2 (Chapter 3) and V . 2  (Chapter 5) . 
145 
Vmax,p (maximum rate; 3 ,60±L53 --7 0.92±0.3 1  Jlg/min; p < 0.05), while the " affinity" 
term, Km,p, was unchanged by temperature (76.8±46.4 VS. 84.7±38 .3  Jlg) . The behavior of 
4 .3 kDa F-PHEA's kinetic descriptors were similar to those seen with 7.4 kDa F-PHEA 
(Table IV.2;  Chapter 4). 
Structural-specificity and/or size-selectivity for transepithelial transporters or 
carriers have been documented previously in lung (Helliwell et ai. , 1 994; Knickelbein et 
aI. , 1 997 ; Yamashita et aI. , 1 998) as well as the other organs (Lepage and Gros, 1 993 ;  
Gan e t  a i "  1997; Ogihara e t  ai. , 1 999). These were mostly limited to  small solute 
transport systems such as amino acids, monocarboxylic acids and di- or tri- peptides 
(Knickelbein et aI. , 1 997 ; Yamashita et ai. , 1 998;  Ogihara et aI. , 1 999). In general, these 
transporters or carriers were shown to be highly specific to particular chemical structures 
up to certain molecular sizes. For example, dipeptide transporters for carnosine (�-Ala­
L-His) on rabbit tracheal epithelial cells were shown to be only specific to L-configured 
dipeptides, but not to either amino acids (�-alanine and L-histidine) or D-configured 
dipeptides (�-Ala-D-His) or tri-peptides (TRH; Yamashita et ai. , 1 998). Meanwhile, a 
multi drug resistance protein, P-glycoprotein (Pgp) is known to transport structurally­
and/or pharmacologiCallY- unrelated compounds out of the cell quite efficiently (Lepage 
and Gros,  1 993 ; Seelig, 1 998a and 1 998b). Its broad spectrum of the substrate specificity 
was shown to cover anthracyclines (doxorubicin, daunorubicin), alkaloids (reserpine, 
vinblastine) , steroid hormones (aldosterone, hydrocortisone), anesthetics (dibucaine), dye 
molecules (rhodamine 1 23)  and specific peptides (valinomycin,  cyclosporin A), and their 
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molecular sizes were ranged from 183  Da (phenoxazine) to 1 647 Da (a-factor 
pheromone; Seelig, 1 998a and 1 998b). In this case, it was speculated that two electron 
donor groups with a spatial separation of either 2 .5±0.3 or 4 .6±O.6 A were necessary as 
the substrate specificity, rather than particular chemical structures (Lepage and Gros ,  
1 993 ;  Seeling, 1998a and 1 998b). I t  seems quite possible therefore, that F-PHEA 
transporters, specifically recognizing either chemical structures, molecular moieties or 
spaces with favorable size limitation exist in lung, which function to transcytose 
macromolecules quite rapidly from the airways. 
Disposition parameters for 4 .3 and 7.4 kDa F-PHEA, FD-4 and F-Na are compared 
in Tables V.3 and V.4 at 37 and 25 DC, respectively. Despite the reduced precision of 
parameter estimation in the case of 4.3 kDa F-PHEA, there was no significant difference 
in the polymer's active absorption kinetics; V max.P and Km.p were unchanged (based on the 
overlapped 95%CI) . While F-PHEA's two molecular weight distributions (MWD) 
overlapped (Fig. V . l ) ,  the passive absorption rate constant, ka,p for 4.3 kDa F-PHEA at 
37 DC was significantly greater than that for 7.4 kDa F-PHEA (O. O I 4±O.003 vs. 
0OO l±O.00 1 min- I ; mean±SD;  p < 0.05). Furthermore, values of ka,p for 4.3 kDa F-PHEA 
were consistent with those for similar-sized 4.4 kDa FD-4 at each temperature. 
In contrast to active absorption, passive absorption is generally believed to be 
regulated by diffusion and partitioning (Notari, 1987;  Byron and Philips, 1 990; Byron 
and Patton,  1 994) . Specifically for highly hydrophilic solutes like F-PHEA, such 
absorption should be predominantly controlled by diffusion through membranes where 
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Table V.3. Disposition parameters for active/passive absorption and mucociliary 
clearance for 7.4 and 4.3 kDa F-PHEA, FD-4 and F-Na following their 
administration into the airways of the isolated perfused rat lung (IPRL) at 37 °C. 
Active Passive Mucociliary 
Solutes absorption absorption clearance MSC; R2 
(Mw) Vrnax,P Km,p V rnax,p/Km,p k.,p kE,PT 
[flglmin] [flg] [min· l ] [min·l ]  [min· l ] 
F-PHEA 4.37 56 .6  0 .077 0.00 1 0 .023 3 . 1 2 ;  0.986 
(7.4 kDa) (0.57) ( 14.7) (0.001 ) (0.00 1 )  
F-PHEA 3 . 60 76 .8  0 .047 0 .0 1 4  0 .0 1 6  3 . 70; 0.996 
(4.3 kDa) ( 1 .53) (46 .4) (0.003) (0.001 )  
FD-4 N/A N/A N/A 0.0 1 6  0 .029 2 .83 ;  0.990 
(4.4 kDa) (0.001 )  (0.003) 
F-Na N/A N/A N/A 0.048 0. 022 3 . 37 ;  0.992 
(376 Da) (0.003) (0.002) 
Values are the best estimates (SD) following analysis of across-dose data from: 
7. 4 kDa F-PHEA - nominal doses: 0. 1 ,  0.2, 0.5, 1 .0 and 5.0 mg; 4. 3 kDa F-PHEA -
nominal doses: 0. 1 ,  0.2 and 1 .0 mg; FD-4 - nominal doses: 0. 1 and 0.2 mg; F-Na ­
nominal doses: 0.0 1 ,  0.02 and 0.04 mg. 
MSC (Model Selection Criterion) and R2 (R-squared) were as calculated by "Scientist" 
(Appendix VI) . 
N/A indicates "not applicable" (no dose-dependency was observed). 
There were no significant difference between solutes for values of V max p, K", P and kE PT 
(based on overlapped 95% confidence intervals). 
. . . 
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Table V.4. Disposition parameters for active/passive absorption and mucociliary 
clearance for 7.4 and 4.3 kDa F-PHEA, FD-4 and F-Na following their 
administration into the airways of the isolated perfused rat lung (IPRL) at 25 °C. 
Active Passive Mucociliary 
Solutes absorption absorption clearance 
(Mw) kE,PT MSC;  R2 Vmax,P Km,p V max,p/Km,p k.,p 
[J.!g1min] [J.!g] [min-I ] [min-I ] [min-I ] 
F-PHEA 0.67 30 .3  0 .022 0 .002 0 .0 1 6  3 . 74; 0 .99 1 
(7.4 kDa) (0. 1 0) ( 1 6.4) (0.00 1 )  (0.00 1 )  
F-PHEA 0.92 84.7 0 .0 1 1 0.005 0 .0 1 2  4.68; 0.998 
(4.3 kDa) (0.3 1 )  (39.3) (0.00 1 )  (0.00 1 )  
FD-4 N/A N/A N/A 0.008 0 .0 1 2  2.87 ; 0 .985 
(4.4 kDa) (0.00 1 )  (0.002) 
F-Na N/A N/A N/A 0.023 0 .0 1 0  3 . 1 2 ;  0 .987 
(376 Da) (0.00 1 )  (0.002) 
Values are the best estimates (SD) following analysis of across-dose data from: 
7. 4 kDa F-PHEA - nominal doses: 0.2, 0.5, 1 .0 and 5.0 mg; 4. 3 kDa F-PHEA - nominal 
doses: 0. 1 , 0.2 and 1 .0 mg; FD-4 - nominal doses: 0. 1 and 0.2 mg; F-Na - nominal 
doses : 0.0 1 , 0.02 and 0.04 mg. 
MSC (Model Selection Criterion) and R2 (R-squared) were as calculated by "Scientist" 
(Appendix VI) . 
N/ A indicates "not applicable" (no dose-dependency was observed) . 
There were no significant difference between solutes for values of V max,P' Km,p and kE,PT 
(based on overlapped 95% confidence intervals). 
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restricted "pore-sizes" exist ( "restricted diffusion theory") ,  for example via tight junctions 
and due to negligible partitioning (Hastings et ai. , 1 992; Folkesson et ai. , 1 996; Kim and 
Crandall , 1 996). In such a situation, molecular weight and solvated molecular volumes 
become critical determinants of passive absorption rates where either Stokes-Einstein or 
Wilke-Chang correlation equations may be of some predictive value (Kydonieus ,  1 99 1 ;  
Byron and Patton, 1 994). In the case o f  rat alveolar epithelial cell membranes, it i s  
believed that equivalent pore diameters for restricted diffusion are in the range of 0.4-50 
nm (Chandra et ai. , 1 992). Such a wide range excludes very little and certainly includes 
hydrodynamic diameters determined from GPC elution profiles of 3.7 nm for 7.4 kDa F­
PHEA (Sun, 1995). Therefore, as molecular size is decreased, passive absorption is more 
likely to be pronounced in alveolar and tracheal epithelial monolayer systems (Mathias et  
ai. , 1 996; Matsukawa et ai. , 1 997 ; Dodoo et ai. , 2000) as well as in vivo (Effros and 
Mason; 1 983) .  
These results for ka,p are thus consistent with the existence of molecular size­
selectivity and simple restricted diffusion occurring through pulmonary membranes, as 
seen in other studies (smaller solutes diffuse faster; Effros and Mason, 1983 ;  Hastings et 
ai. , 1 992; Byron and Patton, 1 994; Folkesson et ai. , 1 996; Kim and Crandall, 1 996). The 
rate constants for mucociliary clearance, kE,PT, were found to differ insignificantly across  
solutes at  each fixed temperature (based on the overlapped 95%CI), adding further 
weight to the validity of the model developed in this thesis for IPRL solute disposition. 
V.d SUMMARY AND CONCLUSION 
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Kinetic modeling and across-dose curve fitting enabled the characterization of both 
the active and passive absorption kinetics of 4.3 kDa F-PHEA from the pulmonary 
airways of the IPRL, in the presence of competing mucociliary clearance. Mucociliary 
clearance was temperature-dependent, but solute-independent. The values of this smaller 
F-PHEA's disposition parameters were consistent with the size-selective passive 
absorption of F-PHEA through tight junctions as expected. Passive absorption rate 
constants, ka•p, were found to be an inverse function of molecular size and those for 4.3 
kDa F-PHEA were similar to those for 4.4 kDa FDA (0.0 14  VS. 0.0 1 6  min· l , respectively; 
Table V.3) .  Thus, despite the presence of polydisperse MWD for F-PHEA polymers, 4.3 
kDa F-PHEA showed a higher ka.P value than its larger counterpart (0.0 14 VS. 0.00 1 min' 
I , respectively; Table V.3) .  It is  likely therefore, that solutes � 4 kDa are not readily 
absorbed by passive absorption and that their (larger molecular weight) absorption half­
lives were � 45 minutes (Fig. V. l ) .  In contrast, it appeared that the active absorption 
kinetics (V max,P and Kno.p) for 7.4 and 4.3 kDa F-PHEA were identical . This evidence 
suggested that the F-PHEA transporter specifically transported overlapped portions � 4 
kDa of the MWD of both polymers (Fig. V. I ) .  Consequently, the absorption of 4.3 kDa 
F-PHEA from the pulmonary airways was found to be more rapid than that of its 7.4 kDa 
counterpart (Figs. V.2, V.4 and V.S) .  However, this was achieved due to an increase in 
restricted passive diffusion of small oligomers in the distribution, while the transporter 
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kinetics unchanged. Thus, F-PHEA active transport was PHEA structure-specific with its 
molecular size-selectivity ;::: 4 kDa. 
CHAPTER VI 
SUMMARY AND GENERAL CONCLUSIONS 
The kinetics of macromolecular solute absorption from the airways were studied 
and modeled successfully in vivo and in vitro, in the presence of competing mucociliary 
clearance. The kinetics of the mucociliary escalator appeared to be largely solute­
independent and unaffected by lung isolation over the 1 80 minute duration of isolated 
perfused rat lung (IPRL) experiments . Specifically, the mechanisms and pathways 
involved with pulmonary-region-specific, active and passive absorption of model 
polypeptidic polymers, fluorophore-labeled polyhydroxyethylaspartamide (F-PHEA), 
were kinetically characterized using a new disposition model in the rat lung (Fig. III . 3, 
Chapter 3). The primary macromolecules used in this thesis were weight-averaged (Mw), 
7.4 and 4.3 kDa F-PHEA. These polyaspartamides were bicompatibile, non­
immunogenic (Neri et ai. , 1 973) and were shown to be chemically and metabolically 
stable (Appendix V). The stable fluorophore, attached to each polymer, was used as an 
analytical marker and this enabled a highly sensitive high performance gel permeation 
chromatography (HPGPC) assay to be employed in a variety of analytical matrixes 
(Appendix IV). Furthermore, metabolically-stable (Appendix IV), sodium fluorescein (F-
152 
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Na) and FITC-labeled dextran (Mw = 4.4 kDa) were also used in the absorption studies as  
small and macromolecular reference solutes, especially to validate the kinetics of the 
IPRL model with respect to its descriptors of passive, molecular weight-dependent 
absorption and mucociliary clearance. 
The IPRL used in this thesis enabled studies to be performed in a whole lung organ, 
housed in a physiologic orientation in a well-controlled environment. The preparation 
retained the structural and functional integrity of the whole organ and thus, enabled direct 
prediction of in vivo absorption results for F-PHEA. In all experiments of in vivo and in  
vitro, solutes were administered into the airways as  a coarse spray of aqueous dosing 
solution by "forced solution instillation" .  Solute absorption (or disappearance from the 
airways) was followed as a function of time throughout the lifetime of the preparation. 
Statistically identical initial regional lung distribution was achieved using "forced 
solution instillation" both in vivo and in vitro (p > 0.05 ; Figs. I1I.4 and III.5 ,  Chapter 3 ) .  
Thus, a comparison of solute distribution over time, in vivo and in vitro, enabled the 
IPRL's mucociliary clearance process to be studied and shown to be predictive of that 
seen in the intact animal. Similarly, F-PHEA absorption in the IPRL was found to be 
predictive of that seen in vivo (Fig. III .S ,  Chapter 3) ,  due to the preparation's comparable 
absorption kinetics and mucociliary clearance. Thus, it was not likely that F-PHEA was 
absorbed significantly from the tracheo-bronchial regions, either by passive or active 
mechanisms (Fig. III .9, Chapter 3). On the other hand, the absorption of a small (376 Da) 
model solute, F-Na was quite different in vivo and in vitro (Fig. 111 .6, Chapter 3), due to 
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the presence of its significant tracheo-bronchial absorption in vivo (Fig. III .? ,  Chapter 3 ) .  
While F-Na absorption in vitro, underestimated in  vivo absorption (Fig. III.6,  Chapter 3 ) ,  
its study in  the IPRL and correct kinetic modeling enabled successful estimation of its 
regional rate constants for passive absorption (ka•TB = O.042±O.O l l min- I and ka•p = 
O.048±O.003 min- I ; Table III .3 ,  Chapter 3) .  Therefore, for the first time, F-Na's 
pulmonary disposition was correctly described in this thesis in the presence of the 
mucociliary clearance and its absorption was shown to be independent of its regional 
deposition in the lung. 
A new kinetic model incorporating active and passive absorption alongside 
simultaneous mucociliary clearance was developed to characterize solute absorption from 
the rat lung in vivo and in vitro. This model was used throughout the thesis. Across-dose 
fitting of solute absorption data enabled the detailed analysis of dose-dependent, 
Michaelis-Menten-type active absorption of F-PHEA alongside its simultaneous passive 
absorption and mucociliary clearance components . Hence, the capacity and affinity of F­
PHEA's airway-to-blood transporter were precisely characterized. Because the IPRL 
preparation could also be maintained at lowered temperature (25 °C) and in the presence 
of metabolic inhibitors, the effects of these perturbations on F-PHEA absorption were 
also studied. The preparation was shown to be viable in all such cases (Appendix I and 
Chapter 4). 
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Kinetic modeling and across-dose fitting of each solute's airway-to-perfusate 
transport data enabled a series of conclusions to be drawn: 
( 1 )  At 37 DC, mucociliary clearance (kE,PT) was found to be solute-independent and 
relatively rapid (half-lives ranged between 24 and 32 minutes). Thus, mucociliary 
clearance competed significantly with the solute absorption in most cases (Table V .3 ,  
Chapter 5) ,  The process was slowed by between 45 and 70 % at  25  DC (Table VA, 
Chapter 5), and this was apparently related to its energy-dependent regulation (ATP 
or cAMP; Lansley, 1 993;  Camner and Mossberg, 1 993). 
(2) Pulmonary-region-specific rate constants for passive absorption (ka,p) were inversely 
related to solute molecular weight at both 37 and 25 DC (Tables V,3 and VA, Chapter 
5, respectively), This observation was consistent with passive solute absorption 
occurring via tight junctions in pulmonary epithelium. The lowered ($ 50 %) rate 
constants for passive absorption, ka.p at 25 DC may have been due to a combination of 
lowered solute diffusivity and/or partitioning to the membranes at lower temperatures 
(Notari, 1987; Martin, 1 993) alongside the possibility that tight junctions may have 
been perturbed by the temperature transition, 
(3) Pulmonary-region-specific descriptors for the active absorption of 7 04 kDa F-PHEA 
were found to be Vmax.P = 4,37±O,57 !1g/min and Km,p = 56,6±14,7 !1g at 37 Dc.  The 
"intrinsic rate constant" for its active absorption, V max.p/Km,p, was much greater (0,077 
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min- I ) than i t s  passive absorption counterpart (ka,p = 0,002±O_00 1 min- I ; Table III .2 ,  
Chapter 3) .  This clearly demonstrated that the polymer was predominantly absorbed 
by an active mechanism throughout experimental dosing ranges ::; 5.0 mg (Fig.  IV,3 ,  
Chapter 4 ) .  As  expected, F-PHEA absorption was dramatically suppressed a t  25 °C 
(Fig. IV.4, Chapter 4). Kinetic modeling and associated curve fitting at 25 °C showed 
that absorption suppression was dominated by a significant decrease in the value of 
V max,P (maximum rate; 4.37±0.57 � 0.67±0. 1O  f..lg/min;  p < 0.05 ; Table IV.2 ,  Chapter 
4), while the "affinity" remained effectively constant (Km.P = 56.6±14.7 f..lg (37 °C) 
and 30.3±16 .4 f..lg (25 °C); Table IV.2, Chapter 4) .  Thus, the "intrinsic rate constant" 
for active absorption, V max,pl Km,p, was decreased by 7 1 .4 % (from 0.077 to 0.022 
min- I ; Table IV.2, Chapter 4) by reducing the temperature to 25 °C, while passive 
absorption was largely unchanged (Table IV.2,  Chapter 4). 
(4) 4 .3 kDa F-PHEA's active absorption descriptors (Vmax,P and Km,p) were statistically 
identical to those of its larger counterpart (Table V.3 ,  Chapter 5). Despite the 
presence of polydispersity in these F-PHEA polymers, the passive absorption rate 
constant, ka,p, for 4.3 kDa F-PHEA was much greater than that for the 7 .4 kDa 
polymer (0.0 14±0.003 and 0.00 1±0.00 1 min- I for 4.3 and 7.4 kDa F-PHEA, 
respectively; Table V.3 ,  Chapter 5). As expected, the value of ka,p was most similar to 
that for 4.4 kDa FD-4 (0.0 14±O.003 and 0.0 1 6±O.00 1 min- I for 4.3 kDa F-PHEA and 
4.4 kDa FD-4, respectively; Table V.3 ,  Chapter 5) .  It is likely therefore, that solutes � 
4 kDa in molecular weight are not readily absorbed from the lung by passive 
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absorption. Overall, the absorption of 4 .3 kDa F-PHEA from the pulmonary airways 
was found to be more rapid than that of the 7,4 kDa polymer (Figs. V.2, V,4 and V.S ,  
Chapter 5) ,  but this was only achieved by an increase in passive absorption of smaller 
molecules, while the transporter's kinetics were unchanged. Active absorption of the 
macromolecular polysaccharide, FD-4 did not occur. This molecule showed only 
dose-independent passive absorption from the airways (Fig. V,4, Chapter 5) .  
The fact that F-PHEA's active absorption was temperature-sensitive, suggested the 
existence of a cellular energy requirement for its active absorption. Thus, experimental 
protocols showing maximum inhibition of F-PHEA absorption without unnecessarily 
shortening the viable lifetime of the IPRL were optimized for the metabolic inhibitors, 
2,4-dinitrophenol (DNP), ouabain (OUA), monensin (MON) and nocodazole (NOC). As 
a result, 15 minute pre-perfusion periods were employed prior to solute administration in 
DNP and �UA protocols, while co-administration of solute and inhibitor was used with 
MON and NOC. In each of these protocols, the airway-to-perfusate absorption profile of 
a passively-absorbed small solute, F-Na, showed no significant changes in the presence 
of each inhibitor (1 mM DNP or 100 11M �UA in perfusate or 1 00 11M MON or NOC in 
the airways ;  Fig. IV.8 ,  Chapter 4), demonstrating that passive absorption and mucociliary 
clearance kinetics (which modified absorption from the pulmonary compartment) were 
unaffected by these inhibitors. Furthermore, % absorption of 7,4 kDa F-PHEA in the first 
30 minutes following administration was unaffected by the presence of a 15 minute pre-
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perfusion interval (for DNP or  �UA studies) or  the use of EtOH and DMSO in the dosing 
vehicles (for MON and NOC studies; Fig. IV. 16 ,  Chapter 4). Therefore, inhibitory effects 
of these chemical agents on F-PHEA's active absorption were thought to be indicative of 
their effects on the transporter itself. F-PHEA active absorption was inhibited by DNP, 
�UA, MON and NOC in a concentration-dependent fashion (Fig. IV . lO, m. 1 2  and 
IIU 5,  Chapter 4). Their effective concentrations (ICso values = 0.5- 1 .0 mM, 30-50 �M, 
10-30 � and 1 -5 � for DNP, �UA, MON and NOC, respectively) were consistent 
with literature reports (Tables IV.5-IV.8 ,  Chapter 4). Inhibition by 1 mM DNP indicated 
a requirement for ATP-derived intracellular energy, while MON (30 �M) and NOC (30 
�M) inhibition suggested that endosomal formation and microtubular transcytosis were 
required for F-PHEA's active absorption (transcytosis) from airways to interstituim and 
perfusate. Indirect, ion (Na+ and/or Ca2+) -driven secondary active absorption mechanism 
remained a possible explanation of the inhibition seen by the use of �UA ( 1 00 �). 
However, this was unlikely with respect to Na+, based on our previous findings of apical­
Na+-independent absorption of this polymer (Sun, 1 995) .  Unfortunately, additional 
substantiation is required for its mechanistic conclusions. Consequently, it was 
demonstrated that 7.4 kDa F-PHEA was absorbed from the airways of the rat lung by an 
ATP-driven energy-dependent, intracellular vesicular transcytotic mechanism, probably 
via a specific transporter, as illustrated schematically in Fig. IV. 1 8  (Chapter 4). 
At lower doses (::; nominal 0.2 mg dose) , 7.4 kDa F-PHEA polymer was capable of 
achieving greater or similar absorption rates from the airways to that of 376 Da sodium 
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fluoresein (F-Na) , despite the more than 20-fold difference in their molecular weights. 
This was due to the presence of an ATP-driven energy-dependent, intracellular vesicular 
transcytosis, which accelerates the airway-to-perfusate transfer of this polymer and its co­
polymers (Sun et ai. , 1 999). Based on kinetic analysis, the F-PHEA transporter was 
found to function across molecular weights between 4.3 and 7.4 kDa and to enhance 
absorption from the airways of the rat lung significantly. The use and discovery of 
transporters like this, in the pulmonary lung compartment, may enable systemic delivery 
of certain macromolecules via inhalation to replace their otherwise painful parenteral 
administration. 
ApPENDICES 
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ApPENDIX I 
THE ISOLATED PERFUSED RAT LUNG PREPARATION 
OPERATING PROCEDURE 
AI.a INTRODUCTION 
The isolated perfused rat lung (IPRL) preparation has been widely used in several 
laboratories as an experimental model for studying pulmonary physiology, 
pharmacology, metabolism and disposition of various endogenous and exogenous 
substances (Levey, 1 966; Young, 1 976; Mehendale et aI. , 1 98 1 ;  Roberts, 1 984; Niven 
1988 ;  Uhlig and Wollin, 1 994; Baker et aI. , 1 999). The preparation retains the structural 
and functional integrity of the organ and closely maintains physiological conditions for a 
maximum 3 hours without introducing whole body complications. Over the last 20 years, 
our group has developed this preparation for studying the pulmonary absorption of small 
and macromolecular solutes from the airways after their presentation in solutions or as 
aerosols. The preparation employs horizontal IPRL suspension (Roberts, 1 984; Niven, 
1988 ;  Sun, 1 995), as opposed to vertical suspension from the trachea, to avoid tracheal 
stretching as in most other IPRL systems (Young, 1 976; Mehendale et aI. , 1 98 1 ;  Baker et 
16 1  
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ai. , 1 999). As a result, the preparation avoids rapid edema formation, which often 
occurred in the vertical IPRL systems without any challenges to the circulatory 
performance (Roberts, 1 984; Niven, 1 988 ;  Sun, 1 995) .  Furthermore, the horizontal IPRL 
suspension allows solute administration into the peripheral airways either by forced 
solution instillation or as aerosols. 
The preparation, despite the presence of minor preparative differences among 
laboratories, is capable of maintaining its viability for :::: 1 80 minutes at 37 °C with 
respect to morphological , histological, functional and biochemical parameters (Veith et 
al. , 1 967 ; Niemeier and Bingham 1972; Mehendale et ai. , 1 98 1 ;  Baker et al. , 1 999). On 
the other hand, its viability under low temperature perfusion seems controversial ,  since 
most IPRL studies in the literature were performed in less than 30 minutes ,  unless 
autologous blood or plasma perfusion was employed (Table IVA in Chapter 4) . In fact, 
earlier studies in our laboratory confirmed that 4 °c perfusion enabled only 12 minutes 
viability before the preparation became edematous (Sun, 1 995) .  
The research described in this thesis primarily employed the IPRL preparation to 
study pulmonary disposition and mechanisms of macromolecular solute absorption from 
the airways. All IPRL preparations were carefully controlled in our laboratory, noting 
that reproducible results from viable IPRL preparations can be only obtained by highly 
trained and competent researchers. Most operational details in this thesis adhere to the 
methods developed by previous workers (Roberts, 1 984; Niven, 1988 ;  Sun, 1 995 ;  Visich, 
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1 996). In this appendix ,  the details are documented as " in-house experimental method" to 
ensure successful and comparable studies .  Method details focus especially on the 
preparation and assessment of viability at lower temperatures and in the presence of 
metabolic inhibitors . Future workers are encouraged to refer to the "step-by-step standard 
operating procedures" described by previous researchers (Niven, 1 988 ;  Sun, 1 995 ;  
Visich, 1 996). 
AI.b MATERIALS AND METHODS 
Al.b. 1 PERFUSATE 
Perfusate was substituted for circulating blood to maintain the viability of the 
isolated organ. Krebs-Henseleit solution (KHS ; Krebs and Henseleit, 1 932) with 4 % 
(w/v) bovine serum albumin (BSA) was the circulating perfusate through pulmonary 
vasculature of the IPRL. One liter of perfusate contained, in order of addition: ( I )  2.00 g 
D-glucose, (2) 0.35 g KCI, (3) 0.29 g MgS04·7HzO, (4) 2. 10  g NaHC03, (5) 0 .37 g 
CaCIz·2HzO, (6) 6.92 g NaC!, (7) 0. 1 6  g KHzP04 and (8) 40.0 g BSA, in deionized 
water; this order of addition was critical to avoid precipitate formation. Perfusate was 
stored in a refrigerator (;S; 4 0c) and used within 48 hours of preparation. The perfusate 
was filtered through a filter paper (Grade 802; size 32.0 cm; 1 00 folded circles, particle 
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size retention = 1 5  /lm; Reeve Angel 802 ; Whatman Inc . ,  Clifton, NJ) and its pH was 
adjusted to 7.40±0.05 prior to each experiment. Glucose and salts were purchased from 
Fisher Scientific (Raleigh, NC) and BSA (powder, fraction V) was from Sigma Chemical 
Company (St. Louis, MO) . 
ALb. 2 IPRL ApPARATUS COMPONENTS 
The IPRL apparatus was composed of the following components : ( I )  artificial glass 
thorax; (2) perfusate conductor; (3) perfusate pumps; (4) perfusate reservoir; (5) perfusate 
flow lines and (6) thermostatically-controlled water circulator. A whole apparatus set-up 
is shown in Fig. AI. ! and each component is described below: 
(1 ) Artificial Glass Thorax (Fig. AL l ,  d and Fig. AL2) 
The artificial glass thorax (AGT, Research Glass ,  Richmond, V A) was used to 
house the isolated rat lung. The AGT was water-jacketed to maintain constant 
temperature and its internal volume was 1000 mL. A removable plexi-glass lid covered 
the AGT and was securely held in place using Cello-Grease (Fisher Scientific, Raleigh, 
NC) for an airtight fit. The pulmonary artery cannula (PAC) was connected to a perfusate 
flow line inlet through the lid by a tube fitting (Swagelok ™ tube fitting; Crawford Fitting 
Co. ,  Solon, OH). A pressure gauge (Magnahelic Gauge; Dwyer Inst. Inc . ,  Mich. City, IN) 
was also connected through another tube fitting on the lid, attached with a 50 mL syringe, 
(8) 
Figure AI.1 .  A scheme of  the isolated perfused rat lung (IPRL) preparation (A) 
and circulating water flow chart (B). Dashed lines represent flow connections and 
arrows indicate flow direction. An isolated lung was housed in the artificial glass 
thorax (AGT; d) after pulmonary artery cannulation. 
Key: a - perfusate reservoir; b - "supply" pump; c - perfusate conductor; d -
artificial glass thorax (AGT); e - "retum"pump;f - thermostatically-controlled 
water circulator. (adapted from Sun, 1 995) 
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Figure AI.2. A removal plexi-glass lid (A) and artificial glass thorax (AGT; B) .  
Key: a - perfusate line orifice; b - pressure gauge orifice; c - pressure gauge; d - 50 
mL syringe; e - tracheal exit cannula;f - esophagus support rod; g - glass 
supporters for esophagus support rod; h - perfusate exit; i - water jacket inlet ;} -
water jacket outlet. (adapted from Sun, 1 995) 
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so that a slightly negative pressure (2-5 cmH20) would be maintained in the AGT 
throughout experiments (to ensure partial lung inflation). A stainless-steel tubing (od = 
2.5 mm, id = 2.0 mm and I = 75 mm), attached to the AGT using size #4 rubber stopper, 
was exteriorized as a tracheal cannula and to enable solute administration into the 
airways . The isolated rat lung was suspended horizontally in the AGT by a stainless-steel 
rod through the esophagus of the rat. The bottom of the AGT was curved to collect the 
perfusate and subsequently, perfusate was pumped back to the perfusate reservoir 
(recirculation) ; stainless-steel tubing (od = 3.0 mm, id = 2.0 mm and I = 50 mm) was 
attached to the AGT via a size #2 rubber stopper at the bottom of the AGT. 
(2) Perfusate Conductor (Fig. AI. l ,  c and Fig. AI.3 )  
A glass perfusate conductor was connected to  the perfusate flow line tubing and 
placed between the perfusate reservoir and the AGT. The conductor serves as an air­
bubble trap (to collect bubbles in the prefusate) and a thermo-conductor to ensure 
constant perfusate temperature. 
(3) Perfusate Pumps (Fig. AI. l ,  b and e) 
Two MasterFlex ™ peristaltic pumps (Model 7520-25 ;  standard pump head, Model 
70 14-2 1 ;  MasterFlex size #14  silicone tubing; Cole-Parmer Instrument Co. ,  Vernon Hills, 
IL) were used as "supply" pump and "return" pump for recirculation through the IPRL. 
Their flow rates were adjusted to 15 mUmin throughout the experiments. 
-+-- c 
a �  
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Figure AI.3.  Perfusate conductor. 
Key: a - perfusate inlet; b - perfusate outlet; c - water jacket inlet; d - water jacket 
outlet; e - bubble trap. (adapted from Sun, 1 995) 
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(4) Perfusate Reservoir (Fig. ALl , a and Fig. AI.4) 
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The perfusate reservoir was a water-jacketed glass container (double-fused beakers ; 
Research Glass, Richmond, VA) and its internal volume was either 600 or 300 mL. The 
reservoir was topped with a plexi-glass lid possessing six ports for; ( I )  perfusate inlet 
tubing (to "supply" pump), (2) perfusate outlet tubing (from "return" pump), (3) pH 
electrode (Cat. # 476530; pH meter 220; Corning, Corning, NY), (4) thermometer (Fisher 
Scientific, Raleigh, NC), (5) carbogen gas (95% O2 and 5 % CO2; Airco Co., Richmond, 
V A) and (6) perfusate samples . Carbogen gas was delivered at about 2 Umin onto the 
perfusate surface in the reservoir throughout experiments . This rate was known to 
maintain O2 saturation from previous work (Byron et aI. , 1 986). The perfusate (adjusted 
to pH 7 .40±0.05) was well-stirred with a teflon fluorocarbon resin-coated magnetic stir 
bar (I = 3.5 cm; Fisher Scientific, Raleigh, NC) and a stirring plate (Model PC-353 ;  
Corning, Corning, NY). 
(5) Perfusate Flow Lines (Fig. ALl ) 
MasterFlex™ size #14  silicone tubing (od = 5 . 3  mm, id = 1 .6 mm, Cole-Parmer 
Instrument Co. ,  Vernon Hills, IL) was used to connect the perfusate flow lines between 
the IPRL components. The flow line started from the perfusate reservoir, through the 
"supply" pump, the perfusate conductor and the PAC, and from the bottom of the AGT, 
through the "return" pump to the reservoir. The PAC was a Silastic™ silicone tubing (od 
= 3 .2  mm, id = 2. 1 mm; Dow Corning, Midland, MI) with hard tubing (od = 2.0 mm, id = 
1 .6 mm and I = 10.0 mm; Clay Adams, Parsippany, NJ) inserted at the end of the PAC; 
e 
f � 
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Figure Al.4. Perfusate reservoir. 
Key: a - reservoir lid; b - perfusate inlet (from "return" pump) ; c - perfusate outlet 
(to "supply" pump); d - pH probe; e - thermometer;!  - carbogen inlet; 
g - perfusate; h - magnetic stir bar (1 = 3 . 5  cm); i - stirring plate (Model PC-353 ,  
Coming, NY);} - water jacket inlet; k - water jacket outlet. (adapted from Sun, 
1 995) 
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the hard tubing was inserted t o  prevent flow line occlusion, when a ligature was tied 
around the cannulated vessel . The total volume of the flow lines (including internal 
volume of perfusate conductor) was 22.2 mL. 
(6) Thennostatically-controlled Water Circulator (Fig. AI. l )  
A constant temperature circulator (Model 9505, Fisher Scientific, Pittsburgh, PA) 
was used to maintain the perfusate temperature by delivering 37,  30 or 25 °C water to the 
water-jacketed flow lines of the perfusate reservoir, the perfusate conductor and the AGT. 
ALb.3 ANIMAL HUSBANDRY AND ANESTHESIA 
The research adhered to the NIH Principles of Laboratory Care and was approved 
by the Institutional Animal Care and Use Committee (IACUC; Project 97 10-2468) at 
Virginia Commonwealth University (VCU). The animals were housed and cared for by 
the Division of Animal Resources eVCU), based on the NIH Principles, and were handled 
according to the "Occupational Health Program for Animal Handlers " (OHPAH1 ,  1 996, 
VCU) . 
Specific pathogen free (C.V.F.-certified virus free), male Sprague-Dawley rats 
weighing 3 10-390 g were purchased from Hilltop Lab Animals Inc. (Scottsdale, PA) . The 
animals were singly housed in polycarbonate cages ( 1 8  x 10 x 7 in inch) and the 
perforated ceilings of each cage covered with non-woven, spun nylon microisolator fabric 
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to prevent cross contamination. The animals had free access to  water and food (RMH 
3000 Rodent Chow pellets; Agway, Inc . ,  Ithaca, NY) and were housed in rooms 
controlled between 1 8-26 °C at 40-70 % relative humidity. Dark/light cycling occurred 
every 12 hours and animals were acclimated for � 7 days prior to use. 
A rat was weighed and anesthetized intraperitoneally with pentobarbital (50 mg/kg; 
pentobarbital sodium injection, 50 mglmL, Abbott Laboratories, Chicago, IL) . The rat 
was gently held in the upright position and its abdomen exposed. Pentobarbital was 
injected using a Tuberculin syringe (1 cc; Becton Dickinson & Company, Franklin Lakes ,  
NJ) . The degree and adequacy of anesthesia was visually determined by the absence of 
pedal reflex (withdrawal of the extended hind limb) and corneal reflex (eye-blink 
following a gentle touch to the corneal surface) . The use of pentobarbital was rigorously 
recorded on the "Controlled Substances Record" supervised by the Aerosol Research 
Group, VCU (Drug Enforcement Administration (DEA) Registration, AM44 14962). 
ALbA SURGICAL PROCEDURE FOR ISOLATING THE LUNG 
Surgical procedures for the isolated perfused rat lung (IPRL) contain numerous 
steps and a successful operation largely depends on the operator' s  skills, experience and 
understanding. A "step-by-step standard operating procedure" was well-documented by 
previous researchers (Niven, 1 988 ;  Sun, 1 995 ; Visich, 1 996) and is not duplicated here. 
Rather, an " in-house experimental method" was documented to ensure successful and 
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comparable operations with those of previous researchers (Niven, 1988 ;  Sun, 1 995 ;  
Visich, 1 996). 
In this thesis, the perfusion temperatures were varied yet held constant at 37, 30 and 
25 °C to kinetically characterize active/passive absorption of solutes from the airways. 
Furthermore, despite edema formation which was found to occur rapidly, perfusion 
temperatures were further lowered to < 25 °c to find the minimum temperature at which 
1 80 minute lung viability could be maintained. In these cases, the perfusion temperatures 
were simply adjusted and maintained by the thermostatically-controlled water circulator 
throughout the experiment. 
(1) Pre-surgical Preparation 
The surgical procedures for successful IPRL preparation required prompt and 
smooth operation following pre-surgical preparation. All surgical materials and 
instruments were clean and in place, as described in the " standard operating procedure" 
(Sun, 1 995;  Visich, 1996). The glassware and the perfusate flow lines were washed, 
rinsed and dried-up following each experiment. Periodically, the system was 
disassembled for thorough cleaning under sonication to remove precipitated protein 
residues .  The perfusate pumps, pH meter and rodent ventilator were calibrated prior to 
each experiment. 
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(2) Tracheal Cannulation: Tracheotomy 
Following anesthesia, a rat was placed in a supine position and its neck and chest 
area was dampened with detergent solution applied on a tissue. A 3 cm longitudinal 
incision was made at the neck skin around 5 cm below the mouth. The neck muscle and 
the tracheal muscle sheath were vertically cut and separated to expose the trachea and 
esophagus hidden underneath. At 5th tracheal cartilaginous ring, a piece of thread was tied 
loosely around the trachea (through an eyelet created through connecting tissues between 
trachea and esophagus). Then, the trachea was laterally incised between the 4th and 5th 
cartilaginous rings and the stainless-steel tracheal cannula (od = 2.2 mm, id = 1 .9 mm, I = 
32 mm) was inserted through the incision. The thread was tightly tied to retain the 
cannula in place; 22 mm of the cannula was inserted into the trachea from the 5th tracheal 
cartilaginous ring. 
(3) Opening Thoracic Cavity 
The abdomen was first opened transversely below the xiphoid cartilage. A small 
incision was made through the abdominal diaphragm from the ventral side of the thoracic 
cavity, the rib cage on both sides of the sternum was cut through and the whole thoracic 
cavity opened. The rib cages were flapped backward in the cranial direction and held in 
place with a pair of haemostatic forceps to expose the lungs and heart. 
(4) Pulmonary Artery Cannulation (PAC) 
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Heparin (0. 1 mL; heparin sodium injection, USP; 1000 U/mL, Pharmacia & Upjohn 
Company, Kalamazoo, MI) was slowly injected intravenously into the upper right 
ventricle and subsequently, the thymus (white tissue covering anterior-ventral part of 
heart) was removed. At about 30 seconds following heparin injection as anticoagulant, 
the PAC tip (looped back into the perfusate reservoir at this time) was withdrawn from 
the reservoir and placed near the lung. A 6 mm long incision, perpendicular to pulmonary 
artery, was made in the upper right ventricle for the PAC and the bottom of the left 
auricle and both sides of each ventricle amputated to allow the blood to be flushed from 
the pulmonary circulation. The PAC was immediately inserted into the pulmonary artery 
through the incision and kept in place temporarily with a pair of artery clips. In a period 
of 5-7 time positive pressure ventilation via the tracheal cannula (tidal volume = 4.5 mL 
and respiration rate = 16 Imin; Model 802, New England Medical Instruments Inc. ,  
Medway, MA), with perfusate flowing at 1 5  mUmin, the blood was completely removed 
from the lung. A ligature was inserted to tie the pulmonary artery cannula in place 
throughout the remainder of the experiment. 
(5) Lung and Heart Isolation 
The flapped rib cages were removed and the trachea, lung and heart were 
completely exposed. The trachea and esophagus were held together with the tracheal 
cannula and subsequently, the lung and heart with the PAC were isolated from the body. 
Unnecessary tissues (connecting tissues, diaphragm and blood vessels) were carefully 
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removed and finally, the lung was isolated with both tracheal and pulmonary artery 
cannulations. The stainless-steel support rod (Fig. AI. l )  was slipped through the 
esophagus and the outer surface of the lung was rinsed by pre-warmed perfusate. The 
whole procedure from tracheal cannulation to lung removal took no longer than 1 0  
minutes. 
(6) Perfusion a/ the Lung 
The isolated rat lung was transferred to the AGT and suspended horizontally by the 
support rod; the PAC line was allowed to coil inside the AGT without twisting or 
touching the lung. The tracheal cannula was tightly connected to the exteriorized tracheal 
cannula port (a stainless-steel tubing attached to the AGT) . The plexi-glass lid was placed 
on the top of the AGT, creating an air-tight condition. Any perfusate lost through the 
pulmonary circulation was collected and pumped back by the "return" pump to the 
reservoir (the "return" tubing was previously returned to a waste beaker at this time). A 
negative pressure (2-5 em H20) inside the AGT was created and maintained by adjusting 
the syringe, attached to the pressure gauge. Following 3-7 minutes ,  the "return" tubing 
was put back into the perfusate reservoir for recirculation. After the re-circulation 
commenced, the perfusate surface was adjusted to a pre-determined mark (either 200 or 
100 mL was employed) . Consequently, total volumes of the perfusate were 222.2 or 
122.2 mL, respectively (total volume of the flow lines = 22.2 mL) . The AGT pressure, 
perfusate pH, temperature and carbogen gas flow were all checked and adjusted 
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appropriately to maintain constancy throughout experiments. The perfusate pH values 
were maintained at 7 .40±0.05 . 
The protocols to study solute absorption in the presence of 2,4-dinitrophenol (DNP) 
and ouabain (OUA) required 15 minutes perfusion prior to solute administration, as 
described in Section IV.c .2 (Chapter 4). In these experiments, after the recirculation was 
commenced, 50 mL of the perfusate was removed from the perfusate reservoir and 
replaced with 50 mL of fresh perfusate containing various concentrations of DNP and 
OUA. Subsequently, at time = 15 minutes ,  solute was administered, as described below. 
ALb.S  SOLUTE DOSING (Fig. ALS)  
The dosing method, "forced solution instillation" was developed by previous 
researchers (Niven, 1 988 ;  Sun, 1 995;  Visich, 1 996) and used unchanged in this thesis .  A 
silicone tubing (od = 2.0 mm, id = 1 .0 mm , I = 230 mm, marked for 0. 1 mL solution) ,  
attached to a Tuberculin syringe ( I  cc; Becton Dickinson & Company, Franklin Lakes,  
NJ) was used as a dosing adapter. A 0. 1 mL aliquot of solute dosing solution was exactly 
measured by the dosing adapter tubing and loaded into a stainless-steel tubing (od = 1 .2 
mm, id = 1 .0 mm, I = 1 38  mm) used as a dosing cartridge. The cartridge containing solute 
solution was slipped through the tracheal cannula port exteriorized outside the AGT, until 
its tip projected 0.5 mm beyond the cannula terminus, into the trachea. A metered dose 
inhaler (MDI, containing fluorocarbon propellants alone, 40 % P- l l  and 60 % P- 12  
a 
f 
Figure AI.S. Solute dosing method; "forced solution instillation". 
Aqueous dosing solution in the dosing cartridge was propelled into the lung as a 
coarse spray with simultaneous inflation by MDI actuation. 
Key: a - MDI (propellant only); b - a teflon tubing; c - dosing cartridge containing 
0. 1 mL dosing solution; d - rubber stopper; e - artificial glass thorax (AGT) ;f­
exit tracheal cannula; g - tracheal cannula; h - rat trachea. (adapted from Sun, 
1 995) 
178 
179 
(w/w), 50.5 psig at 25 °C, 25 ilL per actuation) was connected to the other side of the 
cartridge and actuated once. The dosing solution was propelled into the lung as a coarse 
spray and the lung was inflated simultaneously with 5 . 5  mL of propellant vapor. 
Immediately, the dosing cartridge and MDI were removed from the tracheal cannula port 
and the lung allowed to deflate to a residual volume dictated by the maintenance of the 2-
5 cm H20 negative pressure inside the AGT. 
After administration, administered solute doses were determined by subtracting the 
amount of solute recovered from all non-biological components from the known amounts 
of solute loaded into the dosing cartridge. A 0. 1 mL aliquot of each solute solution was 
independently, but similarly measured using the dosing adapter and placed into known 
volumes of deionized water ( "loaded" solute in the cartridge) . The dosing cartridge and 
the tracheal cannula (with the tracheal cannula port) were rinsed with 50 mL deionized 
water immediately following administration and at the end of the experiments ,  
respectively ( "recovered" solute from non-biological dosing components) .  Both "loaded" 
and "recovered" solutes were determined using validated analytical methods described in 
Appendix IV and were then used to determine each administered dose. 
ALb.6 PERFUSATE SAMPLING 
0.5 or 1 .0 mL of perfusate was withdrawn from the perfusate reservoir prior to 
dosing (time = 0 [minute] ) and at various time intervals (depending on solutes) following 
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solute administration by "forced solution instillation" .  Fresh perfusate was not replaced to 
compensate for sampling losses; rather, these sampling losses were assessed and 
corrected during data handling to determine each amount of solute in perfusate vs. time 
profiles. 
ALb.7 REGIONAL SOLUTE DISTRIBUTION IN LUNG 
In some experiments, the initial and final regional solute distribution was 
determined. On these occasions, IPRL perfusion was halted immediately following solute 
administration (initial distribution) or at the end of the experiment (final distribution). 
Subsequently, the lung was removed from the AGT and dissected into tracheo-bronchi 
and five lung lobe regions (Fig. AI.6 ;  left lung lobe (L), right postcaval or median lobe 
(PC) , right superior or apical lobe (RS), right middle lobe (RM) and right inferior or 
diaphragmatic lobe (RI» . Each component was stored in 20 mL glass vials (Fisher 
Scientific, Raleigh, NC) at � - 20 °C prior to analysis. Following homogenization and 
clean up, remaining solutes were determined by using validated analytical methods 
described in Appendix IV. 
RI  
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Figure AI.6. Schematic representation of  rat trachea and lung lobes. 
Key: T - trachea; L - left long lobe; PC - right postcaval or median lobe; RS - right 
superior or apical lobe; RM - right middle lobe; Rl - right inferior or diaphragmatic 
lobe. (adapted from Sun, 1 995) 
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ALe RESULTS AND DISCUSSION 
ASSESSMENT OF IPRL VIABILITY 
Several criteria and/or indicators to assess the IPRL viability quantitatively and 
qualitatively have been proposed in the literature (Basset and Fisher, 1 976; Wiersma and 
Roth, 1 980; Fisher et aI. , 1 980; Mehendale et aI. , 1 98 1 ;  Roberts, 1 984; Basset et aI. , 
1987a; Niven, 1 988;  Baker et aI. , 1999). These were visual inspection for signs of 
pulmonary edema (Roberts, 1984; Byron et al. , 1 986; Niven, 1 988 ;  Byron and Niven, 
1 990), wet/dry lung weight ratios (:5: 6.2 as viable lungs ; Basset and Fisher, 1 976; Fisher 
et at. , 1 980; Uhlig and Wollin, 1 994), potassium efflux (Ward and Buttery, 1 979), 
filtration coefficient measurement (Uhlig and Wollin, 1 994), biochemical parameter 
changes (ATP content, reduced glutathione and glutathione reductase; Fisher et aI. , 1 980; 
Baker et at. , 1999) and histopathologic examination (Mehendale et aI. , 1 98 1 ;  Okumura et 
at. , 1 978 ;  Ward and Buttery, 1 979). In this thesis, similar to the methods used by our 
previous researchers (Roberts, 1 984; Niven, 1 988 ;  Sun, 1 995 ; Visich, 1996), signs of 
pulmonary edema were carefully monitored by visual inspection. Any sign of pulmonary 
edema was cause for the IPRL preparation to be designated "non-viable" .  Results from 
"non-viable" preparations were rejected and are not reported in this thesis .  This method 
was used owing to its sensitivity as a means of identification and detection of 
physiological abnormalities in the IPRL. 
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At 37 °C, the IPRL was known to maintain viability for 1 80 minutes .  This was 
evidenced by the absence of any signs of pulmonary edema. Similarly, 1 80 minutes 
viability could be maintained at 30 and 25 °C. However, at 4- 1 5  °C, pulmonary edema 
occurred within 30 minutes following preparation, regardless of solute administration. 
This resulted in lung swelling, followed by fluid flooding from the tracheal cannula. 
When edema occurred, the (blood-free) lungs changed in outside color and texture from 
smooth white to a gray and/or patchy appearance, which was identified during 
experiments .  In contrast, other indicators like wet/dry lung weight ratios could be 
obtained only after experiments terminated. Wet-dry weight ratios were shown to be 
insensitive measures of non-viability, especially in its early phases (Roberts, 1 984) ; 
accordingly these ratios were not determined in this thesis. 
A discontinuity in solute transfer profiles (airway-to-perfusate permeability 
changes) was also useful for identifying viability changes of direct importance to these 
studies (Sun, 1995). Figure AI.7 (A) shows F-PHEA transfer profiles in the presence of 
pulmonary edema created by intentional scratching of the left lung lobe during 
preparation (lung surface must not be touched during isolation; Roberts, 1 984). At 1 0  
min, immediately after pulmonary edema was visually observed i n  the left lung lobe, the 
solute transfer profiles showed a sudden discontinuity. Even in this case, it is  unlikely 
that a wet/dry lung weight ratio was markedly elevated, since the other four lung lobes 
appeared to be completely viable. In fact, this IPRL showed a fluid flooding from the 
tracheal cannula at time = 45 minutes (35 minutes after the lung appearance was 
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Figure AI.7. Percentage of administered dose of 7.4 kDa F-PHEA absorbed 
from the airways of the IPRL into the perfusate vs. time (A) after pulmonary 
edema was created by intentional scratching of the left lung lobe during 
preparation and (B) by holding the IPRL at 1 5 °C. 
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edematous). Similar discontinuous solute airway-to-perfusate transfer was also observed 
at 1 5 °C, as shown in Figure Al,7 (B) .  In this case, pulmonary edema was gradually 
fonned, but a fluid flooding from the tracheal cannula was not observed even at 60 
minutes. There was no such discontinuity in the solute transfer profiles seen at 30 and 25 
DC, as shown in Figs. IV .4, IV.6 and IV.7 (Chapter 4) nor was there any appearance of 
edema. For these reasons, it was possible to ensure 1 80 minutes viability at 25, 30 and 37 
DC. 
In Chapter IV, to kinetically characterize the mechanisms responsible for the active 
absorption of F-PHEA from the airways, the IPRL studies were performed in the 
presence of various metabolic inhibitors, 2,4-dinitrophenol (DNP), ouabain (OUA), 
monensin (MON) and nocodazole (NOC). The experimental protocols using these 
inhibitors were optimized based upon preliminary studies and/or conditions selected from 
literature information (Basset and Fisher, 1 976; Goodman et ai. , 1 983 ;  Basset et aI. , 
1 987;  Effros et at. , 1 988 ;  Hastings et aI. , 1 994; Wangensteen et aI. , 1996) . As a result, 
prior to solute administration, 15 minutes pre-dosing perfusion intervals were required in 
the case of DNP and �UA, while 1 .5 % (v/v) EtOH and DMSO solutions were used as 
administration vehicles for MON and NOC, respectively. Because of these protocol and 
dosing solution changes ,  IPRL preparation began to show pulmonary edema formation 
(glossy appearance) at 60 minutes in the presence of DNP ( 1  mM) and OU A ( 1 00 fJ.M) in 
perfusate and at 1 20 minutes in the presence of MON ( 1 00 fJ.M) and NOC ( 100 fJ.M) in 
the airways. Accordingly, data is  only reported from these experiments for times at which 
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edema was absent. Clearly, some changes in IPRL viability are unavoidable, due 
probably to the simultaneous inhibition of fluid absorption from the airways by some of 
these inhibitors (Hostetter et aI. , 1 98 1 ;  Serikov et aI. , 1 993 ;  Basset et al. , 1 994; Cott, 
1 994; Effros, 1994; Hastings et al. , 1 994; Wangensteen et aI. , 1 996). 
Al.d SUMMARY AND CONCLUSION 
An isolated perfused rat lung (IRPL) preparation was validated and employed to 
study the pulmonary absorption kinetics of small and macromolecular solutes from the 
airways. The apparatus components and surgical steps were carefully controlled by 
adhering to the "standard operating procedure" described by our previous researchers 
(Niven, 1988 ;  Sun 1995; Visich, 1 996). Methods followed in this thesis to ensure 
successful and comparable IPRL studies were only changed as necessary to enable the 
required experimental perturbations. The viability/non-viability of the IPRL was assessed 
based upon its appearance (sign of pulmonary edema by visual inspection) and the 
resultant solute transfer profiles (discontinuity of the profiles), as described in previous 
studies (Niven, 1988 ;  Sun 1 995; Visich, 1 996) . Consequently, � 25 °C perfusion was 
found to maintain the viability for 1 80 minutes ,  whereas < 25 °c perfusion rapidly 
induced edema formation, precluding the use of such conditions for absorption studies. 
Similarly, the IPRL viability could be maintained for 60 or 1 20 minutes in the presence 
of metabolic inhibitors, DNP and OUA or MON and NOC, respectively. 
APPENDIX II 
THE OPERATING PROCEDURE FOR IN VIVO WHOLE 
RAT STUDIES 
AII.a INTRODUCTION 
In vivo whole animal (rat) studies for solute absorption from the lung were 
originally developed by Enna and Schanker ( 1 972), employing an intratracheal solution 
instillation technique for solute administration into the airways. Profiles for solute 
remaining unabsorbed from the airways and the lungs vs. time were used to provide data 
on solute disposition in vivo, in the presence of anesthesia. Unfortunately, and while the 
technique is widely used, it has been shown that considerable animal sacrifice is  required 
to obtain such absorption profiles and to avoid huge inter-rat variations in derived data 
(Brain et at. , 1 976; Pitchard et aI. , 1985 ;  Folkesson et aI. , 1996; Leong et aI. , 1 998) .  
Much of the variation reported in the literature is associated with non-reproducible dosing 
and it is because of the uncertainties associated with the technique that inter-study 
comparisons are difficult with the exception of a small series performed by Schanker's 
group (Enna and Schanker, 1972; Lanman et aI. , 1973 ; Burton and Schanker, 1974a and 
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1 974b ; Burton e t  al. , 1 974; Schanker and Burton, 1 976; Schanker and Hemberger, 1 983 ;  
Brown and Schanker, 1983) .  
The in vivo whole rat studies described in this thesis were used to perform an in 
vivo - in vitro correlation and to compare results directly with those obtained in the in 
vitro isolated perfused rat lung (IPRL) preparation. Because the regional deposition of 
solutes in the lung is believed to be a determinant of subsequent absorption and 
mucociliary clearance kinetics (Byron, 1 986; Byron and Phillips, 1 990; Colthorpe et al. , 
1 992; Byron and Patton, 1 994; Hill et al. , 1 996), it was necessary to employ an identical 
and reproducible forced solution instillation for solute administration into the airways, 
exactly as used in the IPRL. This device-oriented technique has been shown to maximize 
dosing consistency and hence, minimize the variability "between-rats" and "between- and 
within- operators" (Byron and Niven, 1 988 ;  Sun, 1 995), enabling the initial solute 
distribution both in vivo and in vitro (IPRL) to be comparable. Importantly, reproducible 
results can only be obtained, when the procedure adheres to the standard operating 
procedure described in this appendix. It is especially important to ensure that the 
anesthetic regime used in vivo and in vitro is identical for the results to remain 
comparable. Future workers are encouraged to refer to the original methods developed by 
Enna and Schanker ( 1 972) for animal surgery and Byron and Niven ( 1 988) for solute 
dosing and blood removal from pulmonary circulation prior to lung removal from the 
animal. 
1 89 
AII.b MATERIALS AND METHODS 
AII.b . I PERFUSATE AND THE IPRL ApPARATUS 
Krebs-Henseleit solution with 4% (w/v) bovine serum albumin (BSA) was 
prepared, as described in Appendix ALb. I and used as perfusate for clearing the blood 
from the pulmonary circulation at the time of animal sacrifice following solute 
administration. Perfusate was stored in a refrigerator (::; 4 0c) and used within 48 hours of 
preparation following filtration through a filter paper (Grade 802; size 32.0 cm; 1 00 
folded circles, particle size retention = 1 5  )lm; Reeve Angel 802; What man Inc . ,  Clifton,  
NJ) .  The perfusate reservoir, conductor, " supply" pump and flow lines used in the IPRL 
(Appendix ALb.2) were utilized to pump the perfusate into the pulmonary circulation via 
the pulmonary artery cannula. The whole set-up was maintained at 37 °C using a 
thermostatically-controlled water circulator (Model 9505, Fisher Scientific, Pittsburgh, 
PA) . 
AII.b. 2 ANIMAL HUSBANDRY 
The research adhered to the NIH Principles of Laboratory Care and was approved 
by the Institutional Animal Care and Use Committee (IACUC; Project 97 1 0-2468) at 
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Virginia Commonwealth University (VCU) . The animals were housed and cared for by 
the Division of Animal Resources (VCU) and handled according to the "Occupational 
Health Program for Animal Handlers " (OHPAH I ,  1 996, VCU). 
Specific pathogen free (C.V.F.-certified virus free) , male Sprague-Dawley rats 
(3 10-390 g; Hilltop Lab Animals Inc . ,  Scottdale, PA) were used throughout. The animals 
were housed singly in rooms controlled between 1 8-26 °c and 40-70 % relative humidity 
and allowed free access to water and food (RMH 3000 Rodent Chow pellets; Agway, 
Inc . ,  Ithaca, NY) . Dark/light cycling occurred every 12 hours and animals were 
acclimated for ;::: 7 days prior to use. 
AILb.3  PROCEDURE FOR IN VIVO WHOLE RAT STUDIES 
Surgical procedures for in vivo whole rat studies were originally developed by Enna 
and Schanker ( 1 972) and modified by our laboratory. The reproducible "forced solution 
instillation" technique (identical to that used in the IPRL) was employed for solute 
administration into the airways. At different sacrifice times following administration, the 
blood was removed from the pulmonary circulation, the lung removed from the body and 
remaining solutes in the lung determined from each of these excised lungs by use of the 
validated analytical methods described in Appendix IV. The procedure described below 
in detail is subdivided as follows :  ( I )  tracheal cannulation (tracheotomy), (2) solute 
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dosing ( "forced solution instillation") ,  ( 3 )  pulmonary blood removal and (4) lung and 
heart isolation. 
These surgical procedures required prompt and smooth operation following pre­
surgical animal preparation. All surgical materials and instruments were clean and in 
place, as described in Appendix Alb.4. 
(1 ) Tracheal Cannulation: Tracheotomy 
The procedure was identical to that described for the IPRL (Appendix Alb.4). 
Briefly, a rat was weighed and anesthetized by intraperitoneal injection of pentobarbital 
(50 mglkg; pentobarbital sodium injection, 50 mg/mL, Abbott Laboratories, North 
Chicago, IL) . [In the event that dosing and sacrifice were to be separated for 2': 60 
minutes, further anesthetic was administered at 60 minute intervals in doses of 25 mg/kg 
intraperitoneally. ] Each rat was placed in the supine position and a longitudinal incision 
was made at the neck skin. Subsequently, the neck muscle and the tracheal muscle sheath 
were vertically separated to expose the trachea and esophagus hidden beneath. The 
stainless-steel tracheal cannula (od = 2.2 mm, id = 1 .9 mm, I = 32 mm) was inserted 
through the incision made at the 4th tracheal cartilaginous ring. This was then tied tightly 
and secured in place using cotton thread; 22 mm of the cannula was inserted into the 
trachea from the 5th tracheal cartilaginous ring. The tracheal cannula was left in place 
throughout each experiment, irrespective of the time allowed for absorption to preclude 
solute absorption from swallowed materials .  The cannula was washed and the washings 
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also analyzed at the end of each experiment using the validated analytical methods 
described in Appendix IV. 
(2) Solute Dosing 
Forced aqueous solution instillation (Appendix AI.b.S) was used to provide 
identical initial solute distribution in vivo and in vitro. The technique was unchanged 
when performing the in vivo experiments except that care was employed to phase 
administration along with the rat inspiration. A silicone tubing (od = 2.0 mm, id = 1 .0 
mm, I = 230 mm, marked for 0. 1 mL solution) and a stainless-steel tubing (od = 1 .2 mm, 
id = 1 .0 mm, I = 138  mm) were used as a dosing adapter and a dosing cartridge, 
respectively. A 0. 1 mL aliquot of F-PHEA or F-Na solution was precisely measured by 
the dosing adapter and loaded into the dosing cartridge (Appendix AI.b.5) .  Immediately 
following natural expiration, the metal dosing cartridge was inserted through the tracheal 
cannula until its tip projected O.S mm beyond the cannula terminus, into the rat's trachea. 
A propellant-only metered dose inhaler (MDI, 40 % P- l l  and 60 % P- 12  (w/w), SO.S psig 
at 25 °C, 25 ilL per actuation) connected to the other side of the cartridge was actuated 
once. Thus, the dosing solution was expelled as a coarse spray into the airways ; this 
inflated the lung with about 5.5 mL of propellant vapor and simultaneously, 
accomplished "forced solution instillation" (time = 0 [minute] ) .  The dosing cartridge was 
removed within 1 -2 seconds of actuation allowing the recommencement of normal 
respiration; in the event that natural respiration was not rapidly (:<;; 1 minute) 
recommenced, the rat was sacrificed as before, but the lung was discarded prior to data 
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collection. The administered solute doses were determined, as described in Appendix 
AI.b .5 .  Body temperatures were maintained using a heat lamp. Adequacy of anesthesia 
was assessed by the absence of pedal and/or corneal reflexes and maintained by repeat 
pentobarbital intraperitoneal injection (25 mg/kg every 60 minutes). 
(3) Pulmonary Blood Removal 
At 3 minutes prior to each designated sacrifice time, while the rats continued to 
respire under anesthesia through the endotracheal tube, the abdomen was opened 
transversely and the rib cage was severed, on both sides of the sternum (from the 
abdominal diaphragm). The ribs were flapped backward to expose the lung and heart. 
Heparin (0. 1 mL; heparin sodium injection, USP; 1 000 U/mL, Pharmacia & Upjohn 
Company, Kalamazoo, MI) was slowly injected (over a period of 10 seconds) into the 
upper right ventricle and the tip of the pulmonary artery cannula (PAC; which was 
supplied with flowing perfusate from the reservoir) was inserted through an incision 
made in the upper right ventricle. The bottom of the left auricle and both sides of each 
ventricle were promptly amputated and the blood flushed from the lung by continuous 
free perfusion of oxygenated perfusate through the PAC at a flow rate of 15 mUmin. 
Blood removal was completed with the lung respirated using positive pressure ventilation 
(tidal volume = 4.5 mL, respiration rate = 16 /min; Model 802, New England Medical 
Instruments Inc . ,  Medway, MA) for 1 -2 minutes by attaching a small animal ventilator to 
the tracheal cannula. Complete blood removal took � 3 minutes. Sacrifice times were 
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adjusted accordingly, by noting the actual time between dosing the airways and complete 
lung isolation. 
(4) Lung and Heart Isolation 
The blood-free lung and heart were promptly removed from the body exactly as if  
an WRL preparation was to be performed (Byron and Niven, 1988 ;  Sun, 1995;  Appendix 
I) except that the removal was immediately followed by visual inspection for any signs of 
pulmonary edema (glossy appearance on lung lobes; Roberts, 1 984; Sun, 1995;  Sun et 
aI. , 1999); lung preparations showing edema were discarded. The PAC, heart and 
unnecessary tissues (connecting tissues, diaphragm and blood vessels) were carefully 
removed and the lung was isolated. The complete procedure from first incision to tissue 
isolation was accomplished in ::; 5 minutes .  Viable lungs were dissected into tracheo­
bronchi and the five lung lobe regions (Fig. AI.6 ;  left lung (L) , right postcaval or median 
lobe (PC), right superior or apical lobe (RS), right middle lobe (RM) and right inferior or 
diaphragmatic lobe (RI» . Each component was stored in 20 mL glass vials (Fisher 
Scientific, Raleigh, NC) at - 20 DC prior to analysis. Each lung region was weighed and 
solutes remaining to be absorbed from each lung region were determined by the methods 
described in Appendix IV following homogenization and centrifugation. At each sacrifice 
time, four fully viable lungs were studied for each dosing solution. 
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AII .b .4 ASSESMENT OF VIABLE CONDITION 
Long-term anesthesia (maximum 3 hours) maintained by repeat pentobarbital 
injection, with or without forced lung inflation by MDI actuation during solute dosing, 
were occasionally found to induce "abnormal respiration" (e .g . ,  bronchospasm) . Animals 
showing such problems were sacrificed as before, but discarded prior to data collection. 
The incidence of such effects was about 3 .0 % .  Lungs showing signs of pulmonary 
edema had a much lower incidence (::; 1 .0 %) and were also excluded from sets subjected 
to chemical and data analysis. 
ApPENDIX III 
SYNTHESIS AND CHARACTERIZATION OF 
FLUOROPHORE-LABELED POL Y -a,�-[N(2-
HYDROXYETHYL)-D,L-ASPARTAMIDE] (F -PHEA) 
Two, weight-averaged 7.4 and 4.3 kDa fluorophore-labeled poly-a,J3- [N(2-
hydroxyethyl)-D,L-aspartamide] (F-PHEA; Fig. Am. l )  were synthesized, purified and 
characterized by Dr. Frantisek Rypacek at the Institute of Macromolecular Chemistry 
(IMC), Prague, Czech Republic. Their molecular weight distribution (MWD) and content 
of fluorophore label were determined following reconstitution of lyophilized polymers by 
Dr. Rypacek in Prague prior to shipping. A single batch (FR7 1 50 and FR7002-5 for 7 .4 
and 4 .3  kDa F-PHEA, respectively) of each was used throughout this thesis .  
The model macromolecule, poly-a,J3-[N(2-hydroxyethyl)-D,L-aspartamide] 
(PHEA) used in this thesis was originally designed and synthesized for use as a plasma 
expander (Neri et ai. , 1 973 ;  Antoni et at. , 1 974) and/or drug carrier (Drobnik et at. , 
1 979a; Giammona et al. , 1 994). Chemically, the polymer is highly water-soluble 
(aqueous solubility 2: 50 mglmL) and hydrophilic (partition coefficient between octanol 
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and phosphate buffer (pH7.4), KD < 0.00 1 at 37 DC) due to its hydrogen bonding capacity 
(Neri et ai. , 1974) . It is believed to be biocompatibile and non-toxic and in fact, in vivo 
rabbit studies showed no critical immunogenicity and antigenicity following intravenous 
administration (LDso > 300 mg/kg; Neri et ai. , 1 973) .  Importantly, the polymer appears to 
have high resistance to enzymatic proteolysis due to random distribution of u- and �-
peptidic linkages and synthesis from a racemic mixture of D- and L- configured aspartic 
acid residues (Drobnik et ai. , 1 979a and b; Rypacek et ai. , 1 980; Byron et ai. , 199 1 ) .  As a 
result, no degradation, metabolism or significant tissue sequestration was seen for this 
polymer in the rat lung, as shown in Appendix V. 
The synthesis of F-PHEA used in this thesis is fully described elsewhere (Rypacek 
et ai. , 1979; Rypacek et ai. , 1980; Niven, et ai. , 1990; Sun, 1995) and is shown 
schematically in Fig. AIII. 1 .  Briefly, polysuccinimide (PSI) was prepared and 
fractionated by a fractional precipitation method (Vlasak et ai. , 1979) and reacted with 2-
aminoethyl-carbonyl-6-aminofluorescein (F; Rypacek et ai. , 1 980) . Typically, 3 g of PSI 
was reacted with 162 mg F for 4 days at 60 °C in 30 mL dimethylformamide (DMF) 
containing 0.4 mmol triethylamine. This fluorophore-labeled PSI (F-PSI) was then 
precipitated with methanol (for removal of unreacted F) and the product was dried under 
vacuum (80 DC, 48 hours). The product was re-dissolved in DMF and subsequently, the 
solution was cooled at 0 DC, followed by an addition of excess ethanolamine (2 mol 
equivalents with respect to succinimide units) to give the completely ring-opened 
product, F-PHEA. The mixture was stirred for 24 hours at ambient temperature, 
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Figure AlIl.t .  Synthetic route of 7.4 and 4.3 kDa F-PHEA from D,L-aspartic acid 
via polysuccinimide (PSI) . 0.3 % R groups in F-PHEA were substituted by F 
(fluorophore) and the remainder of the R groups were HE (hydroxyethyl). 
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neutralized with acetic acid, dialyzed exhaustively against distilled water and finally, 
concentrated under vacuum. F-PHEA was purified by preparative gel permeation 
chromatography (GPC) on a Sephadex G-25 Fine column (50 x 400 mm, Pharmacia, 
Uppsala, Sweden) using water as the mobile phase to remove small molecular weight 
materials .  The final F-PHEA was isolated from collected fractions, followed by freeze­
drying. Samples with a narrow molecular weight distribution (MWD) were prepared by 
dissolving F-PHEA in pH 7.8 phosphate buffered saline (PBS ;  0.05 M phosphate 
containing 0. 1 5  M NaCl) followed by GPC on Sephacryl S-200 (40 x 700 mm column; 
Pharmacia) using the same buffer as the mobile phase. Individual fractions from the 
broad polymer peak were concentrated to � 20 mL and desalted by GPC on Sephadex 25-
F (50 x 400 mm column; Pharmacia) in water. A typical yield from 3 g of PSI was about 
3 . 1  g F-PHEA (Sun, 1995). Following freeze-drying, lyophilized polymers were stored in 
the dark over silica gel prior to use (Niven et aI. , 1 990). Target weight-averaged 
molecular weights were achieved by the use of controlled reaction temperatures during 
acid catalyzed thermal polycondensation and final fractional precipitation of PSI from 
DMF/water solution (Niven et aI. , 1 990; Sun, 1 995). For example, for synthesis of 
weight-averaged 7.4 kDa F-PHEA, the reaction temperature for polycondensation was 
maintained between 145 and 155 °C in order to obtain PSI with molecular weight = 1 04. 
The molecular weight distributions (MWD) of F-PHEA were determined by 
quantitative, high performance gel permeation chromatography (HPGPC) on a HEMA­
Bio 40 high-pressure column (8 x 250 mm, 10 J..lm particle size; Tessek Ltd . ,  Prague, 
200 
Czech Republic) with guard column (3 x 30 mm). All HPGPC measurements were 
performed in a mobile phase of 0.05 M phosphate buffer (pH 7 .4) containing 0 . 1 5  M 
NaCl, supplied at 1 .0 mUmin. Typical chromatograms for 4 .3 kDa F-PHEA (FR7002-5) 
determined by UV absorbance at 220 nm in Prague and by fluorescence (excitation and 
emission wavelengths = 486 and 5 1 6  nm, respectively) in Richmond are shown in Fig. 
AIII.2. Both chromatograms were totally superimposable (ANDV A) with respect to 
elution profiles, successfully demonstrating that the columns were universally calibrated 
between the two institutions . 
The calibration curve for this HPGPC column system is shown in Fig. AIII.3 .  In 
this calibration, the elution curve was monitored by Waters Model 484 UV -VIS 
absorbance detector at 220 nm with Waters Baseline-8 1O Datastation. The column was 
calibrated with three samples of PHEA with known molecular weight distributions 
(MWD),  monodispersed polyethyleneoxide (PED), hydroxyethyl glutamine (HEG) and 
water. The calibration was plotted in terms of log ( [TI) 'MW) vs. elution volume ( [TI ) :  
viscosity; Fig. AIII.3) .  Subsequently, the molecular weight was derived from this plot 
using coefficients of the Mark-Houwink equation ([TIl = KMWa; Yau et ai. , 1 979) for 
PHEA (K = 2.32 x 10.3 mUg, a = 0.87) and PED (K = 5 .05 x 10.2 mUg, a = 0.67). 
The molecular weight distributions of the prepared F-PHEA were determined from 
the calibration curve (assuming that GPC chromatogram height, hi, was proportional to 
mass of polymer with MWi) and the chromatograms of each sample by the curve 
summation method of Yau et ai. ( 1 979). The normalized molecular weight distributions 
of two, differently-sized F-PHEA (FR7 1 50 and FR7002-5), determined by Dr. Rypacek 
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Figure AIII.2. Typical gel permeation chromatograms for 4.3 kDa F-PHEA 
(FR7002-5) determined by UV absorbance at 220 nm in Prague and fluorescence 
(excitation and emission wavelengths = 486 and 5 1 6  nm, respectively) in 
Richmond. Data was normalized so that mean values for Y max between UV and 
fluorescence measurements were equal. High performance GPC (HPGPC) was 
performed in 0.05 M phosphate buffer (PH 7.4) containing 0. 1 5  M NaCl, supplied 
at 1 .0 mL/min. UV data was supplied by Dr. Rypacek (n=l) and fluorescence data 
was mean±sample standard deviations (n=5) .  
Both profiles were statistically superimposable (ANOV A). 
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Figure AlII.3. Calibration curve for HEMA-Bio40 gel permeation column. The 
molecular weight was derived using coefficients of the Mark-Houwink equation 
(Yau et aI. , 1 979) . Three PHEA standards (PHEA1 ,  2 and 3), monodispersed 
polyethyleneoxide (PEO), monohydroxyethyl glutamine (HEG) and water were 
used for constructing the calibration curve. Data was supplied by Dr. Rypacek in 
Prague. 
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in Prague are shown in Figs . AIII.4 and AIII .S, respectively. Weight- (Mw) and number-
(Mn) averaged molecular weights and polydispersity (Pd) were calculated from the 
following equations and are shown in Table Am. l :  
Mw = (L(Wj·MWj» / L Wj 
Mn = LWj / L (W/MWj) 
(Eqn. AIIU) 
(Eqn. AIII.2) 
(Eqn. AIII .3) 
where Wj is the fraction of the i th molecular weight fraction by weight, MWj (Yau et al. , 
1979). As a result, weight-averaged molecular weights (Mw) of these two, differently­
sized F-PHEA (FR7 1 S0 and FR7002-S) were found to be 7420 and 4308 Da, 
respectively, as shown in Table AIIU . Hence, the polymers were named as 7 .4 and 4 .3  
kDa F-PHEA, respectively throughout this thesis. 
The content of fluorophore label in the polymers was determined from the 
absorption spectrum of their solutions in 0. 1 N NaOH using I: = 88 [mM·cmr' as the 
absorption coefficient of N-aspartylamidoethyl-carbonyl-6-fluorescein at 492 nm (pH = 
9.0; Neri et al. , 1 973), assuming that its absorptivity was unchanged, when bound to 
PHEA. The fluorophore labels were randomly uniform across polymers (Rypacek, 1 990-
1 999; personal communications) and found to be 0.3 mole% in both batches of F-PHEA 
with respect to the monomer subunits. 
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Figure AIII.S. Normalized weight-based molecular weight distribution of 
4.3 kDa F-PHEA (FR7002-5) .  Weight- (Mw) and number- (�) averaged 
molecular weights were calculated to be 4308 and 2245 Da, respectively. Data 
was supplied by Dr. Rypacek in Prague. 
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Table AIII.1 .  Fluorophore content and molecular weight characterization for F-
PHEA. 
Ra [mol%] M e M e p d  
F-PHEA w n d 
Fb HEb [Da] [Da] 
FR7150 0.3  99.7 7420 6620 1 . 1 2 
FR7002-5 0.3 99.7 4308 2245 1 .92 
a A substituent group, R in F-PHEA structure shown below. Mol% is with respect to 
monomer subunits. 
b F and HE are fluorophore and hydroxyethyl substituents, respectively. 
C Mw and Mn are HPGPC-determined weight- and number- averaged molecular 
weights, respectively, based upon column calibration using PHEA standards. 
d Pd = Mw / � ; polydispersity. 
ApPENDIX IV 
QUANTITATIVE DETERMINATION OF MODEL 
SOLUTES IN AQUEOUS, PERFUSATE AND LUNG 
HOMOGENATE SAMPLES 
AIV.a INTRODUCTION 
Highly sensitive and quantitative methods were necessary to precisely characterize 
solute disposition in the airways following administration in small doses . These analytical 
methods were rigorously validated for each solute through the use of appropriate 
validation protocols (Linder and Wainer, 1 996). In this thesis, weight-averaged 7 .4 and 
4.3 kDa fluorophore-iabeled poly-a,�-[N(2-hydroxyethyl)-D,L-aspartamidel (F-PHEA), 
fluorescein isothiocyanate (FITC)- labeled dextran 40 (FD-4) and sodium fluorescein 
were used as model macromolecular and small solutes by virtue of their stable 
fluorescence labels for sensitive detection. Each of these solutes had the same (constant) 
fluorophore/chromophore and could thus be detected in a similar fashion. F-PHEA and 
FD-4 were analyzed by high performance gel permeation chromatography (HPGPC), 
coupled with fluorescence detection, whereas F-Na was determined by fluorimetry. Each 
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solute was analyzed in aqueous,  perfusate and lung homogenate samples for 
determination of the dose, absorption and regional lung distribution in both in vitro 
isolated perfused rat lung (IPRL) and in vivo whole rat studies .  A common complication 
introduced by the use of these matrixes was found to be the low level fluorescence 
contribution of proteins present in each matrix. There was also a need to prove that under 
typical assay conditions, analyte loss due to binding to matrix component was not an 
issue. Therefore, in this appendix, all quantitative analytical methods are described for 
each solute in each matrix sample after validation according to the recent ICH guidelines 
(ICH4, 1 996) . These methods were used to ensure analytical validity throughout the 
experiments described in this thesis. 
AIV.b DEFINITIONS AND CALCULATIONS 
(1 ) Specificity or Selectivity 
Specificity or selectivity was defined as the measure of the analytical method's 
ability to specifically isolate the solutes of interest from other possible matrix 
constituents ,  which may interfere with the quantification. During analyses in this thesis, 
perfusate and lung homogenate were used as matrixes. These interference could be 
detected from proteins in the matrixes, which caused overlapped elution profiles in 
HPGPC for F-PHEA and FD-4 (as shown in Fig. AIV. I ) ,  and additional fluorescence 
intensity during fluorimetry for F-Na. However, it appeared that no critical effects , such 
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Figure AIV_I .  A typical high perfonnance gel penneation chromatogram for 7.4 
kDa F-PHEA (FR7 1 50) in IPRL perfusate, blank perfusate and the solute, F­
PHEA, which was constructed by curve stripping. 
209 
2 1 0  
a s  binding and/or quenching were observed (e.g . ,  homogenate samples contained � 98 .0 
% of the expected concentrations of fluorophore in all cases) and these were found to be 
present as  simple additional fluorescence in all of those samples . As a result, quantitative 
determination could be achieved by rigorously stripping interference profiles in HPGPC 
for F-PHEA and FD-4 and by constructing calibration curves for fluorescence of F-Na 
following adequate dilution of the matrixes in 0. 1 N aqueous N aOH. 
(2) Linearity of Calibration 
Linearity was evaluated across the range of concentrations to be used for actual 
analytical determinations . Linearity of calibration curves was assessed using appropriate 
statistical methods. In this thesis, regression analysis (regression equation and correlation 
coefficient) was performed from various solute concentrations (n � 6) and documented 
alongside each actual calibration curve. 
(3) Detection and Quantification Limits: LOD and LOQ 
LOD and LOQ are defined as the smallest concentrations of the solutes of interest 
that can be detected and quantified in the samples, respectively, with a given level of 
confidence. Currently, ICH is promoting the use of the standard deviation of the response 
intercept of calibration curves (response vs. concentration) using linear least-square­
regression for the determination (ICH Q2B , 1 996; Paino and Moore, 1999). LOD and 
LOQ values were calculated from this standard deviation and the slope of calibration 
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curve and hence, for 95 and 99 % of confidence, these were given by the following 
equations: 
LOD = 3 .3 ·(j/S 
LOQ = lO'(j/S 
(Eqn. AIV. I )  
(Eqn. AIV.2) 
where (j and S are the standard deviation of the response intercept and the slope, 
respectively, both of which are calculated from the calibration curves. Values for LOD 
and LOQ were calculated for all of the assays used in this thesis in each of the matrixes. 
(4) Precision or Repeatability 
Precision or repeatability was defined as relative standard deviation (RSD) from six 
identical determinations using control samples (samples with known concentration) and 
calculated from the following equation: 
SD 
RSD x 1 00 (Eqn. AIV.3) 
Mean 
where Mean and SD, respectively, were sample mean and standard deviation of six 
determinations for each control sample. In this thesis, three different concentration 
samples (high, middle and low) covering the extremes and center of the analytical range 
to be determined were used as control samples for which RSD values were calculated. 
(5) Accuracy 
2 1 2  
Accuracy was similarly defined as % error (%error = DFN; % difference from 
nominal concentration) for six determinations using control samples with known 
concentrations. Values for %error were calculated from the following equation: 
%error = x 100 (Eqn. AIV.4) 
where Cnom and Cmes, respectively are known and measured concentrations of control 
samples. In this thesis, three different concentration samples (high, middle and low) 
covering the extremes and center of the analytical range to be determined were used as 
control samples for which %error values were calculated. 
AIV.c 
AIV.c. l 
ANALYTICAL VALIDATION FOR QUANTITATIVE 
DETERMINATION 
PREPARATION OF VALIDATION SAMPLES 
Perfusate was prepared as described in Appendix ALb. 1 ,  whereas lung 
homogenates were derived from homogenization of tissue samples in 10 mL phosphate 
buffered saline (PBS;  pH 7.4, 0.05 M phosphate in 0. 1 5  M NaCl) at room temperature 
2 1 3  
using a BioHomogenizer ( 10,000 rpm for 2 minutes; Fisher Scientific, Springfield, NJ). 
Validation samples (for calibration curve and precision/accuracy) were prepared by 
spiking different, but known amounts of each model solute into either aqueous buffer, 
perfusate or lung homogenate. Aqueous and perfusate samples were analyzed directly or 
following appropriate dilution by the methods described below. Those in lung 
homogenates were determined after filtration of supernatant samples (0.45 /llll, nylon, 
4mm, Alltech Associates, Deerfield, IL) derived from centrifugation (Marathon 22K; 
1 ,500 g for 15 minutes, Fisher Scientific, Springfield, NJ) of the lung homogenate. All 
spiking volumes were minimized, compared to matrix volumes (less than 10 % volume 
additions were used) and theoretical concentrations were mathematically calculated, 
based on spiking method employed. 
AIV.c.2 QUANTIFICATION OF 7.4 AND 4.3 kDa F-PHEA AND FD-4 
High performance gel permeation chromatography (HPGPC), coupled with 
fluorescence detection was used for quantitative determination of 7.4 and 4.3 kDa F­
PHEA and FD-4 regardless of the sample matrix. The HPGPC column was a Separon ™ 
HEMA-Bio 40 high-pressure column (8 x 250 mm, 1 0  !lm particle size; Tessek Ltd . ,  
Prague, Czech Republic) with a guard column (HEMA-Bio 40;  4 .6 x 10 mm, 10  !lm 
particle size; Tessek Ltd. ,  Prague, Czech Republic) . The mobile phase was phosphate 
buffered saline solution (PBS;  pH 7.4, 0.05 M phosphate in 0. 1 5  M NaCl solution), 
2 1 4  
supplied at 1 .0 mUmin by  a HPLC pump (Model LC-7A B io  Liquid Chromatograph;  
Shimadzu Corporation, Kyoto, Japan). Samples ( 1 00 J.lL) were introduced onto the 
column by Rheodyne injection valve ( 1 00 J.lL; Model 7 1 25 ;  Cotati, CA). Fluorescence 
intensity was detected using 486 and 5 1 6  nm excitation ("-ex> and emission ("-em) 
wavelengths, respectively (Model RF-535 Fluorescence HPLC Monitor; Shimadzu 
Corporation, Kyoto, Japan) . Output was recorded with a calibrated chart recorder ( I  
cm/min; Fisher Recordall, Series 5000; Fisher Scientific, Springfield, NJ). All chemicals 
were purchased from Fisher Scientific (Raleigh, NC) and the freshly-prepared mobile 
phase was vacuum-filtered through a 0.45 J.lm filter (plain; nylon; 47 mm; Alltech, 
Deerfield, IL) prior to each analysis .  
The HPGPC chromatograms for polydispersed F-PHEA and FD-4 were digitized 
manually by measuring their heights (hi) at every 0.2 mL of elution volume (Ve) between 
4.0 and 1 2 .0 mL and reconstructed on a spreadsheet, as shown in Table AIV. 1 .  The area 
under the curves (AUCi) in each elution volume (Ve,i) interval due to the solute were 
calculated by the trapezoidal rule and summed to determine the cumulative AUC values 
(LAUC) as fluorescence-elution peak areas due to solute in the samples .  The protein 
content of the perfusate (4 % BSA) and the filtered supernatant of lung homogenate 
contained a fluorescent component interfering with the early portion of F-PHEA and FD-
4 chromatograms following their direct injection into the HPGPC system, as shown in 
Fig. AIV. l ;  the chromatograms were typified by 7.4 kDa F-PHEA. Thus, a rigorous 
curve stripping procedure was employed for the AUC determination of the 
chromatograms, as described previously (Table AIV. ! and Fig. AIV. I ;  Byron et ai. ,  
Table AIV.I .  Data sheet example ofF-PHEA quantification in a perfusate 
sample by use of a rigorous curve stripping procedure [7.4 kDa F-PHEA 
nominal dose : 5.0 mg; sampling time: 20 minutes] . 
2 1 5  
h i  B 1  and hi B2 are the chromatogram heights of two-sets of blank, solute-free 
<perfusate:only) samples and hi Bmean is the average value at each elution volume (this 
data provided the baseline chromatogram). hi and h; ' represent the apparent and the 
corrected heights, respectively, of the F-PHEA elution chromatogram; the latter is 
calculated from h; - hi,Bmean ' 
2 1 6  
1 990; Sun, 1 995). This involved two-sets o f  blank, matrix-only chromatograms and a 
determination of their average heights (hi.Bmean) .  Values for the matrix were subtracted 
from the apparent heights (hi) of solute-containing chromatograms of either perfusate or 
filtered supernatant samples .  Thus, the corrected heights (hi ') ,  determined after baseline 
subtraction, enabled a calculation of the total area under the chromatogram due to the 
solute (LAUC), which was related directly to the solute concentration in those samples 
(Table IV. l ) .  
Analytical validation for 7 0 4  and 4 . 3  kDa F-PHEA and FD-4 in  each sample 
(aqueous, perfusate and lung homogenate samples) are summarized in Tables AIV.2,  
AIV.3 and AlVA, respectively and their calibration curves are shown in Fig. AIV.2 .  
Corrected (stripped) HPGPC chromatograms obtained from solute-spiked perfusate and 
filtered supernatant of lung homogenate were found to be insignificantly different from 
original chromatograms following solute injection in aqueous buffer. This was true with 
respect to both molecular weight distribution (MWD), as evidenced by elution curve 
shape and values for resultant LAUC, as shown in Fig. AlV. 3 (ANOV A); the 
chromatograms were typified by 704 kDa F-PHEA. This result was clear evidence that 
protein binding and quenching of these macromolecules due to the presence of the matrix 
components was negligible at the concentrations being studied (Byron et aI. , 1 990) . 
Consequently, analyses were effectively unchanged across matrixes and remained highly 
sensitive with unchanged response factors (LOD $ 0. 1 Ilg/mL). These fluorescence­
HPGPC methods were successfully validated for both F-PHEA and FD-4 with values for 
Table AIV.2. A summary of the analytical validation performed for 7 .4 kDa F-PHEA (FR7 1 50) 
determinations in aqueous, perfusate and lung homogenate samples 
Calibration range4 [/-1g!mL] 
Regression5 
R6 
LOD7 [/-1g!mL] 
LOQ8 [/-1g/mL] 
Nominal conc. [/-1g!mL] 
Precision9 [%] (RSD) 
Accuracy/O [%] (%error) 
Aqueous buffer' 
0.09-2 . 5  
Y = 90.42 X + 1 . 1 3  
0. 1  
9 .3 
1 .6 
0.9997 
0.03 
0.09 
1 .0 
2 .3 
2 .9 
2 .0 
2 .5 
1 .3 
IPRL perfusate2 
0.33-2 .5 
Y = 93 .46 X + 2 . 1 5  
0.4 
4.2 
7.7 
0.9967 
0. 1 1  
0 .33 
1 .3 
4.4 
1 . 5  
1 . 8 
2 .4 
0 .8 
Lung homogenate3 
0. 1 5-2 .5 
Y = 90.49 X + 2 .3 1 
0.2 
8 .7  
8 .2 
0.9997 
0.05 
0. 1 5  
0.9 
3 .9 
2 .2 
2 . 1  
1 . 5 
0.2 
, Phosphate buffered saline (PBS; pH 7.4, 0.05 M phosphate in 0. 1 5  M NaCl) ; 2 Krebs-Henseleit buffer solution 
containing 4 % (w/v) bovine serum albumin; 3 lung tissue homogenized in 1 0  mL PBS;  4 concentration range in which 
linearity was proven; 5 regression equation between total area under the curve (LAUC) of the corrected (stripped) 
chromatogram (Y: [mm·mLl) and F-PHEA concentration (X: [/-1g!mLl) from n � 6; 6 correlation coefficient of the 
regression equation; 7 detection limit determined by Eqn. AIV. I ;  8 quantification limit determined by Eqn. AIV.2; 
9 RSD determined by Eqn. AlV.3 (n=6) and '0 % error (difference from nominal) determined by Eqn. AlV.4 (n=6) .  
N 
-..] 
Table AIV.3. A summary of the analytical validation performed for 4 .3 kDa F-PHEA (FR7002-5) 
determinations in aqueous, perfusate and lung homogenate samples 
Calibration range4 [f.lg/mL] 
Regression5 
R6 
LOD7 [f.lg/mL] 
LOQ8 [f.lg/mL] 
Nominal conc. [f.lg/mL] 
Precision9 [%] (RSD) 
Accuracy10 [%] (%error) 
Aqueous buffer1 
0.02- 1 .0 
Y = 1 80.27 X + 0 .5 1 
0. 1  
8 . 5  
3 . 5  
0.9999 
0.006 
0.024 
0.4 
2 . 1  
2 . 1  
0 .8 
1 .2 
1 .5 
IPRL perfusate2 
0.06- 1 .0 
Y = 1 82 .72 X + 0.70 
0. 1 
7 .9 
6 .2 
0.9994 
0.0 1 9  
0.062 
0.4 
1 .4 
3 . 5  
0 .8 
1 .2 
1 . 5  
Lung homogenate3 
0.06- 1 .0 
Y = 1 79 .94 X + 1 .40 
0. 1 
5 .4  
3 .9  
0.9990 
0.0 1 9  
0.063 
0.4 
1 . 1  
2 .2 
0 .8 
1 . 5 
1 .3 
1 Phosphate buffered saline (PBS ;  pH 7.4, 0.05 M phosphate in 0. 1 5  M NaCl); 2 Krebs-Henseleit buffer solution 
containing 4 % (w/v) bovine serum albumin; 3 lung tissue homogenized in 10 mL PBS;  4 concentration range in which 
linearity was proven; 5 regression equation between total area under the curve (LAUC) of the corrected (stripped) 
chromatogram (Y: [mm·mL]) and F-PHEA concentration (X: [J.lg/mL]) from n 2: 6; 6 correlation coefficient of the 
regression equation; 7 detection limit determined by Eqn. AlV. l ;  8 quantification limit determinedby Eqn. AlV.2 ; 
9 RSD determined by Eqn. AN.3 (n=6) and 10 % error (difference from nominal) determined by Eqn. AlV.4 (n=6) .  N 
00 
Table AlV.4. A summary of the analytical validation performed for 4.4 kDa FITC-dextran 40 (FD-4) 
determinations in aqueous, perfusate and lung homogenate samples 
Calibration range4 [flglmL] 
Regression5 
R6 
LOD7 [flglmL] 
LOQ8 [flg/mL] 
Nominal cone. [flglmL] 
Precision9 [%] (RSD) 
AccuracylO [%] (%error) 
Aqueous bufferl 
0.08- 1 . 8  
Y = 1 6 l .43 X - l .2 1  
0.9996 
0.027 
0.080 
0. 1 0 .6 
1 0.7 1 . 5 
8 .8  0 .8 
1 . 1  
1 . 1  
l .0 
IPRL perfusate2 
0.04- 1 .7 
Y = 1 62 . 53  X + l .49 
0.9998 
0 .0 14 
0.04 1  
0 .3 0.7 l . 3 
5 . 3  4. 1 6 . 1  
4 .9 2 . 1 0.4 
Lung homogenate3 
0.07- l .6 
Y = 1 6 l .06 X + 2.46 
0.3 
9 .4 
5 .2 
0.9997 
0.022 
0.066 
0 .7 
3 .9 
l .8 
1 .4 
2 .9 
1 . 5 
1 Phosphate buffered saline (PBS; pH 7.4, 0.05 M phosphate in 0. 1 5  M NaCl); 2 Krebs-Henseleit buffer solution 
containing 4 % (w/v) bovine serum albumin; 3 lung tissue homogenized in 1 0  mL PBS;  4 concentration range in which 
linearity was proven; 5 regression equation between total area under the curve (LAUC) of the corrected (stripped) 
chromatogram (Y: [mm·mL]) and FD-4 concentration (X: [flglmL]) from n � 6; 6 correlation coefficient of the 
regression equation; 7 detection limit determined by Eqn. AIV. 1 ;  8 quantification limit determined by Eqn. AIV.2; 
9 RSD determined by Eqn. AIV.3 (n=6) and 1 0 % error (difference from nominal) determined by Eqn. AlV.4 (n=6) . 
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Figure AIV.2. Calibration curves for 7.4 and 4.3 Da F-PHEA and FD-4 in 
aqueous, perfusate and lung homogenate samples. These were detected by 
fluorescence (excitation and emission wavelengths = 486 and 5 1 6  nm, 
respectively) following HPGPc. HPGPC was performed in 0.05 M phosphate 
buffer (PH 7 .4) containing 0. 1 5  M NaC!, supplied at 1 .0 mLlmin. Most error 
bars for sample standard deviations (n=4) are smaller than symbol sizes. 
Solid lines are the results of linear regression of each data set. 
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Figure AIV.3. A high performance gel permeation chromatogram for 7.4 kDa F­
PHEA (FR71 50) constructed from elution profiles ofF-PHEA/perfusate samples 
by curve stripping (as shown in Fig. AIV.I ) ,  compared to the original polymer 's 
chromatogram after solution preparation in buffer. The original chromatogram is 
shown as mean ± sample standard deviation (n=5) .  
The profiles differed insignificantly (ANOV A). 
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precision (RSD :s; 1 0.7 %) and accuracy (%error :s; 8 . 8  %), which enabled their use in 
Chapters 3-5 of this thesis. 
AIV.c .3  QUANTIFICATION OF SODIUM FLUORESCEIN (F-Na) 
F-Na was analyzed by fluorimetry using a luminescence spectrometer (Model LS 
50; slit == 10 nm, integration == 1 .0 second; Perkin Elmer Ltd. ,  Norwalk, CT) at 490 and 
520 nm of excitation (Aex) and emission (Aem) wavelengths, respectively. All 
concentrations for F-Na in this thesis were corrected for water content and are expressed 
in terms of the mass of the anhydrous material (Byron et aI. , 1 986). At these 
wavelengths, it was found that substantial fluorescence intensity could originate both 
from the perfusate and the filtered supernatant of lung homogenate. However, these were 
found to be simple background fluorescence in all cases without showing evidence of 
analyte binding, quenching or metabolism. Thus, it was possible to minimize the effect 
by a � IO-fold sample dilution in 0. 1 N NaOH. In most cases, 0.3 mL of perfusate or 
filtered supernatant of lung homogenate was diluted with 3 .0 mL of 0. 1 N NaOH ( 1 1 -fold 
dilution) .  Fluorescence intensity was measured in a quartz cell (3mL, 1 cm, Fisher 
Scientific, Pittsburgh, PA) . 
Analytical validation across matrixes for F-Na in aqueous,  perfusate and lung 
homogenate samples is summarized in Table AIV.5 and calibration curves from three 
Table AlV.S. A summary of the analytical validation performed for sodium fluorescein (F-Na) determinations 
in aqueous, perfusate and lung homogenate samples 
Calibration range4 [ng/mL] 
Regression5 
R6 
LOD7 [ng/mL] 
LOQ8 [ng/mL] 
Nominal conc. [ng/mL] 
Precision9 [%] (RSD) 
AccuracylO [%] (%error) 
Aqueous bufferl 
1 .6-50.0 
Y = 1 6 . 5 1  X + 1 . 85  
0 .9  
1 04 
0.2 
0.9995 
0 .53 
1 .62 
5 . 5  
0. 1 
1 . 5 
28 .0  
0 .2  
2 .0  
IPRL perfusate2 
1 .7-50.0 
Y = 1 6.68 X + 6 . 5 7  
1 .0 
0 .8  
9 . 1  
0.9995 
0 .55  
1 .65 
5 .0 
0.2 
1 .0 
20.0 
0. 1 
0.2 
Lung homogenate3 
1 . 5-50.0 
Y = 1 6 . 5 6  X + 1 6 .63 
0.6 
3 . 0  
2.2 
0.9998 
0048 
1 046 
5 . 9  
1 .0 
0. 1 
22.7 
0 . 1  
0 . 8  
1 Phosphate buffered saline (PBS ; p H  7 04, 0.05 M phosphate i n  0. 1 5  M NaCl); 2 Krebs-Henseleit buffer solution 
containing 4 % (w/v) bovine serum albumin; 3 1ung tissue homogenized in 1 0  mL PBS ;  4 concentration range in which 
linearity was proven; 5 regression equation between fluorescence intensity (Y: [-l) and F-Na concentration (X: [ng/mLl) 
from n � 6; 6 correlation coefficient of the regression equation; 7 detection limit determined by Eqn. AlV. l ;  
8 quantification limit determined by Eqn. AN.2;  9 RSD determined by Eqn. AlV.3  (n=6) and 10 % error (difference from 
nominal) determined by Eqn. AlVA (n=6).  N N '" 
224 
matrix samples are shown in Fig. AIV.4. Negligible fluorescence intensities (4.6±0.2 and 
1 3 .3±O. 1 from the perfusate and the filtered supernatant of lung homogenate samples, 
respectively; mean±SD, n=4) were present as background fluorescence following l l -fold 
dilution and hence, the LaD for the worst scenario was found to be 0.55 ngimL. The 
analyses were not different across sample matrixes (Table AIV.5) .  Consequently, this 
highly sensitive fluorimetric method was successfully validated for F-Na with precision 
(RSD :::; 3 .0 %) and accuracy (%error :::; 9 . 1 %), sufficient for use in this thesis. 
AIY.e.4 SAMPLE ANALYSIS FROM THE IPRL AND IN VIVO 
All samples were analyzed by adhering to the validated methods and the sample 
preparation described above. In no cases were results quoted for solute concentrations 
where assayed concentration was less than LOQ. More than two spiked standard samples 
were analyzed along with a blank, matrix-only sample for each analytical series collected. 
These were used to construct calibratiun curves for the analytical series in question. The 
consistency of the LAUC values or the values for fluorescence intensity of the standards 
were checked in each analysis alongside the calibration curves and standards were found 
to be reproducible throughout the experiments performed in this thesis (responses 
differed by < 5 % from expected values in all cases). 
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Figure AlV.4. Calibration curves for F-Na in aqueous, perfusate and lung 
homogenate samples. The latter two samples were diluted 2: I I -fold with 0 . 1 N 
NaOH. These were detected by fluorimetry (excitation and emission wavelengths 
= 490 and 520 nm, respectively). All error bars for sample standard deviations 
(n=4) are smaller than symbol sizes. Solid lines are the results of linear regression 
of each data set. 
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ApPENDIX V 
METABOLISM AND TISSUE BINDING OF MODEL 
SOLUTES IN THE RAT LUNG 
AV.a INTRODUCTION 
Although the use of the isolated perfused rat lung (IPRL) preparation precludes 
" systemic " clearance, solute disposition in the lung may still be complicated by "local" 
clearance, such as lung metabolism and tissue/protein binding (Byron, 1 986; Byron and 
Phillips, 1 990) . These effects were precluded in the case of the model solutes ,  
fluorophore-Iabeled poly-a,�- [N(2-hydroxyethyl)-D,L-aspartamide] (F-PHEA), FITC-
dextran 40 (FD-4) and sodium fluorescein (F-Na) . These were first selected to reduce the 
likelihood of their showing metabolism and binding by the rat lung, based both on 
previous studies (Neri, et ai. , 1 973 ;  Niven, 1988; Sun, 1 995) and literature reports 
(Takada et ai. , 1 978 ;  Ohtani et ai. , 199 1 ;  Matsukawa et ai. , 1 997). Indeed, the 
metabolism in and binding to the IPRL system was shown to be negligible, as described 
in this appendix. 
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AV.b SOLUTE METABOLISM BY THE RAT LUNG: 
IN VITRO STUDIES USING LUNG HOMOGENATE 
Blood-free lungs were obtained, according to the operating procedure of the IPRL 
(Appendix I) . The lung was homogenized in 60 mL phosphate buffered saline (PBS ;  0.05 
M phosphate and 0. 1 5  M NaCl; pH 7 .4) using a BioHomogenizer ( 1 0,000 rpm for 2 
minutes; Fisher Scientific, Springfield, NJ) at room temperature. The homogenate 
suspension (50 mL) was placed in a 200 mL water-jacketed glass beaker (Research Glass ,  
Richmond, V A),  maintained at 37 DC and stirred on a stirring plate (Model PC-353 ;  
Corning, Corning, NY) with a teflon fluorocarbon resin-coated magnetic stir bar ( I  = 3 . 5  
cm; Fisher Scientific, Raleigh, NC) throughout experiments. After :2: 5 minutes ,  a PBS 
solution (25 J..lL) containing either 7.4 or 4.3 kDa F-PHEA (0.02 mg) or FD-4 (0.02 mg) 
or F-Na (0.005 mg) was added to the suspension and incubation commenced at 37 DC 
(time = 0 [minute]) . At different time intervals over a 1 20- 1 80 minutes incubation period, 
samples (0.5 mL) were withdrawn from the homogenate suspension and centrifuged at 
room temperature for 1 5  minutes ( 1 725 rpm; Savent® Speed Vac, SCI  10 ,  Forma 
Scientific, Inc . ,  Marietta, OH). Subsequently, the supernatant was filtered through an 0.45 
J..lm syringe filter (4 mm, cellulose acetate, Alltech Associates, Deerfield, IL) and 
analyzed by the validated methods described in Appendix IV. 
Average solute concentrations (± SD; n = 4) in the incubation homogenate for 7.4 
and 4 .3 kDa F-PHEA, FD-4 and F-Na vs. time are shown in Fig.  AV. ! .  Each measured 
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Figure AV.1 .  Average concentrations (± SD; n=4) of 7.4 and 4.3 kDa F-PHEA, 
FD-4 and F-Na in lung homogenate vs. time. Each solute was incubated in the 
lung homogenate at 37 °C. Dashed lines were theoretical concentrations; 0.4 
llg/mL for F-PHEA and FD-4 and 0. 1 llg/mL for F-Na. 
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solute concentration was incubation time-independent and consistent with the theoretical 
value ± 3 % (0.4 !1g/mL for F-PHEA and FD-4; 0. 1 !1g/mL for F-Na) throughout the 1 20-
1 80 minutes incubation at 37 °C. The molecular weight distributions (MWD) for 7.4 and 
4.3 kDa F-PHEA and FD-4 at the end of incubation ( 1 80 and 1 50 minutes for F-PHEA 
and FD-4, respectively) are shown in Fig. AV.2, compared to each of original MWD. 
These were unchanged following incubation, demonstrating the absence of significant 
metabolic cleavage of the polypeptides due to incubation. 
F-PHEA molecules appeared to have a high resistance to enzymatic proteolysis due 
to the random distribution of (J.- and p- peptidic linkages and synthesis with a racemic 
mixture of D- and L- configured aspartic acid residues (Drobnik et ai. , 1 979a and 1 979b; 
Rypacek et ai. , 1 980; Byron et ai. , 1 99 1 ) . The fluorescence labels attached as shown in 
Fig. AIII. I (Appendix III) were also shown to be chemically stable (Rypacek et ai. , 1 979; 
Rypacek et ai. , 1980) and in fact, there was no evidence of detachment during incubation. 
These arguments were well-supported by Figs. AV. l and AV.2 (a) and (b), which 
showed unchanged concentrations and MWDs during incubation. Similarly, FD-4 was 
shown to be stable with respect to both glucose unit structures and its fluorescent label 
(Riggs et ai. , 1 958 ;  Arfors and Hint, 1 97 1 ;  Ringsdorf, 1 975),  as shown in Figs AV. I and 
AV.2 (c). F-Na has been extensively studied both in vivo and in vitro in the IPRL and no 
chemical or metabolic degradation has been reported for this solute in the literature 
(Byron and Clark, 1 985a; Byron et ai. , 1 986; Niven and Byron, 1 988 ;  Niven and Byron, 
1 990) or in this study (Fig. AV. l ) .  
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Figure AV.2. High performance gel permeation chromatograms for (a) 7 .4 and 
(b) 4.3 kDa F-PHEA after 1 80 minutes incubation with lung homogenate at 37 oC, 
compared to each original chromatogram. The profiles were obtained following 
curve stripping, as described in Appendix IV. Data was mean±sample standard 
deviations (n=4). 
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Figure AV.2. High performance gel permeation chromatogram for (c) FD-4 after 
1 50 minutes incubation with lung homogenate at 37 DC, compared to the original 
chromatogram. The profiles were obtained following curve stripping, as described 
in Appendix IV. Data was mean±sample standard deviations (n=4). 
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The lung homogenate prepared with the BioHomogenizer ( 10,000 rpm for 2 
minutes) contains proteolytic enzymes from both extracellular and cytosolic fractions 
alongside subcellular pellets (Liu et ai. , 1 992; Shen et at. , 1 999). In fact, even in the 
absence of co-factors, it was demonstrated that a tri-peptide, thyrotropin-releasing 
hormone (TRH) was metabolized in these lung homogenate at 37 °C extensively and 
quite rapidly (� 80 % was metabolized within 20 minutes; Visich, 1 996) . Therefore, in 
this incubation study, model solutes were subjected to all possible lung enzymes and in 
such an "extreme" condition, no significant metabolism was observed for these solutes 
over the IPRL study period employed in this thesis .  
AV.c TISSUE BINDING BY THE RAT LUNG: SOLUTE 
UPTAKE FROM THE PERFUSATE INTO LUNG TISSUE 
The IPRL was prepared according to the operating procedure described in  
Appendix I and used unchanged except that solutes were administered into perfusate 
rather than the airways in concentrations representative of those seen in the remainder of 
the thesis .  After perfusion commenced in the IPRL (Appendix ALb.4), 50 �L of 
phosphate buffered saline solution (PBS;  0 .05 M phosphate and 0. 1 5  M NaCl; pH 7 .4) 
containing either 7.4 or 4.3 kDa F-PHEA (0.05 mg) or FD-4 (0.05 mg) or F-Na (0.005 
mg) was added to the perfusate reservoir ( 1 22.2 mL including flow line volumes ; time = 
o [minute]) .  At different time intervals ,  the perfusate samples (0.5 mL) were taken from 
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the reservoir and analyzed by the methods described in Appendix IV. All studies were 
performed at 37 °C. 
Solute amounts added into the perfusate were a half of each of the minimum doses 
for each solute studied in the IPRL and thus, the pefusate concentrations. Average solute 
concentrations (± SD; n = 4) in the perfusate for 7A and 4 .3 kDa F-PHEA, FD-4 and F-
Na vs. time are shown in Fig. AV.3 .  Each measured solute concentration was found to be 
time-independent and consistent with theory, assuming no uptake into lung tissue (OA I 
llg/mL for F-PHEA and FD-4; 0.04 Ilg/mL for F-Na) . The molecular weight distributions 
(MWD) of the perfusate samples for 7A and 4.3 kDa F-PHEA and FD-4 at the end of 
perfusion ( 1 80 and 1 50 minutes for F-PHEA and FD-4, respectively) were compared to 
each of the original MWDs, as shown in Fig. AVA. There was no detectable difference in 
the MWD during perfusion (similar to the situation seen with lung homogenates earlier) . 
It is unlikely therefore, that the model solutes used in this thesis underwent any 
significant tissue or protein binding-induced accumulation in the IPRL or in vivo. 
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Figure AV.3. Average concentrations (± SD; n=4) of 7.4 and 4.3 kDa F-PHEA, 
FD-4 and F-Na in the perfusate in the IPRL vs. time. Each solute was added into 
the perfusate at 37 °C. Dashed lines were theoretical concentrations; 0 .41 /lg/mL 
for F-PHEA and FD-4 and 0.04 JlglmL for F-Na. 
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Figure AV.4. High perfonnance gel penneation chromatograms for (a) 7 .4 and 
(b) 4.3 kDa F-PHEA after 1 80 minutes perfusion in the IPRL at 37 °C, compared 
to each original chromatogram. The profiles were obtained following curve 
stripping, as described in Appendix IV. Data was mean±sample standard 
deviations (n=4). 
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Figure AV.4. High performance gel permeation chromatogram for (c) FD-4 after 
1 50 minutes perfusion in the IPRL at 37 °C, compared to the original 
chromatogram. The profiles were obtained following curve stripping, as described 
in Appendix IV. Data was mean±sample standard deviations (n=4). 
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ApPENDIX VI 
ACROSS-DOSE CURVE FITTING BY "SCIENTIST" 
AVI.a INTRODUCTION 
In this thesis, a nonlinear least-mean-square regression routine was employed to 
permit across-dose curve fitting of solute absorption VS. time data to a new kinetic model 
shown in Fig. A VI. l ,  in vitro (isolated perfused rat lung: IPRL) and in vivo, using a 
program, "Scientist" for Windows® (MicroMath Scientific Software, Salt Lake City, UT) . 
The program required three types of electronic files for curve fitting. These were a Model 
File, a Data File and a Parameter File. The Model File defined independent- (time and/or 
dose) and dependent- (% transfer to perfusate (in vitro IPRL) or % remaining in lung (in 
vivo» variables, the model's parameters (F, ka.p, kE•PT, V max.P, Km,p and/or ka,TB) and their 
mathematical interrelationships (differential equations and initial conditions). The Data 
File contained experimentally-observed values for all the independent- and dependent­
variables defined in the Model File and these were obtained directly following either 
IPRL or in vivo studies, The Parameter File was comprised of a set of the model 's 
parameters, defined in the Model File; these depended on the solute under investigation 
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Figure AVI.1 .  A new kinetic model for solutes administered into the airways of the 
rat lung. 
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* Passive absorption from the tracheo-bronchial region is not present in the IPRL due 
to the severance of the bronchial circulation during surgery (ka TB = 0 in the IPRL). 
Key :  F - initial average penetration fraction following administration (0.9 1 ) ;  Vmux P 
and Kill P - the maximum rate and "affinity" of Michaelis-Menten-type active 
. 
absorption, respectively; ka P and ka TB - first-order rate constants for passive absorption 
from the pulmonary and th� trache�-bronchial regions, respectively; kE.PT - first-order 
rate constant for mucociliary clearance. 
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and initially, initial estimates were assigned for each set of experimental data, as 
described in detail below. All three electronic files were necessary and subsequently, 
nonlinear regression was performed to obtain the best parameter estimates for the model, 
which provided a minimum sum of squared residuals (between experiment and theory) 
according to the program's minimization algorithms. The program, "Scientist" 
implemented Simplex and modified Gauss-Newton algorithms for this purpose. In this 
thesis, the Simplex technique was initially used to locate the region of the minimums and 
hence, to provide improved parameter estimates ,  compared to the initial estimates 
assigned by the operator. Subsequently, the best parameter estimates providing the 
minimum sum of squared residuals were obtained by the modified Gauss-Newton 
technique and the results were saved in the Parameter File. The best estimates and their 
"goodness-of-fit" were statistically assessed by several statistical parameters provided by 
the program's Statistical Output File. The "goodness-of-fit" was also visually inspected 
by generating the plots using the best estimates, as provided by the program's  Plot File. 
In this appendix, the procedure of across-dose curve fitting for 7.4 kDa F-PHEA 
and F-Na disposition in the IPRL at 37 DC are described, followed by that for F-Na 
disposition in vivo, as examples of in vivo curve fitting. The IPRL curve fittings for 4 .3 
kDa F-PHEA and FD-4 and those at  25 DC were performed similarly to either 7 .4 kDa F­
PHEA or F-Na and thus, are not documented here. 
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AVl.b EXAMPLES OF CURVE FITTING 
(1 ) Across-dose curvefittingfor 7.4 kDa F-PHEA disposition in the 1PRL at 37 "C 
The Model File, Parameter File (with initial estimates) and Data File are shown in 
Fig. A VI.2. The Model File defined time (T) and dose (DOSE) as independent-variables 
and % transfer to perfusate (FP) as a dependent-variable, followed by the model 's 
parameters, the differential equations and the initial conditions. Based on the model 
shown in Fig. A VI. I , the differential equations were derived and are shown as follows:  
(d[P]/dt)Activc+Passive.lPRL = V max,P' [M]p/(Km,p + [M]p) + ka,P '  [M]p 
(d[M]p/dt)[PRL = - (d[P]/dt) - kE,pr [M]p 
(d[MhB/dt)lPRL = kE,PT· [M]p 
(Eqn. A VI. l )  
(Eqn. A VI.2) 
(Eqn. A VI.3) 
where [P] is the cumulative solute amount absorbed from the pulmonary region into the 
recirculating perfusate of the IPRL, [M]p and [MhB are the solute amounts remaining 
unabsorbed in the pulmonary and the tracheo-bronchial regions, respectively; V max,P is  
the maximum rate of active absorption, Km,p is the "affinity" or dose at which the active 
absorption rate = 0.5 ·  V max,P, ka,p is  the first-order passive absorption rate constant from 
the pulmonary region and kE,PT is the first-order mucociliary clearance rate constant from 
the pulmonary to the tracheo-bronchial region, In the Model File (Fig. A VI.2), symbols, 
P, A and U represent [P] , [M]p and [MhB, respectively and the parameters, F, KA, KE, 
VMAX and KM, respectively, were assigned to F, ka,p, kE,PT, Vmax,P and Km,p, in the 
(a) 
(b) 
II 
II July 1 0 , 1 998 
II Masahiro Sakagami ,  MCVNCU 
II 
II F-PHEA Transfer Model in the IPRL study 
II Final Vers ion 
II 
II Passive & Active Transport involved 
II Mucoci l iary Transport involved 
II 
II A :  Alveol i  
II U : Upper Airway 
li P :  Perfusate 
II 
I ndVars: T, DOSE 
DepVars : FP 
Params: F ,  KA, KE,  VMAX, KM 
II 
FP=P/DOSE*1 00 
A'=-(KA+KE)*A-VMAX*N(KM+A) 
U'=KE*A 
P'=KA* A+VMAX* N(KM+A) 
II 
II 
II I n it ial Condit ions; 
T=O 
A=DOSE*F 
U=DOSE*( 1 -F) 
p=o 
F 
KA 
KE 
VMAX 
KM 
Min  
- I nfinity 
0 .000000000 
0 .000000000 
0 .000000000 
0 .000000000 
Parameter 
0 .91 00000 
0 .0020000 
0 .0350000 
1 0 .200000 
202 .40000 
24 1 
Max 
I nfin ity 
I nfin ity 
I nfin i ty 
I nfin ity 
I nfin ity 
Figure AVI.2. Model File (a) and Parameter File (b) of "Scientist"to be used for 
fitting 7.4 kDa F-PHEA absorption data obtained from the IPRL at 37 DC.  Parameter 
values shown in (b) are initial estimates used for across-dose curve fitting. 
Data File is shown in Fig. A VI.2 (c). 
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(C) T DOSE FP T DOSE FP 
0 .00000000 1 00 .000000 0 .00000000 0 .00000000 1 000.00000 0 .00000000 
5 .00000000 1 00.000000 1 5.8200000 5.00000000 1 000.00000 3 .89000000 
1 0 .0000000 1 00 .000000 25.91 00000 1 0 .0000000 1 000 .00000 7 .77000000 
1 5.0000000 1 00 .000000 30.8500000 1 5.0000000 1 000.00000 1 0 .4600000 
20.0000000 1 00.000000 36 . 1 500000 20 .0000000 1 000.00000 1 2 .2800000 
25.0000000 1 00 .000000 44.8200000 25 .0000000 1 000.00000 1 3 .6600000 
30.0000000 1 00 .000000 47.31 00000 30.0000000 1 000 .00000 1 4 .8500000 
45.0000000 1 00 .000000 53.0900000 45.0000000 1 000.00000 1 7 .7000000 
60.0000000 1 00 .000000 59.4800000 60 .0000000 1 000.00000 1 9 .8400000 
90.0000000 1 00 .000000 57.7400000 90.0000000 1 000.00000 23 .5000000 
1 20 .000000 1 00.000000 60 . 1 500000 1 20.000000 1 000.00000 27 .2400000 
1 50 .000000 1 00.000000 61 .4500000 1 50.000000 1 000.00000 3 1 .9800000 
1 80 .000000 1 00.000000 63.81 00000 1 80.000000 1 000.00000 34.6600000 
0 .00000000 200.000000 0 .00000000 0 .00000000 5000.00000 0 .00000000 
5 .00000000 200.000000 1 8 .0300000 5.00000000 5000 .00000 1 .90000000 
1 0 .0000000 200.000000 25.6600000 1 0 .0000000 5000 .00000 3 . 1 1 000000 
1 5 .0000000 200.000000 32.2400000 1 5 .0000000 5000.00000 4 . 1 8000000 
20 .0000000 200.000000 34.5300000 20.0000000 5000 .00000 4 .84000000 
25 .0000000 200.000000 39.3500000 25.0000000 5000.00000 5 .89000000 
30.0000000 200.000000 44.3200000 30.0000000 5000 .00000 6 .22000000 
45.0000000 200.000000 49.8000000 45 .0000000 5000 .00000 7 .68000000 
60.0000000 200.000000 56.2300000 60.0000000 5000 .00000 8 .44000000 
90.0000000 200 .000000 58 . 1 900000 90.0000000 5000 .00000 1 0 .6000000 
1 20 .000000 200 .000000 62.0600000 1 20.000000 5000 .00000 1 0 .9200000 
1 50 .000000 200 .000000 61 . 1 700000 1 50 .000000 5000 .00000 1 2 .3700000 
1 80 .000000 200.000000 63 .4300000 1 80.000000 5000 .00000 1 3 .6200000 
0 .00000000 500.000000 0 .00000000 
5.00000000 500 .000000 4 .90000000 
1 0.0000000 500.000000 9 . 1 2000000 
1 5 .0000000 500.000000 1 4 .8000000 
20.0000000 500.000000 1 9 .81 00000 
25 .0000000 500.000000 22.0400000 
30.0000000 500.000000 24.5800000 
45.0000000 500.000000 28.0600000 
60.0000000 500 .000000 3 1 . 1 800000 
90 .0000000 500.000000 34 .41 00000 
1 20 .000000 500.000000 36.91 00000 
1 50 .000000 500.000000 38 .4200000 
1 80 .000000 500.000000 39.9400000 
Figure AVI.2. Data File (c) of "Scientist" for 7.4 kDa F-PHEA absorption data 
obtained from the IPRL at 37 °C. 
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model ; no tracheo-bronchial absorption could occur in the IPRL (ka,TB = 0), unlike the 
situation in vivo. In order to use % transfer values (FP) as a dependent-variable in the 
program with the solute amount-based differential equations, Eqns, AVI. 1 to A VI.3 (also 
as Eqns . III.3-5 in Section IILb.7, Chapter 3) ,  the following equation was incorporated in 
the program (Fig. A VI.2) : 
Amount in perfusate (P) 
% Transfer to perfusate (FP) = __________ x 100 (Eqn. AVIA) 
Administered dose (DOSE) 
Once all three files (Model, Data and Parameter Files) were compiled, the 
independent- and dependent- variables used in the Model File were automatically 
assigned in the Data File and hence, mean data for % transfer to perfusate was tabulated 
as a combination of dose and time (all data points in Fig. IlL I 0), as shown in Fig. A VI.2 .  
Similarly, each of the parameters (F ,  ka,p, kE,PT, V max.P and Km,p) was assigned in the 
Parameter File. In order to perform curve fitting, initial estimates were assigned, based on 
the following assumptions and calculations : 
Initial estimates: 
• F (F) : 
The initial fraction of each administered dose delivered to the pulmonary 
compartment (Fig. A VLl ) was experimentally determined to be 0 .91  (0. 91O±O.OO3; 
mean±SD; n= 12) .  This was fixed throughout data fitting. 
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• ka,p (KA), V max,P (VMAX) and Km,p (KM): 
The rate equation for F-PHEA absorption into perfusate (Eqn, AVU ) was modified 
to obtain the initial estimates for curve fitting, assuming two extreme conditions for low 
and high dosing conditions : 
When the amount of F-PHEA in the pulmonary compartment ( [M]p) was much 
larger than Km,p ( [M]p » Km,p), Eqn, A VU was simplified to give: 
(d[P]/dt)lPRL = V max,P + ka,p· [M]p (Eqn. A VJ.S) 
Assuming that this was true at the higher S.O and 1 ,0 mg F-PHEA doses, the absorption 
rates at each dose, (d[P]/dt)lPRL, were calculated from the experimental slopes of the 
absorption profiles over the first 30 minutes .  Thus, 
at S .O mg: 
at 1 .0 mg: 
1 8 .0 [flg/min] = V max,P + ka,p- (SOOO (flg)]p 
1 1 , 8  [flg/min] = Vmax,P + ka,p- [ 1 000 (flg)]p 
(Eqn. A VJ.6) 
(Eqn. A VI.7) 
These equations yielded values for V max,P = 10.2 [flg/min] and ka,p = 0.002 [min- I ] . 
On the other hand, when the amount of F-PHEA in the pulmonary compartment 
( [M]p) was much smaller than Km,p ( [M]p « Km,p), Eqn. AVI. l was simplified to give: 
(d[P]/dt)IPRL = V max,p· [M]p/Km,p + ka,p. [M]p 
= (V max,p/(Km,p + ka,p)) · [M]p 
(Eqn. AVL8) 
(Eqn. A V1,9) 
Assuming that this was true at the lowest 0, 1 mg dose, logarithmic plots of remaining F­
PHEA in lung vs. time provided a negative slope, Vmax,p/(Km,p + ka,p) = 0.OS2 [min-\ as 
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an apparent first-order rate constant for absorption. Using the values for V max.P = 1 0.2 
[Ilg/min] and ka.P = 0.002 [min· l ] estimated above, the value for Km,p was estimated to be 
202.4 [Ilg] . 
• kE,PT (KE) : 
If absorption was assumed to be apparent first-order (at the lowest 0, 1 mg F-PHEA 
dose), then as time � = ,  the ratio of % loss to the tracheo-bronchial region to % transfer 
to perfusate (Fig, AVI, I )  was determined by Eqn. AVI, 1 O  (Notari, 1 987): 
% loss to the tracheo-bronchial region kE•TB 
% transfer to perfusate ka,app 
(Eqn. A VI. 1 0) 
At the lowest, 0, 1 mg F-PHEA dose, the final (asymptotic) % transfer to perfusate for F­
PHEA was roughly 60 % (thus, the % loss to the tracheo-bronchial region = 40 %) and 
the apparent first-order rate constant (ka•p + kE,PT) was found to be 0,052 [min- I ] , 
Therefore, the initial value for kE,PT was estimated: 
% loss to the tracheo-bronchial region (40 [%]) 
kE•PT = ka,app (0,052 [min-I ] )  x ----------------
% transfer to perfusate (60 [%]) 
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Curve fitting: 
Following assignment of data, initial estimates and the definition of the model, as 
described above, "Scientist" was instructed to perform nonlinear least-mean-square 
regression analysis .  In the example described above, this resulted in the Plot and 
Statistical Outputs shown as Figs . AVI.3 and AVI.4, respectively. 
(2) Across-dose curve fitting for F-Na disposition in the IPRL at 37 °C 
The Model File, Parameter File (with initial estimates) and Data File are shown in 
Fig. A VLS. The dose-independence seen in the profiles for F-Na (Fig. III .6; Chapter 3) 
enabled to preclude the active absorption component from the kinetic model shown in 
Fig .  A VI. I (V max.P = Km,p = 0) and hence, the differential equations in the Model File are 
described as follows (the equations are also shown as Eqns. III .2, III .4 and IlLS in 
Section III.b.7, Chapter 3) : 
(d[PjJdt)Passive,IPRL = ka,p- [Mjp 
(d[MjpJdt)IPRL = - (d[PjJdt)Passive,IPRL - kE,PT· [Mjp 
(d[MhBJdt)IPRL = kE,pr[Mjp 
(Eqn. A VI. ! 1 )  
(Eqn. AVI. 1 2) 
(Eqn. A VI. 1 3 )  
The symbols i n  the Model File were assigned unchanged from those for F-PHEA. The 
Data File was prepared using mean data for % transfer to perfusate as a combination of 
dose and time following compilation (Fig. A VLS) .  Each of the parameters (F, ka.P and 
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Figure AVI.3. Plot File obtained from across-dose fitting for 7.4 kDa F-PHEA 
absorption data in the IPRL at 37 °C. Data plots are experimental mean absorption 
data at different doses and curves are generated from the best parameter etimates 
obtained by the curve fitting; these are shown in Table 111.2 (Chapter 3). 
... MicroMath Sclentist Statlstics Report ..... 
Model Ale Name: 
Data File Name: 
Param FIle Name : 
a:\f-pheaeqn 
a:\data-37.mmd 
a:\3J'·iI1l.par 
Goodness-d-ftt statistics for data set: a:'data-Y.ri1md 
Data Column Name: FP 
Sum of squared observations : 
Sum of squared deviations : 
Standard deviation of !Jata : 
R-squared : 
Coefficient of determInatiOn : 
Correlation ; 
Weighted 
70937.6348 
1004.40593 
4.05n9139 
0.985841001 
0.961031051 
0.980978323 
Data Set Name: a:\data-37.mmd 
Sum of squared observations: 
Sum of squared deviations : 
Standard de'liatloo of data : 
A-squared : 
CoefflCl�t of determination : 
Correlation : 
Model Selection Criterion : 
Confidence Intervals: 
Parameter Name : 
Estimate Value II 
Weighted 
70937.6348 
1004.40593 
4.05779139 
0.985841001 
0.961031051 
0.980978323 
3.12191322 
KA 
0.00117717508 
Standard Deviation • 0.000693588225 
95% Range (Univar) • 
95% Range (S·P\ane) = 
Parameter Name : 
Estimate Value'. 
Standard Deviation :::r 
95% Ranga (Unlvar) • 
95% Ranga (S·PIano) = 
Parameter Name : 
Estimate Value '" 
Standard Deviation -
95% Ranga (Univar) • 
95% Ranga (S·Plane) = 
Parameter Name: 
Estimate Value -
Standard Deviation = 
95% Ranga (UnIvar) = 
95% Ranga (S·Plana) • 
Varlance-covariance Matrix: 
4.81064627E-7 
2.33468801 E·7 
-0.000302486774 
-0.00702507801 
Correlation Matrix: 
1.00000000 
0.194401155 1.00000000 
-0.000209740293 
-0.00102604148 
KE 
0.0233379971 
0.00173152314 
0.0198756026 
0.0178377300 
VMAA 
4.36600215 
0.585159738 
3.23589541 5.49610889 
2.57074489 6.16125941 
KM 
56.5958869 
14.7080819 
27.1852595 86.0065143 
9.87495304 103.316821 
2.99817239E-6 
5.87178927E·5 0.319405530 
-0.00586100968 7.57068919 
-0.771673280 0.0600027210 1.00000000 
-0.688641832 ·0.230137876 0.910768839 1.00000000 
Residual AnalysIs: 
Unweighted 
70937.6348 
1004.40593 
4.05779139 
0.985641001 
0.961031051 
0.980978323 
Unwelghted 
70937.6348 
1004:40593 
4.05779139 
0.985841001 
0.961031051 
0.980978323 
3.12191322 
0.00256409046 
0.00338039164 
0.0268003916 
0.0288382641 
216.327672 
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The following are oormaNzed parameters With an e)lJ)8Cted vall,18 of 0.0. Values are In units of standard deviations from the expected value. 
The serial correlation Is 6.06: which Indicates a systematiC non-random trend In the residuals. 
Sk_ is -0.60 which is probably not significant 
Kurtosis is ·(1.00 which Is probably not significant. 
The weighting factor was 0.00 leading to a heteroscedactlclty of 0.79 which suggests an optimal weight factor' forthis fit of about 0.79 
Figure AVI.4. Statistical Output obtained from across-dose fitting for 7.4 kDa F­
PHEA absorption data in the IPRL at 37°C. 
(a) 
(b) 
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II August 1 9 , 1 998 
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II 
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II Final Version 
II 
II Passive Transport involved 
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II 
II A : Alveol i  
II U : Upper Airway 
li P :  Perfusate 
II 
I ndVars: T, DOSE 
DepVars : FP 
Params: F,  KA,  KE 
II 
FP=P/DOSE*1 00 
A'=-(KA+KE)*A 
U'=KE*A 
P'=KA*A 
II 
II 
II I n it ial Condit ions; 
T=O 
A=DOSE*F 
U=DOSE*( 1 -F) 
p=o 
F 
KA 
KE 
Min  
- Infin i ty 
0 .000000000 
0 .000000000 
Parameter 
0 .91 0000000 
0 .072000000 
0 .048000000 
Max 
Infin ity 
Infin ity 
I nfin ity 
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Figure AVI.S. Model File (a) and Parameter File (b) of "Scientist"to be used for 
fitting F-Na absorption data obtained from the IPRL at 37 °C .  Parameter values shown 
in (b) are initial estimates used for across-dose curve fitting. 
Data File is shown in Fig. A VI. 5 (c) . 
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(C) T DOSE FP 0 .00000000 1 0 .0000000 0 .00000000 
1 .00000000 1 0 .0000000 1 .45000000 
3 .00000000 1 0 .0000000 8 .22000000 
5 .00000000 1 0 .0000000 1 7 .3200000 
1 0 .0000000 1 0 .0000000 34.0400000 
1 5.0000000 1 0 .0000000 45 . 1 900000 
20.0000000 1 0 .0000000 51 .2000000 
30.0000000 1 0 .0000000 56.5900000 
40 .0000000 1 0 .0000000 59.0900000 
50.0000000 1 0 .0000000 60.5400000 
60.0000000 1 0 .0000000 61 .2400000 
75.0000000 1 0 .0000000 6 1 .5700000 
90.0000000 1 0 .0000000 62.0700000 
1 20 .000000 1 0 .0000000 62.3900000 
0 .00000000 20 .0000000 0 .00000000 
1 .00000000 20 .0000000 0 .00000000 
3 .00000000 20.0000000 4 .26000000 
5 .00000000 20.0000000 1 0 .6600000 
1 0 .0000000 20.0000000 25.3500000 
1 5.0000000 20 .0000000 36 . 1 700000 
20.0000000 20.0000000 43.8800000 
30.0000000 20 .0000000 49.9800000 
40.0000000 20.0000000 52.9500000 
50.0000000 20.0000000 54.9800000 
60.0000000 20 .0000000 56.2300000 
75.0000000 20 .0000000 56.8200000 
90.0000000 20.0000000 57.9900000 
1 20 .000000 20.0000000 57.9500000 
0 .00000000 40 .0000000 0 .00000000 
1 .00000000 40 .0000000 0 .41 000000 
3 .00000000 40.0000000 4 . 1 7000000 
5 .00000000 40.0000000 1 6 .4600000 
1 0 .0000000 40 .0000000 35.7700000 
1 5 .0000000 40 .0000000 47.0500000 
20.0000000 40 .0000000 54.4000000 
30.0000000 40 .0000000 59.8800000 
40.0000000 40.0000000 63.8500000 
50 .0000000 40.0000000 64.2900000 
60.0000000 40.0000000 64.9000000 
75.0000000 40 .0000000 65.4200000 
90.0000000 40.0000000 66 .4200000 
1 20 .000000 40 .0000000 66.0500000 
Figure AVI.S. Data File (c) of "Scientist"for F-Na absorption data obtained from the 
IPRL at 37 °C. 
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kE•PT) was assigned in the Parameter File as initial estimates, based on the following 
assumptions and calculations: 
Initial estimates: 
• F (F) : 
The initial fraction of each administered dose delivered to the pulmonary 
compartment (Fig. AVI. l )  was experimentally determined to be 0 .91  (0. 9 1O±0.003 ; 
mean±SD; n= 12) .  This was fixed throughout data fitting. 
• ka,P (KA) : 
The rate equation for F-Na absorption into perfusate (Eqn. AVI. l l ) was assumed to 
be first-order. Thus, logarithmic plots of remaining F-Na in lung vs. time (Fig .  III. l l , 
Chapter 3) provided a negative slope, ka•p = 0.072 [min' I ] as an apparent first-order rate 
constant for absorption and this value was used as the initial estimate. 
If absorption was assumed to be apparent first-order, then as time -7 00 ,  the ratio of 
% loss to the tracheo-bronchial region to % transfer to perfusate (Fig. A VLl) was 
determined by Eqn. AVI. lO .  At all doses, The final (asymptotic) % transfer to perfusate 
for F-Na was roughly 60 % (thus, the % loss to the tracheo-bronchial region = 40 %) and 
the apparent first-order rate constant (ka'p + kE•PT) was found to be 0.072 [min,I ] (Fig. 
III. 1 1 , Chapter 3) .  Therefore, the initial value for kE,PT was estimated: 
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% loss to the tracheo-bronchial region (40 [%] )  
kE,IT = ka,app (0,072 [min-
I ] )  x -----------------
% transfer to perfusate (60 [%] ) 
= 0,04S [min- I ] 
Curve fitting: 
Following assignment of data, initial estimates and the definition of the model , as 
described above, "Scientist" was instructed to perform nonlinear least-mean-square 
regression analysis, In the example described above, this resulted in the Plot and 
Statistical Outputs shown as Figs, AVI,6 and AVI,7, respectively, 
(3) Across-dose curve fitting for F-Na disposition in vivo 
Single-dose curve fitting was employed to describe the in vivo disposition of F-Na. 
The Model File, Parameter File (with initial estimates) and Data File are shown in Fig, 
A VI,S ,  The Model File defined time (T) and % remaining unabsorbed from the lung (FL) 
as independent- and dependent-variables, respectively, This was followed by a definition 
of the model parameters, the differential equations and the initial conditions, Based on 
the model shown in Fig, A VI, 1, the differential equations were derived for F-Na as 
follows (the equations are also shown as Eqns, IIL2, III ,7 ,  IlLS and IlL9 in Section 
III ,b,7, Chapter 3) :  
(d[B]/dt)in vivo = ka,p · [M]p + ka,TB , [MhB (Eqn, AVL 14) 
(d[M)p/dt)in vivo = - ka,P - [M]p - kE,IT, [M]p (Eqn, A VL 1 5) 
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Figure AVI.6. Plot File obtained from across-dose fitting for F-Na absorption data in 
the IPRL at 3 7  DC. Data plots are experimental mean absorption data at different doses 
and curves are generated from the best parameter etimates obtained by the curve 
fitting; these are shown in Table III.2 (Chapter 3).  
... MicroMath Scientist Statistics Report ... 
Model File Name : 
Data File Name : 
Param File Name : 
a:\f-na.eqn 
a:lfna-37.mmd 
Untitled1 
Goodness-of-fit statistics for data set: 
Data Column Name: FP 
Sum of squared observations : 
Sum of squared deviations : 
Standard deviation of data : 
R-squared : 
Coefficient of detennination : 
Correlation : 
a:\fna-37.mmd 
Weighted 
93084. 1 888 
765.1 32504 
4.37359264 
0.99 1 7802 1 0  
0.968771 561 
0.985809251 
Data Set Name: a:lfna-37.mmd 
Sum of squared observetions : 
Sum of squared deviations : 
Standard deviation of data : 
R-squared : 
Coefficient of determination : 
Correlation : 
Model Selection Criterion : 
Confidence Intervals: 
Parameter Name : 
Estimate Value = 
Standard Deviation = 
95% Range (Univar) = 
95% Range (S-Plane) = 
Parameter Name : 
Estimate Value = 
Standard Deviation- = 
95% Range (UniVar) = 
95% Range (S-Plane) = 
Variance--Covariance Matrix: 
7.93465682E-6 
Weighted 
93084. 1 888 
765.1 32504 
4.37359264 
0.991 7802 1 0  
0.968771561 
0.985809251 
3.371 1 8801 
KA 
0.0477436096 
0.00281 685229 
0.042Q505388 
0.0405822348 
KE 
0.021 8780006 
0.002201 4 1 465 
0 .01 74287756 
0.01 6281 2728 
5.24027804E-6 4.84622845E-6 
Correlation Matrix: 
1 .00000000 
0.845061 672 1 .00000000 
Residual Analysis: 
Unweighted 
93084.1 888 
765.1 32504 
4.37359264 
0.991 78021 0  
0.96877 1 56 1  
0.985809251 
Unweighted 
93084. 1 888 
165. 1 32504 
4.37359264 
0.991 7802 1 0  
0.96877 1 56 1  
0.985809251 
3.3711 8801 
0.0534366805 
0.0549049844 
0.0263272255 
0.0274747283 
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The following are nonnalized parameters with an expected value of 0.0. Values are in units of standard deviations from the 
expected value. 
The serial correlation is- 5.44 which indicates a systematic non-random trend i n  the residuals. 
Skewness is 0.43 which is probably not significant. 
Kurtosis is -0:00 which is probably not significant. 
The weighting factor was 0.00 leading to a heteroscedacticity of -0. 1 6  which suggests an optimal weight factor for this fit of about 
-0. 1 6  
Figure AVI.7. Statistical Output obtained from across-dose fitting for F-Na 
absorption data in the IPRL at 37 °C. 
(a ) II II August 1 9 , 1 998 
(b ) 
II Masah iro Sakagami,  MCVNCU 
II 
II F-Na Transfer Model in in vivo study 
II Final Version 
II 
II Passive Transport involved 
II Mucoci l iary Transport involved 
II 
II A :  Alveoli 
II U : Upper Airway 
Il L :  Upper airway + Alveol i  
I I  P : Blood 
II 
I ndVars: T 
DepVars: FL 
Params: DOSE,  F ,  KAA, KAU ,  KE 
II 
L=A+U 
FL=UDOSE* 1 00 
A'=-(KAA+KE)*A 
U'=-KAU*U+KE*A 
P'=KAA * A+KAU*U 
II 
II 
II I n it ial Condit ions; 
T=O 
A=DOSE*F 
U=DOSE*( 1 -F) 
P=O 
DOSE 
F 
KAA 
KAU 
KE 
Min  
- Infin i ty 
0 .000000000 
0 .000000000 
0 .000000000 
0 .000000000 
(c) 
T 
0 .00000000 
5 .00000000 
1 0 .0000000 
20.0000000 
30.0000000 
60.0000000 
1 20.000000 
Parameter Max 
FL 
1 00.000000 
84.2400000 
59.4900000 
34.4500000 
1 8 .4900000 
7 .51 000000 
0 .53000000 
0 .020000000 Infin ity 
0 .91 0000000 Infin ity 
0 .048000000 Infin ity 
0 .048000000 Infin ity 
0 .022000000 Infin ity 
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Figure AVI.8. Model File (a), Parameter File (b) and Data File (c) of "Scientist" to be 
used for fitting in vivo F-Na absorption data. Parameter values shown in (b) are initial 
estimates used for across-dose curve fitting. 
(d [MhB/dt)in vivo = kE,pdM]p - ka,TB · [M1TB 
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(Eqn. A VI. l 6) 
where [B] is the cumulative F-Na amount absorbed from both the pulmonary and tracheo­
bronchial regions into blood. [M]p  and [MhB are the F-Na amounts remaining 
unabsorbed in the pulmonary and the tracheo-bronchial regions, respectively; ka,p and 
ka,TB are the first-order passive absorption rate constants from the pulmonary and the 
tracheo-bronchial regions, respectively, and kE,PT is the first-order mucociliary clearance 
rate constant from the pulmonary to the tracheo-bronchial region. In the Model File (Fig.  
A VI.S) ,  symbols, P, A, U and L were used to represent [B] , [M]p, [MhB and [M]p+[MhB, 
respectively, and DOSE, F, KAA, KAU and KE, respectively, were the dose, F, ka,p, ka,TB 
and kE,PT; active absorption was assumed absent for F-Na in vivo (V max,P = Km,p = 0). In 
order to use % remaining unabsorbed in lung (FL) as a dependent-variable in this 
program, with the solute amount-based differential equations (Eqns, AVI. l4  to AVI. 1 6) ,  
the following equations were incorporated in the program (Fig. AVI.4) : 
Amount in a whole lung (L) 
= Sum of amounts in the pulmonary and the tracheo-bronchial regions (A + U) 
(Eqn. A VI. ! 7) 
% Remaining to be absorbed in a whole lung (FL) 
Amount remaining unabsorbed in lung (L) 
Administered dose (DOSE) 
x 1 00 (Eqn, AVI. l S) 
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Following compilation, mean data for % remaining unabsorbed in lung (F-Na 
nominal dose = 0.02 mg; Fig. III .6, Chapter 3) were tabulated in the Data File (Fig. 
A VI.8). Each parameter (F, ka•p, ka•TB and kE•TB) was initially obtained from the IPRL 
profiles (Fig. III. 6, Chapter 3) and used as an initial estimate, based on the following 
assumptions and calculations : 
• F (F) : 
The fraction of the administered dose delivered to the pulmonary compartment was 
experimentally determined to be 0.9 1 (0.9 1 O±0.004; mean±SD; n=4). This was fixed 
throughout data fitting . 
• ka•p (KAA) and kE.PT (KE): 
Absorption from the pulmonary region and the mucociliary clearance from the 
pulmonary to the tracheo-bronchial regions were assumed to be the same as those 
determined in vitro. Therefore, values for ka•p and kE•PT, obtained from the IPRL data are 
the same as those in Table III .2 (ka•p = 0.048 [min-I ] and kE•PT = 0.022 [min-I ] ;  Chapter 3 ) .  
These were fixed throughout data fitting. 
• ka•TB (KAU) : 
It was not possible to estimate a value for ka•TB from the experimental data. 
Therefore, an identical value to that for ka•p, 0.048 [min-I ] ,  was used as an initial estimate 
to perform the data fitting. 
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In this case, all parameters, dose (0.02 mg), F, ka,p and kE,PT were fixed at their 
initial estimates and only ka,TB was floated during data fitting; ka,TB was constrained 
between 0 and infinity (Fig. A VI.S) .  The data fitting was initially performed by the 
Simplex algorithm, followed by the Gauss-Newton technique to provide the best estimate 
for ka,TB in the kinetic model (Table III .3 ,  Chapter 3) .  
AVI.c "GOODNESS-OF-FIT" PARAMETERS 
The model fits were assessed using "goodness-of-fit" parameters provided by the 
program's statistical output. In this thesis, Model Selection Criterion (MSC) and R-
squared (R2) were used. These are described below: 
<Model Selection Criterion (MSC» 
Model Selection Criterion (MSC) was calculated as follows : 
(Eqn. AI, 1 9) 
where Wi is the weight applied to each data point, Yobs,i and Ycal,i are the observed and the 
calculated data values, respectively, Yobs,mean is the weighted mean of the observed data, p 
is the number of parameters and n is the number of data points . Values for MSC provided 
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the rankings between the models ,  independent of the scaling of the data points. Thus ,  the 
values allowed a selection of the most appropriate model as well as indicating how well 
the model described the data. Generally, greater MSC values indicate better fits. 
<R-squared (If» 
R-squared (R2) values were calculated as follows: 
I L [Wj'Yobs}l - L [wj " (Yobs,j - Ycal,ll l 
L[Wj 'Yobs}l 
(Eqn. AI.20) 
The R-squared (R2) values were used to assess what proportion of the data could be 
described by the theoretical model with appropriate (best) parameter estimates .  
APPENDIX VII 
ORIGINAL DATA 
This appendix summarizes the original and individual data obtained from each of 
the isolated perfused rat lung (IPRL) and in vivo whole rat studies. The appendix is 
followed by all statistical outputs of across-dose curve fitting by "Scientist" .  These are 
reported here for completeness and to allow a regeneration of the plots and/or further data 
derivation in future stages .  
The appendix is comprised of: 
• Tables A VII. I to A VII. I 0: Initial solute regional distribution in lung in vitro 
and in vivo. 
• Tables AVII. I I  to A VIL I 3 :  Dose and remaining solute amount in each lung 
component at different sacrifice time in vivo. 
• Tables AVII. 1 4  to AVII.63 : Dose, and amount and % absorbed from airways to 
perfusate in the IPRL. 
• Figs. A VII. 1 to A VII.8 :  Statistical output of across-dose curve fitting by  
"Scientist" .  
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The following abbreviations are used throughout: 
BW: Body weight of the rat. 
Dose: 
DL: Loading solute dose in the dosing cartridge. 
Dctg: Solute amount remaining in the dosing cartridge after 
administration. 
Dcnl : Solute amount remaining in the tracheal cannula after 
administration. 
Dad: Administered dose, calculated by DL - (Dctg + Dcnl) . 
Lung component (Fig. AI.6): 
TB : Tracheo and bronchi 
L: Left lung lobe 
PC: Right postcaval or median lobe 
RS : Right superior or apical lobe 
RC: Right middle lobe 
RI: Right inferior or diaphragmatic lobe 
26 1 
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Table A VII.1 Initial regional distribution of 7.4 kDa F-PHEA in lung in vitro. The solute 
was administered into the airways of the IPRL at 37 °C (FR71 50; nominal dose = 0.2 mg; 
used in Section m.b.7, Chapter 3). 
Wet weight: 
Rat# mean SD 
1-5 1-6 1-7 1-8 
BW [g] 354 349 360 338 350.25 9.32 
TB [g] 0.34 0 .28 0 .24 0 .22 0.27 0.05 
L [g] 0.54 0.45 0.51 0 .49 0.50 0 .04 
PC [g] 0. 1 8  0 . 1 4  0 . 1 9  0 . 1 7  0. 1 7  0.02 
RS [g] 0.20 0. 1 8  0.21 0.20 0 .20 0 . 0 1  
RC [g] 0.22 0 . 1 9 0.20 0 . 1 9  0.20 0 . 0 1  
RI [g] 0.41 0.39 0.40 0 .44 0.41 0.02 
Total [g] 1 .89 1 .63 1 .75 1 .7 1  1 .75 0 . 1 1 
%TB [%] 1 7.99 1 7 . 1 8  1 3.71 1 2 .87 1 5.44 2 .52 
%Lobe [%] 82 .01  82.82 86.29 87. 1 3  84.56 2 .52 
Amount delivered: 
Rat# mean SO 
1-5 1-6 1-7 1-8 
OL [J.lg] 234.37 226.30 231 .75 206.70 224.78 1 2 . 5 1  
°ctg [J.lg] 25.72 1 2.68 6.58 7 .41  1 3 . 1 0  8 .84 
Dc" [J.lg] 3.87 1 7.39 1 6 .64 1 4 .32 1 3.06 6.26 
Dad [J.lg] 204.78 1 96.23 208 .53 1 84.97 1 98.63 1 0 .46 
TB [J.lg] 1 7 .82 8.57 24.90 1 7 .89 1 7 .30 6.70 
L [J.lg] 47.27 33.21 1 05.05 57.52 60.76 3 1 . 1 6  
PC [J.lg] 1 2 .72 1 5.88 7.57 2 .51  9.67 5.87 
RS [J.lg] 34.70 46.05 1 6.09 1 7 .96 28.70 1 4 .28 
RC [J.lg] 24.95 1 0.02 1 2.45 6.69 1 3.53 7.97 
RI [J.lg] 52.04 75.78 29.42 70.64 56.97 2 1 .01  
Total (D,) [J.lgJ 1 89.50 1 89.51 1 95.48 1 73 .21  1 86.93 9.57 
% delivered: 
Rat# mean SO 
1-1 1-2 1-3 1-4 
TB [%] 9.40 4.52 1 2 .74 1 0 .33 9.25 3.45 
L [%] 24.94 1 7.52 53.74 33.21  32.35 1 5 .63 
PC [%] 6.71 8 .38 3.87 1 .45 5 . 1 0 3.07 
RS [%] 1 8.31  24.30 8.23 1 0.37 1 5.30 7 .40 
RC [%] 1 3. 1 7  5.29 6.37 3.86 7 . 1 7  4 . 1 3 
RI [%] 27.46 39.99 1 5.05 40.78 30.82 1 2 . 1 6  
Total [%] 1 00.00 1 00.00 1 00.00 1 00.00 1 00.00 0.00 
%TB [%] 9.40 4.52 1 2 .74 1 0.33 9.25 3.45 
%Lobe [%] 90.60 95.48 87.2q 89.67 90.75 3.45 
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Table A VII.2 Initial regional distribution of 7.4 kDa F-PHEA in lung in vitro. The solute 
was administered into the airways of the IPRL at 37 °C (FR71 50; nominal dose = 1 .0 mg; 
used in Fig. ill.5, Chapter 3). 
Wet weight: 
Rat# mean SD 
1-1 1 -2 1-3 1-4 
BW [9] 360 354 349 348 352.75 5 .50 
TB [9] 0.21 0.30 0.22 0 .28 0.25 0 . 04 
L [9] 0.64 0.54 0 .45 0.57 0.55 0.08 
PC [9] 0 . 1 3  0. 1 8  0 . 1 7  0 . 1 7 0 . 1 6  0.02 
RS [9] 0 . 1 6  0 . 1 5  0 . 1 3  0 . 1 6  0 . 1 5  0 . 0 1  
RC [9] 0 . 1 8  0.20 0 . 1 9 0.20 0 . 1 9  0 . 0 1  
RI  [9] 0.41 0.38 0.41 0 .43 0.41 0 . 02 
Total [9] 1 .73 1 .75 1 .57 1 .8 1  1 .72 0 . 1 0  
%TB [%] 1 2 . 1 4  1 7. 1 4  1 4.01  1 5.47 1 4.69 2 . 1 3  
%Lobe [%] 87.86 82.86 85.99 84.53 85.31 2 . 1 3  
Amount delivered: 
Rat# mean SD 
1-1 1-2 1-3 1-4 
DL [1-19] 1 030.92 1 1 90.00 1 095.00 1 055.00 1 092.73 70.03 
Dctg [1-19] 5.35 1 4.70 1 9.65 45.95 21 .41 1 7 .40 
Dc .. [1-19] 40.95 1 9.55 1 9. 1 0  22.85 25.61 1 0 .36 
Dad [1-19] 984.62 1 1 55.75 1 056.25 986.20 1 045.71 80.61  
TB [1-19] 50.50 94 .71 66.99 33.22 6 1 .36 26 . 1 6  
L [1-19] 386.59 4 1 0.82 367.65 276.54 360.40 58.63 
PC [1-19] 4 .95 4.29 7.59 1 1 1 .54 32.09 52.98 
RS [1-19] 37.62 44.55 1 02.96 1 97.78 95.73 74.08 
RC [1-19] 30.69 1 5.51  39.27 1 00.76 46.56 37.45 
RI [1-19] 400. 1 4  279. 1 0  3 1 8.42 9 1 .74 272.35 1 30 . 54 
Total (Dr) [I-I9J 9 1 0.49 848.98 902.88 8 1 1 .58 868.48 46.78 
% delivered: 
Rat# mean SD 
1-1 1-2 1-3 1-4 
TB [%] 5.55 1 1 . 1 6  7.42 4.09 7.05 3 .05 
L [%] 42.46 48.39 40.72 34.07 4 1 .41 5.89 
PC [%] 0.54 0.51  0 .84 1 3 .74 3 .91  6 . 56 
RS [%] 4 . 1 3  5.25 1 1 .40 24.37 1 1 .29 9 .29 
RC [%] 3.37 1 .83 4.35 1 2 .42 5.49 4.73 
RI [%] 43.95 32.87 35.27 1 1 .30 30.85 1 3 .87 
Total [%] 1 00.00 1 00.00 1 00.00 1 00.00 1 00.00 0.00 
%TB [%] 5.55 1 1 . 1 6  7.42 4.09 7 .05 3 . 05 
%Lobe [%] 94.45 88.84 92.58 95.91 92.95 3.05 
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Table A VII.3 Initial regional distribution of 7.4 kDa F-PHEA in lung in vitro. The solute 
was administered into the airways of the IPRL at 25 °C (FR7l 50; nominal dose = 1 .0 mg; 
used in Section N.bA, Chapter 4). 
Wet weight: 
Rat# mean SD 
1-9 1-1 0 1-1 1 1 -1 2 
BW [g] 352 334 328 348 340.50 1 1 .36 
TB [g] 0 .27 0.29 0 .22 0.30 0.27 0 . 04 
L [g] 0.54 0.48 0 .55 0 .50 0.52 0.03 
PC [g] 0 . 1 4  0 . 1 4  0 . 1 6 0 . 1 3  0 . 1 4  0 .01  
RS [g] 0.30 0.35 0.28 0.34 0 .32 0.03 
RC [g] 0.22 0 . 1 7  0 .23 0 . 1 7 0 .20 0.03 
RI [g] 0.45 0.46 0.43 0.38 0 .43 0 . 04 
Total [g] 1 .92 1 .89 1 .87 1 .82 1 .88 0 .04 
%TB [%] 1 4.06 1 5.34 1 1 .76 1 6 .48 1 4.41 2.02 
%Lobe [%] 85.94 84.66 88.24 83.52 85.59 2 .02 
Amount delivered: 
Rat# mean SD 
1-9 1-1 0 1-1 1 1-1 2 
DL [Ilg] 1 032.40 1 026.30 1 0 1 0.34 973 .53 1 0 1 0.64 26.43 
Dctg [Ilg] 22.30 1 7.35 30.00 37.98 26.91 9.03 
Dcnl [Ilg] 40.53 24.27 34.25 25.50 3 1 . 1 4  7.68 
Dad rllgl 969.57 984 .68 946.09 9 1 0.05 852.60 32. 5 1  
TB [Ilg] 92.41 1 05.34 1 03.67 38.41 84 .96 3 1 .56 
L [119] 389.74 352 .36 297.90 332.45 343. 1 1  38.37 
PC [Ilg] 1 0.21 5.29 35.80 28.97 20.07 1 4.63 
RS [Ilg] 32.09 31 .79 45.20 36.98 36.52 6.26 
RC [Ilg] 35.01 55.27 6 1 .20 67 .42 54.73 1 4.05 
RI [Ilg] 384 . 1 0  405.90 358.74 374 . 1 2  380.72 1 9.77 
Total (Dr) rll91 943.56 955.95 902.51 878.35 920.09 36.00 
% delivered: 
Rat# mean SD 
1-9 1-1 0 1-1 1 1-1 2 
TB [%] 9.79 1 1 .02 1 1 .49 4.37 9 . 1 7  3.28 
L [%] 4 1 . 3 1  36.86 33.01 37.85 37.26 3 .41  
PC [%] 1 .08 0.55 3.97 3 .30 2.23 1 .66 
RS [%] 3.40 3.33 5.01 4.21 3.99 0.79 
RC [%] 3.71 5.78 6.78 7 .68 5.99 1 .70 
RI [%] 40.71 42.46 39.75 42.59 4 1 .38 1 .38 
Total [%] 1 00.00 1 00.00 1 00.00 1 00 .00 1 00.00 0.00 
%TB [%] 9.79 1 1 .02 1 1 .49 4 .37 9 . 1 7  3 .28 
%Lobe [%] 90.21 88.98 88.51 95.63 90.83 3 .28 
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Table A VII.4 Initial regional distribution of 4.3 kDa F-PHEA in lung in vitro. The solute 
was administered into the airways of the IPRL at 37 °C (FR7DD2-5 ; nominal dose = D . 1  
mg; used in  Section V.b.3,  Chapter 5). 
Wet weight: 
Rat# mean SD 
1-25 1-26 1-27 1-28 
BW [g] 335 328 350 348 340.25 1 0 .53 
TB [g] 0.26 0 .24 0.29 0.25 0.26 0.02 
L [g] 0.58 0.57 0.55 0.53 0.56 0 .02 
PC [g] 0. 1 8  0.22 0 . 1 8 0 . 1 8  0. 1 9  0.02 
RS [9] 0.20 0. 1 7  0. 1 7  0 .23 0 . 19  0.03 
RC [9] 0.21 0.23 0 . 1 7 0 . 1 6  0 . 19  0.03 
RI [9] 0.42 0.50 0.41 0 .42 0.44 0 .04 
Total [9] 1 .85 1 .93 1 .77 1 .77 1 .83 0 .08 
%TB [%] 14.05 1 2 .44 1 6.38 14 . 1 2  14.25 1 .62 
%Lobe [%] 85.95 87.56 83.62 85.88 85.75 1 .62 
Amount delivered: 
Rat# mean SD 
1-25 1-26 1-27 1-28 
Dl [Ilg] 1 72.71 1 72 .71 96.87 96.87 1 34.79 43.79 
Dctg [119] 21 .58 1 4 .75 2.08 9.02 1 1 .86 8.30 
DcnI [119] 30.03 32.67 2 1 . 1 7  1 7.43 25.32 7.20 
Dad [1l9l 12 1 . 1 0  1 25.30 73.62 70 .42 97.61 29.63 
TB [119] 9.24 1 3.53 5. 1 7  3.52 7.87 4.48 
L [119] 24.20 1 7.05 1 7.38 1 2 .98 1 7 .90 4.65 
PC [Ilg] 1 2 . 1 0  25. 1 9  1 1 .99 1 0.67 14 .99 6 .83 
RS [1l9] 23.98 1 3.42 1 1 .2 1  1 3 .63 1 5.56 5.72 
RC !J.l9] 22.00 1 6 .06 1 0 .94 8 .74 14 .44 5.90 
RI [1l9] 1 3 .80 1 3.40 1 4.90 20 .40 1 5.63 3 .25 
Total (Dr) [1l9] 1 05.32 98.65 71 .59 69.94 86.38 1 8 .24 
% delivered : 
Rat# mean SD 
1-25 1-26 1-27 1-28 
TB [%] 8.77 1 3 .72 7.22 5.03 8.69 3.69 
L [%] 22.98 1 7.28 24.28 1 8 .56 20.77 3.38 
PC [%] 1 1 .49 25.53 1 6 .75 1 5.26 1 7 .26 5.95 
RS [%] 22.77 1 3 .60 1 5.66 1 9 .49 1 7.88 4.07 
RC [%] 20.89 1 6 .28 1 5.28 1 2 .50 1 6 .24 3.49 
RI [%] 1 3 . 1 0  1 3 .58 20.81 29. 1 7  1 9 . 1 7  7.54 
Total [%] 1 00.00 1 00 .00 1 00.00 1 00.00 1 00.00 0.00 
%TB [%] 8.77 1 3 .72 7.22 5.03 8 .69 3.69 
%Lobe [%] 91 .23 86.28 92.78 94.97 9 1 .31 3 .69 
266 
Table A VII.S Initial regional distribution of 4.4 kDa FD-4 in lung in vitro. The solute 
was administered into the airways of the IPRL at 37 °C (nominal dose = 0.2 mg; used in 
Section III.b.7, Chapter 3). 
Wet weight: 
Rat# mean SD 
1-2 1 1-22 1-23 1-24 
BW [g) 330 325 320 327 325.50 4.20 
TB [g] 0 .21 0.22 0.20 0. 1 8  0.20 0 .02 
L [g) 0 .52 0.51 0.47 0.48 0.50 0 .02 
PC [g) 0 . 1 7  0 . 1 6  0. 1 8  0 . 1 9 0 . 1 8  0 .01  
RS [g) 0.20 0.20 0 . 17  0. 1 7  0 . 1 9 0 .02 
RC [g) 0 . 1 9  0 . 1 8  0. 1 7  0.24 0 .20 0.03 
RI [g) 0.39 0 .39 0.44 0 .40 0.41 0.02 
Total [g) 1 .68 1 .66 1 .63 1 .66 1 .66 0.02 
%TB [%] 1 2 .50 1 3.25 12 .27 1 0 .84 1 2 .22 1 .0 1  
%Lobe [%) 87.50 86.75 87.73 89. 1 6  87.78 1 .0 1  
Amount delivered: 
Rat# mean SD 
1-2 1  1-22 1-23 1-24 
DL [Ilg] 291 .46 205. 1 9  256.06 248.47 250.30 35.43 
Dctg [Ilg) 4.50 5.98 1 8.93 1 9 .97 1 2.34 8 .24 
Dcr; [Ilg) 41 .72 1 1 .63 29 .74 29.56 28 . 1 6  1 2 .40 
Dad tllgj 245.24 1 87.58 207 .40 1 98.95 209.79 24.99 
TB (f.1g) 20.05 1 1 .25 13 .20 24.65 1 7 .29 6 . 1 9  
L [1l9) 74.95 47.30 31 .40 43.70 49.34 1 8.38 
PC [Ilg) 1 5.70 5.65 12 .40 1 2 .35 1 1 .53 4 .22 
RS [1l9) 69.40 28.60 19 .35 9.40 3 1 .69 26.34 
RC [Ilg) 1 7.75 20.85 50.70 55.70 36.25 1 9.72 
RI [Ilg) 23.60 43. 1 5  55.30 28.90 37.74 1 4 .33 
Total (Dr) tllgj 221 .45 1 56.80 1 82.35 1 74.70 1 83.83 27.27 
% delivered: 
Rat# mean SD 
1-2 1  1-22 1-23 1-24 
TB [%] 9.05 7 . 1 7  7.24 14 . 1 1 9.39 3.26 
L [%] 33.85 30. 1 7  1 7.22 25.01 26.56 7 .20 
PC [%] 7.09 3.60 6.80 7 .07 6 . 1 4  1 .70 
RS [%) 31 .34 1 8.24 1 0.61 5.38 1 6 .39 1 1 .28 
RC [%] 8 .02 1 3 .30 27.80 3 1 .88 20.25 1 1 .4 1  
RI [%) 1 0 .66 27 .52 30.33 1 6 .54 2 1 .26 9.24 
Total [%) 1 00.00 1 00.00 1 00.00 1 00 .00 1 00.00 0 .00 
%TB [%] 9.05 7 . 1 7  7 .24 14 . 1 1 9.39 3.26 
%Lobe [%) 90.95 92.83 92.76 85.89 90.61 3 .26 
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Table A VlI.7 Initial regional distribution of 376 Da F-Na in lung in vitro. The solute 
was administered into the airways of the IPRL at 25 °C (nominal dose = 0.02 mg; used in 
Section IV.bA, Chapter 4). 
Wet weight: 
Rat# mean SO 
1-1 7 1- 1 8  1-1 9 1-20 
BW [g] 395 360 3 1 0  330 348.75 37.05 
TB [g] 0 .21 0 . 1 9 0 . 1 5  0 . 1 8 0 . 1 8 0.03 
L [g] 0.49 0.52 0.50 0.49 0.50 0 .01  
PC [g] 0 . 1 6 0. 1 9  0 . 14  0 . 1 9  0 . 1 7  0.02 
RS [g] 0 . 1 9  0.22 0.20 0 .21  0 .21  0 .01  
RC [g] 0.20 0.22 0 . 1 8  0.20 0.20 0.02 
RI [g] 0 .43 0.48 0.34 0 .44 0 .42 0.06 
Total [g] 1 .68 1 .82 1 .51 1 .7 1  1 .68 0 . 1 3 
%TB [%] 1 2 .50 1 0.44 9.93 1 0 .53 1 0 .85 1 . 1 3  
%Lobe [%] 87 .50 89.56 90.07 89 .47 89. 1 5  1 . 1 3  
Amount delivered: 
Rat# mean SO 
1-1 7 1-1 8 1-1 9 1-20 
DL [�g] 23.28 2 1 .68 20.46 22.41 2 1 .96 1 . 1 9  
Octg [�g] 0.86 2.61 1 .00 1 .32 1 .45 0.80 
Ocr; [�g] 2.98 3.49 2.22 1 .89 2 .64 0.72 
Oad [�gl 1 9 .44 1 5.58 1 7.25 1 9 .20 1 7 .87 1 .8 1  
TB [�g] 1 .6 1  1 .38 1 .37 0.98 1 .33 0.26 
L [�g] 1 .6 1  6.27 3.81 4 .74 4 . 1 1 1 .95 
PC [�g] 1 .67 1 .30 1 .83 0 .45 1 .3 1  0.62 
RS [�g] 3.80 0.91 2.89 2.29 2 .47 1 .2 1  
RC [�g] 3 .51 1 .65 2.81 1 .47 2.36 0.97 
RI [�g] 3 .24 3.29 3.90 3.56 3.50 0.30 
Total (Dr) [�g] 1 5.44 1 4.79 1 6.61  1 3 .49 1 5 .08 1 .30 
% delivered: 
Rat# mean SO 
1-1 7 1 - 1 8 1-1 9 1-20 
T8 [%] 1 0.41  9.31 8.25 7 .26 8.81 1 .36 
L [%] 1 0.45 42.40 22.93 35. 1 4  27.73 1 4.04 
PC [%] 1 0.80 8 .76 1 1 .0 1  3 .34 8 .48 3 .57 
RS [%] 24.60 6. 1 5  1 7.41 1 6.98 1 6.29 7.61 
RC [%] 22.72 1 1 . 14  1 6.94 1 0.90 1 5.42 5 .61 
RI [%] 2 1 .02 22 .24 23.46 26.39 23.28 2.30 
Total [%] 1 00 .00 1 00.00 1 00.00 1 00.00 1 00.00 0.00 
%T8 [%) 1 0 .41 9.31 8.25 7.26 8 .8 1  1 .36 
%Lobe [%] 89.59 90.69 91 .75 92.74 9 1 . 1 9  1 .36 
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Table A VII.8 Initial regional distribution of 7.4 kDa F-PHEA in lung in vivo. The solute 
was administered into the airways by "forced solution instillation" (nominal dose = 0.2 
mg). 
Wet weight: 
Rat# mean SD 
6 1  62 63 67 
BW [g) 348 349 348 338 345.75 5. 1 9  
TB [g) 0.25 0.21 0.21 0.21 0.22 0.02 
L [g) 0.48 0.50 0.49 0 .53 0.50 0.02 
PC [g) 0 . 1 9  0.20 0 .22 0 . 1 7  0.20 0 . 02 
RS [g) 0.20 0.20 0 . 1 9  0 .23 0.21  0 . 02 
RC [g) 0.21 0.20 0.23 0.20 0.21 0.01 
RI [g) 0.43 0.40 0.46 0.44 0 .43 0 . 02 
Total [g) 1 .76 1 .7 1  1 .80 1 .78 1 .76 0 . 04 
%TB [%) 1 4.20 1 2.28 1 1 .67 1 1 .80 1 2 .49 1 . 1 7  
%Lobe [%) 85.80 87.72 88.33 88.20 87.51 1 . 1 7  
Amount delivered: 
Rat# mean SD 
6 1  62 63 67 
DL [�g) 228.46 245.23 244.71 2 1 4 .06 233 . 1 1 1 4 .90 
Dctg [�g) 4.76 1 .87 4 .77 1 9 .33 7.68 7 .88 
Dcn! [�g) 29 .52 27.09 1 8 .27 44.20 29.77 1 0 .77 
Dad [�gl 1 94 . 1 8  2 1 6.27 221 .67 1 50.53 1 95.66 32.35 
TB [}ig) 1 3 .61 1 8 .38 1 7 . 1 7  1 0 . 1 9  1 4 .84 3.70 
L [�g) 58.45 48.75 67.21 50.20 56. 1 5  8 . 52 
PC [�g) 1 1 .69 1 3.56 1 4.52 1 3.29 1 3 .27 1 . 1 8  
RS [fig) 8.88 1 0.24 1 1 .24 7.95 9.58 1 .4 5  
RC [fig) 2.96 3.47 6 .20 3 .47 4.03 1 .47 
RI [fig) 52.38 1 05.43 70.27 25.69 63 .44 33.45 
Total (Dr) [fig) 1 47.97 1 99.83 1 86.61  1 1 0.79 1 6 1 .30 40.22 
% delivered :  
Rat# mean SO 
6 1  62 63 67 
TB [%] 9.20 9.20 9.20 9.20 9.20 0.00 
L [%) 39.50 24.40 36.02 45.3 1 36.31  8 .82 
PC [%) 7 .90 6.79 7.78 1 2 .00 8.62 2 . 3 1  
RS [%) 6 .00 5. 1 2  6 .02 7. 1 8  6.08 0 .84 
RC [%) 2 .00 1 .74 3.32 3 . 1 3  2 .55 0.80 
RI [%) 35.40 52 .76 37.66 23. 1 9  37.25 1 2 . 1 4  
Total [%) 1 00.00 1 00.00 1 00.00 1 00.00 1 00.00 0.00 
%T8 [%) 9.20 9.20 9 .20 9.20 9.20 0.00 
%Lobe [%) 90.80 90.80 90.80 90.80 90.80 0.00 
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Table A VlI.9 Initial regional distribution of7.4 kDa F-PHEA in lung in vivo. The solute 
was administered into the airways by "forced solution instillation" (nominal dose = 1 .0 
mg; used in Fig. ill.5 and Section ill.b.7, Chapter 3). 
Wet weight: 
Rat# mean SO 
1 63 1 68 1 76 1 79 
BW [g] 350 330 330 320 332.50 1 2 .58 
TB [g] 0.27 0.21 0 .21  0.21 0.23 0.03 
L [g] 0.63 0.50 0 .43 0 .48 0.51 0.09 
PC [g] 0.20 0 . 1 6  0 . 13 0 . 1 8  0 . 1 7  0.03 
RS [g] 0.21 0 . 1 7  0 . 1 2  0 . 1 5  0 . 1 6 0 . 04 
RC [g] 0.25 0.23 0 . 1 4  0 . 1 7  0.20 0.05 
RI [g] 0.49 0.41 0.35 0 .35 0 .40 0.07 
Total [g] 2.05 1 .68 1 .38 1 .54 1 .66 0.29 
%T8 [%] 1 3 . 1 7  1 2.50 1 5.22 1 3 .64 1 3 .63 1 . 1 6  
%Lobe [%] 86.83 87.50 84.78 86.36 86.37 1 . 1 6  
Amount delivered: 
Rat# mean SO 
1 63 1 68 1 76 1 79 
OL [!lg] 928 .04 1 056.47 1 089.94 1 1 58 .40 1 058 .21 96.60 
°ctg [!lg] 1 5.02 47.81 6.94 48.83 29.65 2 1 . 8 1  
Den! [!lg] 1 34 . 1 6  72.70 83.60 367. 1 1  1 64.39 1 37.77 
Dad [!lg] 778.86 935.96 999.40 742 .46 864 . 1 7  1 23.20 
T8 [!lg] 71 .40 51 .95 52.55 47.05 55.74 1 0.73 
L [!lg] 3 1 6.76 295.35 308.70 361 .40 320.55 28.63 
PC [!lg] 44. 1 0  65.60 82.30 82.00 68.50 1 8 .04 
RS [!lg] 4 1 . 1 6  29.45 37.35 40.75 37. 1 8  5.43 
RC [!lg] 1 .26 1 8.20 1 0 . 1 5  24.90 1 3 .63 1 0 . 2 1  
RI [!lg] 265.44 360.70 3 1 9.95 1 80.00 281 .52 78 . 1 3  
Total (D,) !!lg] 740. 1 2  82 1 .25 8 1 1 .00 736. 1 0  777. 1 2  45.27 
% delivered: 
Rat# mean SO 
1 63 1 68 1 76 1 79 
TB [%] 9.65 6.33 6 .48 6 .39 7 .21  1 .63 
L [%] 42.80 35.96 38.06 49. 1 0  4 1 .48 5.83 
PC [%] 5.96 7.99 1 0 . 1 5  1 1 . 1 4  8 .81  2 . 3 1  
RS [%] 5.56 3.59 4 . 6 1  5 .54 4.82 0 .94 
RC [%] 0 . 1 7 2 .22 1 .25 3 . 38 1 .76 1 .37 
RI [%] 35.86 43.92 39.45 24.45 35.92 8 .33 
Total [%] 1 00 .00 1 00.00 1 00 .00 1 00.00 1 00.00 0 .00 
%T8 [%] 9.65 6.33 6.48 6.39 7.21 1 .63 
%Lobe [%] 90.35 93.67 93.52 93.61 92.79 1 .63 
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Table A VII. 1 0  Initial regional distribution of 376 Da F-Na in lung in vivo. The solute 
was administered into the airways by "forced solution instillation" (nominal dose = 0.02 
mg; used in Fig. IDA and Section mb.7, Chapter 3). 
Wet weight: 
Rat# mean SD 
1 2 1  1 24 1 28 1 32 
BW [g] 330 338 335 330 333.25 3.95 
TB [g] 0 . 1 6  0 .24 0.22 0 .26 0 .22 0.04 
L [g] 0.47 0.57 0.56 0 .56 0 .54 0.05 
PC [g] 0 . 1 2  0 . 1 6  0 . 1 7  0 . 1 9  0 . 1 6  0.03 
RS [g] 0 . 1 3  0.20 0.20 0 . 1 7  0 . 1 8  0.03 
RC [9] 0 . 1 4  0. 1 7  0.24 0 . 1 6  0 . 1 8  0 .04 
RI [g] 0.36 0.48 0 .44 0 .47 0.44 0.05 
Total [g] 1 .38 1 .82 1 .83 1 .8 1  1 .71  0 .22 
%TB [%] 1 1 .59 1 3 . 1 9  1 2 .05 1 4 .36 1 2.80 1 .24 
%Lobe [%] 88.41 86.81 87.95 85.64 87.20 1 .24 
Amount delivered: 
Rat# mean SD 
1 2 1  1 24 1 28 1 32 
DL [1l9] 26.72 20.02 22.59 20.45 22.45 3.06 
Dctg [1l9] 0.77 0.48 2 . 1 3  0.20 0.89 0 .86 
Denl [1l9] 1 .68 0 .87 4 .47 1 .08 2.02 1 .67 
Dad [1l9] 24.27 1 8 .67 1 5 .99 1 9 . 1 7  1 9 .53 3.46 
TB [Ilg] 1 .29 1 .40 1 .37 1 .30 1 .34 0.05 
L [1l9] 5. 1 7  4.66 4.90 5.05 4.95 0.22 
PC [1l9] 2.46 1 .4 1  1 .32 1 .42 1 .65 0.54 
RS [1l9] 2.04 1 . 1 7  2 . 1 1 3 .04 2.09 0.76 
RC [Ilg] 1 .09 0.70 1 .38 1 .28 1 . 1 1  0 .30 
RI [Ilg] 5 . 1 3  4.83 4.78 5.40 5.04 0.29 
Total (D,) [1l9l 1 7 . 1 8  1 4 . 1 7 1 5.86 1 7.49 1 6 . 1 8  1 .5 1  
% delivered: 
Rat# mean SD 
1 2 1  1 24 1 28 1 32 
TB [%] 7.51 9 .88 8.64 7 .43 8 .36 1 . 1 5  
L [%] 30.09 32.89 30.90 28.87 30.69 1 .69 
PC [%] 1 4.32 9.95 8 .32 8 . 1 2  1 0 . 1 8  2.88 
RS [%] 1 1 .87 8.26 1 3 .30 1 7 .38 1 2 .70 3.77 
RC [%] 6.34 4.94 8.70 7 .32 6.83 1 .59 
RI [%] 29.86 34 .09 30. 1 4  30.87 3 1 .24 1 .95 
Total [%] 1 00.00 1 00.00 1 00.00 1 00.00 1 00.00 0.00 
%TB [%] 7.51  9.88 8.64 7 .43 8 .36 1 . 1 5  
%Lobe [%] 92.49 90. 1 2  9 1 .36 92.57 9 1 . 64 1 . 1 5  
Table AVII.l 1 .  Dose and remaining 7.4 kDa F-PHEA in each dissected component of the lung at different sacrifice time in 
vivo, following solute administration into the airways by "forced solution instillation" (FR7 l 50; nominal dose = 0.2 mg; used 
in Fig. IlLS, Chapter 3). 
Time Rat# BW Dose [�gl Remaining F-PHEA [�gl Total %Dad 
[min) [g) DL Dctg Dcnl Dad TB L PC RS RC RI [�g) [%) 
61  348 228.46 4.76 29.52 1 94 . 1 8  1 3 .61 58.45 1 1 .69 8.88 2.96 52.38 1 47.97 76.20 
62 349 245.23 1 .87 27.09 2 1 6.27 1 8.38 48.75 1 3 .56 1 0 .24 3.47 1 05.43 1 99.83 92.40 
5 63 348 244.71 4 .77 1 8 .27 221 .67 1 7 . 1 7  67.21 1 4 .52 1 1 .24 6.20 70.27 1 86.61 84. 1 8  
67 338 21 4.06 1 9 .33 44.20 1 50 .5:J 1 0 . 1 9  50.20 1 3.29 7.95 3.47 25.69 1 1 0.79 73.60 
mean 8 1 .60 
SO 8.49 
69 320 259.88 7.61 22.22 230.05 1 6 .96 1 27 .40 1 5.74 25. 1 6  2 .82 8 .04 1 96. 1 2  85.25 
72 325 2 1 6.02 3 . 1 9  8.34 204.49 1 0.78 1 1 7.76 2.80 1 2 .78 0.00 1 6.44 1 60.56 78.52 
1 0  79 340 220.82 3 .77 22.46 1 94.59 1 4.64 40.86 26. 1 2  4.82 9 .50 40.58 1 36.52 70. 1 6  
81 350 21 3.72 5.93 14.97 1 92.82 1 3.08 47.66 4.90 1 5.46 0.00 35.66 1 1 6.76 60.56 
mean 73.62 
SO 1 0.68 
74 325 240 . 1 8  5.87 1 0 .06 224.25 2.80 45.82 6 . 1 0  14 .48 5.20 50.00 1 24.40 55.47 
75 3 1 5  201 .70 1 0 .50 34.06 1 57 . 14  5 . 1 4  54.40 1 . 1 2  1 2 .76 1 .24 24.24 98.90 62.94 
30 83 320 290.00 5 .86 14 .90 269.24 6 .44 1 03.56 9.78 1 7 . 1 8  7.80 36.38 1 8 1 . 1 4  67.28 
84 338 258.93 3.84 1 7.61 237.48 8.20 87.44 35.54 1 3 .44 1 2 .76 5.24 1 62.62 68.48 
mean 63.54 
SO 5.88 
68 325 1 98.46 7 .71 9.70 1 8 1 .05 1 1 .78 36.56 3.66 9 . 1 8  4.96 28.76 94.90 52.42 
71 3 1 5  236.69 1 1 .97 1 2.37 2 1 2.35 4 .24 49. 1 8  0.00 29. 1 0  0.00 24.94 1 07.46 50.60 
60 78 320 256.89 25.69 1 0 .57 220.63 5 . 1 2  32.78 7 .42 3 1 .94 4 .56 20.22 1 02 .04 46.25 
82 338 308.08 7 .46 1 4.90 285.72 1 2 .36 45.46 20.48 25.40 8 .68 51 .88 1 64.26 57.49 
mean 5 1 .69 
SO 4.65 
N -J N 
Table AVII.l 1 .  Dose and remaining 7.4 kDa F-PHEA in each dissected component of the lung at different sacrifice time in 
vivo, following solute administration into the airways by "forced solution instillation" (FR7 1 50;  nominal dose = 0.2 mg; used 
in Fig. III.8,  Chapter 3).  
Time Rat# BW Dose [!1g) Remaining F-PHEA [!1g) Total 'YoDad 
[min) [g) DL Dctg Den! Dad TB L PC RS RC RI [!1g) ['Yo) 
73 320 2 1 0.78 5 .52 1 3 .24 1 92.02 3.82 46.00 9.24 1 4.66 3 .42 1 5.02 92 . 1 6  48.00 
77 325 2 1 5.93 2 1 .59 6.41 1 87.93 2.80 40.54 2.60 22.28 9.30 1 5.42 92.94 49.45 
1 20 86 360 326.06 1 3 .53 1 .00 3 1 1 .53 5.88 4.36 1 5.24 54.30 4.26 59.84 1 43.88 46. 1 8  
87 340 323.67 35.72 27.26 260.69 2.52 84.92 3.44 8.62 1 .70 1 8.92 1 20 . 1 2  46.08 
mean 47.43 
SD 1 .6 1  
70 325 228. 1 3  4. 1 9  26.67 1 97.27 1 0.70 22 .04 1 3 .86 20.26 5.08 25.20 97. 1 4  49.24 
76 325 223.56 22.36 9 . 1 0  1 92. 1 0  0 . 54 39.58 4.60 8 .88 0.00 30. 1 6  83.76 43.60 
1 80 80 340 24 1 .09 1 .29 23.54 2 1 6.26 4.02 20.56 0.00 1 2 .68 1 .08 27.46 65.80 30.43 
85 350 295.83 9 . 1 1 25.24 261 .48 5.30 1 7.38 4.88 2 1 .74 6.32 90.88 1 46 . 50 56.03 
mean 44.82 
SD 1 0.86 
tv .... ..., 
Table AVII.12.  Dose and remaining 7.4 kDa F-PHEA in each dissected component of the lung at different sacrifice time in 
vivo, following solute administration into the airways by " forced solution instillation" (FR7 1 50; nominal dose = 1 .0 mg; used 
in Figs. III .8  and III.9, Chapter 3).  
Time Rat# BW Dose [J.1g] Remaining F-PHEA [J.1g] Total %Dad 
[min] [g] DL Dctg Dcnl Dad TB l PC RS RC RI [J.1g] [%] 
1 63 350 928.04 1 5.02 1 34 . 1 6  778.86 7 1 .40 3 1 6.76 44. 1 0  4 1 . 1 6  1 .26 265.44 740 . 1 2  95.03 
1 68 330 1 056.47 47.81  72.70 935.96 5 1 .95 295.35 65.60 29.45 1 8.20 360.70 8 2 1 .25 87.74 
5 1 76 330 1 089.94 6 .94 83.60 999.40 52.55 308.70 82.30 37.35 1 0. 1 5  3 1 9.95 8 1 1 .00 8 1 . 1 5  
1 79 320 1 1 58.40 48.83 367. 1 1 742 .46 47.05 361 .40 82.00 40.75 24.90 1 80.00 736. 1 0  99. 1 4  
mean 90.77 
SO 7.96 
1 62 345 904.67 1 6 .85 230.27 657.55 26.04 261 .45 42.63 43.26 60. 1 9  1 58.76 592.33 90.08 
1 67 32 1 1 028.30 20.71 95.94 9 1 1 .64 52.65 231 .35 30.95 65.75 1 1 5.65 265.80 762 . 1 5  83.60 
1 0  1 73 350 1 1 1 7 .33 1 0.53 55.37 1 05 1 .44 49.35 261 .80 1 1 2.60 1 28.30 1 32 .40 306. 1 5  990.60 94.21 
1 8 1  380 1 287.26 42. 1 8  1 75.41  1 069.66 63.45 274.35 29.00 1 56.00 38.80 326.25 887.85 83.00 
mean 87.72 
SO 5.38 
1 92 350 1 1 20.39 44.36 9 1 .20 984.84 1 3.80 344.80 2 1 .00 1 1 1 . 1 5  200.00 1 45.60 836.35 84.92 
1 93 350 1 03 1 .82 4.23 42.37 985.22 1 2 .65 303 . 1 0  1 1 .55 1 42.45 1 1 3.80 249.40 832.95 84.54 
20 1 94 330 1 263.78 30.38 2 1 3 .67 1 0 1 9.72 46.85 328.95 59.60 1 03.30 207.00 1 1 5.70 861 .40 84.47 
1 95 340 1 3 1 0 . 1 6  1 0 . 1 3  1 1 6 .74 1 1 83.29 47.90 472 . 1 0  42.65 38.00 2 1 3.65 1 50 . 90 965.20 8 1 .57 
mean 83.88 
SO 1 . 55 
1 6 1  338 8 1 6.45 57. 1 1 1 60.99 598.35 6 .30 1 35.24 7.77 28.35 0.00 335. 1 6  5 1 2.82 85.71 
1 70 320 954.49 1 0.31  5 1 .97 892 .21  1 8 .05 226.55 32.40 47.30 1 8.00 362.90 705.20 79.04 
30 1 75 330 1 1 53.86 1 4 .73 1 5. 6 1  1 1 23 . 52 1 43.90 271 .40 36.30 57.70 1 0.70 3 1 0 . 1 5 830. 1 5  73.89 
1 82 380 1 286.23 50.26 361 .29 874.69 26.00 222.30 35.40 1 9.25 68.20 235.25 606.40 69.33 
mean 76.99 
SO 7.04 -
IV -.J .... 
Table AVII.12.  Dose and remaining 7.4 kDa F-PHEA in each dissected component of the lung at different sacrifice time in 
vivo, following solute administration into the airways by " forced solution instillation" (FR7 1 50; nominal dose = 1 .0 mg; used 
in Figs. III .8 and 111.9, Chapter 3).  
Time Rat# BW Dose [!lg) Remaining F-PHEA [!lg) Total %Dad 
[min) [g) DL Dctg Dc ... Dad TB L PC RS RC RI [Ilg) [%) 
1 96 350 1 302.05 25. 1 3  37.04 1 239.89 230.50 333.45 69.50 47. 1 0  3 1 .60 2 1 8.20 930.35 75.03 
1 97 330 1 1 53.80 29.52 70.82 1 053.46 1 1 9.90 387. 1 0  52.70 40.90 2 1 .55 1 1 3 .55 735.70 69.84 
45 1 98 330 1 225.52 9 .62 7 1 .27 1 1 44.63 1 79.55 4 1 3.50 23.30 30.05 7.95 1 79.45 833.80 72.84 
1 99 320 1 1 76.36 34.64 1 51 .94 989.79 1 78.05 3 1 4.75 50.80 22.20 22.60 1 79.90 768.30 77.62 
mean 73.83 
SO 3.30 
1 60 345 950.09 6 1 .25 1 25.66 763. 1 9  1 28.77 6 1 . 1 1 84.42 7 1 .82 1 0.29 3 1 6.05 672.46 88. 1 1 
1 66 320 1 045.78 44. 8 1  1 36.28 864.70 1 2 1 .80 1 72.60 9.25 49.50 6.85 303.35 663.35 76.71  
60 1 72 350 989.82 1 5.08 1 02.72 872.02 1 20.30 1 99.60 9 . 1 0  64.20 3.35 249 . 1 5  645.70 74.05 
1 83 3 1 0  1 1 79.70 28.92 1 1 9.82 1 030.96 1 45. 1 5  79.85 25.65 1 6 .95 90.60 287.00 645.20 62.58 
mean 75.36 
SO 1 0.48 
1 64 351 945.79 1 6 . 1 9  1 1 5. 1 6  8 1 4 .44 275.40 1 29.50 40.37 45.32 8.03 95.92 594.54 73.00 
1 69 320 976.07 1 2 .80 67.31 895.96 2 1 5.95 1 1 3.05 66.05 53.20 1 0.50 1 1 0.70 569.45 63.56 
1 20 1 74 330 1 1 33.31  1 0.25 8 1 .95 1 04 1 . 1 2  2 1 8.25 1 4 1 .65 1 5.60 59.65 24.55 1 65.95 625.65 60.09 
1 80 380 1 382.36 46. 1 6  1 99.30 1 1 36.89 1 50.20 1 75. 1 5  1 2 .00 0.90 43.55 266.50 648.30 57.02 
mean 63 .42 
SO 6.92 
1 65 358 947.20 1 2 .77 1 08.05 826.38 295.30 1 1 8 .54 39.38 43.22 1 2 .04 94.78 603.26 73.00 
1 7 1 320 1 033. 1 7  1 4 .30 37.04 981 .84 285.65 1 72.35 1 3.45 35.75 1 5.65 6 1 .00 583.85 59.47 
1 80 1 77 320 1 084.58 20.58 87.00 977.00 3 1 0. 1 0  1 72 . 1 5  32.70 53.85 1 5.55 1 38.75 723 . 1 0  74.01  
1 78 320 1 079.29 66.88 201 .29 8 1 1 . 1 2  2 1 0.80 249 .60 26.55 1 8. 1 5  33.75 85.90 624.75 77.02 
mean 70.88 
SO 7.80 -� 
tv --.J V. 
Table AVII.13.  Dose and remaining 376 Da F-Na in each dissected component of the lung at different sacrifice time in vivo, 
following solute administration into the airways by "forced solution instillation" (nominal dose = 0.02 mg; used in Figs. III.6 
and 111.7, Chapter 3). 
Time Rat# BW Dose [",g] Remaining F-Na [",g] Total %Dad 
[min] [g] Dl Dctg DCnI Dad TB L PC RS RC RI [",g] [%] 
1 2 1  330 26.72 0.77 1 .68 24.27 1 .29 5 . 1 7 2 .46 2 .04 1 .09 5 . 1 3  1 7. 1 8  70.78 
1 24 338 20.02 0 .48 0 .87 1 8.67 1 .40 4.66 1 .4 1  1 . 1 7  0.70 4.83 1 4. 1 7  75.90 
5 1 28 335 22.59 2. 1 3  4 .47 1 5.99 1 .37 4.90 1 .32 2 . 1 1 1 .38 4.78 1 5.86 99.20 
1 32 330 20.45 0.20 1 .08 1 9 . 1 8  1 .30 5.05 1 .42 3 .04 1 .28 5.40 1 7.49 9 1 .21  
mean 84.27 
SO 1 3.20 
90 3 1 5  26.85 2.58 4.33 1 9.95 0.63 1 .73 2.06 1 .3 1  0.00 3.29 9.02 45.22 
94 335 25.43 0.37 1 .37 23.69 0.81 4.87 2 . 1 2  1 .73 0 . 1 2  4.82 1 4 .47 6 1 .08 
1 0  1 27 350 2 1 .95 2.02 1 .84 1 8.08 1 .0 1  3.76 0.37 2.36 2. 1 2  3 . 1 8  1 2 .80 70.78 
1 3 1 350 20.78 0.27 2.22 1 8 .29 0 .85 2 .79 0 . 1 5 1 .97 0.95 4.45 1 1 . 1 6  6 1 .00 
mean 59.52 
SO 1 0.58 
92 330 24.24 3.00 6 . 1 2  1 5. 1 2  0 .40 1 .9 1  0.38 1 .33 0.56 1 .22 5.80 38.35 
93 325 25.81 0 .44 2 .36 23 .02 0 .71  1 .42 0.67 1 .58 0 .49 1 .88 6.75 29.32 
20 1 1 9 320 24.27 0.43 2 .46 2 1 .38 0.66 1 .90 1 . 1 5  1 .40 0.36 1 .22 6.69 3 1 .29 
1 30 325 2 1 .32 1 .56 0.97 1 8 .79 1 .22 1 .82 1 .06 1 .38 0 .51  1 .32 7 .31  38.90 
mean 34.47 
SO 4.87 
88 320 27.68 1 .08 2 .67 23.93 0 . 1 9  1 .39 0 . 74 0.56 0 . 1 3  0.72 3.73 1 5.59 
1 22 335 23.67 0.40 0.88 22.40 0 . 1 9  1 .79 0.82 0 .53 0.25 0.69 4.27 1 9.07 
30 1 26 340 2 1 .78 0.83 2.00 1 8 .95 0.38 0.82 0.58 0.53 0.21 0 .52 3 .04 1 6.04 
1 34 350 20.96 0.23 2 .21  1 8.53 0 .44 1 .66 0.35 0.55 0.51 0.82 4.33 23.37 
mean 1 8.52 
SO 3 . 59 
N -J "" 
Table AVII.13.  Dose and remaining 376 Da F-Na in each dissected component of the lung at different sacrifice time in vivo, 
following solute administration into the airways by "forced solution instillation" (nominal dose = 0.02 mg; used in Figs. nu, 
and III.7, Chapter 3). 
Time Rat# BW Dose [�g] Remaining F-Na [�g] Total %Dad 
[min] [g] Dl Dctg Denl Dad TB L PC RS RC RI [�g] [%] 
89 3 1 0  26.24 0.85 1 .90 23.49 3.82 46.00 9 .24 14 .66 3 .42 1 5.02 92. 1 6  392.34 
1 20 330 25.57 2.35 0 .59 22.63 2 .80 40.54 2 .60 22.28 9.30 1 5.42 92.94 4 1 0.78 
60 1 23 330 22 . 1 3  2 .40 1 .42 1 8.30 5.88 4.36 1 5.24 54.30 4.26 59.84 1 43.88 786. 1 9  
1 33 330 1 9 .78 0.23 0.69 1 8.85 2.52 84.92 3 .44 8.62 1 .70 1 8.92 1 20 . 1 2  637 . 1 7  
mean 556.62 
SO 1 89.25 
91 325 25.87 3.81 1 .83 20.23 0 .08 0.00 0 .00 0.00 0.00 0.08 0 . 1 6  0.79 
1 1 8  345 21 .02 3.27 1 .09 1 6.67 0.08 0.03 0.00 0 .04 0.00 0.00 0 . 1 5 0.90 
1 20 1 25 325 2 1 .40 0.84 1 .03 1 9.53 0 .04 0 .04 0 .01  0.00 0.00 0.00 0.09 0 .46 
1 29 340 24.65 0.63 0.78 23.24 0.06 0.03 0.00 0.00 0.00 0.00 0.09 0.39 
mean 0.63 
SO 0.25 ---- - --- -
N -.] -.] 
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Table AVII.14.  Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C. (FR7150; nominal dose = 0. 1 
mg; used in Fig. m. IO, Chapter 3 and Fig. V.4, Chapter 5). 
Amount delivered: 
Rat# 
97 98 99 1 00 
BW [g] 300 340 320 340 
DL [�g] 1 27.53 1 2 1 .03 9 1 . 1 9  9 1 .73 
Dctg [�g] 3.46 7.70 3.38 3 .77 
DcnJ [�g] 23.59 1 9.39 1 .44 22.23 mean SD 
Dad [�gl 1 00.48 93.94 86.37 65.73 86.63 1 5.08 
Transferred amount: [�g] 
Rat# 
97 98 99 1 00 
0 [min] 0.000 0 .000 0.000 0 .000 
5 32.7 1 2  4.8 1 0  1 3. 1 04 6.954 
1 0  49.1 69 6.369 22.31 5 1 4.662 
1 5  43 .496 24.574 23.752 1 7 .550 
20 44.044 2 1 .420 30.968 27.882 
25 43.037 32.052 34.646 4 1 . 1 1 2  
30 44. 1 73 30.732 37.086 45.998 
45 51 .462 49.473 33.938 45.687 
60 55.974 59.009 4 1 . 1 53 47 .420 
90 57.328 49.551 45.1 59 45.552 
1 20 55.27 1 49. 1 38 5 1 .039 49.097 
1 50 58.034 59.070 46.670 47.041 
1 80 59.705 64.734 54.000 42.678 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0 .00 0.00 0.00 0.00 
5 32.56 5 . 1 2  1 5. 1 7  1 0 .58 1 5.86 1 1 .87 
1 0  48.93 6.78 25.84 22.31 25.96 1 7.41 
1 5  43.29 26. 1 6  27.50 26.70 30.91 8.27 
20 43.83 22.80 35.86 42 .42 36.23 9.60 
25 42.83 34. 1 2  40. 1 1 62.55 44.90 1 2.31 
30 43.96 32.71  42.94 69.98 47.40 1 5.89 
45 51 .22 52 .66 39.29 69.51 53. 1 7  1 2.43 
60 55.71 62.82 47.65 72. 1 4  59.58 1 0.42 
90 57.05 52.75 52.29 69.30 57.85 7.93 
1 20 55.01 52. 3 1  59.09 74.69 60.28 1 0.01 
1 50 57.76 62.88 54.03 7 1 .57 61 .56 7.59 
1 80 59 .42 68.91 62.52 64.93 63.95 4.01 
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Table A VII.IS. Dose, and amount and % of administered dose of 7 .4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C. (FR71 50; nominal dose = 0.2 
mg; used in Fig. III.1 D, Chapter 3 and Fig. IV.4, Chapter 4). 
Amount delivered: 
Ral# 
28 29 32 33 
BW [9] 3 1 6  320 320 340 
Dl [!l9] 244.81 222.05 204.45 2 1 0.28 
Dctg [!l9] 4.55 1 .00 1 .27 3.83 
Den! [!l9] 9.31 4 1 .21 5.32 44. 1 4  mean SD 
Dad [!l91 230.95 1 79.84 1 97.86 1 62.31 1 92.74 29.32 
Transferred amount: [!l9] 
Ral# 
28 29 32 33 
0 [min] 0.000 0.000 0.000 0.000 
5 56.305 30.331 33.839 22.367 
1 0  76.241 46.874 54.380 26.071 
1 5  85.250 67. 1 20 66.884 33.979 
20 92 .448 72 .954 66 .533 38.806 
25 1 07.621 9 1 .048 69.982 40.236 
30 95.405 99.755 1 00.574 48. 1 44 
45 1 1 1 .823 1 04.8 1 4  1 1 0.574 59.297 
60 1 27.3 1 5  1 1 9.839 1 1 8 .4 1 7  70.300 
90 1 23.973 1 2 1 .747 1 23.325 79.622 
1 20 1 32.877 1 2 1 .701 1 33.231 90.373 
1 50 1 22.375 1 1 9 .726 1 33.631 93.464 
1 80 1 38.691 1 20.635 1 35.091 94.6 1 9  
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 24.38 1 6.87 1 7. 1 0  1 3.78 1 8.03 4.49 
1 0  33.01 26.06 27.48 1 6.06 25.66 7.06 
1 5  36.91 37.32 33.80 20.93 32.24 7.70 
20 40.03 40.57 33.63 23.91 34.53 7.75 
25 46.60 50.63 35.37 24.79 39.35 1 1 .66 
30 41 .31 55.47 50.83 29.66 44.32 1 1 .41 
45 48 .42 58.28 55.88 36.53 49.78 9.78 
60 55. 1 3  66.64 59.85 43.31 56.23 9.82 
90 53.68 67.70 62.33 49.06 58. 1 9  8.39 
1 20 57.53 67.67 67.34 55.68 62.06 6.34 
1 50 52.99 66.57 67.54 57.58 61 .1 7 7.06 
1 80 60.05 67.08 68.28 58.30 63.43 4.99 
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Table A VlI.1 6. Dose, and amount and % of administered dose of 7 .4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C. (FR71 50; nominal dose = 0.5 
mg; used in Fig. m. IO, Chapter 3) .  
Amount delivered: 
Rat# 
1 0 1  1 02 1 03 1 04 
BW (9) 360 345 330 330 
DL [J.l9) 585.04 566.28 554.78 535.42 
Dctg [J.l9) 23.86 1 6.33 1 1 .33 53. 1 6  
Den! [J.l9) 1 54.46 1 73.75 204.90 1 42.05 mean SD 
Dad [J.l9) 406.72 376.20 338.55 340.21 365.42 32.55 
Transferred amount: [J.l9) 
Rat# 
1 0 1  1 02 1 03 1 04 
0 [min) 0.000 0 .000 0.000 0 .000 
5 0.000 33.594 1 3 .763 22 .44 1 
1 0  7 . 1 24 59.805 26.2 1 9  37.707 
1 5  54.0 1 8  75.2 1 5  3 1 .380 56.604 
20 59.057 97. 1 37 54.873 77. 1 89 
25 74.727 96.4 1 2  50.465 99.465 
30 93.362 1 09 .277 51 .095 1 06.296 
45 1 08.048 1 1 4.903 6 1 .787 1 25.4 1 0 
60 1 35.872 1 32.072 62.9 1 3  1 28.038 
90 1 55.865 1 4 1 .266 76.028 1 33.7 1 7  
1 20 1 65.382 1 38.725 86.855 1 5 1 .252 
1 50 1 65. 1 40 1 59.437 89.380 1 50.71 0 
1 80 1 69.537 1 68.024 9 1 .992 1 57.254 
% transferred: [%) mean SD 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
5 0.00 8 .93 4.07 6.60 4.90 3.82 
1 0  1 .75 1 5.90 7.74 1 1 .08 9 . 1 2  5.94 
1 5  1 3.28 19 .99 9 .27 1 6 .64 1 4.80 4.59 
20 1 4 .52 25.82 1 6.21 22.69 1 9.81 5.33 
25 1 8.37 25.63 1 4 .91  29 .24 22.04 6.56 
30 22.95 29.05 1 5.09 3 1 .24 24.58 7.23 
45 26.57 30.54 1 8.25 36.86 28.06 7.79 
60 33.41 35. 1 1 1 8.58 37.63 3 1 . 1 8  8.58 
90 38.32 37.55 22.46 39.30 34.41 8.00 
1 20 40.66 36.88 25.65 44.46 36.91 8 . 1 2 
1 50 40.60 42.38 26.40 44.30 38.42 8 . 1 5 
1 80 4 1 .68 44.66 27. 1 7  46.22 39.94 8.71 
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Table A VII.17. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C. (FR7 I 50; nominal dose = 1 .0 
mg; used in Fig. m I D, Chapter 3 and Fig. V.5, Chapter 5). 
Amount delivered: 
Rat# 
Pre#1 2 3 
BW [9] 360 335 338 320 
DL [j.l9] 1 056.00 1 1 29.55 997.50 1 0 1 3.42 
Dctg [j.l9] 1 9.61 80.35 1 3.85 78.60 
Dcnj [j.l9] 0.00 2 1 . 1 5  48.60 94.89 mean SO 
Dad [j.l9] 1 036.39 1 028.05 935.05 839.93 959.86 92.21 
Transferred amount: [j.l9] 
Rat# 
Pre#1 2 3 
0 [min] 0.000 0.000 0.000 0.000 
5 44.483 75.571 24.226 1 1 .292 
1 0  73.584 1 36.624 62.9 1 2  33.443 
1 5  1 1 8 .736 1 59.297 82.621 50.870 
20 1 36.952 1 59.607 1 1 8.496 64.783 
25 1 58 .397 1 85.524 1 1 8.549 72.622 
30 1 6 1 .993 205.923 1 3 1 .979 80.887 
45 1 87 . 1 30 240.553 1 55.633 1 06.51 0 
60 2 1 4.321 261 .51 1 1 77 .879 1 1 9.493 
90 2Cl7.6 1 6  284.691 272.887 1 43.433 
1 20 280.357 341 .7 1 8  275.482 1 6 1 .425 
1 50 320.230 459.997 294.658 1 74.395 
1 80 372.001 472.772 330.966 1 79.582 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 4 .29 7.35 2 .59 1 .34 3.89 2.60 
1 0  7 . 1 0  1 3 .29 6.73 3.98 7.77 3.93 
1 5 1 1 .46 1 5.50 8.84 6.06 1 0.46 4.02 
20 1 3 .21 1 5.53 1 2.67 7 .71  1 2.28 3.29 
25 1 5.28 1 8.05 1 2 .68 8.65 1 3.66 4.00 
30 1 5.63 20 .03 14 . 1 1 9.63 1 4.85 4.29 
45 1 8 .06 23 .40 1 6 .64 1 2.68 1 7.70 4.43 
60 20.68 25.44 1 9.02 1 4 .23 1 9.84 4.63 
90 20.03 27.69 29. 1 8  1 7.08 23.50 5.86 
1 20 27.05 33.24 29 .46 1 9 .22 27.24 5.92 
1 50 30.90 44.74 31 .51  20.76 31 .98 9.83 
1 80 35.89 45.99 35.40 21 .38 34.66 1 0. 1 1 
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Table A VII.I S. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C. (FR71 50; nominal dose = 5 .0 
mg;  used in Fig. ill. 10, Chapter 3 and Fig. IV.5, Chapter 4). 
Amount delivered: 
Ral# 
34 63 65 66 
BW [9] 340 3 10  320 3 1 0  
DL [119] 5430.41 491 5.70 5775.32 6066.67 
Dctg 1119] 546.78 51 8.32 396.99 242.53 
Den! [119] 56.67 884.62 887. 1 0  93.87 mean SO 
Dad [119] 4826.96 351 2.76 4491 .23 5730.27 4640.31 91 5.87 
Transferred amount: [119] 
Ral# 
34 63 65 66 
0 [min] 0.000 0.000 0.000 0 .000 
5 68.803 202.030 1 7 .305 1 .953 
1 0  1 56.824 283.563 46.248 6 .232 
1 5  225.552 362.523 68.741 1 1 .668 
20 293.51 5  389.294 89.800 1 2 .056 
25 393.420 442.989 1 08.222 23 . 1 22 
30 384.408 484 . 13 1  1 1 6.577 30.969 
45 468.267 555 . 12 1  1 84.931 63.4 1 9  
60 520.81 5  6 18 .480 1 64 .760 98.076 
90 674 . 1 30 767.234 1 94 .098 1 29 .2 1 6  
1 20 689.220 757 . 194 229. 1 1 0  1 56 .256 
1 50 755.954 871 .323 252 .8 1 9  1 93.961 
1 80 769.876 994.786 303.068 1 98 .277 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 1 .43 5.75 0.39 0.03 1 .90 2.64 
1 0  3.25 8 .07 1 .03 0 . 1 1 3.1 1 3.56 
1 5  4 .67 1 0.32 1 .53 0.20 4.1 8 4.50 
20 6.08 1 1 .08 2 .00 0 .21  4.84 4.83 
25 8 . 1 5 1 2 .61 2.41 0 .40 5 .89 5.55 
30 7.96 1 3.78 2.60 0 .54 6.22 5.93 
45 9.70 1 5.80 4 . 1 2  1 . 1 1  7.68 6.48 
60 1 0.79 1 7.61 3.67 1 .7 1  8.44 7.25 
90 1 3.97 2 1 .84 4.32 2.25 1 0.60 9.07 
1 20 1 4.28 2 1 .56 5 . 1 0 2.73 1 0.92 8.67 
1 50 1 5.66 24.80 5.63 3.38 1 2.37 9.86 
1 80 1 5 .95 28.32 6.75 3 .46 1 3.62 1 1 .1 3  
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Table AVII.19.  Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from aiIWays to perfusate in the IPRL at 30 °C. (FR71 50; nominal dose = 0.2 
mg; used in Fig. IV.4, Chapter 4). 
Amount delivered: 
Rat# 
4 9 50 52 
BW [9] 348 330 340 320 
DL [1l9] 21 3.44 2 1 5.72 204.46 234.1 6 
Dctg [1l9] 2.48 12 .20 1 4.63 8.69 
Dcnl [1l9] 1 6.58 1 8 .96 1 0.20 21 . 1 0  mean SD 
Dad [1l9] 1 94.38 1 84.56 1 79.63 204.37 1 90.74 1 0.96 
Transferred amount: [1l9] 
Rat# 
4 9 50 52 
0 [min] 0.000 0.000 0.000 0.000 
5 1 6.464 1 8.235 1 2 . 1 79 1 5. 1 64 
1 0  24.978 28.736 1 9.759 28.6 12  
15  34.502 35.749 27.376 33.4 14  
20 36 .446 39.385 34.794 4 1 .794 
25 45.524 46.232 42.536 59.962 
30 54. 1 54 56.402 43.506 66.768 
45 60.724 69.505 46. 1 1 1  68.893 
60 68.266 73. 1 04 53.296 69.486 
90 75.556 79.6 1 9  55.4 1 6  67.646 
1 20 76.2 16  79.4 1 6  59.727 71 .734 
1 50 77.1 1 1  79.435 63.068 79.950 
1 80 77.752 77.238 63.625 78.723 
% transferred: [%] mean SD 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
5 8 .47 9.88 6.78 7.42 8 . 1 4  1 .35 
1 0  1 2.85 1 5.57 1 1 .00 1 4.00 1 3.36 1 .93 
1 5  1 7.75 1 9 .37 1 5.24 1 6.35 1 7. 1 8  1 .79 
20 1 8.75 21 .34 1 9.37 20.45 1 9.98 1 .1 5  
25 23.42 25.05 23.68 29.34 25.37 2.74 
30 27.86 30.56 24.22 32.67 28.83 3.65 
45 31 .24 37.66 25.67 33.71 32.07 5.02 
60 35. 1 2  39.61 29.67 34.00 34.60 4.08 
90 38.87 43. 1 4  30.85 33. 1 0  36.49 5.57 
120 39.21 43.03 33.25 35. 1 0  37.65 4.37 
1 50 39.67 43.04 35. 1 1 39. 1 2  39.24 3.25 
1 80 40.00 41 .85 35.42 38.52 38.95 2 .72 
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Table AVII.20. Dose, and amount and % of administered dose on.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C. (FR7 1 50; nominal dose = 0.2 
mg; used in Figs. N.4 and N.6, Chapter 4). 
Amount delivered: 
Rat# 
24 35 36 37 
BW [g) 370 325 358 348 
DL [�g) 293.43 238.61 1 97.71 1 85.08 
Dctg [�g) 4.37 1 .65 8 .92 1 5.38 
Dcnl [�g) 40.34 1 5.72 39.55 7.76 mean SO 
Dad [�g) 248.72 221 .24 1 49.24 1 6 1 .94 1 95.29 47.47 
Transferred amount: [�g) 
Rat# 
24 35 36 37 
0 [min) 0.000 0.000 0.000 0.000 
5 1 0.426 8.745 2 .7 1 7  3.065 
1 0  26.329 1 7.435 4 .554 1 .821 
1 5  29.580 30.200 7.981 6 .4 1 6  
20 3 1 . 1 22 33.635 1 4 .949 7.02 1 
25 39 .222 39.750 1 5.020 14 .948 
30 43.062 43.758 1 7 .932 1 5.700 
45 49.802 62.423 24.941 22.839 
60 6 1 .375 68.499 25. 1 02 30. 1 03 
90 68 .479 78.649 30.771 38 .297 
1 20 70.840 95.968 32.866 4 1 .009 
1 50 70.924 1 03.339 33.574 40 .626 
1 80 76.842 1 09.9 1 0  34.773 47 .524 
% transferred: [0/0) mean SO 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
5 4 . 19  3.95 1 .82 1 .89 2.96 1 .28 
10 1 0.59 7.88 3.05 1 . 1 2  5.66 4.34 
1 5  1 1 .89 1 3.65 5.35 3.96 8.71 4.77 
20 1 2.51 1 5.20 1 0.02 4.34 1 0.52 4.63 
25 1 5.77 1 7 .97 1 0.06 9.23 1 3.26 4.28 
30 1 7.31 1 9.78 1 2.02 9.69 1 4.70 4.65 
45 20.02 28.22 1 6.71  1 4 . 1 0 1 9.76 6.1 3 
60 24.68 30.96 1 6.82 1 8.59 22.76 6.42 
90 27.53 35.55 20.62 23.65 26.84 6.46 
1 20 28.48 43.38 22.02 25.32 29.80 9.43 
1 50 28.52 46.7 1 22.50 25.09 30.70 1 0.95 
1 80 30.89 49.68 23.30 29.35 33.31 1 1 .40 
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Table A VII.21 .  Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C. (FR7150; nominal dose = 0.5 
mg; used in Figs. IV.6, Chapter 4). 
Amount delivered: 
Rat# 
1 35 1 36 1 37 1 38 
BW [g) 380 320 350 360 
DL [fig) 581 .75 558.07 546.82 502.47 
Dctg [fig) 25.47 25.69 43 .47 27.70 
Denl [fig) 85.26 84.76 1 3.32 1 02.66 mean SD 
Dad rflgl 471 .02 447.62 490.03 372. 1 1  445.20 5 1 .72 
Transferred amount: [fig) 
Rat# 
1 35 1 36 1 37 1 38 
0 [min) 0.000 0.000 0.000 0 .000 
5 5.076 5.889 0.000 0 .825 
1 0  1 0 .558 7.061 8 . 1 1 8  9 .803 
1 5  1 1 .284 9 .736 9. 1 03 1 8 .946 
20 1 9 . 1 9 1  1 4 .634 21 .397 25.6 1 2  
25 46.064 1 8 .400 33.071 37.561 
30 54.976 1 9 .428 35. 1 86 45. 1 4 1  
45 63. 1 7 1  32 .31 4  59.479 55.767 
60 75.351 32.4 1 5  71 .060 72.739 
90 93.653 52.266 93.774 87.030 
1 20 1 1 3.870 56.326 1 0 1 .555 98.467 
1 50 1 27.337 59.0 1 0  1 09.874 1 06.971 
1 80 1 37.952 75.359 1 36.360 1 1 9 .380 
% transferred: [%) mean SD 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
5 1 .08 1 .32 0.00 0.22 0.65 0.64 
1 0  2 .24 1 .58 1 .66 2.63 2.03 0.50 
1 5  2.40 2 . 1 8  1 .86 5.09 2.88 1 .49 
20 4 .07 3.27 4.37 6.88 4.65 1 .56 
25 9.78 4 . 1 1 6.75 1 0.09 7.68 2.82 
30 1 1 .67 4.34 7. 1 8  1 2 . 1 3  8.83 3.74 
45 1 3.41 7 .22 1 2 . 1 4  14 .99 1 1 .94 3.36 
60 16 .00 7.24 1 4 .50 1 9 .55 1 4.32 5.1 7 
90 1 9.88 1 1 .68 1 9. 1 4  23.39 1 8.52 4.93 
1 20 24. 1 8  1 2 .58 20.72 26 .46 20.99 6.08 
1 50 27.03 1 3 . 1 8  22.42 28.75 22.85 6.97 
1 80 29.29 1 6 .84 27.83 32.08 26.51 6.69 
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Table A VII.22. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C. (FR71 50; nominal dose = 1 .0 
mg; used in Fig. IV.6, Chapter 4). 
Amount delivered: 
Rat# 
5 6 7 1 7  
BW [g] 370 360 364 380 
DL [fig] 1 052.81 1 065.00 1 1 36.98 1 1 35.08 
Dctg lflg] 44.51 37.26 34.40 53.02 
Denl [fig] 1 2 .99 4 1 .30 27.77 1 8 .45 mean SO 
Dad [fig] 995.31 986.44 1 074 .81 1 063.61 1 030.04 45.60 
Transferred amount: [fig] 
Rat# 
5 6 7 1 7  
0 [min] 0 .000 0.000 0.000 0 .000 
5 3.500 0 .407 1 0.856 0 . 1 79 
1 0  1 1 .646 1 5.202 7.967 8 .834 
1 5  23.566 1 8.937 2 1 .059 1 9.728 
20 25.586 25.786 42. 1 40 28.366 
25 35.308 4 1 .683 59.845 36.074 
30 53.607 47.007 73.509 50.6 1 8 
45 64.4 1 2  67.309 1 08.023 73.830 
60 88.7 1 6  87.096 1 28.680 99.040 
90 1 1 0. 1 09 1 1 0.843 1 76.726 1 23 .029 
1 20 1 33.964 1 32.068 1 92.729 1 58.494 
1 50 1 63.675 1 49.434 2 1 8.081 1 7 1 .724 
1 80 1 7 1 .871 1 52 . 1 32 250.350 1 96 . 1 74 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 0 .35 0 .04 1 .0 1  0.02 0.35 0.46 
1 0  1 . 1 7  1 .54 0 .74 0.83 1 .07 0.36 
1 5  2.37 1 .92 1 .96 1 .85 2.03 0.23 
20 2.57 2 .61  3 .92 2.67 2.94 0 . 65 
25 3.55 4.23 5.57 3.39 4.1 8 0.99 
30 5.39 4.77 6.84 4.76 5.44 0.98 
45 6.47 6 .82 1 0.05 6 .94 7.57 1 .66 
60 8.91  8.83 1 1 .97 9 .31  9.76 1 .49 
90 1 1 .06 1 1 .24 1 6 .44 1 1 .57 1 2.58 2.59 
1 20 1 3 .46 1 3.39 1 7.93 1 4 .90 1 4.92 2.1 3  
1 50 1 6.44 1 5. 1 5  20.29 1 6 . 1 5  1 7.01 2.26 
1 80 1 7 .27 1 5.42 23.29 1 8 .44 1 8.61 3.36 
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Table A VII.23. Dose, and amount and % of administered dose of 7 .4 lcDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C. (FR71 50; nominal dose = 5 .0 
mg; used in Figs. IV.5 and IV.6, Chapter 4). 
Amount delivered: 
Rat# 
44 46 47 49 
BW [9] 385 387 385 335 
Dl [1l9] 4883. 1 5  5485.39 5064 . 19  5272 . 1 3  
Dctg [1l9] 92.36 256.29 38.91 1 4.48 
Dcnl [1l9] 862.98 508.44 747.56 248.99 mean SD 
Dad [Il91 3927.81 4720.66 4277.72 5008.66 4483.71  477.21 
Transferred amount: [1l9] 
Rat# 
44 46 47 49 
0 [min] 0.000 0.000 0.000 0.000 
5 8.6 1 2  5.739 48.966 2 1 .866 
1 0  45.2 1 8  1 8.997 1 82.002 79.023 
1 5  87.678 35. 1 85 252.336 1 1 7 .036 
20 1 38.756 44.91 9  3 1 7 .349 1 64.087 
25 1 85.3 1 7  64.548 353.957 1 98 .745 
30 226.032 82.626 430.032 240.988 
45 295.449 1 26.949 533.042 294 . 1 34 
60 382.533 1 68 .234 586.335 467.801 
90 557.657 2 1 4.567 679.641 561 .391 
1 20 603.952 255.981 831 . 1 23 681 .972 
1 50 649.603 301 .536 841 .936 734.562 
1 80 708.367 370.583 984.380 8 1 8 .2 1 6  
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 0 .22 0. 1 2  1 . 1 4  0 .44 0.48 0.46 
1 0  1 . 1 5  0.40 4.25 1 .58 1 .85 1 .68 
1 5  2.23 0.75 5 .90 2.34 2.80 2.19 
20 3.53 0.95 7 .42 3.28 3.79 2.68 
25 4.72 1 .37 8 .27 3.97 4.58 2.85 
30 5.75 1 .75 1 0.05 4 .81  5.59 3.43 
45 7.52 2.69 1 2.46 5.87 7 . 1 4  4.08 
60 9.74 3 .56 1 3.71 9 .34 9.09 4.1 8 
90 14 .20 4.55 1 5.89 1 1 .2 1  1 1 .46 5.00 
1 20 1 5.38 5.42 1 9 .43 1 3 .62 1 3.46 5.89 
1 50 1 6 .54 6.39 1 9.68 1 4.67 1 4.32 5.68 
1 80 1 8 .03 7.85 23.01 1 6 .34 1 6.31 6.31 
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Table A VII.24. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the absence of DNP/OUA at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. IV.9, IV. I O  and IV. 1 6, Chapter 4). 
Amount delivered: 
Rat# 
2 1 4  2 1 5  2 1 9  221 
BW [9] 350 325 335 335 
DL [119] 248.99 255.33 274.77 263.26 
Dctg [119] 43.40 5.43 2 . 14  2 .93 
Dcnl [119] 1 2.05 62.54 42. 1 9  61 .21 mean SD 
Dad [1191 1 93 .54 1 87.36 230.44 1 99 . 1 2  202.62 1 9 . 1 6  
Transferred amount: [119] 
Rat# 
2 14  2 1 5  2 1 9  221 
0 [min] 0.000 0.000 0.000 0.000 
5 1 3 . 1 75 7.4 1 9  9.4 1 7  1 1 .973 
1 0  34.839 1 8.901 1 7 .780 1 9. 1 74 
1 5  47.4 1 5  26.756 32.5 14  27.035 
20 62.799 33.873 41 .363 45.931 
25 77.01 1 46.046 53.237 70.079 
30 86.923 47.883 69.028 72 . 1 27 
45 1 07.647 58 . 1 1 5  89.277 99.352 
60 1 29.952 62 . 1 49 1 20 .997 1 05.487 
% transfeffed: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 6.81 3.96 4.09 6 .01 5.22 1 .42 
1 0  1 8 .00 1 0 .09 7.72 9.63 1 1 .36 4.55 
1 5  24.50 1 4.28 1 4 . 1 1 1 3 .58 1 6.62 5.26 
20 32.45 1 8.08 1 7.95 23.07 22.89 6.81 
25 39.79 24.58 23. 1 0  35. 1 9  30.67 8 .1 3 
30 44.91 25.56 29.95 36.22 34. 1 6  8 .40 
45 55.62 3 1 .02 38.74 49.90 43.82 1 1 .04 
60 67. 1 4  33 . 1 7  52 .51 52.98 51 .45 1 3.95 
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Table A VII.2S. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 0.05 mM DNP at 37 °C 
(FR7 1 50;  nominal dose = 0.2 mg; used in Figs. IV.9 and IV. l O, Chapter 4). 
Amount delivered: 
Rat# 
244 245 246 247 
BW [9) 325 320 320 320 
DL [119) 225.24 230.78 228.84 2 1 7.86 
Dctg [119) 3.34 3.73 2.86 2.02 
Oro [119) 23.47 70.95 42.32 44.99 mean SO 
Dad (119) 1 98.43 1 56. 1 0  1 83.66 1 70.85 1 77 .26 1 8 .06 
Transferred amount: [119) 
Rat# 
244 245 246 247 
0 [min) 0.000 0.000 0.000 0 .000 
5 1 9 .231 1 0.447 8.795 1 5.470 
1 0  40.742 2 1 . 1 00 22. 1 1 2  29.367 
1 5  50.558 29 .208 35.290 39.806 
20 59.450 39.394 43 .487 42. 1 26 
25 66.959 50.039 52.625 48. 1 51 
30 76.278 56.577 53.526 52.500 
45 95.792 62.650 62.584 64. 1 90 
60 1 00.940 69.504 71 .778 75.1 32 
% transferred: [%) mean SO 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
5 9.69 6.69 4 .79 9.05 7.56 2.25 
1 0  20.53 1 3.52 1 2.04 1 7 . 1 9  1 5.82 3.82 
1 5  25.48 1 8.71 1 9.21 23.30 21 .68 3.26 
20 29 .96 25.24 23.68 24.66 25.88 2.79 
25 33.74 32.06 28.65 28. 1 8  30.66 2.68 
30 38 .44 36.24 29. 1 4  30.73 33.64 4.42 
45 48 .27 40.1 3  34.08 37.57 40.01 6.04 
60 50.87 44.53 39.08 43.98 44 .61 4.84 
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Table A VlI.26. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 0. 1 mM DNP at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. N.9 and N. l O, Chapter 4). 
Amount delivered: 
Rat# 
250 251 25;2 253 
BW [9] 320 350 350 350 
DL [1'9] 237.99 224.53 244.90 247.66 
Dctg [1'9] 2 .40 3.57 2.53 0.85 
Den! [1'9] 36.51 64.03 59.97 54.39 mean SD 
Dad [1'9] 1 99.08 1 56.93 1 82.40 1 92.42 1 82.71 1 8.50 
Transferred amount: [1'9] 
Rat# 
250 251 252 253 
0 [min] 0.000 0.000 0.000 0.000 
5 1 8.040 9.306 1 3.909 2 1 . 1 89 
1 0  25.751 20.0 19  26.228 35.371 
1 5  41 .000 31 .301 39.3 1 5  40.833 
20 35.4 1 1 37.557 41 .982 45.603 
25 45.3 1 3  44.091 48.721 60 .408 
30 48.71 7  46.530 51 .923 63.254 
45 57.871 54.824 60.774 70.588 
60 63.738 64.538 71 .498 84.332 
% transferred: [%] mean SD 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
5 9.06 5.93 7.63 1 1 .01  8.41 2.1 6 
1 0  1 2.94 1 2 .76 14 .38 1 8 .38 1 4.61 2.62 
1 5  20.59 1 9 .95 2 1 .55 2 1 .22 20.83 0.71 
20 1 7.79 23.93 23 .02 23 .70 22. 1 1 2.91 
25 22.76 28. 1 0  26.71 3 1 .39 27.24 3.57 
30 24.47 29.65 28.47 32.87 28.87 3.47 
45 29.07 34.94 33.32 36.68 33.50 3.26 
60 32.02 41 . 1 3  39.20 43.83 39.04 5.05 
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Table A VII.27. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 0.2 mM DNP at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. IV.9 and IV. I O, Chapter 4). 
Amount delivered: 
Rat# 
2 1 3  2 1 6  248 249 
BW [9] 345 320 320 340 
Dl [).l9] 1 92.34 250.72 2 1 9.40 2 1 3.67 
Dctg [).l9] 9.36 2.26 8.73 1 .57 
Dcnl [).l9] 66.63 52.89 5 1 .05 45.85 mean SD 
Dad [).l9] 1 1 6.35 1 95.57 1 59.62 1 66.25 1 59.45 32.70 
Transferred amount: [).l9] 
Rat# 
2 1 3  2 1 6  248 249 
0 [min] 0.000 0.000 0.000 0.000 
5 3.236 9.756 9. 1 79 1 1 .287 
1 0  8.7 1 6  1 7.950 1 6.255 1 9.356 
1 5  1 4 .979 27.265 1 8 .840 28.354 
20 22.3 1 8  33.831 27.264 36.653 
25 30.475 35.028 28.770 38.8 1 9 
30 32.8 1 6  39.250 32 .4 1 8  43.081 
45 39.658 44.687 40.029 5 1 .3 1 5  
60 37.240 57.724 49.041 55.885 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0 .00 0.00 0.00 0.00 
5 2.78 4.99 5.75 6.79 5.08 1 .70 
1 0  7.49 9. 1 8  1 0 . 1 8  1 1 .64 9.62 1 .75 
1 5  1 2.87 1 3.94 1 1 .80 1 7.06 1 3.92 2.27 
20 1 9. 1 8  1 7.30 1 7 .08 22.05 1 8.90 2.30 
25 26. 1 9  1 7.91  1 8 .02 23.35 21 .37 4.1 0 
30 28.20 20.07 20.31 25.9 1 23.62 4.08 
45 34.09 22.85 25.08 30.87 28.22 5.1 7 
60 32 .01 29.52 30.72 33.62 31 .47 1 .76 
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Table AVII.2S. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 0.5 mM DNP at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. IV.9 and IV. 1 0, Chapter 4). 
Amount delivered: 
Rat# 
21 1 2 12  220 222 
BW [9] 355 325 325 330 
DL [1l9] 21 9.30 243.73 247.31 258.56 
Dctg [1l9] 2.25 2 .60 3.59 1 .5 1  
Denl [1l9] 53.70 48.24 62.08 46.62 mean SD 
Dad [1l9] 1 63.35 1 92.89 1 8 1 .64 2 1 0 .43 1 87.08 1 9 .76 
Transferred amount: [1l9] 
Rat# 
21 1 2 12  220 222 
0 [min] 0.000 0.000 0 .000 0 .000 
5 4 .249 7.8 17  8 . 140 1 6.588 
1 0  7.703 1 3.875 1 7.090 1 9 . 1 70 
1 5  1 2.087 1 9.268 23.035 31 .925 
20 13 .935 29.7 12  29.258 40.044 
25 1 1 .564 30.489 24.991 42.983 
30 1 9. 1 22 36.823 41 .078 44.007 
45 23.4 1 0  37.256 4 1 . 1 05 63. 1 28 
60 25.903 36.490 42.6 14  7 1 .871 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0 .00 0.00 0.00 0.00 
5 2.60 4.05 4 .48 7 .88 4.75 2.24 
1 0  4.72 7 . 19  9.41 9 . 1 1 7.61 2 .1 6 
1 5  7 .40 9.99 1 2 .68 1 5. 1 7  1 1 .31 3.36 
20 8.53 1 5.40 1 6. 1 1 1 9 .03 1 4.77 4.44 
25 7.08 1 5.81 1 3.76 20 .43 1 4.27 5.54 
30 1 1 .7 1  1 9.09 22.62 20.91 1 8.58 4.80 
45 1 4.33 1 9.31 22.63 30.00 21 .57 6.57 
60 1 5 .86 1 8.92 23.46 34. 1 5  23. 1 0  8.01 
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Table A VII.29. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 1 .0 mM DNP at 37 °C 
(FR71 50; nominal dose = 0.2 mg; used in Figs. IV.9, IV. l O  and IV. 1 7, Chapter 4). 
Amount delivered: 
Rat# 
209 2 1 0  2 1 7  2 1 8  
BW [9] 330 360 355 345 
DL [).19] 21 3.87 2 1 2.81 245.48 244.89 
Dctg [).19] 3.88 9.59 3.66 2 .68 
Dc", [).19] 52.95 38.57 46.21 34.79 mean SD 
Dad [).19] 1 57.04 1 64.65 1 95.61 207.42 1 8 1 . 1 8  24. 1 7  
Transferred amount: [).19] 
Rat# 
209 2 1 0  2 1 7  2 1 8  
0 [min] 0.000 0.000 0.000 0.000 
5 1 0.748 5.266 6 . 1 48 6 .980 
1 0  1 8 .41 7  8.555 14 .487 1 2.2 1 2  
1 5  2 1 .687 8.061 1 8.581 1 8.704 
20 22.030 1 '1 .240 22. 1 56 23.584 
25 28.957 14 .203 27.486 28.946 
30 33.803 1 4.924 35.268 33.795 
45 42.358 21 . 1 45 39.4 1 9  4 1 . 1 46 
60 43. 1 98 22.877 44.093 44.076 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 6.84 3 .20 3 . 14  3.37 4.1 4 1 .8 1  
1 0  1 1 .73 5.20 7.41 5.89 7.55 2.93 
1 5  1 3.81 4.90 9.50 9.02 9.31 3 .64 
20 1 4:03 6.83 1 1 .33 1 1 .37 1 0.89 2.99 
25 1 8.44 8.63 1 4.05 1 3.96 1 3.77 4.02 
30 21 .53 9 .06 1 8 .03 1 6.29 1 6 .23 5.25 
45 26 .97 1 2 .84 20 . 1 5  1 9.84 1 9.95 5.77 
60 27.51 1 3.89 22.54 2 1 .25 21 .30 5 . 63 
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Table AVlI.30. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 5 11M OUA at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. IV. I I  and IV. 12, Chapter 4). 
Amount delivered: 
Rat# 
223 226 230 231 
BW [g] 325 305 330 345 
DL [Ilg] 255.39 243.76 251 .84 257. 1 2  
Dctg [Ilg] 1 .29 4.79 30.30 3.87 
Dcnl [Ilg] 29.90 43.47 74.88 37.75 mean SD 
Dad [Ilg] 224.20 1 95.50 1 46.66 2 1 5.50 1 95.47 34.68 
Transferred amount: [Ilg] 
Rat# 
223 226 230 231 
0 [min] 0.000 0.000 0 .000 0.000 
5 1 1 .998 1 5.909 14 . 1 94 2 1 .401 
1 0  48.500 25.1 78 24.363 27.006 
1 5  58. 1 89 45.950 40.997 46.999 
20 87.321 63.483 46.365 55.021 
25 95.697 69.790 56 .445 55.584 
30 1 00.768 69.741  67.081 6 1 .240 
45 1 1 1 .978 84.805 68.779 63.978 
60 1 22.581 88.324 69.574 62.9 1 8  
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 5.35 8 . 1 4  9 .68 9.93 8.27 2 . 1 0 
1 0  2 1 .63 1 2 .88 1 6.61 1 2 .53 1 5.91 4.24 
1 5  25.95 23.50 27.95 2 1 .81  24.81 2.70 
20 38.95 32.47 3 1 .61 25.53 32.1 4 5.49 
25 42.68 35.70 38.49 25.79 35.67 7.1 8 
30 44.95 35.67 45.74 28.42 38.69 8 .23 
45 49.95 43.38 46.90 29.69 42.48 8.94 
60 54.67 45. 1 8  47.44 29.20 44. 1 2  1 0.74 
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Table A VII.31 .  Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 50 11M OUA at 37 °C 
(FR7 l 50; nominal dose = 0.2 mg; used in Figs. N. l l  and N.l2, Chapter 4) . 
Amount delivered: 
Rat# 
205 206 207 208 
BW [9] 370 350 350 350 
DL [119] 1 92.52 223.77 227.65 207.84 
Dctg [119] 1 .24 1 .68 3.43 6.53 
Dcnl [119] 30.68 38.70 32 .22 55.86 mean SD 
Dad [119] 1 60.60 1 83.39 1 92.00 1 45.45 1 70 .36 2 1 .24 
Transferred amount: [119] 
Rat# 
205 206 207 208 
0 [min] 0.000 0.000 0 .000 0.000 
5 5.471 6.791 6.651 0 .000 
1 0  7 .870 1 3 . 1 7 1  1 1 .901 4.341 
1 5  1 3 .396 19 .245 1 9.21 1 6 .473 
20 18 .639 20.6 1 2  22.7 14  8.405 
25 22.278 27.731 26.931 8 .845 
30 22.9 1 0  28.705 31 .796 1 0. 1 28 
45 28.850 45.7 1 8  38.339 1 0.739 
60 3 1 .586 45. 1 79 41 .440 1 5.531 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 3.41 3 .70 3.46 0.00 2.64 1 .77 
1 0  4.90 7 . 1 8 6.20 2.98 5.32 1 .8 1  
15  8.34 1 0 .49 1 0.01 4.45 8.32 2 .74 
20 1 1 .6 1  1 1 .24 1 1 .83 5.78 1 0.1 1 2.90 
25 1 3 .87 1 5 . 1 2  1 4.03 6.08 1 2.28 4.1 7 
30 14 .27 1 5.65 1 6 .56 6 .96 1 3.36 4.37 
45 1 7 .96 24.93 1 9 .97 7 .38 17 .56 7 .39 
60 1 9.67 24.64 2 1 .58 1 0 .68 1 9. 1 4  6.00 
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Table AVII.32. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 1 00 j.tM OUA at 37 °C 
(FR71 50;  nominal dose = 0.2 mg; used in Figs. IV.l I ,  IV. 1 2  and IV. 17 ,  Chapter 4). 
Amount delivered: 
Rat# 
201 202 203 204 
BW [g] 345 330 325 335 
Dl [fig] 263.08 264.61 271 .60 230.07 
Dctg [fig] 4.93 36.33 1 . 1 2  6.68 
Denl [fig] 44. 1 0  33.74 23.07 59.95 mean SD 
Dad [fig] 21 4.05 1 94.54 247.4 1 1 63.44 204.86 35.20 
Transferred amount: [fig] 
Rat# 
201 202 203 204 
0 [min] 0.000 0 .000 0 .000 0.000 
5 5 . 1 1 6  4 .632 7.255 9 . 1 45 
1 0  5 .557 7.9 17  7.7 1 0  1 2. 1 78 
1 5  9 .01 8 1 3 .521 1 7.676 1 4 .247 
20 6.300 1 2 .070 2 1 .91 9 1 9.363 
25 1 1 .493 1 3.536 2 1 .239 1 6.895 
30 1 0 .507 1 4 .881 24.270 21 .223 
45 1 3 .474 1 8 . 1 36 37.471 25.544 
60 1 0 .71 1 22.500 39. 1 26 26.787 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 2.39 2.38 2.93 5.60 3.32 1 .54 
1 0  2.60 4.07 3 . 1 2  7 .45 4.31 2.1 8 
1 5  4 .21  6 .95 7 . 14  8 .72 6.76 1 .87 
20 2.94 6 .20 8 .86 1 1 .85 7 .46 3.79 
25 5.37 6.96 8.58 1 0 .34 7.81 2.1 3 
30 4 .91  7.65 9 .81 1 2 .98 8.84 3.42 
45 6.29 9 .32 1 5. 1 5  1 5.63 1 1 .60 4.55 
60 5.00 1 1 .57 1 5.81  1 6 .39 1 2 . 1 9  5.25 
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Table A VII.33. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the absence ofMON at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. IV. 1 3 ,  IV. 1 5  and IV. 1 6, Chapter 4). 
Amount delivered: 
Rat# 
254 255 260 263 
BW [9] 3 1 0  3 1 0  360 330 
DL [Jl9] 242.72 243.74 251 .21 255.84 
Dctg [Jl9] 0.51 2.76 1 2.52 6 .47 
Den! [Jl9] 65.79 51 . 1 6  63. 1 2  1 00.63 mean SD 
Dad [Jl9] 1 76.42 1 89.82 1 75.57 1 48.74 1 72 .64 1 7 .22 
Transferred amount: [Jl9] 
Rat# 
254 255 260 263 
0 [min] 0.000 0.000 0.000 0 .000 
5 14 .855 1 8.881 9.685 7 . 1 87 
1 0  25.1 1 1  32.573 22.9 1 0  1 4.529 
1 5  38. 1 46 47.342 32.025 27.973 
20 50.381 55.087 37.335 42.4 1 7  
25 58.041 61 .226 49 .805 50. 1 35 
30 66.351 74 .6 1 9  53.993 56.080 
45 73.843 86.977 68. 1 78 66.921 
60 77.088 98.550 75.689 75.782 
90 90. 1 98 1 03.949 84.482 79.725 
1 20 94.563 1 1 0.377 92.854 87. 1 09 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 8.42 9.95 5.52 4 .83 7. 1 8  2.41 
1 0  1 4.23 1 7 . 1 6  1 3.05 9.77 1 3.55 3.06 
1 5  2 1 .62 24.94 18 .24 1 8.81 20.90 3.07 
20 28.56 29.02 2 1 .27 28 .52 26.84 3.72 
25 32.90 32.25 28.37 33.71 31 .81 2.37 
30 37.61 39.31 30.75 37.70 36.34 3.81 
45 41 .86 45.82 38.83 44.99 42.88 3.1 9 
60 43.70 51 .92 43. 1 1 50.95 47.42 4.66 
90 51 . 1 3  54 .76 48. 1 2  53.60 51 .90 2.94 
1 20 53.60 58. 1 5  52.89 58.56 55.80 2.97 
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Table A VlI.34. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of S !-1M MON at 37 °C 
(FR7 I SO;  nominal dose = 0.2 mg; used in Figs. IV. l 3  and IV. I S ,  Chapter 4). 
Amount delivered: 
Rat# 
261 265 266 267 
BW [9] 340 340 340 340 
OL [119] 230.85 237.24 233.27 233.47 
°ctg [).i9] 25.79 9.46 2.69 24.94 
Oro [119] 42.23 86.66 33. 1 5  60.34 mean SO 
Oad [1191 1 62.83 14 1 . 12  1 97.43 1 48. 1 9  1 62.39 25.05 
Transferred amount: [119] 
Rat# 
261 265 266 267 
0 [min] 0.000 0.000 0.000 0.000 
5 1 1 .583 4.991 2 1 .524 9. 1 88 
1 0  21 .797 1 4 .952 45.268 9 .850 
1 5  35.039 1 8 .756 64.288 26 .892 
20 41 .965 25.067 71 . 1 04 32. 1 94 
25 49.4 12  28.736 80.201 36.466 
30 52.966 32.388 87.954 36.666 
45 67.929 41 .450 95.522 39.504 
60 73.007 40.508 1 04 . 146 42.428 
90 80.490 45.736 1 1 3.320 51 .997 
120 83.314  54.279 1 23.728 54.844 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 7 . 1 1 3 .54 1 0 .90 6.20 6.94 3.05 
1 0  1 3.39 1 0 .60 22.93 6.65 1 3.39 6.93 
1 5  2 1 .52 1 3 .29 32.56 1 8. 1 5 21 .38 8 .1 8 
20 25.77 1 7 .76 36.01 2 1 .72 25.32 7.84 
25 30.35 20.36 40.62 24.61 28.98 8.77 
30 32.53 22.95 44.55 24.74 31 . 1 9  9.83 
45 4 1 .72 29.37 48.38 26.66 36.53 1 0.26 
60 44.84 28.70 52.75 28.63 38.73 1 2.06 
90 49.43 32 .41 57.40 35.09 43.58 1 1 .86 
120 51 . 1 7  38.46 62.67 37.01 47.33 1 2.04 
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Table A VII.35. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 10  �M MON at 37 °C 
(FR7 1 50; nominal dose = 0.2 mg; used in Figs. IV. 13  and IV. 15 ,  Chapter 4). 
Amount delivered: 
Rat# 
268 269 270 276 
BW [9] 340 340 340 380 
OL [1"9] 263.84 265.92 259.62 295.22 
°ctg [1"9] 4.23 26.57 5.47 0 .48 
Dcnl [1"9] 1 03.04 75.87 90.59 47.57 mean SO 
Dad [1"91 1 56.57 1 63.48 1 63.56 247. 1 7  1 82.70 43. 1 1 
Transferred amount: [1"9] 
Rat# 
268 269 270 276 
0 [min] 0.000 0.000 0 .000 0 .000 
5 4 .9 1 0  2.389 5.829 0 . 000 
1 0  1 1 .339 1 3.576 8.599 1 .206 
1 5  1 6 .803 1 7 .686 1 3 .490 23.878 
20 22.81 1 32 . 1 37 1 4.785 33.282 
25 27.348 33. 1 68 22.3 1 3  58.327 
30 30.427 40.096 31 .652 7 1 .371 
45 39.5 1 9  51 .896 32 .31 7 1 06.762 
60 56.856 66.538 42.281 1 42.935 
90 G9.204 7 1 .801 55.033 1 58.677 
1 20 83.003 82.629 60.876 1 72 .3 1 9  
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 3 . 1 4  1 .46 3.56 0.00 2.04 1 .63 
1 0  7.24 8.30 5.26 0 .49 5.32 3.46 
1 5  1 0.73 1 0.82 8.25 9 .66 9.86 1 .20 
20 1 4.57 . 1 9 .66 9.04 1 3.47 1 4.1 8 4.36 
25 1 7 .47 20.29 1 3.64 23.60 1 8.75 4.23 
30 1 9 .43 24.53 1 9.35 28.88 23.05 4.58 
45 25.24 3 1 .74 1 9.76 43. 1 9  29.98 1 0.08 
60 36.31 40.70 25.85 57.83 40. 1 7  1 3.32 
90 44.20 43.92 33.65 64.20 46.49 1 2 .78 
1 20 53.01 50.54 37.22 69.72 52.62 1 3.34 
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Table A VII.36. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 30 J-lM MON at 37 °C 
(FR71 50; nominal dose = 0.2 mg; used in Figs. N.13,  N. 1 5  and N. 1 7, Chapter 4). 
Amount delivered: 
Rat# 
240 241 242 243 
BW [g] 3 1 0  3 1 0  330 325 
DL !Jlg] 240.99 2 1 4.37 265.98 239.96 
Dctg [�g] 2 .02 1 .93 1 7.04 8 . 1 8 
DcnI [�gl 69. 1 6  64.25 82.99 80.31 mean SD 
Dad r�gl 1 69.81 1 48 . 1 9  1 65.95 1 5 1 .47 1 58.86 1 0.62 
Transferred amount: [�g] 
Rat# 
240 24 1 242 243 
0 [min] 0.000 0.000 0.000 0.000 
5 4.762 7.794 5. 1 39 2 .599 
1 0  1 1 .484 1 2.530 8.804 4 .460 
1 5  25.350 25.806 1 4 .397 7 .469 
20 25.629 29.542 1 4 .707 9 .496 
25 30 .274 29.349 1 9 . 1 73 1 1 .896 
30 30.356 36.503 2 1 .4 1 4  1 1 .592 
45 4 1 .389 43.704 26.544 1 5. 542 
60 42.870 45.671 27.659 1 7.799 
90 48.476 5 1 .277 33.723 2 1 . 1 95 
1 20 53.768 57.283 36.447 23.465 
% transferred: [%] mean SD 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
5 2.80 5.26 3 . 1 0  1 .72 3.22 1 .48 
1 0  6.76 8 .46 5.31 2 .94 5.87 2.34 
1 5  1 4.93 1 7.41 8.68 4.93 1 1 .49 5.71 
20 1 5.09 1 9.94 8.86 6.27 1 2.54 6.1 7 
25 1 7.83 1 9.80 1 1 .55 7.85 1 4.26 �.�3 
30 1 7.88 24.63 1 2.90 7.65 1 5.77 7.24 
45 24.37 29.49 1 6.00 1 0.26 20.03 8.57 
60 25.25 30.82 1 6.67 1 1 .75 2 1 . 1 2  8.54 
90 28.55 34.60 20.32 1 3.99 24.37 9.06 
1 20 3 1 .66 38.66 2 1 .96 1 5.49 26.94 1 0.25 
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Table A VII.37. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 100 JlM MON at 37 °C 
(FR71 S0; nominal dose = 0.2 mg; used in Figs. IV. l 3  and IV. I S ,  Chapter 4). 
Amount delivered: 
Rat# 
257 258 259 262 
BW [9] 365 365 365 340 
Dl [119] 223.35 2 1 3.62 230. 1 1 225.72 
Dctg 1Il9] 0.66 1 8. 1 2  8 .48 3.76 
Den! 1Il9] 74 .95 62.55 77.41 77. 1 4  mean SD 
Dad [119] 1 47.74 1 32.95 1 44 .22 1 44.82 1 42 .43 6 .51  
Transferred amount: [119] 
Rat# 
257 258 259 262 
0 [min] 0.000 0.000 0.000 0.000 
5 1 .608 1 .608 5.250 4.850 
1 0  6.771 9.621 6 .858 1 2.093 
1 5  7.61 1 8 .866 1 2. 1 75 1 5.067 
20 1 1 .023 1 1 .363 1 3. 3 1 2  22 .550 
25 1 1 .986 1 3.591 1 5.623 33.527 
30 1 4 . 1 1 3  1 5. 1 45 1 8 . 1 59 26.035 
45 1 6.384 1 9.795 1 8 .672 32.079 
60 1 7.268 23.574 20 .600 35.545 
90 2 1 .306 25.088 25.462 45.052 
1 20 22.0 1 6  32.958 26 .489 48.853 
% transferred: [%] mean SD 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
5 1 .09 1 .2 1  3 .64 3.35 2.32 1 .36 
1 0  4.58 7.24 4 .76 8.35 6.23 1 .86 
1 5  5 . 1 5 6.67 8 .44 1 0.40 7.67 2.27 
20 7.46 8 .55 9 .23 1 5.57 1 0.20 3.65 
25 8 . 1 1 1 0 .22 1 0.83 23 . 1 5  1 3.08 6.81 
30 9.55 1 1 .39 1 2.59 1 7 .98 1 2.88 3.62 
45 1 1 .09 1 4.89 1 2.95 22. 1 5  1 5.27 4.84 
60 1 1 .69 1 7.73 1 4 .28 24 .54 1 7.06 5.57 
90 1 4 .42 1 8.87 1 7.65 3 1 . 1 1 20.51 7.31 
1 20 1 4 .90 24.79 1 8.37 33.73 22.95 8.28 
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Table AVII.38. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the absence ofNOC at 37 °C (FR71 50;  
nominal dose = 0.2 mg; used in Figs. N.14, N. l 5  and N. 16, Chapter 4). 
Amount delivered: 
Rat# 
294 295 296 297 
BW [g] 380 380 375 375 
DL [Ilg] 1 90.2 1 1 95.58 3 15 . 12  3 1 9.41 
Dctg [Ilg] 3.35 2.51 6.82 3.28 
DcnI [Ilg] 65.87 68.33 69.92 62.99 mean SD 
Dad [Ilg] 1 20.99 1 24.74 238.38 253. 1 4  1 84.31 7 1 .23 
Transferred amount: [Ilg] 
Rat# 
294 295 296 297 
0 [min] 0.000 0.000 0.000 0.000 
5 1 8.980 1 9.61 9  27.484 34.086 
1 0  28.3 1 9  27.525 61 .209 72 .267 
1 5  36.386 41 . 1 55 71 .450 85.501 
20 37.420 51 .771 87.359 90.091 
25 47.264 55. 1 06 99.951 1 0 1 .752 
30 48.894 61 .705 1 1 3.41 1 1 07.31 5 
45 61 .507 73.398 1 24 .436 1 33.724 
60 72.806 76.550 1 37 . 134 1 52.696 
90 73.755 78.082 14 1 .484 1 49 .479 
1 20 74.495 79.771 1 47.768 1 38 .822 
% transferred: [%J mean SD 
o [min] 0.00 0.00 0.00 0.00 0 .00 0.00 
5 1 5.69 15 .73 1 1 .53 1 3 .47 1 4. 1 0  2.01 
1 0  23.41 22.07 25.68 28.55 24.92 2.84 
1 5  30.07 32.99 29.97 33.78 31 .70 1 .97 
20 30.93 41 .50 36.65 35.59 36. 1 7  4.34 
25 39.06 44. 1 8  41 .93 40.20 41 .34 2.23 
30 40.41 49.47 47.58 42.39 44.96 4.26 
45 50.84 58.84 52.20 52.83 53.68 3.54 
60 60. 1 8  61 .37 57.53 60.32 59.85 1 .64 
90 60.96 62.60 59.35 59.05 60.49 1 .64 
120 61 .57 63.95 61 .99 54.84 60.59 3.97 
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Table AVII.39. Dose, and amount and % of administered dose of7 .4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 0.5 JlM NOC at 37 °C 
(FR7 I SO ;  nominal dose = 0.2 mg; used in Figs. IV.l4 and IV. I S ,  Chapter 4). 
Amount delivered: 
Rat# 
3 18  3 1 9  320 321 
BW [9] 390 375 360 370 
DL [119] 229.40 248.43 255.08 262.73 
Dctg [119] 2.30 0.00 1 .63 5 . 1 1 
DcnI [119] 78.93 47.47 79.05 6 1 .92 mean SD 
Dad rl191 1 48. 1 7  200.96 1 74.40 1 95.71 1 79.81 24.02 
Transferred amount: [119] 
Rat# 
3 18  3 1 9  320 321 
0 [min] 0.000 0.000 0 .000 0.000 
5 14 .538 14 . 147 1 3.534 1 3 .570 
1 0  29.438 35.895 24.422 24.233 
1 5  50.449 42.588 36.755 37.651 
20 59.820 7 1 .341 47.425 46.624 
25 63.495 79.356 6 1 . 1 37 53.672 
30 67.335 8 1 .522 66.959 62.699 
45 70.790 86 .220 69. 1 47 68.242 
60 78.255 88.996 76.828 78.536 
90 82 . 1 03 98.622 77.824 83.51 1 
1 20 86.7 1 6  1 00.8 12  83.630 86.872 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0 .00 0.00 0.00 0.00 
5 9.81 7 .04 7.76 6.93 7.89 1 .34 
1 0  19 .87 1 7 .86 1 4 .00 1 2 .38 1 6.03 3.44 
1 5  34 .05 2 1 . 1 9  2 1 .08 1 9 .24 23.89 6.83 
20 40.37 35.50 27. 1 9  23.82 31 .72 7.57 
25 42.85 39 .49 35 .06 27.42 36.21 6.67 
30 45.44 40.57 38.39 32.04 39.1 1 5.56 
45 47.78 42.90 39.65 34.87 41 .30 5.43 
60 52.81 44.29 44.05 40. 1 3  45.32 5.35 
90 55.41 49.08 44.62 42.67 47.95 5.65 
1 20 58.53 50. 1 7  47.95 44.39 50.26 6.00 
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Table A VII.40. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 1 .0 IlM NOC at 37 DC 
(FR7 1 S0; nominal dose = 0.2 mg; used in Figs. IV.l4  and IV.lS ,  Chapter 4). 
Amount delivered: 
Rat# 
3 14  31 5 3 1 6  3 1 7  
BW [9) 360 380 370 385 
DL [J.l9) 289.09 288.92 260.85 255.55 
Dctg [J.l9) 1 .48 5.21 0.00 1 .09 
Dro [J.l9) 73. 1 6  55.50 38.92 69.27 mean SD 
Dad [J.l9) 21 4.45 228.21 221 .93 1 85 . 19  2 1 2 .45 1 9.02 
Transferred amount: [J.l9) 
Rat# 
314  31 5 3 16  3 1 7  
0 [min) 0.000 0 .000 0.000 0.000 
5 6.828 5.51 1 8.267 1 1 .497 
1 0  12 .651 1 2.342 1 2 .354 22.7 1 5  
1 5  23.71 1 23.233 25.028 26.099 
20 35.660 35.546 35.868 31 .036 
25 48.774 47.91 5 47.636 43 .439 
30 51 .872 52.274 53.302 47 .069 
45 60.7 12  59.296 60.381 51 .744 
60 66.688 64.908 65.562 51 .9 1 6  
90 78.269 79.071 81 .836 63.979 
1 20 77.350 79.898 83.533 67.677 
% transferred: [%) mean SD 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
5 3 . 1 8  2.41 3.73 6.21 3.88 1 .64 
1 0  5.90 5.41 5.57 1 2 .27 7.28 3.33 
1 5  1 1 .06 1 0. 1 8  1 1 .28 1 4.09 1 1 .65 1 .69 
20 1 6.63 1 5.58 1 6 . 1 6  1 6.76 1 6.28 0.54 
25 22.74 2 1 .00 2 1 .46 23.46 22.1 7 1 . 1 3  
30 24. 1 9  22.91 24.02 25.42 24.1 3 1 .03 
45 28.31 25.98 27.21 27.94 27.36 1 .0 3  
60 31 . 1 0  28 .44 29.54 28.03 29.28 1 .37 
90 36.50 34.65 36.87 34.55 35.64 1 .22 
120 36.07 35.01 37.64 36.54 36.32 1 .09 
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Table AVII.41. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 1 0  JlM NOC at 37 °C 
(FR7 I 50; nominal dose = 0.2 mg; used in Figs. IV. 14  and IV. I 5 ,  Chapter 4). 
Amount delivered: 
Rat# 
3 10  3 1 1 3 12  3 1 3  
BW [9] 360 380 380 370 
DL [119] 204.71 1 96.95 278.59 341 .73 
Dctg [119] 2.57 3 .06 5.34 4.67 
DcnJ [119] 58. 1 5  70.57 97.62 1 33.04 mean SO 
Dad [1191 1 43.99 1 23.32 1 75.63 204.02 1 6 1 .74 35.46 
Transferred amount: [119] 
Rat# 
3 1 0  31 1 3 12  3 13  
0 [min] 0.000 0.000 0.000 0.000 
5 0.000 0 .000 6.744 2 .966 
1 0  6.669 2 .572 6.703 6 .379 
1 5  1 1 .598 6.622 9.059 1 3 . 1 9 1  
20 1 5.790 8 .372 16 .472 1 3 .276 
25 2 1 .843 1 5 . 1 88 13 .436 20.1 83 
30 20.381 1 4.920 20. 1 86 23.936 
45 30.920 1 8.61 7 28.899 25.8 1 2  
60 31 .312 1 8 .9 1 7  29.240 24.384 
90 39.533 27 .667 41 .286 35.81 4  
1 20 49.081 26.746 42.805 41 .981 
% transferred: [%] mean SO 
o [min] 0.00 0,00 0.00 0.00 0.00 0.00 
5 0 .00 0 ,00 3 .84 1 .45 1 .32 1 .81  
1 0  4 .63 2 ,09 3.82 3 . 1 3  3.42 1 .08 
1 5  8.05 5 ,37 5. 1 6  6.47 6.26 1 .33 
20 1 0.97 6.79 9.38 6.51 B.41 2 .1 4 
25 1 5. 1 7  1 2 .32 7.65 9.89 1 1 .26 3.23 
30 14 . 1 5  1 2 . 1 0  1 1 .49 1 1 .73 1 2.37 1 .22 
45 21 .47 1 5. 1 0  1 6.45 1 2.65 1 6.42 3.72 
60 21 .75 1 5.34 1 6.65 1 1 .95 1 6.42 4.06 
90 27 .46 22.44 23.51 1 7 ,55 22.74 4.07 
1 20 34.09 2 1 .69 24.37 20.58 25. 1 8  6.1 5 
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Table A VII.42. Dose, and amount and % of administered dose of 7.4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 30 IlM NOC at 37 °C 
(FR7 l S0; nominal dose = 0.2 mg; used in Figs. N.14, N. l S  and N. 1 7, Chapter 4). 
Amount delivered: 
Rat# 
290 291 292 293 
BW [9] 330 335 335 330 
DL [119] 268.03 275.86 226.06 225.82 
Dctg [119] 1 .93 1 .82 5.77 1 2 .05 
Den! [119] 70.03 68.50 85.84 57.52 mean SO 
Dad [1191 1 96.07 205.54 1 34.45 1 56.25 1 73.08 33.46 
Transferred amount: [119] 
Rat# 
290 291 292 293 
0 [min] 0.000 0.000 0.000 0.000 
5 1 .946 4 .706 3.802 1 .078 
1 0  8 .000 5.91 1 6.777 4 . 1 58 
1 5  8 . 120 1 0.660 1 0.562 7.527 
20 12 .657 14 .692 1 3.425 9 .946 
25 1 7.251 1 9 .437 1 2 .693 1 3.426 
30 1 7.920 25.435 20.063 1 4 . 1 38 
45 20.770 34 .491 20.374 1 6 .441 
60 21 .223 44.6 1 9  24.985 25.024 
90 27.939 49 .327 28.975 25.889 
1 20 29. 1 45 52.987 37.005 27.035 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0 .00 0.00 0.00 
5 0.99 2 .29 2.83 0.69 1 .70 1 .02 
1 0  4.08 2 .88 5.04 2 .66 3.66 1 .1 1  
1 5  4 . 14  5 . 1 9 7.86 4.82 5.50 1 .63 
20 6.46 7 . 1 5 9.99 6.37 7.49 1 .70 
25 8.80 9 .46 9 .44 8.59 9.07 0.44 
30 9 . 14  1 2 .37 1 4.92 9.05 1 1 .37 2.83 
45 1 0.59 1 6 .78 1 5. 1 5  1 0.52 1 3.26 3.1 9 
60 1 0.82 2 1 .71 1 8 .58 1 6 .02 1 6.78 4.60 
90 1 4.25 24.00 2 1 .55 1 6.57 1 9.09 4.47 
1 20 1 4 .86 25.78 27.52 1 7 .30 21 .37 6.22 
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Table AVII.43. Dose, and amount and % of administered dose of 7 .4 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL in the presence of 1 00 11M NOC at 37 °C 
(FR71 50; nominal dose = 0.2 mg; used in Figs . IV.14 and IV.1 5 ,  Chapter 4). 
Amount delivered: 
Rat# 
302 303 304 305 
BW [g] 340 370 370 330 
DL [Ilg] 295.34 305.93 3 1 1 .43 280.24 
Dctg [Ilg] 3.01 9.08 3.53 1 .02 
Denl [Ilg) 44.49 72.32 76.87 94. 1 3  mean SD 
Dad [figJ 247.84 224.53 231 .03 1 85.09 222 . 12  26.57 
Transferred amount: [Ilg] 
Rat# 
302 303 304 305 
0 [min] 0.000 0 .000 0.000 0.000 
5 6.622 1 .304 1 . 1 1 6  0.986 
1 0  1 7.606 8.607 3.576 4 .275 
1 5  22.076 1 3 .639 4.257 9 .887 
20 29.472 1 8 .687 1 0.391 1 2.567 
25 34.331 21 . 9 17  1 3 .475 1 5.975 
30 41 .398 23.561 1 6.389 1 7. 1 49 
45 54.296 31 .626 21 .365 1 9 .988 
60 60.249 31 .342 25.673 26.094 
90 69.548 38.928 30.534 30.082 
1 20 74.394 40.543 28.278 35.831 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 2.67 0 .58 0.48 0.53 1 .07 1 .07 
1 0  7 . 1 0  3.83 1 .55 2.31 3.70 2.46 
1 5  8.91 6 .07 1 .84 5.34 5.54 2.91 
20 1 1 .89 8 .32 4.50 6.79 7.88 3.1 0 
25 1 3.85 9.76 5.83 8.63 9.52 3.33 
30 1 6 .70 1 0.49 7.09 9.27 1 0.89 4.1 2 
45 21 .91 1 4 .09 9.25 1 0 .80 1 4.01 5 .64 
60 24.31 1 3 .96 1 1 . 1 1  1 4 . 1 0  1 5.87 5.79 
90 28.06 1 7 .34 1 3 .22 1 6 .25 1 8.72 6.47 
1 20 30.02 1 8 .06 12 .24 1 9 .36 1 9.92 7.41 
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Table A VII.44. Dose, and amount and % of administered dose of 4.3 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C (FR7002-5 ; nominal dose = 0. 1 
mg; used in Figs. V.2 and V.4, Chapter 4). 
Amount delivered: 
Rat# 
97 98 99 1 00 
BW [g] 282 283 284 287 
DL [!lg] 1 28 .02 1 30.25 1 24 .94 1 65.57 
Ddg [!lg] 1 .53 0.34 1 .75. 1 .25 
Deli [!lg] 24.20 43.45 32.86 41 .08 mean SD 
Dad [!lgl 1 02.29 86 .46 90.33 1 23.24 1 00.58 1 6 .54 
Transferred amount: [!lg] 
Rat# 
97 98 99 1 00 
0 [min] 0.000 0.000 0 .000 0.000 
5 1 8 .509 3.727 14 .379 1 7 . 1 04 
1 0  32.301 9 .898 29.1 93 37.029 
1 5  47.829 1 9 .006 38.800 48.900 
20 56.582 26.390 48 .470 55.686 
25 60.689 31 .748 49.866 66.796 
30 64. 1 53 37.932 50.226 68.773 
45 65.761 43.071 48.6 1 8  75.282 
60 68.230 49.862 55.554 78.524 
90 "12 . 1 56 50.345 58.521 84.868 
1 20 73.461 53.005 60.481 86.331 
1 50 73 .444 57.626 62 .250 83.968 
1 80 73.324 56.006 63.404 85.250 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 1 8.09 4.31 1 5.92 1 3 .88 1 3.05 6.08 
1 0  3 1 .58 1 1 .45 32.32 30.05 26.35 9.98 
1 5  46.76 2 1 .98 42.95 39.68 37.84 1 0.96 
20 55.32 30.52 53.66 45. 1 9  46. 1 7  1 1 .34 
25 59.33 36.72 55.20 54 .20 51 .36 1 0.01 
30 62.72 43.87 55.60 55.80 54.50 7.82 
45 64.29 49.82 53.82 6 1 .09 57.25 6.61 
60 66.70 57.67 6 1 .50 63.72 62.40 3.80 
90 70.54 58.23 64.79 68.86 65.60 5.48 
1 20 71 .82 6 1 .31  66.96 70.05 67.53 4.61 
1 50 71 .80 66.65 68.91 68. 1 3  68.87 2. 1 6  
1 80 7 1 .68 64.78 70. 1 9  69. 1 7  68.96 2.97 
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Table A VII.45. Dose, and amount and % of administered dose of 4.3 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C (FR7002-5; nominal dose = 0.2 
mg; used in Fig. V.2, Chapter 4). 
Amount delivered: 
Rat# 
256 264 271 277 
BW [9] 325 340 350 360 
DL [1l9] 224.54 283.54 270.57 256.43 
Dctg [1l9] 3.35 5.91 1 .02 5.61 
Dc,; [1l9] 3 .22 75.98 71 .66 61 .72 mean SD 
Dad [1l91 21 7.97 201 .65 1 97.89 1 89. 1 0  201 .65 1 2 .08 
Transferred amount: [1l9] 
Rat# 
256 264 271 277 
0 [min] 0.000 0 .000 0.000 0 .000 
5 36. 1 6 1  29.554 22.582 35.226 
1 0  56.0 1 3  46. 1 53 44.9 1 1 48.635 
1 5  69.321 60.476 54.763 56.090 
20 95. 1 92 76.007 66.485 66.699 
25 1 1 2 .665 83.939 73.7 1 0  77.488 
30 1 1 7.772 94.938 78. 1 93 9 1 .056 
45 1 30 . 124 1 1 2.765 88 .882 1 0 1 .51 8 
60 145.375 1 1 9.862 89.736 1 06.325 
90 1 48.051 1 24.2 1 5  1 1 0 .794 1 1 3 .400 
1 20 1 56.7 1 9  1 3 1 . 1 72 1 20.777 1 1 8.781 
1 50 1 56.887 1 39.4 1 3  1 25.974 1 24.495 
1 80 1 57.583 140.664 144.435 1 33.301 
% transferred: [%] mean SD 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
5 1 6 .59 14 .66 1 1 .4 1  1 8 .63 1 5.32 3.07 
1 0  25.70 22.89 22.69 25.72 24.25 1 .69 
1 5  3 1 .80 29.99 27.67 29.66 29.78 1 .69 
20 43.67 37.69 33.60 35.27 37.56 4.41 
25 51 .69 41 .63 37.25 40.98 42.88 6. 1 8  
30 54.03 47.08 39.51 48. 1 5  47. 1 9  5.96 
45 59.70 55.92 44.91 53.68 53.55 6.27 
60 66.69 59.44 45.35 56.23 56.93 8.88 
90 67.92 61 .60 55.99 59.97 61 .37 4.96 
1 20 71 .90 65.05 61 .03 62.81 65.20 4.76 
1 50 71 .98 69. 1 4  63.66 65.84 67.65 3.66 
1 80 72.30 69.76 72.99 70.49 71 .38 1 .51 
3 1 0  
Table A VII.46. Dose, and amount and % of administered dose of  4 . 3  kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 37 °C (FR7002-5 ; nominal dose = 1 .0 
mg; used in Figs. V.2 and V.4, Chapter 4). 
Amount delivered: 
Rat# 
1 88 1 89 1 90 1 91 
BW [g] 350 365 345 345 
DL [�g] 1 083.94 1 1 33 . 14  1 093.49 1 1 39 .29 
Dctg [�g] 0.80 36.38 41 . 1 7  2 1 .76 
Den! [�g] 251 .28 467.51 50.07 42.33 mean SD 
Dad [�gl 831 .86 629.25 1 002.25 1 075.20 884.64 1 98.46 
Transferred amount: [�g] 
Rat# 
1 88 1 89 1 90 1 9 1  
0 [min] 0.000 0.000 0.000 0 .000 
5 78.888 29.964 1 30 .369 52.779 
1 0  1 55. 1 2 1  70.537 270.782 1 38 .935 
1 5  21 1 .261 1 08 . 1 90 326.644 1 93.632 
20 250.761 1 23.052 347.553 255.627 
25 277.972 1 37.654 423.464 283.645 
30 31 1 .987 1 6 1 .425 4 10 .3 13  320.606 
45 331 .744 1 89.480 472.267 357.346 
60 371 .982 202 .460 501 .964 4 1 5 . 1 40 
90 428.084 231 .7 12  544.230 467.286 
1 20 443. 1 1 5  257. 1 72 557.534 533.298 
1 50 458.076 249.526 565.926 583.208 
1 80 442.730 251 .382 627.268 691 .795 
% transferred: [%] mean SD 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
5 9.48 4 .76 1 3.01 4 .91  8.04 3.97 
1 0  1 8.65 1 1 .2 1  27.02 1 2 .92 1 7.45 7.1 3 
1 5  25.40 1 7. 1 9  32.59 1 8.01 23.30 7.21 
20 30. 1 4  1 9.56 34.68 23.77 27.04 6.70 
25 33.42 2 1 .88 42.25 26.38 30.98 8.89 
30 37.50 25.65 40.94 29.82 33.48 6.99 
45 39 .88 30. 1 1 47. 1 2  33.24 37.59 7.55 
60 44.72 32. 1 7  50.08 38.61 41 .40 7.73 
90 51 .46 36.82 54 .30 43.46 46.51 7.92 
1 20 53.27 40 .87 55.63 49.60 49.84 6.48 
1 50 55.07 39.65 56.47 54.24 51 .36 7.86 
1 80 53.22 39.95 62.59 64.34 55.02 1 1 .1 7  
3 1 1  
Table A VII.47. Dose, and amount and % o f  administered dose o f  4.3 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C (FR7002-5 ; nominal dose = 0. 1 
mg; used in Fig. V.3, Chapter 4). 
Amount delivered: 
Rat# 
285 286 288 289 
BW [g] 320 320 330 330 
DL [)ig] 1 30.44 1 33.09 1 52.52 1 53.95 
Dctg [Ilg] 1 .23 0.58 3.99 1 .60 
Denl [1l9] 23.83 31 .49 34 .37 48. 1 3  mean SD 
Dad [1l91 1 05.38 1 01 .02 1 1 4 . 1 6 1 04 .22 1 06.20 5.62 
Transferred amount: [Ilg] 
Rat# 
285 286 288 289 
0 [min] 0.000 0.000 0.000 0 .000 
5 1 .825 0.901 3.257 3 .073 
1 0  6.081 4.494 8 . 1 36 7 .982 
1 5  9 . 146 9.965 1 8.988 1 8.528 
20 1 3.488 14 .402 22. 1 1 7  22 .232 
25 1 6 .922 1 6.719 27.074 28.050 
30 21 .788 20.227 31 .023 31 .477 
45 1 9 .596 28.271 40.9 1 9  37.0 1 6  
60 28 .694 33.996 45.550 42.659 
90 38.537 40.050 48.576 48.91 1 
1 20 39.840 43.998 49.280 50.697 
1 50 42.781 48.684 52.562 51 .702 
1 80 38.505 49.092 55.007 51 .812 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 1 .73 0.89 2.85 2 .95 2.1 1 0.98 
1 0  5.77 4 .45 7 . 13  7.66 6.25 1 .44 
1 5  8.68 9.86 1 6.63 1 7.78 1 3.24 4.63 
20 1 2 .80 14 .26 1 9.37 2 1 .33 1 6.94 4.06 
25 1 6.06 1 6 .55 23.72 26.91 20.81 5.37 
30 20.68 20.02 27. 1 8  30.20 24.52 4.98 
45 1 8.60 27.99 35.84 35.52 29.49 8.1 2 
60 27.23 33.65 39.90 40.93 35.43 6.34 
90 36.57 39.65 42.55 46 .93 41 .42 4.41 
120 37.81 43.55 43. 1 7  48.64 43.29 4.43 
1 50 40.60 48. 1 9  46.04 49.61 46. 1 1  3.96 
1 80 36.54 48.60 48. 1 8  49.71 45.76 6.1 8 
3 12 
Table A VII.48. Dose, and amount and % of administered dose of 4.3 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C (FR7002-5 ; nominal dose = 0.2 
mg; used in Fig. V.3, Chapter 4). 
Amount delivered: 
Rat# 
278 279 280 281 
BW [g] 360 320 320 320 
Dl [J.1g] 263.99 264.50 270.62 243.28 
Dctg [).ig] 0.39 0.95 1 .30 2.94 
Dcn! [J.1g] 45.54 48.06 66.08 3.30 mean SD 
Dad [J.1g1 21 8.06 21 5.49 203.24 237.04 21 8 .46 1 3.97 
Transferred amount: [J.1g] 
Rat# 
278 279 280 281 
0 [min] 0.000 0.000 0.000 0 .000 
5 3.357 5.808 7 .693 6 .289 
1 0  8.562 1 5.201 1 8.304 1 5.01 6 
1 5  1 8 . 1 83 22.675 34.468 2 1 .978 
20 24.355 33.9 1 9  39.8 1 1 29.826 
25 28.649 40.264 46.6 1 6  34.923 
30 32 .069 44.580 52.090 45.598 
45 48.584 58.71 8  63.431 55.834 
60 51 .968 71 .476 72.682 59.289 
90 64. 12 1  83.631 89.064 73.755 
1 20 70.630 95.656 88.684 73.978 
1 50 8 1 .007 97.002 89.1 32 79.521 
1 80 86.009 99.885 9 1 . 1 20 86.1 99 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0 .00 0.00 0.00 
5 1 .54 2 .70 3.79 2 .65 2.67 0.92 
1 0  3.93 7.05 9.01 6 .33 6.58 2.1 0 
1 5  8.34 1 0 .52 1 6 .96 9 .27 1 1 .27 3.89 
20 1 1 . 1 7  1 5.74 1 9 .59 1 2 .58 1 4.77 3.74 
25 1 3 . 1 4  1 8.68 22.94 1 4.73 1 7 .37 4.38 
30 1 4.71 20.69 25.63 1 9 .24 20.07 4.50 
45 22.28 27.25 3 1 .21 23.55 26.07 4.02 
60 23.83 33. 1 7  35.76 25.01 29.44 5.91 
90 29.41 38.81 43.82 3 1 . 1 2  35.79 6.74 
1 20 32.39 44.39 43.64 31 .21 37.91 7.07 
1 50 37. 1 5  45.01 43.86 33.55 39.89 5.47 
1 80 39.44 46.35 44.83 36.36 41 .75 4.66 
3 1 3  
Table AVII.49. Dose, and amount and % of  administered dose of4.3 kDa F-PHEA 
absorbed from airways to perfusate in the IPRL at 25 °C (FR7002-5 ; nominal dose = 1 .0 
mg; used in Fig. V.3, Chapter 4). 
Amount delivered: 
Rat# 
1 84 1 85 1 86 1 87 
BW [9] 330 330 3 1 0  365 
DL [J.l9] 1 056.99 1 1 1 8 .89 1 1 35.40 1 084. 1 0  
Dctg [J.l9] 8.56 1 4.85 1 2.85 93.47 
DcnI [J.l9] 1 99.71 246.39 264.86 75.36 mean SO 
Dad IJ.l9] 848.72 857.65 857.69 9 1 5.27 869.83 30.58 
Transferred amount: [J.l9] 
Rat# 
1 84 1 85 1 86 1 87 
0 [min] 0.000 0.000 0 .000 0 . 000 
5 7 .484 1 3.394 9.486 7.658 
1 0  26.263 36.409 30.554 29 .840 
1 5  58.1 1 9  58.693 56.509 48.387 
20 88.833 8 1 .750 63.398 7 1 . 1 76 
25 1 1 2.81 3 98.7 1 5 76.587 90.993 
30 1 37.505 1 1 5.425 84. 8 1 8  1 1 1 . 543 
45 1 99.207 1 65. 1 53 1 22 .678 1 49 . 532 
60 248 .901 1 8 1 .707 1 56. 1 1 5  1 92.091 
90 322.247 238.437 1 98.307 234.359 
1 20 327. 1 40 241 .943 230 .448 245.866 
1 50 384.336 271 .826 249. 1 04 265.883 
1 80 408.294 366.262 256.938 260 . 5 1 3 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0 . 00 0.00 0.00 
5 0.88 1 .56 1 . 1 1  0 . 84 1 . 1 0  0.33 
1 0  3.09 4.25 3 .56 3.26 3.54 0.51 
1 5  6.85 6 .84 6.59 5 .29 6.39 0.75 
20 1 0.47 9 .53 7.39 7 . 78 8.79 1 .45 
25 1 3 .29 1 1 .51  8 .93 9.94 1 0.92 1 .9 1  
3 0  1 6.20 1 3.46 9.89 1 2 . 1 9  1 2.93 2.63 
45 23.47 1 9.26 1 4 .30 1 6 .34 1 8.34 3.98 
60 29.33 2 1 . 1 9  1 8 .20 20.99 22.43 4.80 
90 37.97 27.80 23 . 1 2  25.61 28.62 6.52 
1 20 38.55 28.21 26.87 26.86 30. 1 2  5.65 
1 50 45.28 3 1 .69 29.04 29.05 33.77 7.78 
1 80 48 . 1 1 42 .71  29.96 28 .46 37.31 9.63 
3 1 4  
Table A VII.SO. Dose, and amount and % of  administered dose of  4 04  kDa FD-4 
absorbed from airways to perfusate in the IPRL at 37 °C (nominal dose = 0.1  mg; used in 
Figs. III .6 and III. 1 1, Chapter 3 and Fig. VA, Chapter 5). 
Amount delivered: 
Rat# 
FD4-1 FD4-2 FD4-3 FD4-4 
BW [g] 340 3 1 0  329 325 
DL [�g] 1 00.67 1 05.03 1 02.21 1 09.37 
Dctg [�g] 1 .77 4 . 1 5  2 .88 1 .70 
DcnJ [�g] 3 1 .36 3.75 1 5.41 1 4.26 mean SD 
Dad l�gl 67.54 97. 1 4  83.92 93.41 85.50 1 3. 2 1  
Transferred amount: [�g] 
Rat# 
FD4-1 FD4-2 FD4-3 FD4-4 
0 [min] 0.000 0.000 0.000 0.000 
5 1 .763 1 1 .439 6 .697 5 . 1 1 0  
1 0  4.074 2 1 .2 1 2  1 4 .334 9 .892 
1 5  7.335 24.660 23.682 9.360 
20 8.942 · 30.580 24.930 1 2 .461 
25 1 1 .435 32.4 1 2  29.401 1 6.384 
30 1 5.992 3 1 .280 26.6 1 2  20.401 
45 1 5 .776 34.495 30.877 1 5.366 
60 1 5.437 38.378 33.498 1 8.645 
90 20 .250 38.504 36.296 22.596 
1 20 20 .665 37.494 37 .038 2 1 .7 1 8  
1 50 1 9 .535 38. 1 24 37.283 25.0 1 5  
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 2.61 1 1 .78 7.98 5.47 6.96 3.89 
1 0  6 .03 2 1 .84 1 7.08 1 0.59 1 3.88 6.98 
1 5  1 0.86 25.39 28.22 1 0.02 1 8.62 9.52 
20 1 3 .24 3 1 .48 29.71 1 3.34 2 1 .94 1 0.02 
25 1 7.00 33.37 35.03 1 7.54 25.74 9.80 
30 23.68 32.20 3 1 .71  2 1 .84 27.36 5.37 
45 23.36 35.51 36.79 1 6.45 28.03 9.81 
60 22.86 39.51 39.92 1 9.96 30.56 1 0 .63 
90 29.98 39.64 43.25 24 . 1 9  34.26 8.74 
1 20 30.60 38.60 44. 1 3  23.25 34. 1 4  9 . 1 4  
1 50 28.92 39.25 44.43 26.78 34.84 8.39 
3 1 5  
Table A VII.51.  Dose, and amount and % of  administered dose of  4.4 kDa FD-4 
absorbed from airways to perfusate in the IPRL at 37 DC (nominal dose = 0.2 mg; used in 
Figs. Ill.6  and III. I I ,  Chapter 3 and Fig. V.4, Chapter 5). 
Amount delivered: 
Rat# 
FD4-5 FD4-6 FD4�7 FD4-8 
BW [g] 342 320 325 320 
DL [�g] 255.07 223.42 232 . 1 2  2 1 8.63 
Dctg Wg] 9.05 8.39 5.54 8.75 
Den! [�g] 2.44 38.66 3 1 .57 9.91  mean SD 
Dad [�gl 243.58 1 76.37 1 95.02 1 99.98 203.74 28.44 
Transferred amount: [�g] 
Rat# 
FD4-5 FD4-6 FD4-7 FD4-8 
0 [min] 0.000 0.000 0.000 0.000 
5 5.575 5.51 9 20. 1 78 9.985 
1 0  1 2.279 6.498 32.437 24.788 
1 5  2 1 .208 1 3 .596 47. 1 33 3 1 .404 
20 30.940 1 6.062 58.821 34.894 
25 36.931 1 8 .977 63.638 40.801 
30 38.686 20.830 66 .473 44.056 
45 45.955 24.832 74.583 5 1 .270 
60 5 1 . 9 1 4  28.702 76.262 55. 1 44 
90 58.803 30.266 85.581 6 1 .057 
1 20 59.278 36.561 9 1 . 1 35 64.273 
1 50 60.695 40.945 90.258 63 .845 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 2.29 3 . 1 3  1 0.35 4.99 5.1 9 3.62 
1 0  5.04 3.68 1 6.63 1 2 .40 9.44 6.1 4  
1 5  8 .71  7 .71  24. 1 7  1 5.70 1 4.07 7.61 
20 1 2 .70 9 . 1 1 30 . 1 6  1 7 .45 17.36 9.20 
25 1 5. 1 6  1 0 .76 32.63 20.40 1 9.74 9.46 
30 1 5.88 1 1 .8 1  34.09 22.03 20.95 9.71 
45 1 8.87 1 4 .08 38.24 25.64 24.21 1 0.49 
60 2 1 .31 1 6.27 39. 1 1 27.58 26.07 9.85 
90 24. 1 4  1 7. 1 6  43.88 30.53 28.93 1 1 .37 
1 20 24.34 20.73 46.73 32. 1 4  30.98 1 1 .53 
1 50 24.92 23.22 46.28 3 1 .93 31 .59 1 0.50 
3 1 6  
Table A VII.52. Dose, and amount and % of  administered dose of 4 .4  kDa FD-4 
absorbed from airways to perfusate in the IPRL at 25 °C (nominal dose = 0 . 1  mg; used in 
Fig . IV.7, Chapter 4). 
Amount delivered: 
Rat# 
FD4-9 FD4-1 0 FD4-1 1 FD4-1 2  
BW [g] 320 3 1 5  3 1 0  340 
DL [�g] 1 28 .86 1 1 9.22 1 1 7.91 1 1 0.90 
Dctg [).ig] 4 . 1 2  9.98 2.97 2.36 
DcnI [�g] 1 6 .85 4.32 9.30 1 2.75 mean SO 
Dad t�gl 1 07.89 1 04.93 1 05.65 95.79 1 03.56 5.33 
Transferred amount: [�g] 
Rat# 
FD4-9 FD4- 1 0  FD4-1 1 FD4-1 2  
0 [min] 0.000 0 .000 0.000 0 .000 
5 1 .035 3 .322 2.960 0.723 
1 0  6.8 1 8  5.690 1 1 .086 1 .724 
1 5  5.564 1 5.233 1 1 .881 2 .503 
20 1 0.01 5 1 3 .861 1 8 .745 4 .065 
25 1 1 .961 1 9.571 2 1 .275 5.296 
30 1 4.379 26.761 20.892 5.926 
45 1 8 .056 28.965 26.626 9.678 
60 22.527 32 .446 36.276 1 0. 1 1 3  
90 28.891 4 1 .958 34.341 1 2 .926 
1 20 28.394 38.376 43.702 1 3. 1 74 
1 50 3 1 .035 4 1 .779 43.833 1 4.445 
% transferred: [%] mean SO 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
5 0.96 3 . 1 7 2.80 0.75 1 .92 1 .24 
1 0  6.32 5 .42 1 0.49 1 .80 6.01 3.57 
1 5  5 . 1 6  1 4. 52 1 1 .25 2.61  8.38 5.46 
20 9.28 1 3.21 1 7 .74 4 .24 1 1 .1 2  5.74 
25 1 1 .09 1 8.65 20. 1 4  5.53 1 3.85 6.82 
30 1 3.33 25.50 1 9.78 6 . 1 9 1 6.20 8.32 
45 1 6.74 27.60 25.20 1 0. 1 0  1 9.91 8.03 
60 20.88 30.92 34.34 1 0.56 24.1 7  1 0.73 
90 26.78 39.99 32.51 1 3 .49 28.1 9 1 1 .1 9  
1 20 26.32 36.57 4 1 .37 1 3.75 29.50 1 2.23 
1 50 28.77 39.82 4 1 .49 1 5.08 31 .29 1 2. 1 9  
3 1 7  
Table A VII.S3. Dose, and amount and % of administered dose of 4 .4  kDa FD-4 
absorbed from airways to perfusate in the IPRL at 25 °C (nominal dose = 0.2 mg; used in 
Fig. N.7, Chapter 4). 
Amount delivered: 
Rat# 
FD4·1 3 FD4·1 4  FD4·1 5 FD4·1 6 
BW [g] 360 350 340 370 
DL [!lg] 201 . 54 243.33 227.33 1 81 .63 
Dctg [!lg] 2 .23 2 .67 8.41 1 8.47 
Dcnl [!lg] 1 9 .89 29.61 1 5.36 47.79 mean SD 
Dad [!lg] 1 79.42 2 1 1 .06 203.56 1 1 5.36 1 77.35 43.48 
Transferred amount: [!lg] 
Rat# 
FD4·1 3 FD4·1 4  FD4·1 5 FD4· 1 6  
0 [min] 0.000 0.000 0.000 0 .000 
5 5 .772 1 3.560 1 0 .535 2.361 
10 1 3. 1 3 1  23. 1 52 8 .268 2 .556 
1 5  23. 1 32 33.580 1 1 .673 7 . 1 28 
20 30.352 42.753 1 7 .280 1 0.936 
25 40.000 5 1 .601 23 .242 1 2 .603 
30 45.581 56. 1 94 28.878 1 3 .694 
45 58.248 62.407 43. 1 54 1 8.965 
60 66 .398 80.675 49. 1 45 22.601 
90 76. 1 48 85.894 64 .589 27.244 
1 20 88. 1 95 95.320 69.756 30.896 
1 50 89 .472 1 0 1 . 1 39 77 .494 35.257 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
5 3 .22 6 .42 5 . 1 8  2.05 4.22 1 .96 
1 0  7.32 1 0 .97 4 .06 2 .22 6.1 4 3.85 
1 5  1 2 .89 1 5.91 5.73 6 . 1 8 1 0.1 8 5.03 
20 1 6.92 20.26 8.49 9.48 1 3.79 5.72 
25 22.29 24.45 1 1 .42 1 0.92 1 7.27 7.1 0 
30 25.40 26.62 1 4 . 1 9  1 1 .87 1 9.52 7.57 
45 32.46 29.57 2 1 .20 1 6.44 24.92 7.40 
60 37.01 38.22 24 . 1 4  1 9.59 29.74 9.29 
90 42.44 40.70 3 1 .73 23.62 34.62 8.71 
1 20 49. 1 6  45. 1 6  34.27 26.78 38.84 1 0.21 
1 50 49.87 47.92 38.07 30.56 41 .60 8.99 
3 1 8  
Table A VII.54. Dose, and amount and % o f  administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL at 37 °C (nominal dose = 0.01 mg; used in Figs. 
ill.6  and ill. 1 1, Chapter 3). 
Amount delivered: 
Rat# 
1 1  1 2  1 3  1 9  
BW [9] 360 375 368 335 
DL [1l9] 1 0.87 1 0.66 1 0.46 9.76 
Dctg [1l9] 1 .63 1 .25 1 .25 1 .89 
DcnI [1l9] 1 .03 0 .68 0.76 0 . 1 6 mean SD 
Dad r1l9] 8.21 8.73 8 .46 7.70 8.28 0 .44 
Transferred amount: [1l9] 
Rat# 
1 1  1 2  1 3  1 9  
0 [min] 0 .000 0.000 0 .000 0.000 
1 0 . 1 2 1  0 .000 0.254 0 . 1 0 1  
3 0.660 0.309 1 . 1 70 0.576 
5 1 .5 1 7  0 .972 1 .926 1 .304 
1 0  3.344 22.391 3 . 1 38 2 .386 
1 5  4.264 3 .433 3.981 3.271 
20 4.627 4.043 4.562 3 .7 1 6  
30 5.062 4.467 5.078 4 . 1 24 
40 5 . 1 52 4.895 5.279 4 .250 
50 5.222 5 .069 5.453 4 .31 7 
60 5.325 5. 1 32 5.459 4.377 
75 5.252 5.231 5.539 4.387 
90 5.396 5.235 5.529 4.41 1 
1 20 5 .334 5.401 5.571 4 . 383 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
1 .47 0.00 3.00 1 .3 1  1 .45 1 .23 
3 8 .04 3 .54 1 3 .83 7 .48 8.22 4.24 
5 1 8 .47 1 1 . 1 4  22.76 1 6 .93 1 7.32 4.81 
1 0  40.71 256.51 37.09 30.98 91 .32 1 1 0.20 
1 5  5 1 .91  39.33 47.05 42.47 45. 1 9  5.49 
20 56.33 46.32 53.92 48.25 51 .20 4.70 
30 6 1 .63 5 1 . 1 7  60.02 53.54 56.59 5.02 
40 62.72 56.08 62.39 55. 1 8  59.09 4.02 
50 63.57 58.07 64.45 56.05 60.54 4.1 1 
60 64.83 58.79 64.52 56.83 61 .24 4.04 
75 63.94 59.93 65.47 56.96 61 .57 3.86 
90 65.69 59.97 65.35 57.27 62.07 4.1 3  
1 20 64.94 6 1 .87 65.84 56.91 62.39 4.03 
3 1 9  
Table A VII.55. Dose, and amount and % of  administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL at 37 °C (nominal dose = 0.02 mg; used in Figs. 
Ill. 6  and III. 1 1 , Chapter 3) .  
Amount delivered: 
Rat# 
39 42 44 96 
BW [9] 350 354 348 320 
DL [119] 22.82 20.57 1 9.90 20.88 
Dctg [119] 1 .54 0.58 1 . 1 7  1 . 1 8  
DcnI [119] 5. 1 3  2 .47 0.71  0.88 mean SD 
Dad lll91 1 6 . 1 6  1 7.53 1 8 .03 1 8.81  1 7.63 1 . 1 2  
Transferred amount: [119] 
Rat# 
39 42 44 96 
0 [min] 0.000 0 .000 0.000 0.000 
1 0.000 0 . 1 86 0 .2 1 2  0 .000 
3 0.576 0.678 1 .573 0. 1 65 
5 1 .890 1 .730 2.937 0 .898 
1 0  4 .564 4 .4 1 7  5.872 2 .894 
1 5  6.920 6 .268 7.765 4.333 
20 8 .447 7.556 8.752 5.943 
30 9.655 7.8 1 6  9 .783 7 .778 
40 1 0 . 1 88 8.281 1 0 .404 8.239 
50 1 0.499 8 . 5 1 0  1 0.8 1 6  8.733 
60 1 0 .632 8 .626 1 1 . 1 1 6 9 .080 
75 1 0.722 8 .897 1 1 .024 9.221 
90 1 0 .844 9.066 1 1 . 1 75 9 .623 
1 20 1 0 .869 9.234 1 1 .071 9.495 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
0.00 1 .06 1 . 1 8  0.00 0.56 0.65 
3 3.57 3 .87 8.72 0 .88 4.26 3.27 
5 1 1 .70 9.87 1 6.29 4.77 1 0.66 4.76 
1 0  28.25 25.20 32.56 1 5.38 25.35 7.30 
1 5  42.83 35.76 43.06 23.03 36. 1 7  9.39 
20 52.28 43. 1 1 48.53 3 1 .59 43.88 9.02 
30 59.76 44 .59 54.25 4 1 .34 49.98 8 .52 
40 63.06 47.24 57.69 43.79 52.95 8.97 
50 64.99 48.55 59.98 46 .42 54.98 8.94 
60 65.81 49.21 6 1 .64 48.26 56.23 8.83 
75 66.37 50.76 6 1 . 1 3  49.01 56.82 8 .32 
90 67. 1 2  51 .72 6 1 .97 5 1 . 1 5  57.99 7.86 
1 20 67.28 52.68 6 1 .39 50.47 57.95 7.80 
320 
Table A VII.56. Dose, and amount and % of administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL at 37 °C (nominal dose = 0.04 mg; used in Figs. 
III.6 and Ill. l l ,  Chapter 3). 
Amount delivered: 
Rat# 
1 06 1 07 1 08 1 09 
BW [g] 380 365 380 340 
Dl [fIg] 41 .48 43.61 4 1 . 53 50.53 
Dctg [fIg] 1 .00 1 . 1 2  2 .48 2 . 1 1  
Denl [fIg] 8.69 8 .23 3.91  8 .40 mean SD 
Dad [fIg] 31 .80 34.26 35. 1 4  40.02 35.30 3.45 
Transferred amount: [fIg] 
Rat# 
1 06 1 07 1 08 1 09 
0 [min] 0.000 0.000 0 .000 0.000 
1 0.082 0. 1 79 0 . 1 68 0 . 1 58 
3 1 .830 3 .54 1  2 .51 6 2 . 1 73 
5 5.308 7 .579 4 .81 3 5 .334 
1 0  1 2 .512 1 3.020 1 2 .056 1 2 .582 
1 5  1 6 . 1 5 1  1 6 .960 1 5.956 1 7.009 
20 1 8.91 4 1 9 . 1 70 1 8 .657 1 9.646 
30 20.907 2 1 . 1 83 20.030 2 1 .993 
40 22.802 2 1 .773 2 1 .933 23. 1 08 
50 22.362 2 1 .920 22.568 23.470 
60 22.865 22. 1 79 22.777 23.271 
75 23 .494 22.492 22 . 1 83 23.622 
90 24.0 1 3  22.776 22.667 23.679 
1 20 23.970 22.559 22 .796 23.255 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
1 0.26 0.52 0 .48 0.39 0.41 0 . 1 2  
3 5.75 1 0 .34 7 . 1 6  5.43 7.1 7 2.24 
5 1 6 .69 22. 1 2  1 3.70 1 3.33 1 6.46 4.06 
1 0  39.34 38.01 34.31  3 1 .44 35.77 3.59 
1 5  50.79 49.51 45.41 42.50 47.05 3.80 
20 59.47 55.96 53. 1 0  49.09 54.40 4.40 
30 65.74 6 1 .83 57.00 54 .96 59.88 4.85 
40 7 1 .70 63.56 62.42 57.74 63.85 5.80 
50 70.32 63.99 64.23 58.65 64.29 4.77 
60 7 1 .90 64.74 64.82 58. 1 5  64.90 5.62 
75 73.88 65.65 63. 1 3  59.03 65.42 6.26 
90 75.51 66.48 64.51  59. 1 7  66.42 6.80 
1 20 75.37 65.85 64.88 58 . 1 1 66.05 7.1 0 
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Table A VII.57. Dose, and amount and % of administered dose of376 Da F-Na absorbed 
from airways to perfusate in the IPRL at 25 °C (nominal dose = 0.01 mg; used in Fig. 
IV.7, Chapter 4). 
Amount delivered: 
Rat# 
1 4  1 5  1 6  1 8  
BW [g] 3 1 8  320 340 378 
DL [!lg] 1 0.87 1 0. 1 8  1 2. 1 8  1 1 .46 
Dctg !!lg] 0.90 0 . 1 0  0.56 0.95 
DcnI [!lg] 0.23 0.35 0.29 0.79 mean SD 
Dad t!lg] 9.74 9.73 1 1 .34 9 .72 1 0. 1 3  0.80 
Transferred amount: [!lg] 
Rat# 
1 4  1 5  1 6  1 8  
0 [min] 0.000 0.000 0 .000 0.000 
1 0.000 0 . 1 0 1  0.067 0.041 
3 0.230 0.637 0 .990 0 . 1 85 
5 0.736 1 . 1 75 1 .999 0 .449 
1 0  2 .062 2 .298 3 .275 1 . 1 54 
1 5  3 . 1 1 8  3 .036 4.094 1 .778 
20 3.749 3.4 1 8  4 .783 2 .355 
30 4 .765 4 . 1 48 5.552 3.252 
40 5.442 4 . 546 6 . 1 75 4 .023 
50 5.850 4.925 6 .578 4.551 
60 6 . 1 07 5.282 6.855 5.057 
75 6.301 5.657 7.247 5.536 
90 6 .226 5.832 7 .4 1 6  5.863 
1 20 6 .225 5 .8 1 3  7 .603 5.963 
% transferred: [%] mean SD 
o [min] 0.00 0 .00 0.00 0.00 0.00 0.00 
0.00 1 .04 0.59 0.42 0.51 0 .43 
3 2 .36 6.55 8.73 1 .90 4.89 3.31 
5 7.56 1 2 .08 1 7.63 4 .62 1 0.47 5.67 
1 0  2 1 . 1 7  23.62 28.89 1 1 .87 21 .39 7.1 1 
1 5  32.02 3 1 .21  36. 1 1 1 8.29 29.41 7.71 
20 38.50 35. 1 3  42. 1 9  24.23 35.01 7.74 
30 48.93 42.64 48.97 33.46 43.50 7.33 
40 55.88 46.73 54.47 4 1 .39 49.62 6.80 
50 60.07 50.62 58.02 46.83 53.89 6.22 
60 62.71 54 .29 60.47 52.03 57.38 5.04 
75 64.71  58. 1 5  63.92 56.96 60.93 3.95 
90 63.94 59.94 65.41 60.33 62.40 2.69 
1 20 63.92 59.75 67.06 6 1 .35 63.02 3.20 
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Table AVII.58. Dose, and amount and % of administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL at 25 °C (nominal dose = 0.02 mg; used in Fig. 
N.7, Chapter 4). 
Amount delivered: 
Rat# 
40 4 1  43- 95 
BW [g] 366 358 358 300 
DL [Ilg] 22.78 20.92 2 1 .33 2 1 .50 
Dctg [Ilg] 1 .20 0.3-4 0.77 0.87 
DcnI [Ilg] 2 . 1 2  3.09 4 .45 0.61 mean SO 
Dad [Ilg] 1 9.46 1 7.50 1 6. 1 2  20.02 1 8.28 1 .80 
Transferred amount: [Ilg] 
Rat# 
40 4 1  4 3  95 
0 [min] 0.000 0.000 0 .000 0.000 
1 0.028 0 .050 0 .000 0 . 1 1 8  
3 0.266 0 .33-4 0 . 1 1 7  1 . 1 44 
5 0.694 0 .6 1 4  0.371 1 .974 
1 0  1 .778 1 .487 1 . 1 48 4 . 1 43 
1 5  2.846 2 .277 2 .027 5.232 
20 3 .758 3 . 1 36 2 .943 7.251 
30 5.332 4 .564 4 .690 8.41 1 
40 6.761 6 .404 5.861 9 .060 
50 7 .632 6.561 6 .865 1 0 .431 
60 8.483 7 . 5 1 4  7 .350 1 1 .732 
75 8.950 8 .529 8 .2 1 9  1 2 .080 
90 9.323 8.942 8 . 543 1 2 .426 
1 20 1 0 . 1 00 9 . 1 75 9 .050 1 2 .356 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
0 . 1 4  0.29 0.00 0 . 59 0.25 0.25 
3 1 .37 1 .9 1  0.73 5.71 2.43 2.24 
5 3.57 3 . 5 1  2 .30 9.86 4.81 3.42 
1 0  9 . 1 4  8 .50 7 . 1 2  20.69 1 1 .36 6.28 
1 5  1 4.62 1 3.01  1 2.58 26. 1 3  1 6.59 6.42 
20 1 9.31 1 7 .92 1 8 .26 36.21 22.93 8.88 
30 27 .40 26.08 29. 1 0  42.01 31 .1 5 7.34 
40 34.74 36.60 36.36 45.25 38.24 4.75 
50 39.21 37.50 42.59 52. 1 0  42.85 6.52 
60 43.59 42.94 45.60 58.59 47.68 7.36 
75 45.99 48.75 50.99 60.33 51 .51 6.22 
90 47.90 5 1 . 1 1 53.00 62.06 53.52 6.07 
1 20 51 .90 52 .44 56. 1 5  6 1 . 7 1  55.55 4.52 
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Table AVII.59. Dose, and amount and % of administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL at 25 °C (nominal dose = 0.04 mg; used in Fig. 
IV.7, Chapter 4). 
Amount delivered: 
Rat# 
1 1 4 1 1 5  1 1 6 1 1 7 
BW [9) 320 3 1 0  330 340 
Dl [J.I9) 46.51 54. 1 1 49.61 42.29 
Dctg [J.I9) 1 . 1 2  1 .99 4.34 2 .68 
DcnI [J.I9) 4.87 1 2 . 1 8  4.39 1 . 1 7  mean SD 
Dad [J.I9J 40.53 39.94 40.89 38.44 39.95 1 .08 
Transferred amount: [J.I9) 
Rat# 
1 1 4 1 1 5  1 1 6 1 1 7 
0 [min) 0.000 0 .000 0.000 0.000 
1 0.099 0 .3 1 5  0 .086 0. 1 07 
3 1 .869 1 .630 1 .283 1 .3 1 8  
5 4 .403 3 .882 3 .467 3.331 
1 0  8.774 8 .524 7.442 7.704 
1 5  1 2 .508 1 0. 2 1 4  1 1 .221 1 1 .088 
20 1 5.060 1 2 .233 1 4 .076 1 3 .861 
30 1 8 .405 1 7 .467 1 9.026 1 7 .386 
40 2 1 .253 2 1 .330 2 1 .967 1 9.866 
50 22.900 22.287 24. 1 36 2 1 .543 
60 23.837 22.743 25.506 22 .359 
75 24.6 1 3  23.433 26.683 23.271 
90 25.2 1 9  23.608 27.226 23.574 
1 20 25.6 1 7  23.801 27.800 24.086 
% transferred: [%) mean SD 
o [min) 0.00 0 .00 0.00 0.00 0.00 0.00 
0 .24 0.79 0.21 0.28 0.38 0.27 
3 4.61 4.08 3 . 1 4  3.43 3.81 0.66 
5 1 0.86 9 .72 8.48 8.67 9.43 1 .1 0  
1 0  2 1 .65 2 1 .34 1 8.20 20.04 20.31 1 .57 
1 5  30.86 25.57 27 .44 28.84 28.1 8 2.23 
20 37. 1 6  30.63 34.43 36.06 34.57 2.86 
30 45.41 43.73 46.53 45.23 45.22 1 .1 5  
40 52.44 53.40 53.73 5 1 .68 52.81 0.93 
50 56.50 55.80 59.03 56.04 56.84 1 .49 
60 58.81 56.94 62.38 58. 1 7  59.07 2.34 
75 60.72 58.66 65.26 60.54 61 .30 2.80 
90 62.22 59. 1 0  66.59 6 1 .33 62.31 3 . 1 4  
1 20 63.20 59.59 67.99 62.66 63.36 3.47 
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Table A VII.60. Dose, and amount and % of administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL in the presence of 1 roM DNP at 37 °C (nominal 
dose = 0.02 mg; used in Fig. N.8, Chapter 4). 
Amount delivered: 
Rat# 
234 235 236 237 
BW [9] 31 5 31 5 340 345 
DL 1J!9] 20.54 2 1 . 1 8  24.27 25.48 
Dctg [J.I9] 0.29 0.32 0 . 1 0  0 .74 
Den [J.I9] 5.06 5.32 2 .89 5.09 mean SD 
Dad [J.I9] 1 5. 1 9  1 5.54 2 1 .28 1 9.65 1 7.92 3 .02 
Transferred amount: [J.I9] 
Rat# 
234 235 236 237 
0 [min] 0.000 0.000 0 .000 0 .000 
1 0 . 1 0 1  0.387 0 .680 0.082 
3 1 .249 2.754 4 .040 1 .733 
5 2.555 4.637 7 .337 3 .863 
1 0  4 .270 7.266 1 0.761 7.327 
1 5  5. 1 62 9.336 1 2 .926 8.756 
20 5.435 1 0.024 1 3. 3 1 2  9 .683 
30 5.730 1 0 .434 1 4 .323 1 0.587 
40 5.754 1 0.592 1 5.029 1 0.874 
50 6 . 1 65 1 0 .761 1 4. 9 1 4  1 0.873 
60 6 . 1 57 1 0.701 1 4 .840 1 1 . 1 03 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
0 .66 2.49 3 .20 0.42 1 .69 1 .36 
3 8.22 1 7.72 1 8.98 8.82 1 3.44 5.71 
5 1 6.82 29.84 34.48 1 9.66 25.20 8.34 
1 0  28. 1 1 46.76 50.57 37.29 40.68 1 0.07 
1 5  33.98 60.08 60.74 44.56 49.84 1 2.95 
20 35.78 64.50 62.56 49.28 53.03 1 3.34 
30 37.72 67. 1 4  67.31 53.88 56.51 1 4.02 
40 37.88 68. 1 6  70.63 55.34 58.00 1 4.99 
50 40.59 69.25 70.08 55.33 58.81 1 3.91 
60 40.53 68.86 69.74 56.50 58.91 1 3.66 
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Table A VII.61 .  Dose, and amount and % of administered dose of376 Da F-Na absorbed 
from airways to perfusate in the IPRL in the presence of 100 /!M OUA at 37 °C (nominal 
dose = 0.02 mg; used in Fig. IV.8, Chapter 4). 
Amount delivered: 
Rat# 
224 225 227 229 
BW [9) 330 330 330 325 
DL [fi9) 20.89 2 1 .44 2 1 .08 2 1 .23 
Dctg [fi9) 0.22 1 .02 0 . 1 2  0.29 
DcnI [fi9) 4.24 3.26 4.62 4.06 mean SD 
Dad [fi9j 1 6.43 1 7 . 1 6  1 6.34 1 6 .88 1 6 .70 0.39 
Transferred amount: [fi9) 
Rat# 
224 225 227 229 
0 [min) 0 .000 0.000 0.000 0.000 
0.035 0.258 0 . 1 7 1  0 .060 
3 3 . 1 30 2.761 2 .463 3.51 1 
5 4.807 4 .558 4.350 5. 1 88 
1 0  . 8 .369 7.669 7 .787 6.321 
1 5  9 .882 9.320 9 . 1 6 1  6 . 547 
20 1 0.7 1 8  1 0.089 1 0. 1 56 8.597 
30 1 1 .5 1 2  1 0.531 1 0.679 9.571 
40 1 1 . 1 80 1 0.990 1 0 .605 9 .962 
50 1 1 .788 1 1 .0 1 5 1 1 .095 9 .949 
60 1 1 .682 1 1 . 1 76 1 1 .221 9 .923 
% transferred: [%) mean SD 
o [min) 0.00 0.00 0.00 0.00 0.00 0.00 
0.21 1 .50 1 .05 0.36 0.78 0.60 
3 1 9.05 1 6.09 1 5.07 20.80 1 7.75 2.64 
5 29.26 26.56 26.62 30.73 28.29 2.06 
1 0  50.94 44.69 47.66 37.45 45. 1 8  5.75 
1 5  60. 1 5  54.31  56.06 38.79 52.33 9.35 
20 65.23 58.79 62. 1 5  50.93 59.28 6.1 6 
30 70.07 6 1 .37 65.35 56.70 63.37 5.69 
40 68.05 64.04 64.90 59.02 64.00 3.74 
50 7 1 .75 64. 1 9  67.90 58.94 65.69 5.46 
60 7 1 . 1 0  65. 1 3  68.67 58.79 65.92 5.35 
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Table A VII.62. Dose, and amount and % of administered dose of 376 Da F-Na absorbed 
from aiIWays to perfusate in the IPRL in the presence of 1 00 IlM MON at 37 °C (nominal 
dose = 0.02 mg; used in Fig. IV.S, Chapter 4). 
Amount delivered: 
Rat# 
272 273 274 275 
BW [g] 380 380 350 330 
Dl [!!g] 20.21 2 1 .56 1 9 .94 1 9.22 
Dctg [!!g] 0.79 1 .89 2 .01  0 .20 
Den! [!!g] 5.20 6 . 1 8 5.77 7 .02 mean SO 
Dad l!!g] 1 4 .22 1 3 .49 1 2 . 1 6  1 2 .00 1 2.97 1 .07 
Transferred amount: [!!g] 
Rat# 
272 273 274 275 
0 [min] 0. 000 0 .000 0 .000 0 . 000 
1 0.022 0.000 0.204 0 . 1 29 
3 0.785 0.343 0 . 570 1 .531  
5 1 .888 1 .043 1 .441 2 .649 
1 0  5.099 3 . 1 42 3 . 1 99 4 .336 
1 5  6.897 4.586 4.656 5.270 
20 8.01 4 5.609 5 .4 1 4  5.783 
30 8 .650 6.322 6 .320 6 . 1 49 
40 8 .330 6 .7 1 3  6 .535 6 .404 
50 9.447 6.790 6 . 860 6 . 523 
60 9.576 6.889 6.933 6 . 629 
90 9 .274 7 . 0 1 7 7 .395 6.738 
1 20 9 .2 1 0  7 .220 7 . 1 43 6 .686 
% transferred: [%] mean SO 
o [min] 0.00 0.00 0 .00 0.00 0.00 0.00 
1 0 . 1 5  0.00 1 .68 1 .08 0.73 0.79 
3 5.52 2 . 54 4 .69 1 2 .76 6.38 4.44 
5 1 3.28 7.73 1 1 .85 22.08 1 3.73 6.04 
1 0  35.86 23.29 26.31  36. 1 3  30.40 6.58 
1 5  48.50 34.00 38.29 43.92 41 . 1 8  6.35 
20 56.36 4 1 .58 44.52 48 . 1 9  47.66 6.40 
30 60.83 46.86 5 1 .97 5 1 .24 52.73 5.85 
40 58.58 49.76 53 .74 53.37 53.86 3.62 
50 66.43 50.33 56.41 54 .36 56.89 6.85 
60 67.34 51 .07 57 . 0 1  55.24 57.67 6.92 
90 65.22 52.02 60.81  56. 1 5  58.55 5.72 
1 20 64.77 53.52 58.74 55.72 58.1 9 4.88 
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Table A VII.63. Dose, and amount and % of administered dose of 376 Da F-Na absorbed 
from airways to perfusate in the IPRL in the presence of 100 11M NOC at 37 °C (nominal 
dose = 0.02 mg; used in Fig. IV.8, Chapter 4). 
Amount delivered: 
Rat# 
298 299 300 301 
BW [9] 360 370 380 380 
DL [119] 20.56 2 1 .51  22.21 22.63 
Dctg [119] 0.63 0 .46 0.31 0.95 
Den! 1119] 1 .62 1 .69 1 .92 1 .99 mean SD 
Dad [119] 1 8 .32 1 9.36 1 9 .98 1 9 .69 1 9.34 0.73 
Transferred amount: [119] 
Rat# 
298 299 300 301 
0 [min] 0.000 0.000 0 .000 0.000 
1 0 .009 0 .073 0 . 1 03 0 . 1 55 
3 0 .339 1 . 1 1 2 1 . 1 1 5  1 .259 
5 0.949 2.805 2 .803 2 .7 1 3  
1 0  3 . 1 76 6.201 6.075 7.086 
1 5  5 . 1 86 8 .709 8 .375 9.681 
20 6 .866 9 .983 9 .7 1 3  1 0.286 
30 8.462 1 1 .602 1 0.774 1 1 .806 
40 9.694 1 1 .846 1 1 .635 1 2 .632 
50 1 0. 1 1 1  1 2 .437 1 1 .762 1 2.584 
60 1 0 .434 1 2 .7 1 3  1 1 .752 1 2 .4 1 0  
90 1 1 . 1 63 1 2 .683 1 2 .51 2 1 2.772 
1 20 1 1 .579 1 2.399 1 2 .653 1 3. 1 59 
% transferred: [%] mean SD 
o [min] 0.00 0.00 0.00 0.00 0.00 0.00 
1 0.05 0.38 0.52 0.79 0.43 0.31 
3 1 .85 5.74 5.58 6.39 4.89 2.06 
5 5 . 1 8  1 4 .49 1 4 .03 1 3.78 1 1 .87 4.47 
1 0  1 7.34 32.03 30.40 35.98 28.94 8.08 
1 5  28.32 44.98 4 1 .91  49. 1 6  41 .09 9.02 
20 37.49 5 1 .56 48.60 52.23 47.47 6.84 
30 46.20 59.92 53.91 59.95 55.00 6.51 
40 52.93 6 1 . 1 8  58.22 64. 1 4  59.1 2 4.78 
50 55.21 64.24 58.86 63.90 60.55 4.33 
60 56.97 65.66 58.81 63.02 61 . 1 1  3.95 
90 60.95 65.51 62 .61  64.86 63.48 2.09 
1 20 63.22 64.04 63.32 66.82 64.35 1 .69 
- MicroMaIh ScIentist Statistics Report -
Model FIe Name :  
Data FiIe Nane :  
Param Ale Name : 
.:If-phM.oqn 
a;\data-37.mmd 
L-I31-1n1.por 
L"\data-37.mmd 
Data Co/I.mn Name: FP 
Sum of squared _ :  
Sum of squared ckMationa : 
S1Bndard deYiatioo 01 _  : 
R·squared : 
CoeIficient 01 determWletion : 
Correlation : 
Weighted 
70937.6348 
1004.40593 
4.05779139 
0.985841001 
0.961031051 
0.980978323 
Data Set Name: a:'da.ta-37 .mmd 
Sum of squared _ :  
Sum of squared deviations : 
S1Bndard deYiatioo 01 _ :  
R-squared : 
Coetfoclont 01 determlnatloo : 
Correlation : 
Model Solection Criterion : 
Con� 1nI0MIIa: 
Parameter Name : 
Estimate Value . 
WoIghIod 
70937.6348 
1004.40593 
4.05779139 
0.985841001 
0.961 031051 
0.980978323 
3.12191322 
KA 
0.001 17717508 
Sfandanj � - 0.00069358822S 
95% Range (Univar) -
95% Range (5-PIano) -
Parameter Name : 
Estimate Value-. 
Standard DevIation -
95% Range (UnIvar) _ 
95% Range (S-PIano) -
Parameter Name : 
Estimate Value . 
standard DeYIatIoo -
95% Range (UnIvar) -
95% Range (S·PIano) • 
Parameter Name : 
Estimate Value · 
Standard DeYIaIIon • 
05% Range (UrMIr) • 
95% Range (S·PIane) • 
Variance-Covarlanco MatrllC 
4.81084627E·7 
2.33468801 E·7 
-0.000302486774 
-0.00702507801 
ComJiation Matrix: 
1 .00000000 
0. 1 9440 1 1 55  1 .00000000 
-0.000209740293 
-0.00102604149 
KE 
0'<)233379971 
0.00173152314 
0.01 98756026 
0.0178377300 
VMAX 
4.3660021 5  
0.565159738 
3.23589541 5.49510889 
2.57074499 5.16125941 
KM 
56.5958869 
14.70S0819 
27.t852595 86.0065143 
9.8749S304 103.316821 
2.99817239E� 
5.871 78027E·5 0.319405530 
-0.00586100968 7.57068919 
-o.n1673280 0.060002721 0  1.00000000 
-0.668641 632 -0.230 /37878 0.91 0768839 1 .00000000 
Residual AnalysIs: 
---
Unweightad 
70937.6348 
1004.40593 
4.05779139 
0.985841001 
0.961031051 
0.98Q978323 
UnwoIghted 
70937.6348 
1 004:40593 
4.05779139 
0.985841001 
0.961 031051 
0.980978323 
3.12191322 
0.00256409046 
0.00338039184 
0.0268003916 
0.0288382641 
21 6.327872 
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The following are normaized parameters with arI expected vaJl,Je of 0.0. Values ar 8  i'1 units of standard deviations from the mrpected val ... 
The serial correlation Is 6.06 �ch Indicates a systematic non-random trend in the f'8SidupIs. 
Skewness is -0.60 which Is probably oot signilicant 
Kunosis Is .(l.00 _ Is probably oot signIficanL 
The ..... ghting lector .... 0.00 leadilg to • heteroaoadaclk:lty 01 0.79 whk:h suggests an op1ImaI welght factor tor this ftt 01 about 0.79 
Figure A VII. I. Statistical Output obtained from across-dose fitting for 7.4 kDa F­
PHEA absorption data in the !PRL at 37 °C. 
- MictoIAath ScIontls1 _ Roport -
Model FIIo Name : 
Data Ale Name : 
Param Rio Nome : 
L"If-p/wo·OCJI L"\daIa-25.mrnd 
Untlllecne 
_-1ft _ lor _ Nt:  
Data Cokmn Nome: FP 
S..., of oquarod _ :  
S"" of oq _ ___ : 
Standanl de>iation of de .. : 
R-squared : 
Coefficient of dotannInoIIon : 
Correlation : 
wo!ghted 
tl942.32950 
85.02742,54 
' ._,28 
0.99'447937 
0.979576857 
0.989817125 
Data Sot Name: .:'w:tata-25.mmd 
Sum of lQuarod _ :  
Sum of lQuarod dovIatIono : 
Standard deYietion of dille. ! 
R-aquared : 
Coetficiont of dotermlnatlon : 
Corr8Iation : 
Modo! Selection Clttorlcn : 
Con_ Into.-: 
P""'- Noma :  
Estimate Value . 
Standard o.vt.tion . 
95% Range (UnIYar) • 
IIS% Range (S-Aono) . 
Parameter Name : 
E.timate Value • 
Standard 00YiatI0n . 
95% Range (Un/vat) • 
95% Range (s-PIono) . 
Parameter Name : 
Estimate Value • 
Standard DovIatIon • 
95% Range (lJnMII) . 
95% Range (s-PWlo) • 
Parameter Name : 
estimate Value • 
Standard 00Yt0tI0n . 
95% Range (UrMt) .  
95% Range (5-P1ono) • 
Vartance-Covartanc:e MoIrIx: 
5.05m533E-lI 
2.31486683E-7 
-1 .B775298BE-5 
-o.tlO302305785 
Correlation MatriX: 
1.00000000 
0.72673221 1  1 .00000000 
Wolghted 
tl942·32950 
85.0274254 
1.33094128 
0.991 447V37 
0.979576857 
O.9898m25 
3.73723063 
KA 
0.00231607203 
0.000224894983 
0.001_ 
0.OOI5as87186 
KE 
MI60359853 
0.00,.,t535407 
0.0131882148 
0.0114990150 
\/MAX 
0.666531969 
0.103191870 
0.4590508Of1 
0.335979852 
KM 
30.3172395 
16.3686178 
-2.59045317 
-22.1 101505 
2.00B05865E-{; 
-6.42090731E-5 0.0106485826 
-o.015917B918 1 .55774477 267.872723 
-0.809023598 -0.439317662 1 .00000000 
-0.821301176 -0.888672194 0.&22329617 1 .00000000 
Residual AnoIyoIo: 
�od 
9942.32950 
85.0274254 
1 .33094128 
0.891447V37 
0.979576857 
0.98i1877125 
Unwelghtecf 
9942.32950 
85.0274254 
1._'28 
0.991447W 
0:979576857' 
0.989877125 
3.7'3723063 
0.0027682S370 
0.00303647220 
0:0188837560 
0.0205729550 
0.874013330 
0.9970&1085 
63.2248321 
82.7448354 
The toHowIng are normalized parameters with ., expected value of 0.0. Values are in lSllts of standard deviations from the expected value. 
The •• riaI "corrMtion 11 �.20 wNeh IndiCates a .ystematlc non-random trend In -the residuaII. 
Skewness Is .0.22 which Js probably-not " gnttlcant. 
Kur10sls � -0,00 whlcl1 la �not slgnlflcont. 
The weighting lactor was 0.00 loading to a hotoroscedactlct1y of O:n whlch sugg .. ts an optimal woIght lactor lor 11;, fit of about O:n 
Figure A VII.2. Statistical Output obtained from across-dose fitting for 7 .4 kDa F­
PHEA absorption data in the IPRL at 25 °e. 
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- _ ScIontiIt Statiltlea Aaport -
Model file Name : 
Data Fie Name : 
Panun FIle Nome : 
Goodnou-<lI-IIt llallallco for _ MI: 
Oato Column Nome: FP 
SIm of oquarod __ : 
SIm of oquarod _ :  
Standard _lion of _ : 
R-sQUIWd : 
Coefficient of _ :  
Correlation : 
a:\7002-5Vtt-37.mmcl 
welghtod 
83716.4199 
340.155224 
3.1 1 746627 
0.995936616  
0.979804353 
0.990176&48 
Oato Set Name: L'I7OO2-6'111-37.rnrnd 
SIm of oquarod __ : 
Sum of oquarod _ :  
Standard de't4.8Uon of dI1a : 
R-oquanKI : 
Coefficient of __ : 
Correlation : 
Model Seloction CIIterIon : 
Parametw NIme :  
EsUmste VaJue . 
Standard 0e\48ti0n • 
95% Range (UniYoI) • 
95% Range (S-PIano) • 
Parameter Name : 
Estimate Value . 
Standanl 0eY\aII0n • 
95% Range (UniYIl) . 
95% Range (S-PIano) • 
Parameter NatnI ; 
Estimate Value . 
Standard DeviaUon • 
95% Rongo (UniYIl) • 
95% Rongo (5-PIono) • 
Parameter Name : 
Estimate Value • 
Standard t>eYiatIon -
95% Range (Urivor) • 
95% Rongo (5-PIono) • 
Vanance-Covartance MatrIx: 
6.79660601 E-6 
Weighted 
83716.4199 
340.155224 
3.1 1 746627 
0.995938816  
0.9796043S3 
.0.990176649 
3.69715997 
KA 
0.0135128562 
0.00260703011 
0.00822030368 
0.00503866049 
KE 
0.0163476500 
0.00112350182 
0.0140668201 
0.0126956683 
vw.x 
3.59Se8887 
1 .52961 124 
0.490006948 
-1 .37696856 
KM 
76.7630413 
46.4369761 
-17.48903S2 
-74.1611454 
1.27201917E-6 1 .26225635E-6 
'().0037102231 6  .().000500372154 2.34032243 
.().1 06007666 .().01 89567550 69.9596318 2155.39294 
Correlallon MaIrlx: 
1 .00000000 
0.434263996 1 .00000000 
'().930285255 '().291 126342 1 .00000000 
-0.892163790 -0.363350921 0.983387072 1 .00000000 
Residual AnoJysIs: 
UnwoIgI1I8d 
83716.4199 
340.155224 
3.1 1746627 
0.995938818 
0.1J79604353 
0.990176849 
Unwoigh1ed 
83716.4199 
·340.155224 
3.1 1746627 
0.995938816 
0.1J79604353 
·0.990116849 ·3.69715997 
0.0188064087 
0.0219870S19 
0.0186264800 
0.01999961 1 8  
8.70137060 
8.58838630 
171.0551 19 
227.727228 
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The following are normalized parameters Vt'Ith an e xpected  value of 0.0. Values are In ootts of Itanciard deviations from the expected value. 
Th. ,erial correlation 11 3.74 'Which Indicates a IyStematic non-random trend In the resldualI. 
Sk..,.,..s " 0. 1 9  ""Jch " probably not slgnificont. 
Kurtosls Is 0.00 """'" Is probably not sIgnificant. 
Tho woIg,tIng _ .... 0.00 leading 10 a hetoroocedac:ticHy of 0.98 ""Iell suggests an optimal weight t8C1Of to< ttis fit of about 0.98 
Figure A VII.3. Statistical Output obtained from across-dose fitting for 4.3 kDa F­
PHEA absorption data in the IPRL at 37 DC. 
Modei RIo Nome : 
Data Re Name : 
Param Fill Nai'nI .' 
o:V",*--OIJ1 a:\7002-5\1t-25.mmd UnIItIod2 
_-<>f-tlt _ lordata Ht  
Dola CoiuM NImo: FP 
SUm of -",, _ :  
SUm of �  __ : 
Standard do'AatIon of _ : 
R·aquared : 
. 
Coefllcionl of _ :· 
Cooelatl".,.: 
wolghtod . 
25e80.0831 
62.$90477411 
1.337311101 
0.9975834e8 
0:W2470e96 
0. __ 
OetrI Sot Nomo: L'\7002·5\1It·26.rrwnd 
S ... of � _ :  
SOOl of Iquared � :, 
Standaro _tion of _ :  
R·aquarod : 
Coefficien1 of doI_ :. 
Corretatlon .' . 
Model Selodion C<11or\on : 
eon--... .. ..-: 
ParameW Nanw .' 
Eatimatt VaIurt -
wolghtod 
=� 
1 .33731901 
0.997_ 
. O.9924709M 
O:9V6498326 
'.68368430 
KA 
0.�1269451 
St.ldard DeYtdon .  0.000560604780 
95% Range (UnIYOr) • 0.00423349912 
95% Range (s-Ptono) • ·0.00352467870 
Parameter NIme .' KE 
Eatimat, Value • 0.0123984804 
S18ndartI 0e'IIation .  ·0.0008388tl2792 
95% Range (UnIYOr) • 
95% Range (5-PIIno) .  
Paramet. Name .' 
Estimat, Vtiue -
Standard Deviation . 
95% Range (UnIYOr) • 95% Range (S·PIono) • 
Paramlter Name .' 
E.tmate Value • 
Standard DeoAaHon .  
95% Range (lkMr) • 
95% Range (5-PIono) . 
VorIanc:e-CowrIa MobIx: 
3.373341i12E·7 
2.03889954E·7 4.06145667£·7 
0.Q1 1 1015199 
0.0103216480 
vw.x 
0.915892575 
0.3145077112 
0277407812 
-o.l�203S0 
KM 
84.7199845 
39.3D70241 
'.92138317 
-43.0492856 
-0.000170776495 4I.15465858E-6 
-0.0206642082 -0.0124826539 12.1562164 1545.04215 
CoooIoIion Moblx:  
1 .00000000 
0.549487796 1 .00000000 
-0.934902893 -0.405851046 1 .00000000 
-0.905145551 -o.4�87' 0.983324471 1 .00000000 
0.0998151514 
� 
25890.0931 
62._7748 
1.33731901 
0.997_ 
0.992470998 
0._6 
UnweIglOed 
25690.0931 
62.59477411 
1.33731901 
0.�7563488 
0.9924700i6 
0.996496326 
4.66368430 
0.008591_ 
0.00730061032 
0.0138954408 
0.01-44751147 
1 .55437734 
1 .93820550 
164.516366 
212.487015 
The foIlo'Mng are nonnaIlzed parametaB >Mth WI expected vatue of 0.0. Values are In units of standard devlati0n8 from the expected value. 
The serial oorr4llatJon It 3.01 YrHch Indicates a systematic non-random trend In the resklual •. 
Skewnes. 10 -0.1 1  WhIch 10 prot>at;y not � 
KullOsls 10 0.00 ""!ch is probably not " g_. 
The weighting foetor _ 0.00 leading 10 • hrIto<ooeodacti of 0.02 ""Idl sugg_ an opllmaj weight 1ac1Or for this fl1 of about 0.02 
Figure A VIT.4. Statistical Output obtained from across-dose fitting for 4.3 kDa F­
PHEA absorption data in the IPRL at 25 °C. 
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••• MlcroMath Scientist Statlstica RepOrt ... 
Model File Nlune : 
Data File Name : 
Param File Name : 
.:Vd-4.eqn 
a:\fd4-37.mmd 
Untit1ed9 
Goodness-of-fit statlstica \or data HI: 
Data Column Name: FP 
.Sum of squared obOerva1iono : 
Sum of squared �1Ions : 
Standartl deviatioo of data : 
R-squared : . 
Coefficient cI detannlrialioir: 
Correlation : 
Weighted 
13257.6229 
131 .677935 2.44649968 
0.990067757 
0.9S0066223 
0.97471 7342 
DataSet Name:· a:\fd4-37.mmd 
Sum of squored obOervalions : 
Sum of sq.-d deWItiona : 
Standard d8wIalion of daIa : 
R·squared : 
CoatficIent aI determination : 
ComIIation : 
Modtil Seledlon Criterion : 
Parameter _ :  
Estimate V,.. -= 
Standard OIwiation • 
95% Range lUniYar) • 
95% Rango\S-Plana) .. 
Parameter ..... : 
Estimate V .. . 
Standard DeoiiItion • 
95% RangeJIhivaQ . 
95% Rango(S-Plana) • 
Va� -
1 .29560� 
Waighted 
13257.6229 
131 .677935 
2.44649968 
0.990067757 
O.� 
0.974717342 
2.63039094 
KA 
0.0159654945 
0.00 1 1 3833447 
0.01 36247333 
0.0129962147 
KE 
0.0293346619 
0.00299367339 
0.0231261 833 
0.021 4765200 
3.1 1320360E8 8.96208036E.tI 
Comilation lMix: 
1 .00000000 
0.915551 891 UOOOOOOO 
ReSIdual ANIIJoIo: 
-�--
Unwelghled 
1 3257.6229 
1 31 .677935 
2.44649968 
0.990067757 
0.950066223 
0.974717342 
Unwelghted 
1 3257.6229 
13U S77935 . 2;44649968 
0.990067757 
0.950066223 
0.974717342 2.83039094 
0.01 83462557 
0.01 89727743 
0.0355431aos· 
0.0371906439 
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'The loflowilg lIB normalized parameters with an expected value 01 0.0. Values are In units of standard deviations Irom the 
e� 
'The serial.....- is 4.08 whiCh Ind'lC8teo a systematic non-random trend in the residuals. 
SkewnessilA).38 Which Is probably not slgniflCarlt 
1<urtosl8 . Cli12 Which Is probably not significant 
The we.iglWlg _ was ' 0.00 leading to • hetorosce<!ilcticlty of 0.66 Which suggests an optimal weight factor lor this frt of about 
'1);66 
FlRUJ:e.Aftl.5. Statistical Output obtained from across-dose fitting for 4.4 kDa FD-4 
ahsowti:ca data in the IPRL at 37 °e. 
••• MicroMath Scientist Statistics Report HO 
Model File Name : 
Data File Name : 
Param File Name : 
.:\ld-4.eqn 
a:\ld4-25.mmd 
Untltled9 
Goodness-of-fit statistics for data set 
Data Column Name: FP 
Sum ot squared observations : 
Sum of squared deviations : 
Standard deviation of data : 
R-squared : 
CoeffICient of determination : 
Correlation : 
a:lfcl4-25.mmd 
Weighted 
1 1274.9864 
1 69.1 48729 
2.77282862 
0.984997877 
0.952052084 
0.975816838 
Data Set Name: a:\ld4-25.mmd 
Sum of squared obseNalions : 
Sum of squared deviations : 
Standard deviation of data : 
R-squared : 
Coefficient of determination : 
Correlation : 
Model Selection Criterion : 
Confidence Intorvals: 
Parameter Name : 
Estimate Value = 
Standard Deviation = 
95% Range (Univar) � 
95% Range (5-PIane) " 
Parameter Name : 
Estimate VaiUB � 
Standard Deviation � 
95% Range (Univar) " 
95% Range (S-Plane) = 
Varianc ... Covariance Matrix: 
4.1 9029931E-7 
Weighted 
1 1 274.9864 
1 69.148729 
2.77262862 
0.984997877 
0.952052084 
0.975816838 
2.87097327 
KA 
0.00837423934 
0.000647325213 
0.00703176901 
0.00687549300 
KE 
0.01171 31325 
0.001 80269537 
0.00797457108 
0.00698240038 
1 .04026552E-6 3.24971058E-6 
Correlation Matrix: 
1 .00000000 
0.891 454826 1 .00000000 
Residual Analysis: 
,----
Unwelghted 
1 1 274.9684 
1 69.148729 
2.77262862 
0.984997877 
0.952052084 
0.97581 6838 
Unweighted 
1 1 274.9684 
1 69.148729 
2.77262862 
0.984997877 
0.952052084 
0.975816838 
2.87097327 
0.00971 670968 
0.01 00729857 
0.01 54516938 
0.01 64438845 
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The following are normalized parameters with an expected value of 0.0. Values are in un�s of standard deviations from the 
expected value. 
The serial correlation is 3.76 which InalCates a systematic non-random trend In the residuals. 
Skewness is -0. 13  which is probably not signifICant. 
Kurtosis Is 0.04 which Is probably not significant. 
The weighting factor was 0.00 leading to a heteroscedactic� of 1 .55 which suggests an optimal weight factor for this f� of about 
1 .55 
Figure A VII_6_ Statistical Output obtained from across-dose fitting for 4.4 kDa FD-4 
absorption data in the IPRL at 25 °e. 
••• MicroMath Scientist StatiStics Report ••• 
Model File Name : 
Data File Name : 
Param Fi le Name : 
'a:\f-naeqn 
a:\fna-37.mmd 
Vntideq1 
Goodness-of-frt statistics for data set 
Data Column Name: FP 
Sum of squared observations : 
Sum of squared deviationS ; 
Standard deviation 01 data : 
R-squared : 
Coefficient of detenn ination : 
Correlation : 
. 
a:\fna-37 _rillnd 
Weighted 
93084_1 888 
765.1 32504 
4.37359264 
0.9917802 1 0  
0.968IT1 561 
0.985809251 -
Data Set Name: a:\lna-37.mmd 
Sum of squared obserVations : 
Sum of squared deviations : .  
Standard daviation of data : 
R-squared : 
Coefficient of datennination : 
Correlation : 
Model Selection Criterion :. 
Confidence Intervals: 
Parameter Name : 
Estimate Vatue z 
Standard Deviation = 
95% Range (Vnivar) = 
95% Range (S-P lane) = 
Parameter Name : 
Estimate Value = 
Standard Deviation = 
95% Range (UniYar) .. 
95% Range (S-Piane) .. · 
Variance-Covariance Matrix: 
7.93465682E-6 
Weighted , 
93084.1688 
765.132504 
4.37359264 
0.991.7802 1 0  
.o.968IT1561 
0.985809251 
3.371 1 8801 
KA 
O.04IT436096 
0.00281 685229 
.o.042.oSOq368 
.0.0405822348 
KE 
.0 . .021 8780006 
.0.00220141465 
0 . .o1 742Bn56 
.0.01 62812728 
5.24027804E-6 4.84622645E-6 
Correlation Matrix: 
1 .00000000 
0.845061 672 1 .00000000 
Residual Analysis: 
Uhweighted 
93084.1888 
165.132504 
4.37359264 . 
.0.99178021 .0  
.o.968IT1561 
.0.985809251 
Vnweighted 
93084.1888 
165.132504 
4.37359284 
0.991 78.021.0 
.0.968771 561 
.0.98580925.1 
3.37.1 1 8801 
.0 . .05343668.05 
0:0549049844 
.0.0263272255 
.0 . .0274747283 
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The following are norrr.alized parameters with an expected value of .0;.0. Values are in units of standard deviations from the 
expected value. . 
. 
The serial correlation is 5.44 which indicates a systematic non-random. trend iri the. residuals. 
Skewness is .0.43 which is probably not significanl 
Kurtosis is -0;00 which is probably not signiflCSnt.. 
The weighti ng factor was .0 . .00 leading to a heteroscedacticity of -0.1 6  which' suggests an optimal weight factor for this m of about 
·-.0 . 1 6  
Figure A VII. 7. Statistical Output obtained from across-dose fitting for F-Na 
absorption data in the IPRL at 37 °C. 
.- MicroMath Scitintis! Statiolica Report�· 
Model File Name : 
Data Fole Name : Pasam FIle Name : 
a:1t'l1a.eqn 
a:ltna-25.mrnd 
Untitfedl 
Goodness-of-fIt atatiatics for data IIeI: 
Data Column Name: FP 
Sum of squared.oboorvlliona : 
Sum of squared devfaliona : 
Standard devfation of dalat 
R-squared : 
CoeffICient of __ : 
Correlation : 
a:\lne-25.mrnd 
Weighted 
66641 .7283 
661 .526093 
".69448105 
0.966772180 
0.9599637-45 
0.980124204 
Data Sat Name: a:\fna-25.mmd 
Sum of squared aba_liona : 
Sum of squared deviali9na : 
Standard devfation of data : 
R-squared : 
CoeffICient of determination : 
Correlation : 
Modal Saleclion Criterion : 
Confidence Intervoio: 
Parameter Name : 
Estimate Value . 
Standard Deviation • 
95% Range (Univar) . 
95% Range (5-PIane) • 
Parameter "Name : 
Estimate Value • 
Standard Deviation • 
95% Range (Univar) • 
95% Range (5-PIane) • 
Variance-Covariance Matrix: 
2.22347324E-8 
Weighted 
66641.7283 
661 .526093 
4.69448105 
0.966n21 60 
0.959963745 
0.9601 24204 
3.1 2273.176 
I'.A 
0.0233656026 
0.001 491 13163 
0.0203519134 
0,0195746506 
KE 
0.01 02096294 
0.001 62462766 
0.00692592954 
0.00607897658 
2.05607212E-8 2.6400659ZE-8 
Correlation Matrix: 
1 .00000000 
0.848623396 1 .00000000 
Residual Analysi8: 
Unwelghted 
66641.7283 
661 .526093 
4.69448105 
0.986772180 
0.959983745 
0.960124204 
Unweighted 
66641 .7283 
661.526093 
4.69448105 
0.986772160 
0.9599637-45 
0.9801 24204 
3.12273178 
0.0263792919 
0.0271565546 
0.01 34937292 
0.0143406822 
The fonol'olng are normalized parameters with an expected value of 0.0. Valu .. are in units of standard deviations from the 
expected value. 
The serlal correlation ·1s 6.04 which Jndicatas a systematic non-random frand In the residuals. 
Skewness Is 0.80 which Is probably not aignHicanl 
Kurtosis Is -0.00 which Is probably no) "ignificant . 
335 
The weighting factor w u  0.00 leading to • heteroscedacticlty of 0.31 which 8Uggests an optimal weight factor for this fit o f  about 
0.31 
Figure A VII.S. Statistical Output obtained from across-dose fitting for F-Na 
absorption data in the IPRL at 25 °C. 
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